{"PMC7173117": [["IntroductionStress granules (SGs) are discrete foci that contain cytoplasmic mRNAs.", [["IntroductionStress granules", "ANATOMY", 0, 27], ["SGs", "ANATOMY", 29, 32], ["foci", "ANATOMY", 47, 51], ["cytoplasmic", "ANATOMY", 65, 76], ["IntroductionStress", "GENE_OR_GENE_PRODUCT", 0, 18], ["granules", "ORGANISM_SUBSTANCE", 19, 27], ["SGs", "CELLULAR_COMPONENT", 29, 32], ["cytoplasmic", "ORGANISM_SUBSTANCE", 65, 76], ["cytoplasmic mRNAs", "RNA", 65, 82], ["discrete foci", "PROBLEM", 38, 51], ["cytoplasmic mRNAs", "PROBLEM", 65, 82], ["discrete", "OBSERVATION_MODIFIER", 38, 46], ["foci", "OBSERVATION", 47, 51], ["cytoplasmic mRNAs", "OBSERVATION", 65, 82]]], ["The SGs, in which the mRNAs are recruited by TIA1 (T cell internal antigen 1) and TIAR (T-cell restricted intracellular antigen related protein), are generally induced following exposure to a stressor.", [["SGs", "ANATOMY", 4, 7], ["T-cell", "ANATOMY", 88, 94], ["intracellular", "ANATOMY", 106, 119], ["SGs", "CELLULAR_COMPONENT", 4, 7], ["TIA1", "GENE_OR_GENE_PRODUCT", 45, 49], ["T cell internal antigen 1", "GENE_OR_GENE_PRODUCT", 51, 76], ["TIAR", "GENE_OR_GENE_PRODUCT", 82, 86], ["T-cell restricted intracellular antigen related protein", "GENE_OR_GENE_PRODUCT", 88, 143], ["mRNAs", "RNA", 22, 27], ["TIA1", "PROTEIN", 45, 49], ["T cell internal antigen 1", "PROTEIN", 51, 76], ["TIAR", "PROTEIN", 82, 86], ["T-cell restricted intracellular antigen related protein", "PROTEIN", 88, 143], ["The SGs", "PROBLEM", 0, 7], ["TIA1", "TEST", 45, 49], ["T cell internal antigen", "TEST", 51, 74], ["TIAR", "TEST", 82, 86], ["SGs", "OBSERVATION", 4, 7]]], ["Mammalian TIA1 and TIAR are both ARE (adenine and uridine-rich element)\u2013binding proteins that appear to selectively downregulate TNF-\u03b1 production through post-transcriptional regulation, suggesting that they are translational silencers in un-stressed cells [1].", [["cells", "ANATOMY", 251, 256], ["adenine", "CHEMICAL", 38, 45], ["uridine", "CHEMICAL", 50, 57], ["adenine", "CHEMICAL", 38, 45], ["uridine", "CHEMICAL", 50, 57], ["TIA1", "GENE_OR_GENE_PRODUCT", 10, 14], ["TIAR", "GENE_OR_GENE_PRODUCT", 19, 23], ["ARE", "GENE_OR_GENE_PRODUCT", 33, 36], ["adenine", "SIMPLE_CHEMICAL", 38, 45], ["uridine", "SIMPLE_CHEMICAL", 50, 57], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 129, 134], ["cells", "CELL", 251, 256], ["Mammalian TIA1", "PROTEIN", 0, 14], ["TIAR", "PROTEIN", 19, 23], ["ARE (adenine and uridine-rich element)\u2013binding proteins", "PROTEIN", 33, 88], ["TNF", "PROTEIN", 129, 132], ["translational silencers", "DNA", 212, 235], ["Mammalian TIA1 and TIAR", "TREATMENT", 0, 23], ["adenine and uridine-rich element", "TREATMENT", 38, 70], ["\u2013binding proteins", "PROBLEM", 71, 88], ["TNF", "TEST", 129, 132], ["translational silencers", "PROBLEM", 212, 235]]], ["Both TIA1 and TIAR are essential for mammalian embryo development, but their specific functions during development are not known [2].", [["embryo", "ANATOMY", 47, 53], ["TIA1", "GENE_OR_GENE_PRODUCT", 5, 9], ["TIAR", "GENE_OR_GENE_PRODUCT", 14, 18], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 47, 53], ["TIA1", "PROTEIN", 5, 9], ["TIAR", "PROTEIN", 14, 18], ["mammalian embryo development", "PROBLEM", 37, 65], ["mammalian embryo", "OBSERVATION", 37, 53]]], ["As RNA-binding protein, TIA1 and TIAR appear to be functionally redundant, which allows these proteins to sequestrate untranslated mRNA, preventing the initiation of translation and leading to translational arrest [1].", [["RNA-binding protein", "GENE_OR_GENE_PRODUCT", 3, 22], ["TIA1", "GENE_OR_GENE_PRODUCT", 24, 28], ["TIAR", "GENE_OR_GENE_PRODUCT", 33, 37], ["RNA-binding protein", "PROTEIN", 3, 22], ["TIA1", "PROTEIN", 24, 28], ["TIAR", "PROTEIN", 33, 37], ["untranslated mRNA", "RNA", 118, 135], ["RNA-binding protein", "TEST", 3, 22], ["TIA1", "TEST", 24, 28], ["translational arrest", "PROBLEM", 193, 213]]], ["Both TIA1 and TIAR are activated following the stress-induced phosphorylation of eIF-2\u03b1, a translation initiation factor [3].", [["TIA1", "GENE_OR_GENE_PRODUCT", 5, 9], ["TIAR", "GENE_OR_GENE_PRODUCT", 14, 18], ["eIF-2\u03b1", "GENE_OR_GENE_PRODUCT", 81, 87], ["TIA1", "PROTEIN", 5, 9], ["TIAR", "PROTEIN", 14, 18], ["eIF-2\u03b1", "PROTEIN", 81, 87], ["translation initiation factor", "PROTEIN", 91, 120], ["the stress", "TEST", 43, 53]]], ["Once the stressor is removed, the mRNAs are released from the SGs and translated by ribosomes or degraded in processing bodies (P-bodies) [3], [4].", [["SGs", "ANATOMY", 62, 65], ["ribosomes", "ANATOMY", 84, 93], ["SGs", "CELLULAR_COMPONENT", 62, 65], ["ribosomes", "CELLULAR_COMPONENT", 84, 93], ["mRNAs", "RNA", 34, 39], ["SGs", "RNA", 62, 65]]], ["While there are over 500 RNA-binding proteins involved in the formation of mammalian SGs, the primary SG proteins are relatively limited, which include TIA1, TIAR, RasGAP-associated endoribonuclease (G3BP), elongation initiation factor 3 (eIF3), and poly-A binding protein (PABP) [5], [6], [7].", [["SGs", "ANATOMY", 85, 88], ["SGs", "GENE_OR_GENE_PRODUCT", 85, 88], ["SG proteins", "GENE_OR_GENE_PRODUCT", 102, 113], ["TIA1", "GENE_OR_GENE_PRODUCT", 152, 156], ["TIAR", "GENE_OR_GENE_PRODUCT", 158, 162], ["RasGAP-associated endoribonuclease (G3BP), elongation initiation factor 3", "GENE_OR_GENE_PRODUCT", 164, 237], ["eIF3", "GENE_OR_GENE_PRODUCT", 239, 243], ["poly-A binding protein", "GENE_OR_GENE_PRODUCT", 250, 272], ["PABP", "GENE_OR_GENE_PRODUCT", 274, 278], ["[6]", "SIMPLE_CHEMICAL", 285, 288], ["RNA-binding proteins", "PROTEIN", 25, 45], ["primary SG proteins", "PROTEIN", 94, 113], ["TIA1", "PROTEIN", 152, 156], ["TIAR", "PROTEIN", 158, 162], ["RasGAP", "PROTEIN", 164, 170], ["associated endoribonuclease", "PROTEIN", 171, 198], ["G3BP", "PROTEIN", 200, 204], ["elongation initiation factor 3", "PROTEIN", 207, 237], ["eIF3", "PROTEIN", 239, 243], ["poly-A binding protein", "PROTEIN", 250, 272], ["PABP", "PROTEIN", 274, 278], ["the primary SG proteins", "TEST", 90, 113], ["TIA1", "TEST", 152, 156], ["RasGAP", "TEST", 164, 170], ["elongation initiation factor", "PROBLEM", 207, 235], ["poly-A binding protein (PABP)", "TREATMENT", 250, 279], ["mammalian SGs", "OBSERVATION", 75, 88]]], ["SG formation can be induced by overexpressing the component protein(s) including TIA1, TIAR, and G3BP.", [["SG", "MULTI-TISSUE_STRUCTURE", 0, 2], ["TIA1", "GENE_OR_GENE_PRODUCT", 81, 85], ["TIAR", "GENE_OR_GENE_PRODUCT", 87, 91], ["G3BP", "GENE_OR_GENE_PRODUCT", 97, 101], ["component protein", "PROTEIN", 50, 67], ["TIA1", "PROTEIN", 81, 85], ["TIAR", "PROTEIN", 87, 91], ["G3BP", "PROTEIN", 97, 101], ["TIA1", "TEST", 81, 85], ["TIAR", "TEST", 87, 91]]], ["TIA1 and G3BP are thought to be the critical effectors of SG formation because truncated forms of the proteins inhibit SG formation [6], [8], [9].", [["TIA1", "GENE_OR_GENE_PRODUCT", 0, 4], ["G3BP", "GENE_OR_GENE_PRODUCT", 9, 13], ["SG", "GENE_OR_GENE_PRODUCT", 58, 60], ["SG", "SIMPLE_CHEMICAL", 119, 121], ["[8]", "SIMPLE_CHEMICAL", 137, 140], ["TIA1", "PROTEIN", 0, 4], ["G3BP", "PROTEIN", 9, 13], ["thought to be", "UNCERTAINTY", 18, 31]]], ["Until now, very little has been known on SG biomarkers of aquatic animals and most knowledge on SG comes from the study on mammalian animals including human and mouse.IntroductionViruses have evolved to interact with the SG pathway in very different ways.", [["human", "ORGANISM", 151, 156], ["mouse", "ORGANISM", 161, 166], ["SG", "GENE_OR_GENE_PRODUCT", 221, 223], ["human", "SPECIES", 151, 156], ["mouse", "SPECIES", 161, 166], ["human", "SPECIES", 151, 156], ["mouse", "SPECIES", 161, 166], ["the study", "TEST", 110, 119]]], ["For example, respiratory syncytial virus and coronaviruses take advantage of the SGs as translational silencers and induce SGs to inhibit host translation [10], [11], [12].", [["respiratory syncytial virus", "DISEASE", 13, 40], ["respiratory syncytial virus", "ORGANISM", 13, 40], ["coronaviruses", "ORGANISM", 45, 58], ["SGs", "GENE_OR_GENE_PRODUCT", 81, 84], ["SGs", "GENE_OR_GENE_PRODUCT", 123, 126], ["[11]", "SIMPLE_CHEMICAL", 161, 165], ["SGs", "DNA", 81, 84], ["translational silencers", "DNA", 88, 111], ["respiratory syncytial virus", "SPECIES", 13, 40], ["respiratory syncytial virus", "SPECIES", 13, 40], ["respiratory syncytial virus", "PROBLEM", 13, 40], ["coronaviruses", "PROBLEM", 45, 58], ["translational silencers", "TREATMENT", 88, 111], ["respiratory", "OBSERVATION", 13, 24], ["syncytial virus", "OBSERVATION", 25, 40]]], ["In contrast, rotavirus and cardioviruses inhibit the formation of SGs during infection to prevent the adverse effect of SGs on the translation of viral genes [13], [14].", [["SGs", "ANATOMY", 66, 69], ["infection", "DISEASE", 77, 86], ["rotavirus", "ORGANISM", 13, 22], ["cardioviruses", "GENE_OR_GENE_PRODUCT", 27, 40], ["SGs", "GENE_OR_GENE_PRODUCT", 66, 69], ["SGs", "GENE_OR_GENE_PRODUCT", 120, 123], ["viral genes", "DNA", 146, 157], ["rotavirus", "SPECIES", 13, 22], ["rotavirus", "PROBLEM", 13, 22], ["cardioviruses", "TREATMENT", 27, 40], ["SGs during infection", "PROBLEM", 66, 86], ["the adverse effect of SGs", "PROBLEM", 98, 123], ["viral genes", "PROBLEM", 146, 157], ["infection", "OBSERVATION", 77, 86]]], ["Many viruses, including mammalian reovirus, poliovirus, semliki forest virus, and hepatitis C virus, could induce SGs during early infection to benefit from SG-mediated inhibition of host translation, but during late infection tend to inhibit SG formation to allow efficient viral replication [15], [16], [17].", [["SGs", "ANATOMY", 114, 117], ["hepatitis C virus", "DISEASE", 82, 99], ["infection", "DISEASE", 131, 140], ["SG", "CHEMICAL", 157, 159], ["infection", "DISEASE", 217, 226], ["mammalian reovirus", "ORGANISM", 24, 42], ["poliovirus", "ORGANISM", 44, 54], ["semliki forest virus", "ORGANISM", 56, 76], ["hepatitis C virus", "ORGANISM", 82, 99], ["SGs", "GENE_OR_GENE_PRODUCT", 114, 117], ["SG", "GENE_OR_GENE_PRODUCT", 157, 159], ["SG", "SIMPLE_CHEMICAL", 243, 245], ["[16]", "SIMPLE_CHEMICAL", 299, 303], ["mammalian reovirus", "SPECIES", 24, 42], ["semliki forest virus", "SPECIES", 56, 76], ["hepatitis C virus", "SPECIES", 82, 99], ["mammalian reovirus", "SPECIES", 24, 42], ["semliki forest virus", "SPECIES", 56, 76], ["hepatitis C virus", "SPECIES", 82, 99], ["Many viruses", "PROBLEM", 0, 12], ["mammalian reovirus", "PROBLEM", 24, 42], ["poliovirus", "PROBLEM", 44, 54], ["semliki forest virus", "PROBLEM", 56, 76], ["hepatitis C virus", "PROBLEM", 82, 99], ["SGs", "PROBLEM", 114, 117], ["early infection", "PROBLEM", 125, 140], ["SG", "TREATMENT", 157, 159], ["host translation", "TREATMENT", 183, 199], ["late infection", "PROBLEM", 212, 226], ["SG formation", "PROBLEM", 243, 255], ["efficient viral replication", "PROBLEM", 265, 292], ["viruses", "OBSERVATION", 5, 12], ["mammalian reovirus", "OBSERVATION", 24, 42], ["semliki forest virus", "OBSERVATION", 56, 76]]], ["Finally, TIA1 and TIAR appear to be critical for West Nile virus replication, possibly through their ability to bind specifically to the 3\u02b9 terminus of the viral minus-strand RNA template [18].", [["TIA1", "GENE_OR_GENE_PRODUCT", 9, 13], ["TIAR", "GENE_OR_GENE_PRODUCT", 18, 22], ["West Nile virus", "ORGANISM", 49, 64], ["TIA1", "PROTEIN", 9, 13], ["TIAR", "PROTEIN", 18, 22], ["3\u02b9 terminus", "DNA", 137, 148], ["viral minus-strand RNA template", "DNA", 156, 187], ["Nile virus", "SPECIES", 54, 64], ["West Nile virus", "SPECIES", 49, 64], ["TIA1 and TIAR", "TREATMENT", 9, 22], ["West Nile virus replication", "TREATMENT", 49, 76], ["strand RNA template", "TREATMENT", 168, 187]]], ["Interestingly, TIA1 can self-aggregate into novel foci that lack other SG-defining components in poliovirus-infected cells, suggesting a novel role for TIA1 independent of SGs [19].IntroductionGrass carp reovirus (GCRV) causes a hemorrhagic disease in cultivated grass carp (C. idella) leading to heavy economic losses [20].", [["foci", "ANATOMY", 50, 54], ["cells", "ANATOMY", 117, 122], ["hemorrhagic disease", "DISEASE", 229, 248], ["TIA1", "GENE_OR_GENE_PRODUCT", 15, 19], ["poliovirus", "ORGANISM", 97, 107], ["cells", "CELL", 117, 122], ["TIA1", "GENE_OR_GENE_PRODUCT", 152, 156], ["Grass carp reovirus", "ORGANISM", 193, 212], ["GCRV", "ORGANISM", 214, 218], ["grass carp", "ORGANISM", 263, 273], ["C. idella", "ORGANISM", 275, 284], ["TIA1", "PROTEIN", 15, 19], ["poliovirus-infected cells", "CELL_TYPE", 97, 122], ["TIA1", "PROTEIN", 152, 156], ["carp reovirus", "SPECIES", 199, 212], ["grass carp", "SPECIES", 263, 273], ["C. idella", "SPECIES", 275, 284], ["Grass carp reovirus", "SPECIES", 193, 212], ["GCRV", "SPECIES", 214, 218], ["grass carp", "SPECIES", 263, 273], ["C. idella", "SPECIES", 275, 284], ["novel foci", "PROBLEM", 44, 54], ["poliovirus", "PROBLEM", 97, 107], ["infected cells", "PROBLEM", 108, 122], ["IntroductionGrass carp reovirus", "TREATMENT", 181, 212], ["a hemorrhagic disease", "PROBLEM", 227, 248], ["cultivated grass carp (C. idella", "PROBLEM", 252, 284], ["heavy economic losses", "PROBLEM", 297, 318], ["foci", "OBSERVATION", 50, 54], ["poliovirus", "OBSERVATION", 97, 107], ["infected cells", "OBSERVATION", 108, 122], ["hemorrhagic", "OBSERVATION_MODIFIER", 229, 240], ["disease", "OBSERVATION", 241, 248], ["grass carp", "OBSERVATION", 263, 273], ["heavy", "OBSERVATION_MODIFIER", 297, 302], ["economic losses", "OBSERVATION", 303, 318]]], ["GCRV is considered unique among the known aquareoviruses due to its high pathogenicity [21].", [["GCRV", "CHEMICAL", 0, 4], ["GCRV", "GENE_OR_GENE_PRODUCT", 0, 4], ["aquareoviruses", "CANCER", 42, 56], ["GCRV", "SPECIES", 0, 4], ["GCRV", "PROBLEM", 0, 4], ["the known aquareoviruses", "PROBLEM", 32, 56], ["its high pathogenicity", "PROBLEM", 64, 86]]], ["There are three known types of GCRV: type I (representative strain: GCRV-873) [22], type II (GCRV GD-108) identified in 2012 [23], and type III GCRV (GCRV-104) identified in 2013 [24].", [["GCRV", "GENE_OR_GENE_PRODUCT", 31, 35], ["GCRV-873", "ORGANISM", 68, 76], ["GCRV GD-108", "CANCER", 93, 104], ["type III GCRV", "CANCER", 135, 148], ["GCRV-104", "CELL", 150, 158], ["type III GCRV (GCRV-104", "SPECIES", 135, 158], ["type I", "PROBLEM", 37, 43], ["GCRV", "TEST", 68, 72], ["type II", "PROBLEM", 84, 91], ["GCRV GD", "TEST", 93, 100], ["type III GCRV", "PROBLEM", 135, 148], ["GCRV", "TEST", 150, 154], ["GCRV", "OBSERVATION", 31, 35]]], ["All of the GCRV strains contain a segmented double stranded RNA (dsRNA) genome and share low homogeneity with each other.", [["GCRV strains", "ORGANISM", 11, 23], ["double stranded RNA (dsRNA) genome", "DNA", 44, 78], ["GCRV", "SPECIES", 11, 15], ["the GCRV strains", "PROBLEM", 7, 23], ["a segmented double stranded RNA (dsRNA) genome", "TREATMENT", 32, 78], ["GCRV strains", "OBSERVATION", 11, 23], ["segmented", "OBSERVATION_MODIFIER", 34, 43], ["double", "OBSERVATION_MODIFIER", 44, 50], ["stranded RNA", "OBSERVATION", 51, 63], ["low homogeneity", "OBSERVATION_MODIFIER", 89, 104]]], ["However, all of the GCRV strains belong to the genus aquareovirus, which is significantly different from the genus othoreovirus[25].", [["GCRV strains", "ORGANISM", 20, 32], ["aquareovirus", "GENE_OR_GENE_PRODUCT", 53, 65], ["GCRV", "SPECIES", 20, 24], ["the GCRV strains", "PROBLEM", 16, 32], ["genus aquareovirus", "ANATOMY", 47, 65], ["significantly", "OBSERVATION_MODIFIER", 76, 89], ["different", "OBSERVATION_MODIFIER", 90, 99]]], ["Type I GCRV is widely regarded as the archetype aquareovirus and has been the subject of research in developing diagnostic methods, elucidating virus-host cell interactions, and characterizing viral morphology [26], [27], [28], [29].", [["cell", "ANATOMY", 155, 159], ["Type I GCRV", "GENE_OR_GENE_PRODUCT", 0, 11], ["aquareovirus", "CANCER", 48, 60], ["host cell", "CELL", 150, 159], ["Type I GCRV", "SPECIES", 0, 11], ["Type I GCRV", "PROBLEM", 0, 11], ["elucidating virus", "PROBLEM", 132, 149], ["characterizing viral morphology", "TEST", 178, 209], ["GCRV", "OBSERVATION", 7, 11], ["host cell", "OBSERVATION", 150, 159]]], ["Even with the relatively extensive knowledge pertaining to type I GCRV, little is known about the mechanisms on its replication and pathogenicity in grass carp cells.", [["grass carp cells", "ANATOMY", 149, 165], ["type I GCRV", "GENE_OR_GENE_PRODUCT", 59, 70], ["grass carp cells", "CELL", 149, 165], ["type I GCRV", "PROTEIN", 59, 70], ["grass carp cells", "CELL_TYPE", 149, 165], ["carp", "SPECIES", 155, 159], ["grass carp", "SPECIES", 149, 159], ["type I GCRV", "PROBLEM", 59, 70], ["pathogenicity in grass carp cells", "PROBLEM", 132, 165], ["grass carp cells", "OBSERVATION", 149, 165]]], ["In this study, GCRV refers to the type 1 strain.IntroductionPreviously, two-dimensional electrophoresis (2-DE) and matrix-assisted laser desorption/ionization tandem mass spectroscopy were performed to characterize altered protein expression profiles in C. idella kidney (CIK) cells following GCRV infection.", [["C. idella kidney (CIK) cells", "ANATOMY", 254, 282], ["GCRV", "ANATOMY", 293, 297], ["2-DE", "CHEMICAL", 105, 109], ["infection", "DISEASE", 298, 307], ["C. idella kidney (CIK) cells", "CELL", 254, 282], ["GCRV", "CELL", 293, 297], ["GCRV", "PROTEIN", 15, 19], ["C. idella kidney (CIK) cells", "CELL_LINE", 254, 282], ["C. idella", "SPECIES", 254, 263], ["GCRV", "SPECIES", 15, 19], ["C. idella", "SPECIES", 254, 263], ["GCRV", "SPECIES", 293, 297], ["this study", "TEST", 3, 13], ["GCRV", "PROBLEM", 15, 19], ["the type 1 strain", "PROBLEM", 30, 47], ["matrix-assisted laser desorption/ionization tandem mass spectroscopy", "TEST", 115, 183], ["altered protein expression profiles", "PROBLEM", 215, 250], ["GCRV infection", "PROBLEM", 293, 307], ["protein expression", "OBSERVATION", 223, 241], ["kidney", "ANATOMY", 264, 270], ["GCRV infection", "OBSERVATION", 293, 307]]], ["The experiments revealed that grass carp C. idella TIA1 (CiTIA1) and G3BP1 (CiG3BP1) were significantly upregulated and downregulated, respectively [30], indicating GCRV might unlink CiTIA1 aggregation from SG formation that is similar to the effects of poliovirus in host cells [19].", [["cells", "ANATOMY", 273, 278], ["grass carp", "ORGANISM", 30, 40], ["C. idella", "ORGANISM", 41, 50], ["TIA1", "GENE_OR_GENE_PRODUCT", 51, 55], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 57, 63], ["G3BP1", "GENE_OR_GENE_PRODUCT", 69, 74], ["CiG3BP1", "GENE_OR_GENE_PRODUCT", 76, 83], ["GCRV", "GENE_OR_GENE_PRODUCT", 165, 169], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 183, 189], ["SG", "PATHOLOGICAL_FORMATION", 207, 209], ["host cells", "CELL", 268, 278], ["grass carp C. idella TIA1", "PROTEIN", 30, 55], ["CiTIA1", "PROTEIN", 57, 63], ["G3BP1", "PROTEIN", 69, 74], ["CiG3BP1", "PROTEIN", 76, 83], ["GCRV", "PROTEIN", 165, 169], ["CiTIA1", "PROTEIN", 183, 189], ["host cells", "CELL_TYPE", 268, 278], ["carp", "SPECIES", 36, 40], ["C. idella", "SPECIES", 41, 50], ["grass carp", "SPECIES", 30, 40], ["C. idella", "SPECIES", 41, 50], ["poliovirus", "SPECIES", 254, 264], ["The experiments", "TEST", 0, 15], ["grass carp C. idella TIA1", "TEST", 30, 55], ["CiTIA1", "TEST", 57, 63], ["G3BP1", "TEST", 69, 74], ["CiG3BP1", "TEST", 76, 83], ["GCRV", "PROBLEM", 165, 169], ["CiTIA1 aggregation", "PROBLEM", 183, 201], ["SG formation", "PROBLEM", 207, 219], ["poliovirus in host cells", "PROBLEM", 254, 278]]], ["TIA1 has not been functionally characterized in any fish species to date and potential differences might exist between fish and mammalian TIA1, which merit further characterization of this molecule as an RNA chaperon molecule in grass carp.", [["TIA1", "CHEMICAL", 0, 4], ["TIA1", "GENE_OR_GENE_PRODUCT", 0, 4], ["fish", "ORGANISM", 119, 123], ["TIA1", "GENE_OR_GENE_PRODUCT", 138, 142], ["grass carp", "ORGANISM", 229, 239], ["TIA1", "PROTEIN", 0, 4], ["mammalian TIA1", "PROTEIN", 128, 142], ["RNA chaperon molecule", "PROTEIN", 204, 225], ["carp", "SPECIES", 235, 239], ["grass carp", "SPECIES", 229, 239], ["this molecule", "PROBLEM", 184, 197], ["grass carp", "OBSERVATION", 229, 239]]], ["Although GCRV can efficiently infect and replicate in CIK cells, the presence of GCRV dsRNA in host cells is a signal to induce RNA receptor-mediated antiviral innate immunity, including the RNAi pathway, which has been demonstrated to be effective in grass carp cells; recent studies also demonstrated that chemically synthesized siRNA targeting the viral dsRNA genome inhibited viral replication in CIK cells [31], [32].", [["CIK cells", "ANATOMY", 54, 63], ["cells", "ANATOMY", 100, 105], ["grass carp cells", "ANATOMY", 252, 268], ["CIK cells", "ANATOMY", 401, 410], ["GCRV", "CHEMICAL", 9, 13], ["GCRV", "GENE_OR_GENE_PRODUCT", 9, 13], ["CIK cells", "CELL", 54, 63], ["GCRV", "GENE_OR_GENE_PRODUCT", 81, 85], ["host cells", "CELL", 95, 105], ["grass carp cells", "CELL", 252, 268], ["CIK cells", "CELL", 401, 410], ["GCRV", "PROTEIN", 9, 13], ["CIK cells", "CELL_LINE", 54, 63], ["GCRV dsRNA", "RNA", 81, 91], ["host cells", "CELL_TYPE", 95, 105], ["RNA receptor", "PROTEIN", 128, 140], ["grass carp cells", "CELL_TYPE", 252, 268], ["viral dsRNA genome", "DNA", 351, 369], ["CIK cells", "CELL_LINE", 401, 410], ["carp", "SPECIES", 258, 262], ["GCRV", "SPECIES", 9, 13], ["GCRV", "SPECIES", 81, 85], ["grass carp", "SPECIES", 252, 262], ["GCRV", "PROBLEM", 9, 13], ["CIK cells", "TREATMENT", 54, 63], ["GCRV dsRNA in host cells", "PROBLEM", 81, 105], ["RNA receptor", "TEST", 128, 140], ["the RNAi pathway", "TEST", 187, 203], ["grass carp cells", "PROBLEM", 252, 268], ["recent studies", "TEST", 270, 284], ["chemically synthesized siRNA", "TREATMENT", 308, 336], ["the viral dsRNA genome", "TREATMENT", 347, 369], ["viral replication in CIK cells", "PROBLEM", 380, 410], ["CIK cells", "OBSERVATION", 54, 63], ["GCRV dsRNA", "OBSERVATION", 81, 91], ["viral dsRNA genome", "OBSERVATION", 351, 369]]], ["Given that dsRNA-binding proteins could potentially inhibit RNAi [33], the dsRNA binding activity of CiTIA1 was investigated here both in vitro and in vivo.", [["CiTIA1", "GENE_OR_GENE_PRODUCT", 101, 107], ["dsRNA-binding proteins", "PROTEIN", 11, 33], ["CiTIA1", "PROTEIN", 101, 107], ["dsRNA-binding proteins", "PROBLEM", 11, 33], ["RNAi", "TEST", 60, 64], ["the dsRNA binding activity of CiTIA1", "PROBLEM", 71, 107]]], ["Since whether CiTIA1 aggregation enhances or antagonizes GCRV replication is unknown, we also analyzed the impact of over-expressed CiTIA1 on viral replication in this study.Cell and virus ::: Materials and methodsCIK cells were maintained in M199 medium (100 U/mL Penicillin and 100 \u03bcg/mL Streptomycin) supplemented with 10% fetal bovine serum (Gibco BRL).", [["Cell", "ANATOMY", 174, 178], ["methodsCIK cells", "ANATOMY", 207, 223], ["fetal bovine serum", "ANATOMY", 326, 344], ["Penicillin", "CHEMICAL", 265, 275], ["Streptomycin", "CHEMICAL", 290, 302], ["Penicillin", "CHEMICAL", 265, 275], ["Streptomycin", "CHEMICAL", 290, 302], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 14, 20], ["GCRV", "GENE_OR_GENE_PRODUCT", 57, 61], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 132, 138], ["Cell", "CELL", 174, 178], ["methodsCIK cells", "CELL", 207, 223], ["Penicillin", "SIMPLE_CHEMICAL", 265, 275], ["Streptomycin", "SIMPLE_CHEMICAL", 290, 302], ["bovine", "ORGANISM", 332, 338], ["serum", "ORGANISM_SUBSTANCE", 339, 344], ["Gibco BRL", "CELL", 346, 355], ["CiTIA1", "PROTEIN", 14, 20], ["CiTIA1", "PROTEIN", 132, 138], ["methodsCIK cells", "CELL_LINE", 207, 223], ["bovine", "SPECIES", 332, 338], ["bovine", "SPECIES", 332, 338], ["CiTIA1 aggregation enhances", "PROBLEM", 14, 41], ["antagonizes GCRV replication", "PROBLEM", 45, 73], ["viral replication", "TREATMENT", 142, 159], ["this study", "TEST", 163, 173], ["methodsCIK cells", "TREATMENT", 207, 223], ["Penicillin", "TREATMENT", 265, 275], ["Streptomycin", "TREATMENT", 290, 302], ["10% fetal bovine serum (Gibco BRL", "TREATMENT", 322, 355], ["viral replication", "OBSERVATION", 142, 159], ["virus", "OBSERVATION", 183, 188]]], ["The cells were incubated and infected at 28 \u00b0C. Type I GCRV strain JX-01 was used in this study [34].", [["cells", "ANATOMY", 4, 9], ["JX-01", "CHEMICAL", 67, 72], ["cells", "CELL", 4, 9], ["JX-01", "CELL", 67, 72], ["Type I GCRV strain JX-01", "SPECIES", 48, 72], ["infected", "PROBLEM", 29, 37], ["Type I GCRV strain JX", "PROBLEM", 48, 69], ["this study", "TEST", 85, 95], ["infected", "OBSERVATION_MODIFIER", 29, 37]]], ["The virus was titrated using a standard 50% tissue culture infective dose (TCID50) assay.", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["The virus", "TREATMENT", 0, 9], ["a standard 50% tissue culture infective dose", "TREATMENT", 29, 73], ["virus", "OBSERVATION", 4, 9]]], ["Real-time RT-PCR was established to quantify the transcriptional expression profile of GCRV-S10 gene using CFX96\u2122 Real-Time PCR Detection System (Bio-Rad) [34].Plasmid construction ::: Materials and methodsThe CiTIA1 ORF was amplified by RT-PCR from the total RNA extracted from CIK cells using the primer pair (F-5\u02b9 ccgCTCGAGATGATGGACGACGAGCAGC \u02b93 and R-5\u02b9 cccAAGCTTGTGTGTGTGGTATCCTGCAGT 3\u02b9).", [["CIK cells", "ANATOMY", 279, 288], ["GCRV-S10", "GENE_OR_GENE_PRODUCT", 87, 95], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 210, 216], ["CIK cells", "CELL", 279, 288], ["GCRV-S10 gene", "DNA", 87, 100], ["CFX96", "DNA", 107, 112], ["CiTIA1 ORF", "DNA", 210, 220], ["CIK cells", "CELL_LINE", 279, 288], ["time RT-PCR", "TEST", 5, 16], ["GCRV", "TEST", 87, 91], ["The CiTIA1 ORF", "TEST", 206, 220], ["RT", "TEST", 238, 240], ["PCR", "TEST", 241, 244], ["the total RNA", "TREATMENT", 250, 263], ["CIK cells", "TREATMENT", 279, 288], ["the primer pair", "TEST", 295, 310], ["ccgCTCGAGATGATGGACGACGAGCAGC", "TEST", 317, 345], ["R", "TEST", 353, 354]]], ["The amplified fragment was cloned into the eukaryotic expression vector pEGFP-N1 (Invitrogen) and prokaryotic expression vector pGEX-4T-3 (Invitrogen) to generate pEGFP-TIA1 and pGST-TIA1, respectively.", [["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 72, 80], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 82, 92], ["pGEX-4T-3", "GENE_OR_GENE_PRODUCT", 128, 137], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 139, 149], ["pEGFP", "GENE_OR_GENE_PRODUCT", 163, 168], ["TIA1", "GENE_OR_GENE_PRODUCT", 169, 173], ["pGST-TIA1", "GENE_OR_GENE_PRODUCT", 178, 187], ["amplified fragment", "DNA", 4, 22], ["eukaryotic expression vector pEGFP-N1 (Invitrogen) and prokaryotic expression vector pGEX-4T-3", "DNA", 43, 137], ["pEGFP", "DNA", 163, 168], ["TIA1", "DNA", 169, 173], ["pGST", "DNA", 178, 182], ["TIA1", "DNA", 183, 187], ["The amplified fragment", "PROBLEM", 0, 22], ["prokaryotic expression vector pGEX", "TEST", 98, 132], ["fragment", "OBSERVATION_MODIFIER", 14, 22]]], ["Plasmid extraction and purification was performed using the PureYield Plasmid Midiprep System (Promega).", [["Plasmid", "ANATOMY", 0, 7], ["Plasmid extraction", "TREATMENT", 0, 18], ["purification", "TREATMENT", 23, 35], ["the PureYield Plasmid Midiprep System", "TREATMENT", 56, 93]]], ["The quantity and quality of the extracted DNA was determined by Nanodrop 2000 (Thermo).", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["the extracted DNA", "PROBLEM", 28, 45], ["quantity", "OBSERVATION_MODIFIER", 4, 12]]], ["The plasmid DNA was stored at \u221220 \u00b0C.Recombinant protein expression and polyclonal antibody generation ::: Materials and methodsThe prokaryotic expression plasmid pGST-TIA1 and the vector pGEX-4T-3 was transformed into BL21 competent cells (Tiangen, Shanghai), respectively.", [["plasmid", "ANATOMY", 4, 11], ["cells", "ANATOMY", 234, 239], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["pGST-TIA1", "GENE_OR_GENE_PRODUCT", 163, 172], ["pGEX-4T-3", "GENE_OR_GENE_PRODUCT", 188, 197], ["cells", "CELL", 234, 239], ["plasmid DNA", "DNA", 4, 15], ["prokaryotic expression plasmid", "DNA", 132, 162], ["pGST", "DNA", 163, 167], ["TIA1", "DNA", 168, 172], ["vector pGEX-4T-3", "DNA", 181, 197], ["BL21 competent cells", "CELL_LINE", 219, 239], ["BL21", "SPECIES", 219, 223], ["The plasmid DNA", "TREATMENT", 0, 15], ["Recombinant protein expression", "TEST", 37, 67], ["The prokaryotic expression plasmid pGST", "TEST", 128, 167], ["the vector pGEX", "TEST", 177, 192], ["plasmid DNA", "OBSERVATION", 4, 15], ["protein expression", "OBSERVATION", 49, 67], ["polyclonal antibody generation", "OBSERVATION", 72, 102]]], ["A single colony was picked and incubated in LB broth supplemented with 50 \u03bcg/mL ampicillin at 37 \u00b0C. The expression of GST-TIA1 or GST was induced with 1 mM IPTG at 20 \u00b0C overnight.", [["colony", "ANATOMY", 9, 15], ["ampicillin", "CHEMICAL", 80, 90], ["IPTG", "CHEMICAL", 157, 161], ["ampicillin", "CHEMICAL", 80, 90], ["IPTG", "CHEMICAL", 157, 161], ["ampicillin", "SIMPLE_CHEMICAL", 80, 90], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 119, 127], ["GST", "GENE_OR_GENE_PRODUCT", 131, 134], ["IPTG", "SIMPLE_CHEMICAL", 157, 161], ["GST", "PROTEIN", 119, 122], ["TIA1", "PROTEIN", 123, 127], ["GST", "PROTEIN", 131, 134], ["A single colony", "PROBLEM", 0, 15], ["ampicillin", "TREATMENT", 80, 90], ["1 mM IPTG", "TREATMENT", 152, 161], ["colony", "OBSERVATION", 9, 15]]], ["1 mL of the culture liquid was subjected for SDS-PAGE analysis.", [["the culture liquid", "TEST", 8, 26], ["SDS", "TEST", 45, 48], ["PAGE analysis", "TEST", 49, 62]]], ["The bacteria pellet was then re-suspended in GST binding/wash Buffer (Sangon, Shanghai) containing a bacterial protease inhibitor cocktail.", [["GST", "GENE_OR_GENE_PRODUCT", 45, 48], ["GST", "PROTEIN", 45, 48], ["The bacteria pellet", "PROBLEM", 0, 19], ["a bacterial protease inhibitor cocktail", "TREATMENT", 99, 138], ["bacteria pellet", "OBSERVATION", 4, 19]]], ["After ultrasonication and centrifugation, the cleaned lysates were used to purify recombinant GST-TIA1 using Glutathione\u2122 Sepharose 4B beads (GE Healthcare) according to the manufacturer's protocol.", [["lysates", "ANATOMY", 54, 61], ["lysates", "ORGANISM_SUBSTANCE", 54, 61], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 94, 102], ["Glutathione\u2122", "SIMPLE_CHEMICAL", 109, 121], ["GST", "PROTEIN", 94, 97], ["TIA1", "PROTEIN", 98, 102], ["ultrasonication", "TREATMENT", 6, 21], ["centrifugation", "TREATMENT", 26, 40], ["the cleaned lysates", "TREATMENT", 42, 61], ["Glutathione\u2122 Sepharose 4B beads", "TREATMENT", 109, 140], ["the manufacturer's protocol", "TREATMENT", 170, 197]]], ["Purified proteins were confirmed by Western blot analysis.", [["Purified proteins", "TEST", 0, 17], ["blot analysis", "TEST", 44, 57]]], ["The purified GST-TIA1 protein was used to elicit polyclonal antibodies in New Zealand rabbits.", [["GST", "GENE_OR_GENE_PRODUCT", 13, 16], ["TIA1", "GENE_OR_GENE_PRODUCT", 17, 21], ["rabbits", "ORGANISM", 86, 93], ["GST", "PROTEIN", 13, 16], ["TIA1 protein", "PROTEIN", 17, 29], ["polyclonal antibodies", "PROTEIN", 49, 70], ["rabbits", "SPECIES", 86, 93], ["The purified GST", "TEST", 0, 16], ["TIA1 protein", "PROBLEM", 17, 29], ["polyclonal antibodies", "TEST", 49, 70], ["New Zealand rabbits", "TREATMENT", 74, 93]]], ["Briefly, groups of 4 animals were intraperitoneally immunized with a 50% emulsion of Freud's adjuvant (FCA, Sigma,USA) containing purified recombinant protein (100 \u03bcg per rabbit).", [["animals", "ORGANISM", 21, 28], ["FCA", "SIMPLE_CHEMICAL", 103, 106], ["rabbit", "ORGANISM", 171, 177], ["purified recombinant protein", "PROTEIN", 130, 158], ["rabbit", "SPECIES", 171, 177], ["rabbit", "SPECIES", 171, 177], ["Freud's adjuvant", "TREATMENT", 85, 101], ["purified recombinant protein", "TREATMENT", 130, 158]]], ["The rabbits were boosted twice using the same dose at 3-week intervals.", [["rabbits", "ORGANISM", 4, 11], ["rabbits", "SPECIES", 4, 11], ["rabbits", "SPECIES", 4, 11], ["The rabbits", "TREATMENT", 0, 11]]], ["Immune sera were collected 7 days after the last immunization.", [["sera", "ANATOMY", 7, 11], ["Immune sera", "ORGANISM_SUBSTANCE", 0, 11], ["Immune sera", "TEST", 0, 11], ["the last immunization", "TREATMENT", 40, 61]]], ["The polyclonal antibodies were purified using GL biochem (Shanghai, China), and the serum specificity was confirmed by Western blot analysis.Cell transfection ::: Materials and methodsApproximately 24 h before transfection, CIK cells were grown in a 24-well plate at 4 \u00d7 105 cells per well in M199 supplemented with 10% FBS.", [["serum", "ANATOMY", 84, 89], ["Cell", "ANATOMY", 141, 145], ["CIK cells", "ANATOMY", 224, 233], ["cells", "ANATOMY", 275, 280], ["FBS", "ANATOMY", 320, 323], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["Cell", "CELL", 141, 145], ["CIK cells", "CELL", 224, 233], ["cells", "CELL", 275, 280], ["FBS", "ORGANISM_SUBSTANCE", 320, 323], ["polyclonal antibodies", "PROTEIN", 4, 25], ["CIK cells", "CELL_LINE", 224, 233], ["The polyclonal antibodies", "TEST", 0, 25], ["GL biochem", "TREATMENT", 46, 56], ["the serum specificity", "TEST", 80, 101], ["blot analysis", "TEST", 127, 140], ["transfection", "TEST", 210, 222], ["CIK cells", "TEST", 224, 233]]], ["When the CIK cells reached 70% confluence, they were washed with PBS and the culture supernatants were replaced with Opti-MEM (Invitrogen).", [["CIK cells", "ANATOMY", 9, 18], ["supernatants", "ANATOMY", 85, 97], ["CIK cells", "CELL", 9, 18], ["CIK cells", "CELL_LINE", 9, 18], ["the CIK cells", "TEST", 5, 18], ["PBS", "TREATMENT", 65, 68], ["the culture supernatants", "TEST", 73, 97], ["Opti-MEM (Invitrogen)", "TREATMENT", 117, 138]]], ["The plasmid pEGFP-TIA1 (1 \u03bcg) was transfected into the CIK cells using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol.", [["plasmid", "ANATOMY", 4, 11], ["CIK cells", "ANATOMY", 55, 64], ["Lipofectamine 2000", "CHEMICAL", 71, 89], ["pEGFP-TIA1 (1 \u03bcg", "GENE_OR_GENE_PRODUCT", 12, 28], ["CIK cells", "CELL", 55, 64], ["plasmid pEGFP", "DNA", 4, 17], ["TIA1", "DNA", 18, 22], ["CIK cells", "CELL_LINE", 55, 64], ["The plasmid pEGFP-TIA1", "TREATMENT", 0, 22], ["Lipofectamine", "TREATMENT", 71, 84], ["the manufacturer's protocol", "TREATMENT", 113, 140]]], ["The vector pEGFP-N1 served as the negative control.", [["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 11, 19], ["pEGFP", "DNA", 11, 16], ["N1", "DNA", 17, 19], ["The vector pEGFP", "TREATMENT", 0, 16], ["negative", "OBSERVATION", 34, 42]]], ["EGFP-TIA1 protein expression was monitored 18 h post transfection by detecting the fluorescent signal under the fluorescence microscope (Olympus, Japan).", [["EGFP", "GENE_OR_GENE_PRODUCT", 0, 4], ["TIA1", "GENE_OR_GENE_PRODUCT", 5, 9], ["EGFP", "PROTEIN", 0, 4], ["TIA1", "PROTEIN", 5, 9], ["EGFP", "TEST", 0, 4], ["TIA1 protein expression", "PROBLEM", 5, 28], ["the fluorescence microscope", "TEST", 108, 135]]], ["Transfected CIK cells were also harvested for Western blot analysis to confirm the expression of EGFP-tagged protein.RNA binding assay ::: Materials and methodsSynthetic GCRV-S10-specific (JQ042807.1) ssRNA or dsRNA oligonucleotides in the length of 10 (GACGCCUUAC), 20 (CCACGCUUGUUCACGUCAAC), or 30 (CAACCAAACGAAGCCAUUCGCUCAUUAGUC) nucleotides were employed for the RNA binding assay.", [["CIK cells", "ANATOMY", 12, 21], ["nucleotides", "CHEMICAL", 333, 344], ["CIK cells", "CELL", 12, 21], ["EGFP", "GENE_OR_GENE_PRODUCT", 97, 101], ["CIK cells", "CELL_LINE", 12, 21], ["EGFP", "PROTEIN", 97, 101], ["tagged protein", "PROTEIN", 102, 116], ["GCRV-S10-specific (JQ042807.1) ssRNA", "DNA", 170, 206], ["Transfected CIK cells", "PROBLEM", 0, 21], ["Western blot analysis", "TEST", 46, 67], ["EGFP", "TEST", 97, 101], ["methodsSynthetic GCRV", "TEST", 153, 174], ["ssRNA", "PROBLEM", 201, 206], ["dsRNA oligonucleotides", "TREATMENT", 210, 232], ["the length", "TEST", 236, 246], ["CAACCAAACGAAGCCAUUCGCUCAUUAGUC) nucleotides", "TREATMENT", 301, 344], ["the RNA binding assay", "TEST", 363, 384], ["CIK cells", "OBSERVATION", 12, 21], ["Synthetic GCRV", "OBSERVATION", 160, 174]]], ["Briefly, purified GST-TIA1 or GST alone was diluted in 20 \u03bcL of binding buffer containing 0.1 \u03bcM RNA, 100 mM NaCl, and 50 mM Tris\u2013HCl, pH 7.4.", [["NaCl", "CHEMICAL", 109, 113], ["Tris\u2013HCl", "CHEMICAL", 125, 133], ["NaCl", "CHEMICAL", 109, 113], ["Tris\u2013HCl", "CHEMICAL", 125, 133], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 18, 26], ["GST", "GENE_OR_GENE_PRODUCT", 30, 33], ["Tris\u2013HCl", "SIMPLE_CHEMICAL", 125, 133], ["GST", "PROTEIN", 18, 21], ["TIA1", "PROTEIN", 22, 26], ["GST", "PROTEIN", 30, 33], ["binding buffer", "TREATMENT", 64, 78], ["NaCl", "TREATMENT", 109, 113], ["pH", "TEST", 135, 137]]], ["The reaction mixtures were incubated at 25 \u00b0C for 30 min to allow the protein to bind to the nucleic acid.", [["nucleic acid", "CHEMICAL", 93, 105], ["The reaction mixtures", "PROBLEM", 0, 21], ["the nucleic acid", "TEST", 89, 105]]], ["The mixtures were then resolved by agarose gel electrophoresis at 4 V/cm using 2% gels buffered with TBE.", [["agarose", "SIMPLE_CHEMICAL", 35, 42], ["agarose gel electrophoresis", "TREATMENT", 35, 62], ["2% gels", "TREATMENT", 79, 86], ["TBE", "TREATMENT", 101, 104]]], ["Nucleic acids were visualized with SYBR Green II (Bioteke, China) by staining the gels for 5 min.GST pulldown assay and RNA immunoprecipitation ::: Materials and methodsThe S10 ORF of GCRV was amplified from the viral genome by RT-PCR using the primers F-5\u02b9 GAATTAATACGACTCACTATAGGG AGAATGCCACTTCACATGATTCCG \u02b93 and R-5\u02b9 GAATTAATACGACTCACTATAGGGAGACCAATCGGATGGCTCCAC3 \u02b9.", [["SYBR Green II", "CHEMICAL", 35, 48], ["Nucleic acids", "SIMPLE_CHEMICAL", 0, 13], ["GST", "GENE_OR_GENE_PRODUCT", 97, 100], ["S10", "GENE_OR_GENE_PRODUCT", 173, 176], ["GCRV", "GENE_OR_GENE_PRODUCT", 184, 188], ["SYBR Green II", "PROTEIN", 35, 48], ["GST", "PROTEIN", 97, 100], ["S10 ORF", "DNA", 173, 180], ["GCRV", "DNA", 184, 188], ["viral genome", "DNA", 212, 224], ["primers F-5", "DNA", 245, 256], ["GCRV", "SPECIES", 184, 188], ["Nucleic acids", "TEST", 0, 13], ["GST pulldown assay", "TEST", 97, 115], ["GCRV", "PROBLEM", 184, 188], ["the primers F", "TEST", 241, 254], ["GAATTAATACGACTCACTATAGGG", "TEST", 258, 282], ["AGAATGCCACTTCACATGATTCCG", "TEST", 283, 307], ["GCRV", "OBSERVATION", 184, 188], ["viral genome", "OBSERVATION", 212, 224]]], ["According to the procedure reported previously [30], the dsRNA corresponding to the viral S10 gene was transcribed using the RiboMAX\u2122 Large Scale RNA Production System-T7 kit (Promega, Shanghai) from a recombinant pMD19-T vector (Tiangen, China), where the GCRV S10 ORF was under the control of the T7 promoter.", [["S10", "GENE_OR_GENE_PRODUCT", 90, 93], ["GCRV S10", "GENE_OR_GENE_PRODUCT", 257, 265], ["T7", "GENE_OR_GENE_PRODUCT", 299, 301], ["viral S10 gene", "DNA", 84, 98], ["RiboMAX", "DNA", 125, 132], ["recombinant pMD19-T vector", "DNA", 202, 228], ["GCRV S10 ORF", "DNA", 257, 269], ["T7 promoter", "DNA", 299, 310], ["GCRV", "SPECIES", 257, 261], ["the procedure", "TREATMENT", 13, 26], ["the dsRNA", "PROBLEM", 53, 62], ["the viral S10 gene", "TREATMENT", 80, 98], ["a recombinant pMD19", "TREATMENT", 200, 219], ["the GCRV S10 ORF", "TREATMENT", 253, 269], ["the T7 promoter", "TREATMENT", 295, 310], ["Scale RNA", "OBSERVATION", 140, 149], ["T7", "ANATOMY", 168, 170], ["T7", "ANATOMY", 299, 301]]], ["S10-dsRNA was purified with an RNA purification kit (Qiagen).", [["S10", "GENE_OR_GENE_PRODUCT", 0, 3], ["S10", "PROTEIN", 0, 3], ["an RNA purification kit", "TREATMENT", 28, 51], ["dsRNA", "ANATOMY", 4, 9]]], ["The RNA was then incubated with GST-TIA1 or GST alone in a Glutathione S-Transferase purification mini spin column (Sangon, China) in nuclease-free water at an equimolar concentration.", [["Glutathione", "CHEMICAL", 59, 70], ["Glutathione", "CHEMICAL", 59, 70], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 32, 40], ["GST", "GENE_OR_GENE_PRODUCT", 44, 47], ["Glutathione", "SIMPLE_CHEMICAL", 59, 70], ["GST", "PROTEIN", 32, 35], ["TIA1", "PROTEIN", 36, 40], ["GST", "PROTEIN", 44, 47], ["nuclease", "PROTEIN", 134, 142], ["GST", "TEST", 32, 35], ["a Glutathione", "TEST", 57, 70], ["Transferase purification mini spin column", "TREATMENT", 73, 114], ["an equimolar concentration", "TREATMENT", 157, 183]]], ["The clean lysate was treated with phenol-chloroform (Invitrogen) to clear the protein and then analyzed by Northern blot.", [["lysate", "ANATOMY", 10, 16], ["phenol-chloroform", "CHEMICAL", 34, 51], ["phenol", "CHEMICAL", 34, 40], ["chloroform", "CHEMICAL", 41, 51], ["phenol-chloroform", "SIMPLE_CHEMICAL", 34, 51], ["Invitrogen", "SIMPLE_CHEMICAL", 53, 63], ["The clean lysate", "TREATMENT", 0, 16], ["phenol-chloroform (Invitrogen)", "TREATMENT", 34, 64], ["clean", "OBSERVATION_MODIFIER", 4, 9], ["lysate", "OBSERVATION", 10, 16]]], ["The recombinant plasmid pEGFP-TIA1 or negative control vector pEGFP-N1 were transfected into CIK cells seeded in 6-well plates.", [["plasmid", "ANATOMY", 16, 23], ["CIK cells", "ANATOMY", 93, 102], ["pEGFP", "GENE_OR_GENE_PRODUCT", 24, 29], ["TIA1", "GENE_OR_GENE_PRODUCT", 30, 34], ["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 62, 70], ["CIK cells", "CELL", 93, 102], ["recombinant plasmid pEGFP-TIA1 or negative control vector pEGFP-N1", "DNA", 4, 70], ["CIK cells", "CELL_LINE", 93, 102], ["The recombinant plasmid pEGFP", "TREATMENT", 0, 29], ["TIA1", "TREATMENT", 30, 34], ["CIK cells", "TREATMENT", 93, 102], ["CIK cells", "OBSERVATION", 93, 102]]], ["The cells in each well were then washed with PBS and lysed in 500 \u03bcL of RIPA lysis buffer.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["PBS", "TREATMENT", 45, 48], ["RIPA lysis buffer", "TREATMENT", 72, 89]]], ["Cellular debris was cleared by centrifugation at 12,000 rpm for 10 min at 4 \u00b0C. The lysates were precleared by incubating it with 50 \u03bcL of protein A/G Plus-Agarose (Santa Cruz) for 2 h at 4 \u00b0C. Then monoclonal antibodies against EGFP and 50 \u03bcL of protein A/G Plus-Agarose were added into the cleared lysates and incubated overnight.", [["Cellular debris", "ANATOMY", 0, 15], ["lysates", "ANATOMY", 84, 91], ["lysates", "ANATOMY", 300, 307], ["lysates", "ORGANISM_SUBSTANCE", 84, 91], ["Agarose", "SIMPLE_CHEMICAL", 156, 163], ["EGFP", "GENE_OR_GENE_PRODUCT", 229, 233], ["Agarose", "GENE_OR_GENE_PRODUCT", 264, 271], ["lysates", "ORGANISM_SUBSTANCE", 300, 307], ["monoclonal antibodies", "PROTEIN", 199, 220], ["EGFP", "PROTEIN", 229, 233], ["50 \u03bcL", "PROTEIN", 238, 243], ["protein A", "PROTEIN", 247, 256], ["Cellular debris", "PROBLEM", 0, 15], ["The lysates", "TREATMENT", 80, 91], ["monoclonal antibodies", "TEST", 199, 220], ["EGFP", "TEST", 229, 233], ["protein A/G Plus-Agarose", "TREATMENT", 247, 271], ["debris", "OBSERVATION", 9, 15]]], ["The beads were then pelleted (2500 rpm for 5 min at 4 \u00b0C), and the bound RNA was extracted using Trizol (Invitrogen) and analyzed by Northern blot or RT-PCR.Northern blot assay ::: Materials and methodsCIK cells were grown in 6-well plates and infected with GCRV at an MOI of 1.", [["beads", "ANATOMY", 4, 9], ["methodsCIK cells", "ANATOMY", 195, 211], ["methodsCIK cells", "CELL", 195, 211], ["methodsCIK cells", "CELL_LINE", 195, 211], ["GCRV", "SPECIES", 258, 262], ["The beads", "TREATMENT", 0, 9], ["the bound RNA", "PROBLEM", 63, 76], ["Trizol (Invitrogen)", "TREATMENT", 97, 116], ["methodsCIK cells", "PROBLEM", 195, 211], ["GCRV", "PROBLEM", 258, 262], ["beads", "OBSERVATION_MODIFIER", 4, 9]]], ["Then the cells were transfected with dsRNA-S10 with or without pEGFP-TIA1.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["dsRNA-S10", "GENE_OR_GENE_PRODUCT", 37, 46], ["pEGFP", "GENE_OR_GENE_PRODUCT", 63, 68], ["TIA1", "GENE_OR_GENE_PRODUCT", 69, 73], ["dsRNA-S10", "DNA", 37, 46], ["pEGFP", "PROTEIN", 63, 68], ["TIA1", "PROTEIN", 69, 73], ["dsRNA", "PROBLEM", 37, 42], ["pEGFP", "TREATMENT", 63, 68]]], ["At 48 h post transfection, cells were harvested and the RNA was extracted with Trizol.", [["cells", "ANATOMY", 27, 32], ["cells", "CELL", 27, 32], ["Trizol", "TREATMENT", 79, 85]]], ["The RNA was separated on a 1.5% agarose formaldehyde denaturing gel and transferred to a nitrocellulose membrane using the upward capillary method.", [["membrane", "ANATOMY", 104, 112], ["capillary", "ANATOMY", 130, 139], ["agarose formaldehyde", "CHEMICAL", 32, 52], ["formaldehyde", "CHEMICAL", 40, 52], ["nitrocellulose", "CHEMICAL", 89, 103], ["agarose", "SIMPLE_CHEMICAL", 32, 39], ["formaldehyde", "SIMPLE_CHEMICAL", 40, 52], ["membrane", "CELLULAR_COMPONENT", 104, 112], ["capillary", "TISSUE", 130, 139], ["a 1.5% agarose formaldehyde denaturing gel", "TREATMENT", 25, 67], ["a nitrocellulose membrane", "TREATMENT", 87, 112], ["the upward capillary method", "TREATMENT", 119, 146]]], ["The membrane was pre-hybridized for 30 min using the Dig Easy Hyb Solution (Roche), and then hybridized for 6 h in Dig Easy Hyb Solution containing the synthesized digoxin-labeled dsRNA-S10 probe using Dig RNA Labeling Kit-T7 (Roche).", [["membrane", "ANATOMY", 4, 12], ["digoxin", "CHEMICAL", 164, 171], ["digoxin", "CHEMICAL", 164, 171], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["digoxin", "SIMPLE_CHEMICAL", 164, 171], ["the Dig Easy Hyb Solution", "TREATMENT", 49, 74], ["Dig Easy Hyb Solution", "TREATMENT", 115, 136], ["the synthesized digoxin-labeled dsRNA", "TREATMENT", 148, 185], ["Dig RNA", "TREATMENT", 202, 209], ["T7", "ANATOMY", 223, 225]]], ["The membrane was washed at room temperature in Wash Buffer I (2\u00d7 SSC, 0.1% SDS) and Wash Buffer II (0.1\u00d7 SSC, 0.1% SDS) using each buffer twice for 15 min.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["Wash Buffer II", "TREATMENT", 84, 98]]], ["After hybridization and stringent washing, the membrane was rinsed briefly for 5 min in Wash Buffer III (0.1 M Maleic acid; 0.15 M NaCl; PH 7.5; 0.3% Tween 20), and incubated for 30 min in Blocking solution (Roche).", [["membrane", "ANATOMY", 47, 55], ["NaCl", "CHEMICAL", 131, 135], ["Maleic acid", "CHEMICAL", 111, 122], ["NaCl", "CHEMICAL", 131, 135], ["Tween 20", "CHEMICAL", 150, 158], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["hybridization", "TREATMENT", 6, 19], ["stringent washing", "TREATMENT", 24, 41], ["the membrane", "TREATMENT", 43, 55], ["Wash Buffer III", "TREATMENT", 88, 103], ["Maleic acid", "TREATMENT", 111, 122], ["NaCl", "TEST", 131, 135], ["PH", "TEST", 137, 139]]], ["Then secondary antibody, anti-digoxingenin-AP, was diluted 1:10,000 in Blocking buffer and incubated with the membrane for 30 min.", [["membrane", "ANATOMY", 110, 118], ["anti-digoxingenin", "CHEMICAL", 25, 42], ["anti-digoxingenin-AP", "SIMPLE_CHEMICAL", 25, 45], ["membrane", "CELLULAR_COMPONENT", 110, 118], ["anti-digoxingenin", "PROTEIN", 25, 42], ["AP", "PROTEIN", 43, 45], ["secondary antibody", "TREATMENT", 5, 23], ["anti-digoxingenin", "TREATMENT", 25, 42], ["Blocking buffer", "TREATMENT", 71, 86]]], ["The membrane was then washed twice in Wash Buffer III and equilibrated for 5 min in Detection buffer (Roche).", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["membrane", "OBSERVATION_MODIFIER", 4, 12]]], ["The signal was detected using NBT/BCIP (Roche).CiTIA1 binds to both ssRNA and dsRNA in\u00a0vitro ::: ResultsMammalian TIA1 is an RNA chaperon that binds to mRNA in SG independent of the mRNA sequence; however, it was not clear whether grass carp CiTIA1 bound to RNA in CIK cells.", [["CIK cells", "ANATOMY", 265, 274], ["CiTIA1", "CHEMICAL", 47, 53], ["NBT", "CHEMICAL", 30, 33], ["NBT", "SIMPLE_CHEMICAL", 30, 33], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 47, 53], ["TIA1", "GENE_OR_GENE_PRODUCT", 114, 118], ["grass carp", "ORGANISM", 231, 241], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 242, 248], ["CIK cells", "CELL", 265, 274], ["BCIP", "PROTEIN", 34, 38], ["CiTIA1", "PROTEIN", 47, 53], ["dsRNA", "RNA", 78, 83], ["TIA1", "PROTEIN", 114, 118], ["RNA chaperon", "RNA", 125, 137], ["mRNA", "RNA", 152, 156], ["mRNA sequence", "DNA", 182, 195], ["grass carp CiTIA1", "PROTEIN", 231, 248], ["CIK cells", "CELL_LINE", 265, 274], ["carp", "SPECIES", 237, 241], ["grass carp", "SPECIES", 231, 241], ["NBT", "TEST", 30, 33], ["the mRNA sequence", "TEST", 178, 195], ["grass carp CiTIA1 bound", "PROBLEM", 231, 254], ["both ssRNA", "ANATOMY", 63, 73], ["CIK cells", "OBSERVATION", 265, 274]]], ["Compared with the GST control protein of about 22 KDa (Fig. 1A), purified recombinant CiTIA1 protein (GST-TIA1) was expressed in Escherichia coli as a soluble GST-tagged fusion protein with a size of approximately 70 kDa (Fig. 1B).", [["GST", "GENE_OR_GENE_PRODUCT", 18, 21], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 86, 92], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 102, 110], ["Escherichia coli", "ORGANISM", 129, 145], ["GST", "GENE_OR_GENE_PRODUCT", 159, 162], ["GST control protein", "PROTEIN", 18, 37], ["22 KDa", "PROTEIN", 47, 53], ["Fig. 1A", "PROTEIN", 55, 62], ["CiTIA1 protein", "PROTEIN", 86, 100], ["GST", "PROTEIN", 102, 105], ["TIA1", "PROTEIN", 106, 110], ["GST", "PROTEIN", 159, 162], ["tagged fusion protein", "PROTEIN", 163, 184], ["Fig. 1B", "PROTEIN", 222, 229], ["Escherichia coli", "SPECIES", 129, 145], ["Escherichia coli", "SPECIES", 129, 145], ["the GST control protein", "TEST", 14, 37], ["purified recombinant CiTIA1 protein", "TEST", 65, 100], ["GST", "TEST", 102, 105], ["Escherichia coli", "PROBLEM", 129, 145], ["a soluble GST", "TEST", 149, 162], ["tagged fusion protein", "TEST", 163, 184], ["Escherichia coli", "OBSERVATION", 129, 145]]], ["GST-TIA1 was also used to generate TIA1-specific polyclonal antibodies by immunizing New Zealand rabbits.", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["TIA1", "GENE_OR_GENE_PRODUCT", 4, 8], ["TIA1", "GENE_OR_GENE_PRODUCT", 35, 39], ["rabbits", "ORGANISM", 97, 104], ["GST", "PROTEIN", 0, 3], ["TIA1", "PROTEIN", 4, 8], ["TIA1", "PROTEIN", 35, 39], ["polyclonal antibodies", "PROTEIN", 49, 70], ["rabbits", "SPECIES", 97, 104], ["TIA1", "TEST", 35, 39], ["specific polyclonal antibodies", "TREATMENT", 40, 70]]], ["The specificity of the induced rabbit serum in recognizing endogenous CiTIA1 in CIK cells was validated by Western blot assay (Fig. 1C).", [["serum", "ANATOMY", 38, 43], ["CIK cells", "ANATOMY", 80, 89], ["rabbit", "ORGANISM", 31, 37], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 70, 76], ["CIK cells", "CELL", 80, 89], ["CiTIA1", "PROTEIN", 70, 76], ["CIK cells", "CELL_LINE", 80, 89], ["rabbit", "SPECIES", 31, 37], ["rabbit", "SPECIES", 31, 37], ["the induced rabbit serum", "PROBLEM", 19, 43], ["endogenous CiTIA1", "OBSERVATION", 59, 76], ["CIK cells", "OBSERVATION", 80, 89]]], ["Taking advantage of this antibody, we were able to monitor the steady-state level of CiTIA1 during GCRV infection.", [["infection", "DISEASE", 104, 113], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 85, 91], ["CiTIA1", "PROTEIN", 85, 91], ["GCRV", "SPECIES", 99, 103], ["this antibody", "TREATMENT", 20, 33], ["GCRV infection", "PROBLEM", 99, 113], ["GCRV infection", "OBSERVATION", 99, 113]]], ["In the cellular extracts that were harvested at various time points post viral infection, expression of CiTIA1 was significantly upregulated at 12 h p.i.", [["cellular extracts", "ANATOMY", 7, 24], ["viral infection", "DISEASE", 73, 88], ["cellular extracts", "ORGANISM_SUBSTANCE", 7, 24], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 104, 110], ["CiTIA1", "PROTEIN", 104, 110], ["viral infection", "PROBLEM", 73, 88], ["harvested", "OBSERVATION", 35, 44], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["infection", "OBSERVATION", 79, 88]]], ["As a control, the expression level of GADPH remained constant during the viral infection course (Fig. 1D).CiTIA1 binds to both ssRNA and dsRNA in\u00a0vitro ::: ResultsThe ability of CiTIA1 to bind RNA was tested by incubation with an equimolar concentration of synthesized single or double-stranded RNA oligonucleotides with 10, 20, or 30 residues in length.", [["viral infection", "DISEASE", 73, 88], ["CiTIA1", "CHEMICAL", 106, 112], ["CiTIA1", "CHEMICAL", 178, 184], ["GADPH", "GENE_OR_GENE_PRODUCT", 38, 43], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 106, 112], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 178, 184], ["GADPH", "PROTEIN", 38, 43], ["CiTIA1", "PROTEIN", 106, 112], ["CiTIA1", "PROTEIN", 178, 184], ["the expression level of GADPH", "PROBLEM", 14, 43], ["the viral infection course", "TREATMENT", 69, 95], ["CiTIA1 binds", "TREATMENT", 106, 118], ["CiTIA1 to bind RNA", "TREATMENT", 178, 196], ["an equimolar concentration", "TREATMENT", 227, 253], ["double-stranded RNA oligonucleotides", "TREATMENT", 279, 315], ["viral", "OBSERVATION_MODIFIER", 73, 78], ["infection", "OBSERVATION", 79, 88], ["both ssRNA", "ANATOMY", 122, 132], ["dsRNA", "ANATOMY", 137, 142], ["length", "OBSERVATION_MODIFIER", 347, 353]]], ["GST alone served as the negative control.", [["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["GST", "PROTEIN", 0, 3]]], ["The RNA oligonucleotides sequences were chosen arbitrarily from the GCRV-JX01 S10 gene.", [["GCRV-JX01 S10", "GENE_OR_GENE_PRODUCT", 68, 81], ["GCRV-JX01 S10 gene", "DNA", 68, 86], ["The RNA oligonucleotides sequences", "TEST", 0, 34], ["GCRV", "ANATOMY", 68, 72]]], ["The protein-RNA mixture was analyzed by agarose gel analysis.", [["agarose", "SIMPLE_CHEMICAL", 40, 47], ["The protein-RNA mixture", "TREATMENT", 0, 23], ["agarose gel analysis", "TEST", 40, 60]]], ["A band shift on the agarose gel indicated that TIA1 bound to both ssRNA and dsRNA (Fig. 2).CiTIA1 binds to both ssRNA and dsRNA in\u00a0vitro ::: ResultsWe next investigated the interaction between GST-TIA1 and S10-dsRNA.", [["CiTIA1", "CHEMICAL", 91, 97], ["agarose", "SIMPLE_CHEMICAL", 20, 27], ["TIA1", "GENE_OR_GENE_PRODUCT", 47, 51], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 91, 97], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 193, 201], ["S10-dsRNA", "GENE_OR_GENE_PRODUCT", 206, 215], ["TIA1", "PROTEIN", 47, 51], ["dsRNA", "DNA", 76, 81], ["CiTIA1", "PROTEIN", 91, 97], ["GST", "PROTEIN", 193, 196], ["TIA1", "PROTEIN", 197, 201], ["S10", "PROTEIN", 206, 209], ["A band shift", "PROBLEM", 0, 12], ["the agarose gel", "TREATMENT", 16, 31], ["TIA1 bound", "PROBLEM", 47, 57], ["dsRNA", "PROBLEM", 76, 81], ["CiTIA1 binds", "TREATMENT", 91, 103], ["GST", "TEST", 193, 196], ["dsRNA", "PROBLEM", 210, 215], ["band shift", "OBSERVATION", 2, 12], ["both ssRNA", "OBSERVATION", 61, 71], ["dsRNA", "ANATOMY", 76, 81], ["both ssRNA", "ANATOMY", 107, 117], ["dsRNA", "ANATOMY", 122, 127], ["S10", "ANATOMY", 206, 209], ["dsRNA", "ANATOMY", 210, 215]]], ["The S10-dsRNA and GST-TIA1 protein were mixed and incubated for protein-RNA interaction.", [["S10", "GENE_OR_GENE_PRODUCT", 4, 7], ["GST", "GENE_OR_GENE_PRODUCT", 18, 21], ["TIA1", "GENE_OR_GENE_PRODUCT", 22, 26], ["S10", "PROTEIN", 4, 7], ["GST", "PROTEIN", 18, 21], ["TIA1 protein", "PROTEIN", 22, 34], ["The S10-dsRNA and GST", "TEST", 0, 21], ["TIA1 protein", "TEST", 22, 34], ["protein", "TEST", 64, 71], ["S10", "ANATOMY", 4, 7], ["dsRNA", "ANATOMY", 8, 13]]], ["The mixture was incubated with Glutathione S-transferase Sefinose Resin (Sangon), and then subjected for GST-protein purification.", [["Glutathione", "CHEMICAL", 31, 42], ["Glutathione", "CHEMICAL", 31, 42], ["Glutathione S-transferase", "GENE_OR_GENE_PRODUCT", 31, 56], ["Sangon", "SIMPLE_CHEMICAL", 73, 79], ["GST", "GENE_OR_GENE_PRODUCT", 105, 108], ["Glutathione S-transferase", "PROTEIN", 31, 56], ["GST", "PROTEIN", 105, 108], ["Glutathione S-transferase Sefinose Resin", "TREATMENT", 31, 71], ["GST-protein purification", "TEST", 105, 129]]], ["The purified protein-RNA complex was treated with phenol-chloroform to collect the RNAs bound to GST or GST-TIA1.", [["phenol-chloroform", "CHEMICAL", 50, 67], ["phenol", "CHEMICAL", 50, 56], ["chloroform", "CHEMICAL", 57, 67], ["phenol-chloroform", "SIMPLE_CHEMICAL", 50, 67], ["GST", "GENE_OR_GENE_PRODUCT", 97, 100], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 104, 112], ["purified protein-RNA complex", "PROTEIN", 4, 32], ["GST", "PROTEIN", 97, 100], ["GST", "PROTEIN", 104, 107], ["TIA1", "PROTEIN", 108, 112], ["The purified protein", "TEST", 0, 20], ["phenol-chloroform", "TREATMENT", 50, 67], ["RNA complex", "OBSERVATION_MODIFIER", 21, 32]]], ["A Northern blot analysis demonstrated that S10-dsRNA was pulled down by GST-TIA1, but not GST, indicating the specific interaction of viral dsRNA with GST-TIA1 (Fig. 3).", [["S10", "GENE_OR_GENE_PRODUCT", 43, 46], ["GST", "GENE_OR_GENE_PRODUCT", 72, 75], ["TIA1", "GENE_OR_GENE_PRODUCT", 76, 80], ["GST", "GENE_OR_GENE_PRODUCT", 90, 93], ["GST-TIA1", "GENE_OR_GENE_PRODUCT", 151, 159], ["S10", "PROTEIN", 43, 46], ["GST", "PROTEIN", 72, 75], ["TIA1", "PROTEIN", 76, 80], ["GST", "PROTEIN", 90, 93], ["GST", "PROTEIN", 151, 154], ["TIA1", "PROTEIN", 155, 159], ["Fig. 3", "PROTEIN", 161, 167], ["A Northern blot analysis", "TEST", 0, 24], ["S10-dsRNA", "TREATMENT", 43, 52], ["viral dsRNA", "PROBLEM", 134, 145], ["dsRNA", "ANATOMY", 47, 52], ["viral dsRNA", "OBSERVATION", 134, 145]]], ["Thus, CiTIA1 had the potential to bind RNA with sequence specific for GCRV.CiTIA1 binds to viral RNA in\u00a0vivo ::: ResultsRNA immunoprecipitation was performed on CIK cells transfected with both pEGFP-TIA1 (Fig. 4A) and S10-dsRNA.", [["CIK cells", "ANATOMY", 161, 170], ["CiTIA1", "CHEMICAL", 6, 12], ["CiTIA1", "CHEMICAL", 75, 81], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 6, 12], ["GCRV", "GENE_OR_GENE_PRODUCT", 70, 74], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 75, 81], ["CIK cells", "CELL", 161, 170], ["pEGFP-TIA1 (Fig. 4A", "GENE_OR_GENE_PRODUCT", 193, 212], ["S10-dsRNA", "GENE_OR_GENE_PRODUCT", 218, 227], ["CiTIA1", "PROTEIN", 6, 12], ["GCRV", "PROTEIN", 70, 74], ["CiTIA1", "PROTEIN", 75, 81], ["viral RNA", "RNA", 91, 100], ["CIK cells", "CELL_LINE", 161, 170], ["pEGFP-TIA1 (Fig. 4A) and S10-dsRNA", "DNA", 193, 227], ["GCRV", "PROBLEM", 70, 74], ["ResultsRNA immunoprecipitation", "TEST", 113, 143], ["CIK cells", "TREATMENT", 161, 170], ["pEGFP", "TEST", 193, 198], ["viral RNA", "OBSERVATION", 91, 100], ["dsRNA", "ANATOMY", 222, 227]]], ["The TIA1 complex was immunoprecipitated using an anti-EGFP antibody.", [["TIA1", "GENE_OR_GENE_PRODUCT", 4, 8], ["anti-EGFP", "GENE_OR_GENE_PRODUCT", 49, 58], ["TIA1 complex", "PROTEIN", 4, 16], ["anti-EGFP antibody", "PROTEIN", 49, 67], ["The TIA1 complex", "PROBLEM", 0, 16], ["an anti-EGFP antibody", "TREATMENT", 46, 67]]], ["S10-specific RNA was detected from the immune-precipitated complex using RT-PCR (Fig. 4B).", [["S10", "GENE_OR_GENE_PRODUCT", 0, 3], ["S10-specific RNA", "RNA", 0, 16], ["immune-precipitated complex", "PROTEIN", 39, 66], ["RT-PCR", "TEST", 73, 79]]], ["Northern blot analysis further confirmed that dsRNA specific for the GCRV-S10 gene was associated with the CiTIA1 protein (Fig. 4C).", [["GCRV-S10", "GENE_OR_GENE_PRODUCT", 69, 77], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 107, 113], ["GCRV-S10 gene", "DNA", 69, 82], ["CiTIA1 protein", "PROTEIN", 107, 121], ["Northern blot analysis", "TEST", 0, 22], ["dsRNA", "PROBLEM", 46, 51], ["the GCRV", "TEST", 65, 73], ["the CiTIA1 protein", "TEST", 103, 121]]], ["These results were consistent with our in vitro experiments, indicating that CiTIA1 potentially binds viral dsRNA.CiTIA1 protects dsRNA from degradation in\u00a0vivo ::: ResultsHaving shown that CiTIA1 was able to bind to GCRV RNA, we next assessed whether CiTIA1 protected the viral dsRNA from degradation in vivo.", [["CiTIA1", "CHEMICAL", 77, 83], ["CiTIA1", "CHEMICAL", 190, 196], ["CiTIA1", "CHEMICAL", 252, 258], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 77, 83], ["dsRNA.CiTIA1", "GENE_OR_GENE_PRODUCT", 108, 120], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 190, 196], ["GCRV", "GENE_OR_GENE_PRODUCT", 217, 221], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 252, 258], ["CiTIA1", "PROTEIN", 77, 83], ["dsRNA.CiTIA1", "PROTEIN", 108, 120], ["CiTIA1", "PROTEIN", 190, 196], ["GCRV RNA", "RNA", 217, 225], ["CiTIA1", "PROTEIN", 252, 258], ["viral dsRNA.CiTIA1 protects dsRNA", "TREATMENT", 102, 135], ["the viral dsRNA", "PROBLEM", 269, 284], ["consistent with", "UNCERTAINTY", 19, 34], ["viral dsRNA", "OBSERVATION", 273, 284]]], ["Both pEGFP-TIA1 and GCRV-S10-dsRNA were transfected into CIK cells.", [["CIK cells", "ANATOMY", 57, 66], ["pEGFP-TIA1", "GENE_OR_GENE_PRODUCT", 5, 15], ["GCRV-S10", "GENE_OR_GENE_PRODUCT", 20, 28], ["CIK cells", "CELL", 57, 66], ["pEGFP-TIA1 and GCRV-S10-dsRNA", "DNA", 5, 34], ["CIK cells", "CELL_LINE", 57, 66], ["Both pEGFP", "TEST", 0, 10], ["GCRV", "TEST", 20, 24], ["dsRNA", "PROBLEM", 29, 34], ["GCRV", "ANATOMY", 20, 24], ["CIK cells", "OBSERVATION", 57, 66]]], ["48 h post transfection, the total RNA samples was extracted from the transfected cells (Fig. 5line A); Northern blot analysis (Fig. 5 line A\u2013C) indicated that the presence of overexpressed CiTIA1 reduced the degradation rate of dsRNA in comparison with control cells that were cotransfected with pEGFP and GCRV-S10-dsRNA.", [["samples", "ANATOMY", 38, 45], ["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 261, 266], ["cells", "CELL", 81, 86], ["Fig. 5line A", "CELL", 88, 100], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 189, 195], ["cells", "CELL", 261, 266], ["pEGFP", "GENE_OR_GENE_PRODUCT", 296, 301], ["GCRV-S10", "GENE_OR_GENE_PRODUCT", 306, 314], ["transfected cells", "CELL_LINE", 69, 86], ["CiTIA1", "PROTEIN", 189, 195], ["pEGFP and GCRV-S10-dsRNA", "DNA", 296, 320], ["transfection", "TREATMENT", 10, 22], ["the total RNA samples", "TEST", 24, 45], ["Northern blot analysis", "TEST", 103, 125], ["overexpressed CiTIA1", "PROBLEM", 175, 195], ["the degradation rate of dsRNA", "PROBLEM", 204, 233], ["control cells", "PROBLEM", 253, 266], ["pEGFP", "TEST", 296, 301], ["GCRV", "TEST", 306, 310], ["dsRNA", "PROBLEM", 315, 320], ["transfected cells", "OBSERVATION", 69, 86], ["overexpressed", "OBSERVATION_MODIFIER", 175, 188], ["CiTIA1 reduced", "OBSERVATION", 189, 203], ["dsRNA", "ANATOMY", 315, 320]]], ["In consistence with previous report that GCRV infection resulted in the protection of dsRNA in CIK cells, viral genomic S10 in CIK cells infected with GCRV was protected from degradation into viral sequence-specific small molecular RNA (Fig. 5 line C).", [["CIK cells", "ANATOMY", 95, 104], ["CIK cells", "ANATOMY", 127, 136], ["GCRV infection", "DISEASE", 41, 55], ["GCRV", "CHEMICAL", 151, 155], ["GCRV", "ORGANISM", 41, 45], ["CIK cells", "CELL", 95, 104], ["CIK cells", "CELL", 127, 136], ["GCRV", "GENE_OR_GENE_PRODUCT", 151, 155], ["CIK cells", "CELL_LINE", 95, 104], ["viral genomic S10", "DNA", 106, 123], ["CIK cells", "CELL_LINE", 127, 136], ["viral sequence", "DNA", 192, 206], ["small molecular RNA", "RNA", 216, 235], ["GCRV", "SPECIES", 41, 45], ["GCRV", "SPECIES", 151, 155], ["GCRV infection", "PROBLEM", 41, 55], ["dsRNA in CIK cells", "PROBLEM", 86, 104], ["viral genomic S10 in CIK cells", "PROBLEM", 106, 136], ["GCRV", "PROBLEM", 151, 155], ["viral sequence", "TEST", 192, 206], ["infection", "OBSERVATION", 46, 55], ["viral genomic S10", "OBSERVATION", 106, 123], ["CIK cells", "OBSERVATION", 127, 136], ["small", "OBSERVATION_MODIFIER", 216, 221], ["molecular RNA", "OBSERVATION", 222, 235]]], ["These results suggested that CiTIA1 might be responsible for protecting viral dsRNA from degradation during GCRV infection.Overexpression of CiTIA1 results in enhanced viral replication level ::: ResultsIt was not clear whether the interaction between CiTIA1 and GCRV dsRNA enhanced GCRV replication or inhibited viral infection.", [["CiTIA1", "CHEMICAL", 29, 35], ["infection", "DISEASE", 113, 122], ["CiTIA1", "CHEMICAL", 141, 147], ["viral infection", "DISEASE", 313, 328], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 29, 35], ["GCRV", "CANCER", 108, 112], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 141, 147], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 252, 258], ["GCRV", "GENE_OR_GENE_PRODUCT", 263, 267], ["GCRV", "GENE_OR_GENE_PRODUCT", 283, 287], ["CiTIA1", "PROTEIN", 29, 35], ["CiTIA1", "PROTEIN", 141, 147], ["CiTIA1", "PROTEIN", 252, 258], ["GCRV", "SPECIES", 108, 112], ["GCRV", "SPECIES", 283, 287], ["CiTIA1", "TREATMENT", 29, 35], ["viral dsRNA", "PROBLEM", 72, 83], ["GCRV infection", "PROBLEM", 108, 122], ["CiTIA1", "TREATMENT", 252, 258], ["GCRV dsRNA enhanced GCRV replication", "TREATMENT", 263, 299], ["viral infection", "PROBLEM", 313, 328], ["viral dsRNA", "OBSERVATION", 72, 83], ["GCRV infection", "OBSERVATION", 108, 122], ["viral replication", "OBSERVATION", 168, 185], ["viral", "OBSERVATION_MODIFIER", 313, 318], ["infection", "OBSERVATION", 319, 328]]], ["To assess the effect of TIA1 upregulation on GCRV replication, CiTIA1 was transiently overexpressed in CIK cells by transfection of CIK cells with pEGFP-TIA1.", [["GCRV", "ANATOMY", 45, 49], ["CIK cells", "ANATOMY", 103, 112], ["CIK cells", "ANATOMY", 132, 141], ["TIA1", "GENE_OR_GENE_PRODUCT", 24, 28], ["GCRV", "GENE_OR_GENE_PRODUCT", 45, 49], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 63, 69], ["CIK cells", "CELL", 103, 112], ["CIK cells", "CELL", 132, 141], ["pEGFP-TIA1", "GENE_OR_GENE_PRODUCT", 147, 157], ["TIA1", "PROTEIN", 24, 28], ["CiTIA1", "PROTEIN", 63, 69], ["CIK cells", "CELL_LINE", 103, 112], ["CIK cells", "CELL_LINE", 132, 141], ["pEGFP", "PROTEIN", 147, 152], ["TIA1", "PROTEIN", 153, 157], ["GCRV", "SPECIES", 45, 49], ["TIA1 upregulation", "TREATMENT", 24, 41], ["GCRV replication", "TREATMENT", 45, 61], ["CIK cells", "TREATMENT", 103, 112], ["transfection of CIK cells", "TREATMENT", 116, 141], ["pEGFP", "TEST", 147, 152], ["CIK cells", "OBSERVATION", 132, 141]]], ["24 h after transfection, the cells were infected with GCRV at an MOI of 1.", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["GCRV", "SPECIES", 54, 58], ["transfection", "TREATMENT", 11, 23], ["the cells", "PROBLEM", 25, 34], ["GCRV", "PROBLEM", 54, 58]]], ["The culture supernatant was collected at 4, 8, 12, and 24 h post infection (h pi) and subjected for a virus titration analysis reflected by the gene copy number of virions in the supernatant (Fig. 6).", [["culture supernatant", "ANATOMY", 4, 23], ["virions", "ANATOMY", 164, 171], ["supernatant", "ANATOMY", 179, 190], ["infection", "DISEASE", 65, 74], ["The culture supernatant", "TEST", 0, 23], ["infection", "PROBLEM", 65, 74], ["a virus titration analysis", "TEST", 100, 126], ["infection", "OBSERVATION", 65, 74]]], ["The increased replication levels suggested that CiTIA1 enhanced GCRV replication.", [["CiTIA1", "CHEMICAL", 48, 54], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 48, 54], ["GCRV", "GENE_OR_GENE_PRODUCT", 64, 68], ["CiTIA1", "PROTEIN", 48, 54], ["GCRV", "SPECIES", 64, 68], ["The increased replication levels", "PROBLEM", 0, 32], ["CiTIA1 enhanced GCRV replication", "TREATMENT", 48, 80], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["replication levels", "OBSERVATION", 14, 32], ["GCRV replication", "OBSERVATION", 64, 80]]], ["As negative control, cells transfected with pEGFP-N1 demonstrated no impact on viral replication.TIA1 accumulation and apoptosis ::: DiscussionBy controlling the duration of translational arrest, TIA-1 and TIAR may play a role in determining whether stressed cells survive to repair the stress-induced damage or die by apoptosis [1].", [["cells", "ANATOMY", 21, 26], ["cells", "ANATOMY", 259, 264], ["TIA", "DISEASE", 196, 199], ["cells", "CELL", 21, 26], ["pEGFP-N1", "GENE_OR_GENE_PRODUCT", 44, 52], ["TIA1", "GENE_OR_GENE_PRODUCT", 97, 101], ["TIA-1", "GENE_OR_GENE_PRODUCT", 196, 201], ["TIAR", "GENE_OR_GENE_PRODUCT", 206, 210], ["cells", "CELL", 259, 264], ["pEGFP", "PROTEIN", 44, 49], ["N1", "DNA", 50, 52], ["TIA1", "PROTEIN", 97, 101], ["TIAR", "PROTEIN", 206, 210], ["stressed cells", "CELL_TYPE", 250, 264], ["pEGFP", "TEST", 44, 49], ["viral replication", "TREATMENT", 79, 96], ["TIA1 accumulation", "PROBLEM", 97, 114], ["translational arrest", "PROBLEM", 174, 194], ["TIA", "PROBLEM", 196, 199], ["stressed cells", "PROBLEM", 250, 264], ["repair", "TREATMENT", 276, 282], ["the stress", "PROBLEM", 283, 293], ["no", "UNCERTAINTY", 66, 68], ["viral replication", "OBSERVATION", 79, 96], ["apoptosis", "OBSERVATION", 119, 128]]], ["During GCRV infection, the reduced expression of CiG3BP and increased level of CiTIA1 suggested less functional SGs formed during infection [30].", [["SGs", "ANATOMY", 112, 115], ["GCRV infection", "DISEASE", 7, 21], ["infection", "DISEASE", 130, 139], ["GCRV", "CANCER", 7, 11], ["CiG3BP", "GENE_OR_GENE_PRODUCT", 49, 55], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 79, 85], ["SGs", "GENE_OR_GENE_PRODUCT", 112, 115], ["CiG3BP", "PROTEIN", 49, 55], ["CiTIA1", "PROTEIN", 79, 85], ["GCRV", "SPECIES", 7, 11], ["GCRV infection", "PROBLEM", 7, 21], ["the reduced expression of CiG3BP", "PROBLEM", 23, 55], ["increased level of CiTIA1", "PROBLEM", 60, 85], ["less functional SGs formed during infection", "PROBLEM", 96, 139], ["infection", "OBSERVATION", 12, 21], ["reduced", "OBSERVATION_MODIFIER", 27, 34], ["increased", "OBSERVATION_MODIFIER", 60, 69]]], ["Fewer SGs might reduce the efficiency of both host translational arrest and sequestration of viral RNA, which would favor viral infection under conditions of normal cellular metabolism.", [["cellular", "ANATOMY", 165, 173], ["viral infection", "DISEASE", 122, 137], ["SGs", "GENE_OR_GENE_PRODUCT", 6, 9], ["cellular", "CELL", 165, 173], ["viral RNA", "RNA", 93, 102], ["both host translational arrest", "PROBLEM", 41, 71], ["viral RNA", "PROBLEM", 93, 102], ["viral infection", "PROBLEM", 122, 137], ["efficiency", "OBSERVATION_MODIFIER", 27, 37], ["both", "OBSERVATION_MODIFIER", 41, 45], ["host translational arrest", "OBSERVATION", 46, 71], ["viral RNA", "OBSERVATION", 93, 102], ["viral", "OBSERVATION_MODIFIER", 122, 127], ["infection", "OBSERVATION", 128, 137], ["normal cellular metabolism", "OBSERVATION", 158, 184]]], ["Indeed, many genes were transcriptionally or translationally upregulated during GCRV infection [30].", [["GCRV", "ANATOMY", 80, 84], ["infection", "DISEASE", 85, 94], ["GCRV", "GENE_OR_GENE_PRODUCT", 80, 84], ["GCRV", "SPECIES", 80, 84], ["GCRV infection", "PROBLEM", 80, 94]]], ["Employing a polyclonal antibody against CiTIA1, we were able to show that expression level of CiTIA1 was significantly increased at 12 h p.i.", [["CiTIA1", "GENE_OR_GENE_PRODUCT", 40, 46], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 94, 100], ["polyclonal antibody", "PROTEIN", 12, 31], ["CiTIA1", "PROTEIN", 40, 46], ["CiTIA1", "PROTEIN", 94, 100], ["a polyclonal antibody", "TEST", 10, 31], ["CiTIA1", "TEST", 94, 100]]], ["Similar to the poliovirus, GCRV should unlink the accumulation of TIA1 from SG formation.TIA1 accumulation and apoptosis ::: DiscussionTIA1 accumulation may not always be beneficial for viral infection.", [["viral infection", "DISEASE", 186, 201], ["GCRV", "GENE_OR_GENE_PRODUCT", 27, 31], ["TIA1", "GENE_OR_GENE_PRODUCT", 66, 70], ["SG", "TISSUE", 76, 78], ["TIA1", "GENE_OR_GENE_PRODUCT", 89, 93], ["DiscussionTIA1", "SIMPLE_CHEMICAL", 125, 139], ["TIA1", "PROTEIN", 66, 70], ["TIA1", "PROTEIN", 89, 93], ["poliovirus", "SPECIES", 15, 25], ["GCRV", "SPECIES", 27, 31], ["the poliovirus", "PROBLEM", 11, 25], ["GCRV", "TREATMENT", 27, 31], ["TIA1", "PROBLEM", 66, 70], ["TIA1 accumulation", "PROBLEM", 89, 106], ["DiscussionTIA1 accumulation", "PROBLEM", 125, 152], ["viral infection", "PROBLEM", 186, 201], ["poliovirus", "OBSERVATION", 15, 25], ["accumulation", "OBSERVATION_MODIFIER", 50, 62], ["SG formation", "OBSERVATION", 76, 88], ["apoptosis", "OBSERVATION", 111, 120], ["may not always be", "UNCERTAINTY", 153, 170], ["infection", "OBSERVATION", 192, 201]]], ["TIA1 has been shown to regulate TNF-\u03b1 mRNA and the alternative splicing of a variety of pre-mRNAs including the FAS receptor, suggesting TIA1 is an apoptosis-promoting protein [35].", [["TIA1", "CHEMICAL", 0, 4], ["TIA1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 32, 37], ["FAS receptor", "GENE_OR_GENE_PRODUCT", 112, 124], ["TIA1", "GENE_OR_GENE_PRODUCT", 137, 141], ["TIA1", "PROTEIN", 0, 4], ["TNF-\u03b1 mRNA", "RNA", 32, 42], ["pre-mRNAs", "RNA", 88, 97], ["FAS receptor", "PROTEIN", 112, 124], ["TIA1", "PROTEIN", 137, 141], ["the FAS receptor", "TEST", 108, 124], ["TIA1", "PROBLEM", 137, 141], ["an apoptosis", "PROBLEM", 145, 157], ["apoptosis", "OBSERVATION", 148, 157]]], ["While there are many factors that might contribute to the GCRV-induced apoptosis, expression of CiTIA1 in GCRV-infected CIK cells correlated with the development of apoptosis in GCRV-stressed cells.", [["CIK cells", "ANATOMY", 120, 129], ["cells", "ANATOMY", 192, 197], ["GCRV", "CHEMICAL", 58, 62], ["GCRV", "GENE_OR_GENE_PRODUCT", 58, 62], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 96, 102], ["GCRV", "CELL", 106, 110], ["CIK cells", "CELL", 120, 129], ["GCRV", "SIMPLE_CHEMICAL", 178, 182], ["cells", "CELL", 192, 197], ["CiTIA1", "PROTEIN", 96, 102], ["GCRV-infected CIK cells", "CELL_LINE", 106, 129], ["GCRV-stressed cells", "CELL_LINE", 178, 197], ["GCRV", "SPECIES", 106, 110], ["the GCRV", "PROBLEM", 54, 62], ["apoptosis", "PROBLEM", 71, 80], ["CiTIA1 in GCRV", "PROBLEM", 96, 110], ["infected CIK cells", "PROBLEM", 111, 129], ["apoptosis", "PROBLEM", 165, 174], ["GCRV", "PROBLEM", 178, 182], ["stressed cells", "PROBLEM", 183, 197], ["GCRV", "OBSERVATION", 58, 62], ["infected CIK cells", "OBSERVATION", 111, 129], ["apoptosis", "OBSERVATION", 165, 174], ["GCRV", "OBSERVATION", 178, 182], ["stressed cells", "OBSERVATION", 183, 197]]], ["Here, we have shown that apoptosis-antagonizing protein CiTIA1 induced by GCRV infection might be involved in protecting cells from apoptosis during the viral replication cycle.", [["cells", "ANATOMY", 121, 126], ["GCRV", "CHEMICAL", 74, 78], ["infection", "DISEASE", 79, 88], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 56, 62], ["GCRV", "GENE_OR_GENE_PRODUCT", 74, 78], ["cells", "CELL", 121, 126], ["CiTIA1", "PROTEIN", 56, 62], ["GCRV", "SPECIES", 74, 78], ["apoptosis", "PROBLEM", 25, 34], ["antagonizing protein CiTIA1", "TREATMENT", 35, 62], ["GCRV infection", "PROBLEM", 74, 88], ["apoptosis", "PROBLEM", 132, 141], ["the viral replication cycle", "TREATMENT", 149, 176], ["GCRV infection", "OBSERVATION", 74, 88], ["viral replication", "OBSERVATION", 153, 170]]], ["Interestingly, the Sendai virus trailer RNA binds to TIAR, and is involved in antagonizing TIAR-induced apoptosis [36].", [["TIAR", "CHEMICAL", 91, 95], ["Sendai virus", "ORGANISM", 19, 31], ["TIAR", "GENE_OR_GENE_PRODUCT", 53, 57], ["TIAR", "GENE_OR_GENE_PRODUCT", 91, 95], ["Sendai virus trailer RNA", "RNA", 19, 43], ["TIAR", "PROTEIN", 53, 57], ["TIAR", "PROTEIN", 91, 95], ["Sendai virus", "SPECIES", 19, 31], ["the Sendai virus trailer RNA", "TREATMENT", 15, 43]]], ["This observation suggests that viral RNA might also be able to inhibit apoptosis by interacting with host pro-apoptotic factors.", [["viral RNA", "RNA", 31, 40], ["pro-apoptotic factors", "PROTEIN", 106, 127], ["This observation", "TEST", 0, 16], ["viral RNA", "PROBLEM", 31, 40], ["viral RNA", "OBSERVATION", 31, 40]]], ["The role of CiTIA1 might be better understood by its more positive roles in infected cells beyond apoptosis.", [["cells", "ANATOMY", 85, 90], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 12, 18], ["cells", "CELL", 85, 90], ["CiTIA1", "PROTEIN", 12, 18], ["infected cells", "CELL_TYPE", 76, 90], ["infected cells", "PROBLEM", 76, 90], ["apoptosis", "PROBLEM", 98, 107], ["infected cells", "OBSERVATION", 76, 90], ["apoptosis", "OBSERVATION_MODIFIER", 98, 107]]], ["For example, in mammalian reoviruses, viral mRNAs escape translational repression when SGs are disrupted [16].dsRNA binding of CiTIA1 and dsRNA-induced innate response ::: DiscussionTranslation in the host cell is suppressed during viral infection by the dsRNA kinase PKR, which homodimerizes and undergoes autophosphorylation after binding to dsRNA.", [["SGs", "ANATOMY", 87, 90], ["cell", "ANATOMY", 206, 210], ["infection", "DISEASE", 238, 247], ["reoviruses", "GENE_OR_GENE_PRODUCT", 26, 36], ["SGs", "GENE_OR_GENE_PRODUCT", 87, 90], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 127, 133], ["host cell", "CELL", 201, 210], ["PKR", "GENE_OR_GENE_PRODUCT", 268, 271], ["viral mRNAs", "RNA", 38, 49], ["SGs", "PROTEIN", 87, 90], ["CiTIA1", "PROTEIN", 127, 133], ["dsRNA kinase", "PROTEIN", 255, 267], ["PKR", "PROTEIN", 268, 271], ["mammalian reoviruses", "PROBLEM", 16, 36], ["viral mRNAs escape translational repression", "PROBLEM", 38, 81], ["CiTIA1 and dsRNA", "TREATMENT", 127, 143], ["viral infection", "PROBLEM", 232, 247], ["the dsRNA kinase PKR", "TREATMENT", 251, 271], ["dsRNA", "PROBLEM", 344, 349], ["mammalian reoviruses", "OBSERVATION", 16, 36], ["viral mRNAs", "OBSERVATION", 38, 49], ["host cell", "OBSERVATION", 201, 210], ["viral infection", "OBSERVATION", 232, 247]]], ["In the case of Mammalian reovirus (MRV) infection, the cells attempt to inhibit viral replication by activating PKR and other stress kinases, phosphorylating eIF2, inhibiting the formation of ternary complexes, and forming SGs [16].", [["cells", "ANATOMY", 55, 60], ["Mammalian reovirus (MRV) infection", "DISEASE", 15, 49], ["Mammalian reovirus", "ORGANISM", 15, 33], ["cells", "CELL", 55, 60], ["PKR", "GENE_OR_GENE_PRODUCT", 112, 115], ["eIF2", "GENE_OR_GENE_PRODUCT", 158, 162], ["PKR", "PROTEIN", 112, 115], ["stress kinases", "PROTEIN", 126, 140], ["eIF2", "PROTEIN", 158, 162], ["ternary complexes", "PROTEIN", 192, 209], ["Mammalian reovirus", "SPECIES", 15, 33], ["MRV", "SPECIES", 35, 38], ["Mammalian reovirus (MRV) infection", "PROBLEM", 15, 49], ["the cells", "PROBLEM", 51, 60], ["viral replication", "TREATMENT", 80, 97], ["activating PKR", "TEST", 101, 115], ["other stress kinases", "TEST", 120, 140], ["phosphorylating eIF2", "TREATMENT", 142, 162], ["Mammalian reovirus", "OBSERVATION", 15, 33], ["infection", "OBSERVATION", 40, 49], ["ternary complexes", "OBSERVATION", 192, 209]]], ["MRV-encodes the protein \u03c33, which binds dsRNA and prevents phosphorylation of PKR and eIF2; thus, no SGs form, and neither virus nor cellular translation is inhibited [16].", [["cellular", "ANATOMY", 133, 141], ["\u03c33", "GENE_OR_GENE_PRODUCT", 24, 26], ["PKR", "GENE_OR_GENE_PRODUCT", 78, 81], ["eIF2", "GENE_OR_GENE_PRODUCT", 86, 90], ["SGs", "GENE_OR_GENE_PRODUCT", 101, 104], ["cellular", "CELL", 133, 141], ["MRV", "PROTEIN", 0, 3], ["\u03c33", "PROTEIN", 24, 26], ["PKR", "PROTEIN", 78, 81], ["eIF2", "PROTEIN", 86, 90], ["SGs form", "RNA", 101, 109], ["MRV", "TEST", 0, 3], ["the protein", "TEST", 12, 23], ["PKR", "TEST", 78, 81], ["eIF2", "TEST", 86, 90], ["SGs", "PROBLEM", 101, 104], ["neither virus", "PROBLEM", 115, 128]]], ["However, although GCRV and MRV face similar challenges with regard to dsRNA-induced PKR activation, GCRV does not encode a protein homologous to \u03c33.", [["GCRV", "GENE_OR_GENE_PRODUCT", 18, 22], ["PKR", "GENE_OR_GENE_PRODUCT", 84, 87], ["\u03c33", "GENE_OR_GENE_PRODUCT", 145, 147], ["PKR", "PROTEIN", 84, 87], ["GCRV", "PROTEIN", 100, 104], ["\u03c33", "PROTEIN", 145, 147], ["GCRV", "SPECIES", 18, 22], ["GCRV", "PROBLEM", 18, 22], ["MRV face similar challenges", "TREATMENT", 27, 54], ["dsRNA", "TREATMENT", 70, 75], ["PKR activation", "PROBLEM", 84, 98], ["GCRV", "PROBLEM", 100, 104]]], ["The finding that CiTIA1 associated with dsRNA might suggest that CiTIA1 potentially inhibits PKR activation by sequestering the dsRNA, which could be key for the virus to survive the dsRNA-activated innate immune response.dsRNA binding of CiTIA1 and dsRNA-induced innate response ::: DiscussionThe mechanisms that allow reovirus genomic dsRNA to survive the RNAi pathway, which is triggered by dsRNA and initiated by Dicer, remain to be defined.", [["CiTIA1", "CHEMICAL", 17, 23], ["CiTIA1", "CHEMICAL", 65, 71], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 17, 23], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 65, 71], ["PKR", "GENE_OR_GENE_PRODUCT", 93, 96], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 239, 245], ["reovirus", "ORGANISM", 320, 328], ["Dicer", "GENE_OR_GENE_PRODUCT", 417, 422], ["CiTIA1", "PROTEIN", 17, 23], ["CiTIA1", "PROTEIN", 65, 71], ["PKR", "PROTEIN", 93, 96], ["CiTIA1", "PROTEIN", 239, 245], ["reovirus genomic dsRNA", "DNA", 320, 342], ["Dicer", "PROTEIN", 417, 422], ["dsRNA", "TREATMENT", 40, 45], ["PKR activation", "PROBLEM", 93, 107], ["the dsRNA", "PROBLEM", 124, 133], ["the virus", "PROBLEM", 158, 167], ["the dsRNA", "PROBLEM", 179, 188], ["CiTIA1 and dsRNA", "TREATMENT", 239, 255], ["reovirus genomic dsRNA", "TREATMENT", 320, 342]]], ["A previous study suggested that during mammalian reovirus infection, dsRNA-binding proteins might inhibit the RNAi pathway [33].", [["reovirus infection", "DISEASE", 49, 67], ["mammalian reovirus", "ORGANISM", 39, 57], ["dsRNA-binding proteins", "GENE_OR_GENE_PRODUCT", 69, 91], ["dsRNA-binding proteins", "PROTEIN", 69, 91], ["A previous study", "TEST", 0, 16], ["mammalian reovirus infection", "PROBLEM", 39, 67], ["dsRNA-binding proteins", "PROBLEM", 69, 91], ["reovirus", "OBSERVATION_MODIFIER", 49, 57], ["infection", "OBSERVATION", 58, 67]]], ["There is still little known about the escape mechanism used by GCRV.", [["GCRV", "CANCER", 63, 67], ["GCRV", "SPECIES", 63, 67]]], ["We have previously shown that the genomic dsRNA of GCRV was sensitive to the cellular RNAi pathway, and that unidentified RNAi suppressor protein(s) could contribute to the survival of the viral genome and efficient viral replication [31].", [["cellular", "ANATOMY", 77, 85], ["GCRV", "GENE_OR_GENE_PRODUCT", 51, 55], ["cellular", "CELL", 77, 85], ["GCRV", "PROTEIN", 51, 55], ["RNAi suppressor protein", "PROTEIN", 122, 145], ["viral genome", "DNA", 189, 201], ["the genomic dsRNA of GCRV", "PROBLEM", 30, 55], ["the viral genome", "PROBLEM", 185, 201], ["efficient viral replication", "TREATMENT", 206, 233], ["GCRV", "OBSERVATION", 51, 55], ["viral genome", "OBSERVATION", 189, 201]]], ["From the present study, an alternative hypothesis is that CiTIA1 accumulation may protect the dsRNA from Dicer cleavage and allow GCRV to escape the RNAi pathway.", [["CiTIA1", "CHEMICAL", 58, 64], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 58, 64], ["Dicer", "GENE_OR_GENE_PRODUCT", 105, 110], ["GCRV", "GENE_OR_GENE_PRODUCT", 130, 134], ["CiTIA1", "PROTEIN", 58, 64], ["Dicer", "PROTEIN", 105, 110], ["GCRV", "PROTEIN", 130, 134], ["the present study", "TEST", 5, 22], ["CiTIA1 accumulation", "PROBLEM", 58, 77], ["the dsRNA", "PROBLEM", 90, 99], ["Dicer cleavage", "TREATMENT", 105, 119]]], ["This hypothesis is supported by our finding that dsRNA bound by TIA1 was insensitive to degradation in vivo (Fig. 6).GCRV benefits from CiTIA1 accumulation ::: DiscussionSGs are dynamic, and the components are rapidly shuttled into and out of the complexes, so that changing stress (including virus stress) conditions can be dealt with rapidly.", [["CiTIA1", "CHEMICAL", 136, 142], ["TIA1", "GENE_OR_GENE_PRODUCT", 64, 68], ["CiTIA1", "SIMPLE_CHEMICAL", 136, 142], ["TIA1", "PROTEIN", 64, 68], ["CiTIA1", "PROTEIN", 136, 142], ["dsRNA bound", "PROBLEM", 49, 60], ["changing stress (including virus stress) conditions", "PROBLEM", 266, 317], ["CiTIA1 accumulation", "OBSERVATION", 136, 155]]], ["Many viruses appear to have mechanisms that disrupt the formation of SGs on viral mRNAs, suggesting that SGs are a host defense against infection.", [["SGs", "ANATOMY", 69, 72], ["SGs", "ANATOMY", 105, 108], ["infection", "DISEASE", 136, 145], ["SGs", "GENE_OR_GENE_PRODUCT", 69, 72], ["SGs", "CELLULAR_COMPONENT", 105, 108], ["SGs", "RNA", 69, 72], ["viral mRNAs", "RNA", 76, 87], ["SGs", "CELL_TYPE", 105, 108], ["Many viruses", "PROBLEM", 0, 12], ["SGs on viral mRNAs", "PROBLEM", 69, 87], ["SGs", "PROBLEM", 105, 108], ["infection", "PROBLEM", 136, 145], ["viruses", "OBSERVATION", 5, 12], ["SGs", "OBSERVATION", 69, 72], ["viral mRNAs", "OBSERVATION", 76, 87], ["infection", "OBSERVATION", 136, 145]]], ["SGs have been shown to be induced by a number of viral infections and have been implicated in the cellular defense against infection [4], [19].", [["cellular", "ANATOMY", 98, 106], ["viral infections", "DISEASE", 49, 65], ["infection", "DISEASE", 123, 132], ["SGs", "GENE_OR_GENE_PRODUCT", 0, 3], ["cellular", "CELL", 98, 106], ["[19]", "SIMPLE_CHEMICAL", 138, 142], ["SGs", "PROBLEM", 0, 3], ["viral infections", "PROBLEM", 49, 65], ["infection", "PROBLEM", 123, 132], ["shown to be", "UNCERTAINTY", 14, 25], ["viral", "OBSERVATION_MODIFIER", 49, 54], ["infections", "OBSERVATION", 55, 65]]], ["For example, in Semliki Forest virus infection, SG formation is inhibited when G3BP is bound and sequestered by the C-terminal domain of the viral nonstructural protein 3 [37].", [["infection", "DISEASE", 37, 46], ["G3BP", "CHEMICAL", 79, 83], ["C", "CHEMICAL", 116, 117], ["Semliki Forest virus", "ORGANISM", 16, 36], ["SG", "PATHOLOGICAL_FORMATION", 48, 50], ["G3BP", "GENE_OR_GENE_PRODUCT", 79, 83], ["viral nonstructural protein 3", "GENE_OR_GENE_PRODUCT", 141, 170], ["G3BP", "PROTEIN", 79, 83], ["C-terminal domain", "PROTEIN", 116, 133], ["viral nonstructural protein 3", "PROTEIN", 141, 170], ["Semliki", "SPECIES", 16, 23], ["Semliki Forest virus", "SPECIES", 16, 36], ["Semliki Forest virus infection", "PROBLEM", 16, 46], ["the viral nonstructural protein", "TEST", 137, 168], ["Semliki Forest virus infection", "OBSERVATION", 16, 46]]], ["Recent findings from studies of West Nile and Dengue viruses show that flaviviruses subvert TIAR and TIA1 to interfere with SG formation, aid in viral gene amplification, and to prevent translation inhibition of both viral and cellular mRNAs [38].", [["cellular", "ANATOMY", 227, 235], ["Dengue viruses", "DISEASE", 46, 60], ["West Nile", "ORGANISM", 32, 41], ["Dengue viruses", "ORGANISM", 46, 60], ["flaviviruses", "ORGANISM", 71, 83], ["TIAR", "GENE_OR_GENE_PRODUCT", 92, 96], ["TIA1", "GENE_OR_GENE_PRODUCT", 101, 105], ["SG", "GENE_OR_GENE_PRODUCT", 124, 126], ["cellular", "CELL", 227, 235], ["TIAR", "PROTEIN", 92, 96], ["TIA1", "PROTEIN", 101, 105], ["viral and cellular mRNAs", "RNA", 217, 241], ["West Nile", "SPECIES", 32, 41], ["Dengue viruses", "SPECIES", 46, 60], ["studies", "TEST", 21, 28], ["Dengue viruses", "PROBLEM", 46, 60], ["flaviviruses", "PROBLEM", 71, 83], ["SG formation", "TREATMENT", 124, 136], ["viral gene amplification", "TREATMENT", 145, 169], ["flaviviruses", "OBSERVATION", 71, 83], ["cellular mRNAs", "OBSERVATION", 227, 241]]], ["While there is no experimental evidence that new foci formed by TIA1 contain other SG marker proteins, they may share certain functions.", [["foci", "ANATOMY", 49, 53], ["foci", "CELL", 49, 53], ["TIA1", "GENE_OR_GENE_PRODUCT", 64, 68], ["TIA1", "PROTEIN", 64, 68], ["SG marker proteins", "PROTEIN", 83, 101], ["new foci", "PROBLEM", 45, 53], ["no experimental evidence", "UNCERTAINTY", 15, 39], ["new", "OBSERVATION_MODIFIER", 45, 48], ["foci", "OBSERVATION", 49, 53]]], ["Our findings that GCRV unlinked TIA1 from SG formation and subverted TIA1 to enhance viral replication were consistent with the flavivirus studies.Conclusions and unresolved questions for future research ::: DiscussionMany viruses avoid and subvert subcellular defense structures to facilitate their amplification.", [["SG", "ANATOMY", 42, 44], ["subcellular", "ANATOMY", 249, 260], ["GCRV", "GENE_OR_GENE_PRODUCT", 18, 22], ["TIA1", "GENE_OR_GENE_PRODUCT", 32, 36], ["SG", "TISSUE", 42, 44], ["TIA1", "GENE_OR_GENE_PRODUCT", 69, 73], ["TIA1", "DNA", 32, 36], ["TIA1", "PROTEIN", 69, 73], ["GCRV unlinked TIA1", "PROBLEM", 18, 36], ["SG formation", "PROBLEM", 42, 54], ["subverted TIA1", "PROBLEM", 59, 73], ["viral replication", "PROBLEM", 85, 102], ["the flavivirus studies", "TEST", 124, 146], ["consistent with", "UNCERTAINTY", 108, 123], ["flavivirus", "OBSERVATION", 128, 138], ["subcellular defense", "OBSERVATION", 249, 268]]], ["Important questions about the role of CiTIA1 accumulation and SG formation remain to be answered.", [["CiTIA1", "GENE_OR_GENE_PRODUCT", 38, 44], ["SG", "SIMPLE_CHEMICAL", 62, 64], ["CiTIA1", "PROTEIN", 38, 44], ["CiTIA1 accumulation", "TREATMENT", 38, 57]]], ["Some of the key questions going forward will be: (1) what factor(s) is blocking SG assembly during GCRV infection, (2) why viral replication is unaffected when CiTIA1 is sequestering viral and host RNA, and (3) what is the mechanism that induces the upregulation of CiTIA1 and downregulation of ciG3BP1.", [["infection", "DISEASE", 104, 113], ["CiTIA1", "CHEMICAL", 160, 166], ["SG", "GENE_OR_GENE_PRODUCT", 80, 82], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 160, 166], ["CiTIA1", "GENE_OR_GENE_PRODUCT", 266, 272], ["ciG3BP1", "GENE_OR_GENE_PRODUCT", 295, 302], ["CiTIA1", "PROTEIN", 160, 166], ["viral and host RNA", "RNA", 183, 201], ["CiTIA1", "PROTEIN", 266, 272], ["ciG3BP1", "PROTEIN", 295, 302], ["blocking SG", "PROBLEM", 71, 82], ["GCRV infection", "PROBLEM", 99, 113], ["viral replication", "PROBLEM", 123, 140], ["sequestering viral and host RNA", "PROBLEM", 170, 201], ["CiTIA1", "TREATMENT", 266, 272], ["downregulation of ciG3BP1", "TREATMENT", 277, 302], ["infection", "OBSERVATION", 104, 113], ["host RNA", "OBSERVATION_MODIFIER", 193, 201]]]], "PMC7155908": [["Demand of Intubation and Invasive Ventilation amid the COVID-19 OutbreakCOVID-19 has a wide spectrum of clinical severity, ranging from asymptomatic to critically ill, and ultimately death.1,5,6 A common and prominent complication of advanced COVID-19 is acute hypoxemic respiratory insufficiency or failure requiring oxygen and ventilation therapies (fig. 3).3,4 A recent report showed that 14% of patients developed dyspnea, tachypnea with a respiratory rate greater than or equal to 30 per minute, desaturation with peripheral oxygen saturation (Spo2) less than or equal to 93%, poor oxygenation with a ratio of partial pressure of arterial oxygen (Pao2) to fraction of inspired oxygen (Fio2) less than 300 mmHg, or lung infiltrates greater than 50% within 48 h.1 ARDS occurred in 20% of the 138 patients hospitalized and in 61% of the 36 patients admitted to the intensive care unit (ICU) in Zhongnan Hospital in Wuhan.4 Organ dysfunction, injury, or failure, excluding the lungs, is common.", [["respiratory", "ANATOMY", 271, 282], ["respiratory", "ANATOMY", 444, 455], ["arterial", "ANATOMY", 635, 643], ["lung", "ANATOMY", 719, 723], ["Organ", "ANATOMY", 925, 930], ["lungs", "ANATOMY", 978, 983], ["critically ill", "DISEASE", 152, 166], ["death", "DISEASE", 183, 188], ["1,5,6", "CHEMICAL", 189, 194], ["hypoxemic respiratory insufficiency", "DISEASE", 261, 296], ["oxygen", "CHEMICAL", 318, 324], ["dyspnea", "DISEASE", 418, 425], ["tachypnea", "DISEASE", 427, 436], ["desaturation", "DISEASE", 501, 513], ["oxygen", "CHEMICAL", 530, 536], ["oxygen", "CHEMICAL", 644, 650], ["oxygen", "CHEMICAL", 682, 688], ["ARDS", "DISEASE", 767, 771], ["Organ dysfunction", "DISEASE", 925, 942], ["oxygen", "CHEMICAL", 318, 324], ["oxygen", "CHEMICAL", 530, 536], ["oxygen", "CHEMICAL", 644, 650], ["oxygen", "CHEMICAL", 682, 688], ["1,5,6", "SIMPLE_CHEMICAL", 189, 194], ["oxygen", "SIMPLE_CHEMICAL", 318, 324], ["patients", "ORGANISM", 399, 407], ["oxygen", "SIMPLE_CHEMICAL", 530, 536], ["arterial", "MULTI-TISSUE_STRUCTURE", 635, 643], ["oxygen", "SIMPLE_CHEMICAL", 644, 650], ["Pao2", "SIMPLE_CHEMICAL", 652, 656], ["oxygen", "SIMPLE_CHEMICAL", 682, 688], ["Fio2", "SIMPLE_CHEMICAL", 690, 694], ["lung", "ORGAN", 719, 723], ["patients", "ORGANISM", 799, 807], ["patients", "ORGANISM", 842, 850], ["lungs", "ORGAN", 978, 983], ["patients", "SPECIES", 399, 407], ["patients", "SPECIES", 799, 807], ["patients", "SPECIES", 842, 850], ["Intubation", "TREATMENT", 10, 20], ["Invasive Ventilation", "TREATMENT", 25, 45], ["the COVID", "TEST", 51, 60], ["OutbreakCOVID", "TEST", 64, 77], ["clinical severity", "PROBLEM", 104, 121], ["critically ill", "PROBLEM", 152, 166], ["A common and prominent complication", "PROBLEM", 195, 230], ["advanced COVID", "TEST", 234, 248], ["acute hypoxemic respiratory insufficiency", "PROBLEM", 255, 296], ["failure", "PROBLEM", 300, 307], ["oxygen", "TREATMENT", 318, 324], ["ventilation therapies", "TREATMENT", 329, 350], ["dyspnea", "PROBLEM", 418, 425], ["tachypnea", "PROBLEM", 427, 436], ["a respiratory rate", "TEST", 442, 460], ["desaturation", "PROBLEM", 501, 513], ["peripheral oxygen saturation", "TEST", 519, 547], ["Spo2", "TEST", 549, 553], ["arterial oxygen", "TEST", 635, 650], ["Pao2", "TEST", 652, 656], ["inspired oxygen (Fio2", "TREATMENT", 673, 694], ["lung infiltrates", "PROBLEM", 719, 735], ["ARDS", "PROBLEM", 767, 771], ["4 Organ dysfunction", "PROBLEM", 923, 942], ["injury", "PROBLEM", 944, 950], ["failure", "PROBLEM", 955, 962], ["Intubation", "OBSERVATION", 10, 20], ["Invasive Ventilation", "OBSERVATION", 25, 45], ["prominent", "OBSERVATION_MODIFIER", 208, 217], ["complication", "OBSERVATION", 218, 230], ["acute", "OBSERVATION_MODIFIER", 255, 260], ["hypoxemic", "OBSERVATION_MODIFIER", 261, 270], ["respiratory insufficiency", "OBSERVATION", 271, 296], ["failure", "OBSERVATION", 300, 307], ["oxygen", "OBSERVATION_MODIFIER", 318, 324], ["dyspnea", "OBSERVATION", 418, 425], ["peripheral", "ANATOMY_MODIFIER", 519, 529], ["oxygen saturation", "OBSERVATION", 530, 547], ["arterial oxygen", "OBSERVATION", 635, 650], ["inspired oxygen", "OBSERVATION", 673, 688], ["lung", "ANATOMY", 719, 723], ["infiltrates", "OBSERVATION", 724, 735], ["Organ", "ANATOMY", 925, 930], ["dysfunction", "OBSERVATION", 931, 942], ["injury", "OBSERVATION", 944, 950], ["failure", "OBSERVATION", 955, 962], ["lungs", "ANATOMY", 978, 983]]], ["Cardiac injury occurred in 23%, liver injury in 29%, and acute kidney injury in 29% of critically ill patients.3 Neurocognitive impairments occurred in more than one third of patients with advanced COVID-19.7Demand of Intubation and Invasive Ventilation amid the COVID-19 OutbreakInvasive ventilation via an endotracheal tube is common amid this outbreak.", [["Cardiac", "ANATOMY", 0, 7], ["liver", "ANATOMY", 32, 37], ["kidney", "ANATOMY", 63, 69], ["endotracheal tube", "ANATOMY", 308, 325], ["Cardiac injury", "DISEASE", 0, 14], ["liver injury", "DISEASE", 32, 44], ["acute kidney injury", "DISEASE", 57, 76], ["critically ill", "DISEASE", 87, 101], ["Neurocognitive impairments", "DISEASE", 113, 139], ["COVID", "DISEASE", 198, 203], ["Cardiac", "ORGAN", 0, 7], ["liver", "ORGAN", 32, 37], ["kidney", "ORGAN", 63, 69], ["patients", "ORGANISM", 102, 110], ["patients", "ORGANISM", 175, 183], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 308, 325], ["patients", "SPECIES", 102, 110], ["patients", "SPECIES", 175, 183], ["Cardiac injury", "PROBLEM", 0, 14], ["liver injury", "PROBLEM", 32, 44], ["acute kidney injury", "PROBLEM", 57, 76], ["Neurocognitive impairments", "PROBLEM", 113, 139], ["advanced COVID", "TEST", 189, 203], ["Intubation", "TREATMENT", 218, 228], ["Invasive Ventilation", "TREATMENT", 233, 253], ["the COVID", "TREATMENT", 259, 268], ["OutbreakInvasive ventilation", "TREATMENT", 272, 300], ["an endotracheal tube", "TREATMENT", 305, 325], ["injury", "OBSERVATION", 8, 14], ["liver", "ANATOMY", 32, 37], ["injury", "OBSERVATION", 38, 44], ["29%", "OBSERVATION_MODIFIER", 48, 51], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["kidney", "ANATOMY", 63, 69], ["injury", "OBSERVATION", 70, 76], ["endotracheal tube", "OBSERVATION", 308, 325]]], ["It was performed in 2.3% of the 1,099 patients with confirmed COVID-19 based on the patient cohort from 552 hospitals in 30 provinces, autonomous regions, and municipalities in mainland China,1 in 47% of the 36 patients admitted to the ICU in Zhongnan Hospital in Wuhan,4 and in 42% of the 52 patients admitted to the ICU in Jin Yin Tan Hospital in Wuhan.3Demand of Intubation and Invasive Ventilation amid the COVID-19 OutbreakAlthough elective surgeries were cancelled in the epicenter of Wuhan, emergent surgeries were permitted amid this outbreak.", [["patients", "ORGANISM", 38, 46], ["patient", "ORGANISM", 84, 91], ["patients", "ORGANISM", 211, 219], ["patients", "ORGANISM", 293, 301], ["patients", "SPECIES", 38, 46], ["patient", "SPECIES", 84, 91], ["patients", "SPECIES", 211, 219], ["patients", "SPECIES", 293, 301], ["COVID", "TEST", 62, 67], ["Intubation", "TREATMENT", 366, 376], ["Invasive Ventilation", "TREATMENT", 381, 401], ["the COVID", "TREATMENT", 407, 416], ["elective surgeries", "TREATMENT", 437, 455], ["emergent surgeries", "TREATMENT", 498, 516], ["Intubation", "OBSERVATION", 366, 376], ["Invasive Ventilation", "OBSERVATION", 381, 401]]], ["As of February 29, 2020, a total of 105 emergent surgical procedures, including 90 cesarean sections (classified as emergent surgery amid this outbreak; fig. 4), were performed in patients with confirmed or suspected COVID-19 in Tongji Hospital in Wuhan (data from Dr. Wan).", [["sections", "ANATOMY", 92, 100], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 180, 188], ["emergent surgical procedures", "TREATMENT", 40, 68], ["90 cesarean sections", "TREATMENT", 80, 100], ["emergent surgery", "TREATMENT", 116, 132]]], ["Some of these procedures were performed under general anesthesia with endotracheal intubation.", [["endotracheal", "ANATOMY", 70, 82], ["these procedures", "TREATMENT", 8, 24], ["general anesthesia", "TREATMENT", 46, 64], ["endotracheal intubation", "TREATMENT", 70, 93], ["endotracheal intubation", "OBSERVATION", 70, 93]]], ["The anesthesiologists from the Department of Anesthesiology at Tongji Hospital in Wuhan performed approximately 200 nonoperating room intubations in patients with confirmed COVID-19 as of February 29, 2020.", [["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["intubations", "TREATMENT", 134, 145], ["COVID", "TEST", 173, 178]]], ["This is just a snapshot of the anesthetic practice in the epicenter of Wuhan amid this outbreak.Demand of Intubation and Invasive Ventilation amid the COVID-19 OutbreakCurrently, we do not have data detailing the total number of patients with COVID-19 who received intubation and invasive ventilation or details about the outcomes associated with and after these invasive interventions.", [["patients", "ORGANISM", 229, 237], ["patients", "SPECIES", 229, 237], ["Intubation", "TREATMENT", 106, 116], ["Invasive Ventilation", "TREATMENT", 121, 141], ["the COVID", "TREATMENT", 147, 156], ["COVID", "TREATMENT", 243, 248], ["intubation", "TREATMENT", 265, 275], ["invasive ventilation", "TREATMENT", 280, 300], ["these invasive interventions", "TREATMENT", 357, 385], ["Intubation", "OBSERVATION", 106, 116]]], ["Nonetheless, we can attempt to estimate this based on the available data.", [["the available data", "TEST", 54, 72]]], ["As of February 29, 2020, a total of 2,870 patients with confirmed COVID-19 have died (http://www.nhc.gov.cn/; accessed March 1, 2020).", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["COVID", "TEST", 66, 71]]], ["It is assumed that all of these patients died in ICUs, as most, if not all, of them should have been admitted to the ICU before their death.", [["death", "DISEASE", 134, 139], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40]]], ["We estimate that, if using a mortality rate of 50% among patients who were admitted to the ICU, a total of 5,740 patients would have been admitted to the ICU (2,870 \u00d7 2 = 5,740) as of February 29, 2020.", [["patients", "ORGANISM", 57, 65], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 113, 121]]], ["One recent report showed a mortality rate of 61.5% in patients who were admitted to the ICU.3 The other report showed a mortality rate of 49% among critically ill patients.8 We used a mortality rate of 50% in our estimate.", [["critically ill", "DISEASE", 148, 162], ["patients", "ORGANISM", 54, 62], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 163, 171], ["a mortality rate", "TEST", 25, 41], ["a mortality rate", "TEST", 118, 134], ["a mortality rate", "TEST", 182, 198]]], ["Based on the data reporting an invasive ventilation rate of approximately 45% in patients who were admitted to the ICU,3,4 we estimate that approximately 2,583 patients with COVID-19 received intubation and invasive ventilation, accounting for approximately 3.2% (2,583 of 79,824) of all confirmed COVID-19 cases, as of February 29, 2020, in mainland China.Intubation CriteriaThe decision to intubate can be obvious and require little deliberation, as for patients with cardiopulmonary arrest or a lost or jeopardized airway.", [["cardiopulmonary", "ANATOMY", 470, 485], ["airway", "ANATOMY", 518, 524], ["COVID", "DISEASE", 174, 179], ["COVID", "DISEASE", 298, 303], ["cardiopulmonary arrest", "DISEASE", 470, 492], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 456, 464], ["airway", "MULTI-TISSUE_STRUCTURE", 518, 524], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 456, 464], ["the data", "TEST", 9, 17], ["an invasive ventilation rate", "TEST", 28, 56], ["COVID", "TEST", 174, 179], ["intubation", "TREATMENT", 192, 202], ["invasive ventilation", "TREATMENT", 207, 227], ["COVID", "TEST", 298, 303], ["Intubation", "TREATMENT", 357, 367], ["intubate", "TREATMENT", 392, 400], ["cardiopulmonary arrest", "PROBLEM", 470, 492], ["invasive", "OBSERVATION_MODIFIER", 31, 39], ["invasive ventilation", "OBSERVATION", 207, 227], ["arrest", "OBSERVATION", 486, 492], ["airway", "ANATOMY", 518, 524]]], ["In patients with acute hypoxemic respiratory failure due to COVID-19, it can be challenging when deciding whether to proceed with intubation and invasive ventilation.", [["respiratory", "ANATOMY", 33, 44], ["hypoxemic respiratory failure", "DISEASE", 23, 52], ["COVID-19", "CHEMICAL", 60, 68], ["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["acute hypoxemic respiratory failure", "PROBLEM", 17, 52], ["COVID", "TEST", 60, 65], ["intubation", "TREATMENT", 130, 140], ["invasive ventilation", "TREATMENT", 145, 165], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["hypoxemic", "OBSERVATION_MODIFIER", 23, 32], ["respiratory failure", "OBSERVATION", 33, 52]]], ["The Chinese Society of Anesthesiology Task Force on Airway Management released a fast-track publication with the recommendation to proceed with endotracheal intubation for patients showing no improvement in respiratory distress, tachypnea (respiratory rate greater than 30 per minute), and poor oxygenation (Pao2 to Fio2 ratio less than 150 mmHg) after 2-h high-flow oxygen therapy or noninvasive ventilation.9Intubation CriteriaThese criteria should be regarded as empirical as there is no robust supporting evidence.", [["endotracheal", "ANATOMY", 144, 156], ["respiratory", "ANATOMY", 207, 218], ["respiratory distress", "DISEASE", 207, 227], ["tachypnea", "DISEASE", 229, 238], ["oxygen", "CHEMICAL", 367, 373], ["oxygen", "CHEMICAL", 367, 373], ["Airway", "MULTI-TISSUE_STRUCTURE", 52, 58], ["patients", "ORGANISM", 172, 180], ["oxygen", "SIMPLE_CHEMICAL", 367, 373], ["patients", "SPECIES", 172, 180], ["Airway Management", "TREATMENT", 52, 69], ["endotracheal intubation", "TREATMENT", 144, 167], ["respiratory distress", "PROBLEM", 207, 227], ["tachypnea", "PROBLEM", 229, 238], ["respiratory rate", "TEST", 240, 256], ["Pao2", "TEST", 308, 312], ["Fio2 ratio", "TEST", 316, 326], ["high-flow oxygen therapy", "TREATMENT", 357, 381], ["noninvasive ventilation", "TREATMENT", 385, 408], ["Airway", "ANATOMY", 52, 58], ["respiratory distress", "OBSERVATION", 207, 227], ["poor oxygenation", "OBSERVATION", 290, 306], ["oxygen therapy", "OBSERVATION", 367, 381], ["no robust", "UNCERTAINTY", 488, 497]]], ["The frontline physicians taking care of critically ill patients in Wuhan suggest that intubation and invasive ventilation may have been adversely delayed in some patients.", [["critically ill", "DISEASE", 40, 54], ["patients", "ORGANISM", 55, 63], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 55, 63], ["patients", "SPECIES", 162, 170], ["intubation", "TREATMENT", 86, 96], ["invasive ventilation", "TREATMENT", 101, 121]]], ["They are concerned that, amid this particular outbreak, intubation is more often used as a salvage therapy than a proactive means of supporting patients whose oxygenation is progressively declining and oxygen debt keeps increasing.", [["oxygen", "CHEMICAL", 202, 208], ["oxygen", "CHEMICAL", 202, 208], ["patients", "ORGANISM", 144, 152], ["oxygen", "SIMPLE_CHEMICAL", 202, 208], ["patients", "SPECIES", 144, 152], ["intubation", "TREATMENT", 56, 66], ["a salvage therapy", "TREATMENT", 89, 106]]], ["The most recent report showed that, among the 22 ICU patients who were intubated, 19 (86%) of them died.3 Although most frontline physicians believe the decision of intubation in some critically ill patients with COVID-19 had been adversely delayed, we do not know at this time if early intubation could save more lives.", [["critically ill", "DISEASE", 184, 198], ["COVID-19", "CHEMICAL", 213, 221], ["patients", "ORGANISM", 53, 61], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 53, 61], ["patients", "SPECIES", 199, 207], ["intubated", "TREATMENT", 71, 80], ["intubation", "TREATMENT", 165, 175], ["early intubation", "TREATMENT", 281, 297]]], ["We do know, based on the work performed 30 yr ago by Shoemaker et al., that there is a close association between the oxygen debt accumulated over 48 h and the chance of survival in patients undergoing high-risk surgery and ICU admission afterward.10 Shoemaker et al.\u2019s work highlights the importance of timely stopping an enlarging oxygen debt using effective oxygenation and ventilation therapies.Intubation CriteriaThe decision-making process for nonoperating room intubation used in Wuhan is summarized in figure 5.", [["oxygen", "CHEMICAL", 117, 123], ["oxygen", "CHEMICAL", 332, 338], ["oxygen", "CHEMICAL", 117, 123], ["oxygen", "CHEMICAL", 332, 338], ["oxygen", "SIMPLE_CHEMICAL", 117, 123], ["patients", "ORGANISM", 181, 189], ["oxygen", "SIMPLE_CHEMICAL", 332, 338], ["patients", "SPECIES", 181, 189], ["the oxygen debt", "PROBLEM", 113, 128], ["high-risk surgery", "TREATMENT", 201, 218], ["an enlarging oxygen debt", "TREATMENT", 319, 343], ["effective oxygenation", "TREATMENT", 350, 371], ["ventilation therapies", "TREATMENT", 376, 397], ["Intubation", "TREATMENT", 398, 408], ["nonoperating room intubation", "TREATMENT", 449, 477], ["oxygen debt", "OBSERVATION", 117, 128], ["enlarging", "OBSERVATION_MODIFIER", 322, 331], ["oxygen debt", "OBSERVATION", 332, 343]]], ["Timely, not premature, intubation is the keyword in decision-making.", [["intubation", "TREATMENT", 23, 33]]], ["We added liberal criteria, including Spo2 less than 93% in room air and a Pao2 to Fio2 ratio less than 300 mmHg, to facilitate preparedness for intubation based on the experience of taking care of critically ill patients in Wuhan.", [["critically ill", "DISEASE", 197, 211], ["Pao2", "SIMPLE_CHEMICAL", 74, 78], ["patients", "ORGANISM", 212, 220], ["patients", "SPECIES", 212, 220], ["liberal criteria", "TEST", 9, 25], ["Spo2", "TEST", 37, 41], ["a Pao2", "TEST", 72, 78], ["Fio2 ratio", "TEST", 82, 92], ["intubation", "TREATMENT", 144, 154]]], ["This proposal is justified as unprepared emergent intubation carries more risks, including cross-infection.", [["unprepared emergent intubation", "TREATMENT", 30, 60], ["cross-infection", "PROBLEM", 91, 106]]], ["It is also justified by the observation that some patients are relatively asymptomatic although they have a good degree of hypoxemia for inexplicable reasons (referred to as \u201csilent hypoxemia\u201d in Wuhan).11 Silent hypoxemia may be responsible for the quick deterioration in some patients because it gives a false sense of well-being when the oxygen debt has been actually and asymptomatically increasing.", [["hypoxemia", "DISEASE", 123, 132], ["hypoxemia", "DISEASE", 182, 191], ["hypoxemia", "DISEASE", 213, 222], ["oxygen", "CHEMICAL", 341, 347], ["oxygen", "CHEMICAL", 341, 347], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 278, 286], ["oxygen", "SIMPLE_CHEMICAL", 341, 347], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 278, 286], ["hypoxemia", "PROBLEM", 123, 132], ["silent hypoxemia", "PROBLEM", 175, 191], ["Silent hypoxemia", "PROBLEM", 206, 222], ["the quick deterioration", "PROBLEM", 246, 269], ["the oxygen debt", "PROBLEM", 337, 352], ["hypoxemia", "OBSERVATION", 123, 132], ["hypoxemia", "OBSERVATION", 213, 222], ["may be responsible for", "UNCERTAINTY", 223, 245], ["quick", "OBSERVATION_MODIFIER", 250, 255], ["deterioration", "OBSERVATION", 256, 269], ["asymptomatically", "OBSERVATION_MODIFIER", 375, 391], ["increasing", "OBSERVATION_MODIFIER", 392, 402]]], ["This algorithm emphasizes vigilance by asking two questions for patients with respiratory distress or hypoxemia.", [["respiratory", "ANATOMY", 78, 89], ["respiratory distress", "DISEASE", 78, 98], ["hypoxemia", "DISEASE", 102, 111], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["respiratory distress", "PROBLEM", 78, 98], ["hypoxemia", "PROBLEM", 102, 111], ["hypoxemia", "OBSERVATION", 102, 111]]], ["One is whether the condition has been progressively deteriorating or if it is expected to get worse; if the answer is yes, the next question is whether 2-h high-flow oxygen therapy or noninvasive ventilation is effective.Enhanced Risks and Protective Mandate during Intubation and VentilationBoth patients and healthcare workers have to endure enhanced, but distinctive, risks during intubation and ventilation management amid the COVID-19 outbreak.", [["oxygen", "CHEMICAL", 166, 172], ["oxygen", "CHEMICAL", 166, 172], ["oxygen", "SIMPLE_CHEMICAL", 166, 172], ["patients", "ORGANISM", 297, 305], ["patients", "SPECIES", 297, 305], ["high-flow oxygen therapy", "TREATMENT", 156, 180], ["noninvasive ventilation", "TREATMENT", 184, 207], ["Intubation", "TREATMENT", 266, 276], ["intubation", "TREATMENT", 384, 394], ["ventilation management", "TREATMENT", 399, 421], ["the COVID", "TEST", 427, 436], ["progressively", "OBSERVATION_MODIFIER", 38, 51], ["deteriorating", "OBSERVATION_MODIFIER", 52, 65]]], ["The enhanced risks to patients will be discussed in the coming sections of this article.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30]]], ["The enhanced risk to healthcare workers is cross-infection.Enhanced Risks and Protective Mandate during Intubation and VentilationOf the 138 hospitalized patients with confirmed COVID-19 in Zhongnan Hospital in Wuhan, 40 (29%) patients were healthcare workers with hospital-associated transmission suspected as the mechanism of infection.4 Five anesthesia providers working in Tongji Hospital in Wuhan were diagnosed with COVID-19.", [["infection", "DISEASE", 328, 337], ["patients", "ORGANISM", 154, 162], ["patients", "ORGANISM", 227, 235], ["patients", "SPECIES", 154, 162], ["patients", "SPECIES", 227, 235], ["Intubation", "TREATMENT", 104, 114], ["infection", "PROBLEM", 328, 337], ["COVID", "TEST", 422, 427], ["infection", "OBSERVATION", 328, 337]]], ["Two providers likely contracted the infection when taking care of patients with COVID-19 in December 2019 when the self-protection mandate had not yet been established.", [["infection", "DISEASE", 36, 45], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["the infection", "PROBLEM", 32, 45], ["the self-protection mandate", "TREATMENT", 111, 138], ["contracted", "OBSERVATION", 21, 31], ["infection", "OBSERVATION", 36, 45]]], ["The other three providers likely contracted the infection from family members.", [["infection", "DISEASE", 48, 57], ["the infection", "PROBLEM", 44, 57], ["infection", "OBSERVATION", 48, 57]]], ["Since the establishment of the self-protection mandate in January 2020, no anesthesia providers in Tongji Hospital have contracted the infection.", [["infection", "DISEASE", 135, 144], ["anesthesia providers", "TREATMENT", 75, 95], ["the infection", "PROBLEM", 131, 144], ["infection", "OBSERVATION", 135, 144]]], ["Dr. Shanglong Yao, a well-known anesthesiologist and former vice president of the Union Hospital in Wuhan, was diagnosed with COVID-19, with the infection likely transmitted from his daughter.", [["Yao", "CHEMICAL", 14, 17], ["infection", "DISEASE", 145, 154], ["Dr. Shanglong", "SPECIES", 0, 13], ["COVID", "TEST", 126, 131], ["the infection", "PROBLEM", 141, 154], ["infection", "OBSERVATION", 145, 154]]], ["Dr. Yao was hospitalized for a prolonged 4 weeks for close observation of the new-onset atrial fibrillation and poorly controlled hypertension.", [["atrial", "ANATOMY", 88, 94], ["atrial fibrillation", "DISEASE", 88, 107], ["hypertension", "DISEASE", 130, 142], ["the new-onset atrial fibrillation", "PROBLEM", 74, 107], ["poorly controlled hypertension", "PROBLEM", 112, 142], ["atrial", "ANATOMY", 88, 94], ["fibrillation", "OBSERVATION", 95, 107], ["poorly controlled", "OBSERVATION_MODIFIER", 112, 129], ["hypertension", "OBSERVATION", 130, 142]]], ["He eventually recovered and was discharged home (fig. 6).", [["He", "ORGANISM", 0, 2]]], ["These are just some examples of the situations related to the healthcare providers who were infected.Enhanced Risks and Protective Mandate during Intubation and VentilationIt was estimated that, as of February 11, 2020, a total of 1,716 health workers had confirmed COVID-19 and five had died (0.3%) in mainland China.12 The total number of cases of healthcare worker infections could be much more than this estimate.", [["infections", "DISEASE", 368, 378], ["Protective Mandate", "TREATMENT", 120, 138], ["Intubation", "TREATMENT", 146, 156], ["Ventilation", "TREATMENT", 161, 172], ["COVID", "TEST", 266, 271], ["healthcare worker infections", "TREATMENT", 350, 378], ["total", "OBSERVATION_MODIFIER", 325, 330]]], ["It was an observation that most of these infections occurred at the early stage of this outbreak when the self-protection mandate had not been established and reinforced.", [["infections", "DISEASE", 41, 51], ["these infections", "PROBLEM", 35, 51], ["the self-protection mandate", "TREATMENT", 102, 129], ["infections", "OBSERVATION", 41, 51]]], ["The mechanisms of transmission responsible for these infections are unknown; some cases may be nosocomial infections while the remainder may not be work related.", [["infections", "DISEASE", 53, 63], ["infections", "DISEASE", 106, 116], ["these infections", "PROBLEM", 47, 63], ["nosocomial infections", "PROBLEM", 95, 116], ["infections", "OBSERVATION", 53, 63], ["may be", "UNCERTAINTY", 88, 94], ["nosocomial", "OBSERVATION_MODIFIER", 95, 105], ["infections", "OBSERVATION", 106, 116]]], ["We also do not know how many nosocomial infections are attributable to the intubation process or ventilation management.Enhanced Risks and Protective Mandate during Intubation and VentilationThe lesson we learned from the 2003 SARS outbreak is that, compared with healthcare workers who do not perform intubation or ventilation management, those who perform these tasks have a higher risk of contracting the infection.", [["nosocomial infections", "DISEASE", 29, 50], ["SARS", "DISEASE", 227, 231], ["infection", "DISEASE", 408, 417], ["many nosocomial infections", "PROBLEM", 24, 50], ["the intubation process", "TREATMENT", 71, 93], ["ventilation management", "TREATMENT", 97, 119], ["Protective Mandate", "TREATMENT", 139, 157], ["Intubation", "TREATMENT", 165, 175], ["Ventilation", "TREATMENT", 180, 191], ["intubation", "TREATMENT", 302, 312], ["ventilation management", "TREATMENT", 316, 338], ["these tasks", "TEST", 358, 369], ["the infection", "PROBLEM", 404, 417], ["nosocomial", "OBSERVATION_MODIFIER", 29, 39], ["infections", "OBSERVATION", 40, 50], ["infection", "OBSERVATION", 408, 417]]], ["A systematic review showed that compared with healthcare workers who did not perform aerosol-generating procedures, those who performed tracheal intubation had an increased risk of contracting the 2003 SARS (odds ratio, 6.6), as were those who performed noninvasive ventilation (odds ratio, 3.1), tracheotomy (odds ratio, 4.2), and manual ventilation before intubation (odds ratio, 2.8).13 A separate study found that the protection guidelines failed to thoroughly prevent the transmission of 2003 SARS to healthcare workers and that 9% of the interviewed healthcare workers who had intubated patients contracted SARS.14 However, the cause-effect relationship between infection and intubation in these healthcare workers who contracted SARS was unknown.14Enhanced Risks and Protective Mandate during Intubation and VentilationDespite the enhanced risk to healthcare workers, the potential harm of withholding intubation may outweigh the potential risk of cross-infection in patients who would benefit from invasive ventilation support.15 Whenever intubation and invasive ventilation are needed, they should be timely and effectively provided.", [["tracheal", "ANATOMY", 136, 144], ["SARS", "DISEASE", 202, 206], ["SARS", "DISEASE", 498, 502], ["SARS", "DISEASE", 613, 617], ["infection", "DISEASE", 668, 677], ["SARS", "DISEASE", 736, 740], ["tracheal", "ORGAN", 136, 144], ["workers", "ORGANISM", 567, 574], ["patients", "ORGANISM", 593, 601], ["patients", "ORGANISM", 974, 982], ["patients", "SPECIES", 593, 601], ["patients", "SPECIES", 974, 982], ["A systematic review", "TEST", 0, 19], ["aerosol-generating procedures", "TREATMENT", 85, 114], ["tracheal intubation", "TREATMENT", 136, 155], ["odds ratio", "TEST", 208, 218], ["noninvasive ventilation", "TREATMENT", 254, 277], ["odds ratio", "TEST", 279, 289], ["tracheotomy", "TREATMENT", 297, 308], ["manual ventilation", "TREATMENT", 332, 350], ["intubation", "TREATMENT", 358, 368], ["odds ratio", "TEST", 370, 380], ["A separate study", "TEST", 390, 406], ["the protection guidelines", "TREATMENT", 418, 443], ["infection", "PROBLEM", 668, 677], ["intubation", "TREATMENT", 682, 692], ["Protective Mandate", "TREATMENT", 774, 792], ["Intubation", "TREATMENT", 800, 810], ["VentilationDespite", "TREATMENT", 815, 833], ["intubation", "TREATMENT", 909, 919], ["cross-infection", "PROBLEM", 955, 970], ["invasive ventilation support", "TREATMENT", 1006, 1034], ["intubation", "TREATMENT", 1047, 1057], ["invasive ventilation", "TREATMENT", 1062, 1082], ["tracheal", "ANATOMY", 136, 144], ["increased", "OBSERVATION_MODIFIER", 163, 172], ["infection", "OBSERVATION", 668, 677], ["cross-infection", "OBSERVATION", 955, 970]]], ["The healthcare workers who are involved in caring for patients with known or suspected COVID-19 should strictly adhere to the self-protection mandate (table 2).Enhanced Risks and Protective Mandate during Intubation and VentilationThe self-protection mandate for healthcare workers was quickly established and reinforced throughout different hospitals in Wuhan after the recognition of human-to-human transmission of COVID-19 toward the end of January 2020.", [["patients", "ORGANISM", 54, 62], ["human", "ORGANISM", 386, 391], ["human", "ORGANISM", 395, 400], ["patients", "SPECIES", 54, 62], ["human", "SPECIES", 386, 391], ["human", "SPECIES", 395, 400], ["human", "SPECIES", 386, 391], ["human", "SPECIES", 395, 400], ["Protective Mandate", "TREATMENT", 179, 197], ["Intubation", "TREATMENT", 205, 215], ["Ventilation", "TREATMENT", 220, 231], ["COVID", "TEST", 417, 422]]], ["At the same time, personal protective equipment that was most needed was delivered to Wuhan and the rest of the country where the epidemic was quickly evolving.", [["personal protective equipment", "TREATMENT", 18, 47]]], ["The contact and airborne precautions, with components of personal protective equipment, are presented in table 2.", [["airborne precautions", "TREATMENT", 16, 36], ["personal protective equipment", "TREATMENT", 57, 86]]], ["The different levels of precautions were scaled per the settings of patient care in Wuhan and the rest of China (table 3).", [["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["The different levels of precautions", "TREATMENT", 0, 35], ["different", "OBSERVATION_MODIFIER", 4, 13], ["levels", "OBSERVATION_MODIFIER", 14, 20]]], ["Full precaution (level III) is mandatory for any care that involves direct patient contact, including intubation and ventilation management.Enhanced Risks and Protective Mandate during Intubation and VentilationIn China, it is mandatory to strictly follow the personal protective equipment donning process for high-risk exposure in the following order: disposable hair cover, fit-tested N95 respirator or equivalent, fluid-resistant gown, two layers of gloves, goggle and face shield, and fluid-resistant shoe covers.9 Before entering an isolation area, an experienced nurse or assistant is responsible for checking the donning process (fig. 7).", [["hair", "ANATOMY", 364, 368], ["patient", "ORGANISM", 75, 82], ["hair", "TISSUE", 364, 368], ["patient", "SPECIES", 75, 82], ["intubation", "TREATMENT", 102, 112], ["ventilation management", "TREATMENT", 117, 139], ["Intubation", "TREATMENT", 185, 195], ["VentilationIn China", "TREATMENT", 200, 219], ["disposable hair cover", "TREATMENT", 353, 374], ["N95 respirator", "TREATMENT", 387, 401], ["fluid-resistant gown", "TREATMENT", 417, 437], ["gloves", "TREATMENT", 453, 459], ["goggle and face shield", "TREATMENT", 461, 483], ["fluid-resistant shoe covers", "TREATMENT", 489, 516], ["face shield", "ANATOMY", 472, 483], ["fluid", "OBSERVATION", 489, 494], ["resistant shoe", "OBSERVATION", 495, 509]]], ["It is crucial to make sure the personal protective equipment is donned in the manner that will not interfere with procedures.", [["procedures", "TREATMENT", 114, 124]]], ["It is also mandatory to strictly follow the personal protective equipment doffing process after high-risk exposure in the followingorder: hand hygiene, face shield and goggle removal, fluid-resistant gown removal, outer glove removal, shoe cover removal, inner glove removal, hand hygiene, N95 respirator or equivalent removal, and hair cover removal.9 The doffing process should also be supervised, but not facilitated, to reduce the chance of contamination.", [["hand", "ANATOMY", 138, 142], ["hand", "ANATOMY", 276, 280], ["hair", "ANATOMY", 332, 336], ["hand", "ORGANISM_SUBDIVISION", 138, 142], ["hand", "ORGANISM_SUBDIVISION", 276, 280], ["hand hygiene", "TREATMENT", 138, 150], ["face shield", "TREATMENT", 152, 163], ["goggle removal", "TREATMENT", 168, 182], ["fluid", "TREATMENT", 184, 189], ["resistant gown removal", "TREATMENT", 190, 212], ["outer glove removal", "TREATMENT", 214, 233], ["shoe cover removal", "TREATMENT", 235, 253], ["inner glove removal", "TREATMENT", 255, 274], ["hand hygiene", "TREATMENT", 276, 288], ["N95 respirator", "TREATMENT", 290, 304], ["equivalent removal", "TREATMENT", 308, 326], ["hair cover removal", "TREATMENT", 332, 350], ["contamination", "PROBLEM", 445, 458], ["hand", "ANATOMY", 138, 142], ["glove removal", "OBSERVATION", 220, 233], ["glove removal", "OBSERVATION", 261, 274]]], ["It is mandatory to report any inadvertent contamination of the skin or mucosa to the hospital infection control office to assess the need for quarantine.", [["skin", "ANATOMY", 63, 67], ["mucosa", "ANATOMY", 71, 77], ["infection", "DISEASE", 94, 103], ["skin", "ORGAN", 63, 67], ["mucosa", "MULTI-TISSUE_STRUCTURE", 71, 77], ["any inadvertent contamination of the skin or mucosa", "PROBLEM", 26, 77], ["quarantine", "TREATMENT", 142, 152], ["skin", "ANATOMY", 63, 67], ["mucosa", "ANATOMY", 71, 77]]], ["A shower and the use of oral, nasal, and external auditory canal disinfectants are recommended after the removal of personal protective equipment.Intubation and ExtubationPatients with confirmed or suspected COVID-19 should be regarded as having an augmented risk of presenting potentially difficult and complicated intubation for the following reasons.", [["oral", "ANATOMY", 24, 28], ["nasal", "ANATOMY", 30, 35], ["canal", "ANATOMY", 59, 64], ["oral", "ORGANISM_SUBDIVISION", 24, 28], ["nasal", "ORGANISM_SUBDIVISION", 30, 35], ["auditory canal", "MULTI-TISSUE_STRUCTURE", 50, 64], ["A shower", "TREATMENT", 0, 8], ["oral, nasal, and external auditory canal disinfectants", "TREATMENT", 24, 78], ["the removal of personal protective equipment", "TREATMENT", 101, 145], ["Intubation", "TREATMENT", 146, 156], ["nasal", "ANATOMY", 30, 35], ["external auditory canal", "ANATOMY", 41, 64]]], ["First, when a patient requires intubation for acute hypoxemic respiratory failure, they have minimal to no respiratory reserve, and their compensatory mechanisms have already been exhausted.", [["respiratory", "ANATOMY", 62, 73], ["respiratory", "ANATOMY", 107, 118], ["hypoxemic respiratory failure", "DISEASE", 52, 81], ["patient", "ORGANISM", 14, 21], ["patient", "SPECIES", 14, 21], ["intubation", "TREATMENT", 31, 41], ["acute hypoxemic respiratory failure", "PROBLEM", 46, 81], ["respiratory reserve", "PROBLEM", 107, 126], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["hypoxemic", "OBSERVATION_MODIFIER", 52, 61], ["respiratory failure", "OBSERVATION", 62, 81], ["respiratory reserve", "OBSERVATION", 107, 126]]], ["It is common to see a patient who starts with a dangerously low Spo2 quickly decline after loss of spontaneous breathing, followed by a slow recovery with manual facemask ventilation.", [["loss of spontaneous breathing", "DISEASE", 91, 120], ["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["a dangerously low Spo2", "PROBLEM", 46, 68], ["loss of spontaneous breathing", "PROBLEM", 91, 120], ["manual facemask ventilation", "TREATMENT", 155, 182], ["spontaneous breathing", "OBSERVATION", 99, 120], ["facemask ventilation", "OBSERVATION", 162, 182]]], ["Second, due to strict infection control and the urgency of intubation, a careful airway evaluation is frequently not possible.", [["airway", "ANATOMY", 81, 87], ["infection", "DISEASE", 22, 31], ["airway", "MULTI-TISSUE_STRUCTURE", 81, 87], ["strict infection control", "TREATMENT", 15, 39], ["intubation", "TREATMENT", 59, 69], ["a careful airway evaluation", "TEST", 71, 98], ["infection", "OBSERVATION", 22, 31], ["airway", "ANATOMY", 81, 87]]], ["Third, the personal protective equipment mandated by the level III scaled precaution makes the performance of the procedure clumsy, which may easily compromise the intubation process.", [["the personal protective equipment", "TREATMENT", 7, 40], ["the level III scaled precaution", "TREATMENT", 53, 84], ["the procedure clumsy", "TREATMENT", 110, 130], ["the intubation process", "PROBLEM", 160, 182], ["intubation", "OBSERVATION", 164, 174]]], ["Fourth, strict infection and traffic control restrict backup supplies and helpers from being readily available when they are needed.", [["infection", "DISEASE", 15, 24], ["strict infection", "PROBLEM", 8, 24], ["traffic control restrict backup supplies", "TREATMENT", 29, 69], ["infection", "OBSERVATION", 15, 24]]], ["Fifth, the psychological pressure related to concerns of cross-infection challenges the providers, which may make an otherwise easy intubation complicated.Intubation and ExtubationPreparedness minimizes the chance of cross-infection and improves the chance of smooth intubation.", [["Intubation", "TREATMENT", 155, 165], ["Extubation", "TREATMENT", 170, 180], ["cross-infection", "PROBLEM", 217, 232], ["smooth intubation", "TREATMENT", 260, 277], ["smooth intubation", "OBSERVATION", 260, 277]]], ["The proposed approach to prepare for intubation for patients with confirmed or suspected COVID-19 is summarized in table 4.", [["patients", "ORGANISM", 52, 60], ["patients", "SPECIES", 52, 60], ["intubation", "TREATMENT", 37, 47], ["COVID", "TEST", 89, 94]]], ["We recommend using the acronym OH\u2013MS. MAID\u2014Oxygen, Helper, Monitor, Suction, Machine, Airway supplies, Intravenous access, and Drugs\u2014to facilitate the preparation process for intubation.", [["OH", "CHEMICAL", 31, 33], ["OH", "CHEMICAL", 31, 33], ["Oxygen", "CHEMICAL", 43, 49], ["Oxygen", "SIMPLE_CHEMICAL", 43, 49], ["Oxygen", "TREATMENT", 43, 49], ["Suction", "TREATMENT", 68, 75], ["Airway supplies", "TREATMENT", 86, 101], ["Intravenous access", "TREATMENT", 103, 121], ["the preparation process", "TREATMENT", 147, 170], ["intubation", "TREATMENT", 175, 185], ["Oxygen", "OBSERVATION_MODIFIER", 43, 49], ["Airway", "ANATOMY", 86, 92]]], ["One-time use disposable supplies are preferred.", [["disposable supplies", "TREATMENT", 13, 32]]], ["Equipment that has to be reused is dedicated for patients with confirmed or suspected COVID-19.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Equipment", "TREATMENT", 0, 9], ["COVID", "TEST", 86, 91]]], ["No glitch or imperfection is minor when there is an associated risk.", [["glitch", "PROBLEM", 3, 9], ["glitch", "OBSERVATION", 3, 9], ["imperfection", "OBSERVATION", 13, 25], ["minor", "OBSERVATION_MODIFIER", 29, 34]]], ["Preparedness is even more crucial amid the COVID-19 outbreak, as the chance of contamination may be readily enhanced during the process of a complicated intubation when all attention is devoted to saving a patient\u2019s life.", [["patient", "ORGANISM", 206, 213], ["patient", "SPECIES", 206, 213], ["contamination", "PROBLEM", 79, 92], ["a complicated intubation", "TREATMENT", 139, 163], ["contamination", "OBSERVATION", 79, 92]]], ["A careful and efficient airway evaluation, whenever possible, should be performed ahead of intubation.Intubation and ExtubationEquipment that is used for more than one patient should be cleaned and disinfected before and after each use.", [["airway", "ANATOMY", 24, 30], ["airway", "MULTI-TISSUE_STRUCTURE", 24, 30], ["patient", "ORGANISM", 168, 175], ["patient", "SPECIES", 168, 175], ["A careful and efficient airway evaluation", "TEST", 0, 41], ["intubation", "TREATMENT", 91, 101], ["Intubation", "TREATMENT", 102, 112], ["ExtubationEquipment", "TREATMENT", 117, 136], ["airway", "ANATOMY", 24, 30]]], ["The mixture of ethanol and chlorhexidine is recommended as the disinfecting solution for the breathing circuit in China.", [["ethanol", "CHEMICAL", 15, 22], ["chlorhexidine", "CHEMICAL", 27, 40], ["ethanol", "CHEMICAL", 15, 22], ["chlorhexidine", "CHEMICAL", 27, 40], ["ethanol", "SIMPLE_CHEMICAL", 15, 22], ["chlorhexidine", "SIMPLE_CHEMICAL", 27, 40], ["ethanol", "TREATMENT", 15, 22], ["chlorhexidine", "TREATMENT", 27, 40], ["the disinfecting solution", "TREATMENT", 59, 84], ["the breathing circuit", "TREATMENT", 89, 110]]], ["Two single-use filters (PALL BB50T Breathing Circuit Filter, Pall Corp., USA), placed in the inhalation and exhalation breathing circuits, are used for infection control in Wuhan.", [["infection", "DISEASE", 152, 161], ["use filters", "TREATMENT", 11, 22], ["PALL BB50T Breathing Circuit Filter", "TREATMENT", 24, 59], ["the inhalation", "TREATMENT", 89, 103], ["exhalation breathing circuits", "TREATMENT", 108, 137], ["infection control", "TREATMENT", 152, 169]]], ["This breathing circuit filter appears capable of preventing the spread of influenza A (H1N1) virus from intubated patients,16 and thus is implicated to be equally capable of preventing the spread of the 2019 novel coronavirus.Intubation and ExtubationIn Wuhan, most of the patients were on either high-flow oxygen therapy or bilevel positive airway pressure ventilation when the intubation was called.", [["airway", "ANATOMY", 342, 348], ["influenza A (H1N1) virus", "DISEASE", 74, 98], ["coronavirus", "DISEASE", 214, 225], ["oxygen", "CHEMICAL", 307, 313], ["oxygen", "CHEMICAL", 307, 313], ["influenza A (H1N1) virus", "ORGANISM", 74, 98], ["patients", "ORGANISM", 114, 122], ["coronavirus", "ORGANISM", 214, 225], ["patients", "ORGANISM", 273, 281], ["oxygen", "SIMPLE_CHEMICAL", 307, 313], ["airway", "MULTI-TISSUE_STRUCTURE", 342, 348], ["influenza A (H1N1) virus", "SPECIES", 74, 98], ["patients", "SPECIES", 114, 122], ["patients", "SPECIES", 273, 281], ["influenza A (H1N1) virus", "SPECIES", 74, 98], ["This breathing circuit filter", "TREATMENT", 0, 29], ["influenza A (H1N1) virus", "PROBLEM", 74, 98], ["Intubation", "TREATMENT", 226, 236], ["high-flow oxygen therapy", "TREATMENT", 297, 321], ["bilevel positive airway pressure ventilation", "TREATMENT", 325, 369], ["the intubation", "TREATMENT", 375, 389], ["influenza", "OBSERVATION", 74, 83], ["oxygen therapy", "OBSERVATION", 307, 321], ["airway pressure", "OBSERVATION", 342, 357]]], ["If the patient is on high-flow oxygen therapy, consider using a bag valve mask or a tightly fitting facemask connected to the already prepared ventilator for preoxygenation.", [["oxygen", "CHEMICAL", 31, 37], ["oxygen", "CHEMICAL", 31, 37], ["patient", "ORGANISM", 7, 14], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["patient", "SPECIES", 7, 14], ["high-flow oxygen therapy", "TREATMENT", 21, 45], ["a bag valve mask", "TREATMENT", 62, 78], ["a tightly fitting facemask", "TREATMENT", 82, 108], ["preoxygenation", "TREATMENT", 158, 172], ["bag valve", "OBSERVATION", 64, 73]]], ["If the patient is on a bilevel positive airway pressure machine, continue bilevel positive airway pressure ventilation for preoxygenation (Supplemental Digital Content, http://links.lww.com/ALN/C348).", [["airway", "ANATOMY", 40, 46], ["airway", "ANATOMY", 91, 97], ["patient", "ORGANISM", 7, 14], ["airway", "MULTI-TISSUE_STRUCTURE", 40, 46], ["airway", "MULTI-TISSUE_STRUCTURE", 91, 97], ["patient", "SPECIES", 7, 14], ["a bilevel positive airway pressure machine", "TREATMENT", 21, 63], ["bilevel positive airway pressure ventilation", "TREATMENT", 74, 118], ["preoxygenation", "TREATMENT", 123, 137], ["airway", "ANATOMY", 40, 46], ["airway pressure", "OBSERVATION", 91, 106]]], ["Increase oxygen flow and use 100% Fio2 to maximize oxygenation.", [["oxygen", "CHEMICAL", 9, 15], ["oxygen", "CHEMICAL", 9, 15], ["oxygen", "SIMPLE_CHEMICAL", 9, 15], ["Fio2", "SIMPLE_CHEMICAL", 34, 38], ["Increase oxygen flow", "TREATMENT", 0, 20], ["100% Fio2", "TREATMENT", 29, 38], ["oxygen flow", "OBSERVATION", 9, 20]]], ["Make sure the airway is patent.", [["airway", "ANATOMY", 14, 20], ["airway", "MULTI-TISSUE_STRUCTURE", 14, 20], ["airway", "ANATOMY", 14, 20], ["patent", "OBSERVATION", 24, 30]]], ["It is well advised to apply an oral or nasal airway at the first sign of difficult masking.", [["oral", "ANATOMY", 31, 35], ["nasal airway", "ANATOMY", 39, 51], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["nasal airway", "MULTI-TISSUE_STRUCTURE", 39, 51], ["difficult masking", "PROBLEM", 73, 90], ["nasal airway", "ANATOMY", 39, 51]]], ["Consider manual positive pressure ventilation using a bag valve mask if preoxygenation fails to improve oxygenation.Intubation and ExtubationIt was shown that noninvasive ventilation applied for 3 min before tracheal intubation resulted in better oxygenation than a nonrebreather bag valve mask.17 However, a multicenter randomized trial based on the evaluation of 100% Fio2 administered with noninvasive ventilation versus that with a facemask for 3 min before tracheal intubation failed to demonstrate any benefits of using noninvasive ventilation as a preoxygenation method to reduce organ dysfunction in hypoxemic, critically ill patients.18 Clearly, there is a gap between improved oxygenation and unchanged outcomes.", [["tracheal", "ANATOMY", 208, 216], ["tracheal", "ANATOMY", 462, 470], ["organ", "ANATOMY", 587, 592], ["Fio2", "CHEMICAL", 370, 374], ["organ dysfunction", "DISEASE", 587, 604], ["critically ill", "DISEASE", 619, 633], ["tracheal", "ORGAN", 208, 216], ["Fio2", "SIMPLE_CHEMICAL", 370, 374], ["tracheal", "ORGAN", 462, 470], ["organ", "ORGAN", 587, 592], ["patients", "ORGANISM", 634, 642], ["patients", "SPECIES", 634, 642], ["manual positive pressure ventilation", "TREATMENT", 9, 45], ["a bag valve mask", "TREATMENT", 52, 68], ["Intubation", "TREATMENT", 116, 126], ["Extubation", "TREATMENT", 131, 141], ["noninvasive ventilation", "TREATMENT", 159, 182], ["tracheal intubation", "TREATMENT", 208, 227], ["a nonrebreather bag valve mask", "TREATMENT", 264, 294], ["the evaluation", "TEST", 347, 361], ["100% Fio2", "TREATMENT", 365, 374], ["noninvasive ventilation", "TREATMENT", 393, 416], ["a facemask", "TREATMENT", 434, 444], ["tracheal intubation", "TREATMENT", 462, 481], ["noninvasive ventilation", "TREATMENT", 526, 549], ["a preoxygenation method", "TREATMENT", 553, 576], ["organ dysfunction", "PROBLEM", 587, 604], ["hypoxemic", "PROBLEM", 608, 617], ["pressure ventilation", "OBSERVATION", 25, 45], ["bag valve", "OBSERVATION", 54, 63], ["tracheal", "ANATOMY", 208, 216], ["intubation", "OBSERVATION", 217, 227], ["bag valve", "OBSERVATION", 280, 289], ["hypoxemic", "OBSERVATION", 608, 617], ["improved", "OBSERVATION_MODIFIER", 678, 686], ["oxygenation", "OBSERVATION_MODIFIER", 687, 698], ["unchanged", "OBSERVATION_MODIFIER", 703, 712]]], ["Although the aerosol-generating potential of noninvasive ventilation is a potential concern to some providers,19 the bilevel positive airway pressure machine is widely used amid this outbreak for patients with acute hypoxemic respiratory failure in Wuhan and the rest of China.", [["airway", "ANATOMY", 134, 140], ["respiratory", "ANATOMY", 226, 237], ["hypoxemic respiratory failure", "DISEASE", 216, 245], ["airway", "MULTI-TISSUE_STRUCTURE", 134, 140], ["patients", "ORGANISM", 196, 204], ["patients", "SPECIES", 196, 204], ["noninvasive ventilation", "TREATMENT", 45, 68], ["the bilevel positive airway pressure machine", "TREATMENT", 113, 157], ["acute hypoxemic respiratory failure", "PROBLEM", 210, 245], ["airway pressure", "OBSERVATION", 134, 149], ["acute", "OBSERVATION_MODIFIER", 210, 215], ["hypoxemic", "OBSERVATION_MODIFIER", 216, 225], ["respiratory failure", "OBSERVATION", 226, 245]]], ["We would not recommend using bilevel positive airway pressure for preoxygenation in patients who are not on bilevel positive airway pressure ventilation; however, bilevel positive airway pressure ventilation should be continued if it is already in use.Intubation and ExtubationAfter satisfactory preoxygenation, modified rapid sequence induction is the recommended technique for anesthesia induction.9 Midazolam 1 to 2 mg may be considered for extremely anxious patients.", [["airway", "ANATOMY", 46, 52], ["airway", "ANATOMY", 125, 131], ["airway", "ANATOMY", 180, 186], ["Midazolam", "CHEMICAL", 402, 411], ["anxious", "DISEASE", 454, 461], ["Midazolam", "CHEMICAL", 402, 411], ["airway", "MULTI-TISSUE_STRUCTURE", 46, 52], ["patients", "ORGANISM", 84, 92], ["airway", "MULTI-TISSUE_STRUCTURE", 125, 131], ["airway", "MULTI-TISSUE_STRUCTURE", 180, 186], ["Midazolam", "SIMPLE_CHEMICAL", 402, 411], ["patients", "ORGANISM", 462, 470], ["patients", "SPECIES", 84, 92], ["patients", "SPECIES", 462, 470], ["bilevel positive airway pressure", "TREATMENT", 29, 61], ["bilevel positive airway pressure ventilation", "TREATMENT", 108, 152], ["bilevel positive airway pressure ventilation", "TREATMENT", 163, 207], ["Intubation", "TREATMENT", 252, 262], ["ExtubationAfter satisfactory preoxygenation", "TREATMENT", 267, 310], ["modified rapid sequence induction", "TREATMENT", 312, 345], ["anesthesia induction", "TREATMENT", 379, 399], ["Midazolam", "TREATMENT", 402, 411], ["airway", "ANATOMY", 125, 131], ["pressure ventilation", "OBSERVATION", 132, 152], ["airway pressure", "OBSERVATION", 180, 195]]], ["Intravenous lidocaine, 1.5 mg/kg or more, is effective in suppressing coughing during endotracheal intubation.20 Use a small dose of etomidate (0.2 to 0.3 mg/kg) for patients with hemodynamic instability or propofol (1 to 1.5 mg/kg) for patients with stable hemodynamics for induction.9 Some providers may opt to avoid etomidate due to concerns of adrenal suppression.", [["Intravenous", "ANATOMY", 0, 11], ["endotracheal", "ANATOMY", 86, 98], ["adrenal", "ANATOMY", 348, 355], ["lidocaine", "CHEMICAL", 12, 21], ["coughing", "DISEASE", 70, 78], ["etomidate", "CHEMICAL", 133, 142], ["hemodynamic instability", "DISEASE", 180, 203], ["propofol", "CHEMICAL", 207, 215], ["etomidate", "CHEMICAL", 319, 328], ["adrenal suppression", "DISEASE", 348, 367], ["lidocaine", "CHEMICAL", 12, 21], ["etomidate", "CHEMICAL", 133, 142], ["propofol", "CHEMICAL", 207, 215], ["etomidate", "CHEMICAL", 319, 328], ["lidocaine", "SIMPLE_CHEMICAL", 12, 21], ["etomidate", "SIMPLE_CHEMICAL", 133, 142], ["patients", "ORGANISM", 166, 174], ["propofol", "SIMPLE_CHEMICAL", 207, 215], ["patients", "ORGANISM", 237, 245], ["etomidate", "SIMPLE_CHEMICAL", 319, 328], ["adrenal", "ORGAN", 348, 355], ["patients", "SPECIES", 166, 174], ["patients", "SPECIES", 237, 245], ["Intravenous lidocaine", "TREATMENT", 0, 21], ["suppressing coughing", "PROBLEM", 58, 78], ["endotracheal intubation", "TREATMENT", 86, 109], ["a small dose of etomidate", "TREATMENT", 117, 142], ["hemodynamic instability", "PROBLEM", 180, 203], ["propofol", "TREATMENT", 207, 215], ["etomidate", "TREATMENT", 319, 328], ["adrenal suppression", "PROBLEM", 348, 367], ["endotracheal intubation", "OBSERVATION", 86, 109], ["adrenal", "ANATOMY", 348, 355], ["suppression", "OBSERVATION", 356, 367]]], ["Rocuronium 1 mg/kg or succinylcholine 1 mg/kg is administered immediately after loss of consciousness.", [["Rocuronium", "CHEMICAL", 0, 10], ["succinylcholine", "CHEMICAL", 22, 37], ["loss of consciousness", "DISEASE", 80, 101], ["Rocuronium", "CHEMICAL", 0, 10], ["succinylcholine", "CHEMICAL", 22, 37], ["Rocuronium", "SIMPLE_CHEMICAL", 0, 10], ["succinylcholine", "SIMPLE_CHEMICAL", 22, 37], ["Rocuronium", "TREATMENT", 0, 10], ["succinylcholine", "TREATMENT", 22, 37], ["loss of consciousness", "PROBLEM", 80, 101]]], ["Fentanyl 50 to 100 mcg, sufentanil 10 to 20 mcg, or remifentanil 2.5 mcg/kg21 may be used to suppress laryngeal reflexes and optimize the intubation condition.", [["laryngeal", "ANATOMY", 102, 111], ["Fentanyl", "CHEMICAL", 0, 8], ["sufentanil", "CHEMICAL", 24, 34], ["remifentanil", "CHEMICAL", 52, 64], ["Fentanyl", "CHEMICAL", 0, 8], ["sufentanil", "CHEMICAL", 24, 34], ["remifentanil", "CHEMICAL", 52, 64], ["Fentanyl", "SIMPLE_CHEMICAL", 0, 8], ["sufentanil", "SIMPLE_CHEMICAL", 24, 34], ["laryngeal", "ORGAN", 102, 111], ["Fentanyl", "TREATMENT", 0, 8], ["sufentanil", "TREATMENT", 24, 34], ["remifentanil", "TREATMENT", 52, 64], ["laryngeal reflexes", "TEST", 102, 120], ["the intubation condition", "TREATMENT", 134, 158], ["laryngeal", "ANATOMY", 102, 111]]], ["Because opioids have the potential to cause coughing,22 some providers prefer to give opioids after the accomplishment of satisfactory muscle relaxation.", [["muscle", "ANATOMY", 135, 141], ["coughing", "DISEASE", 44, 52], ["opioids", "SIMPLE_CHEMICAL", 8, 15], ["muscle", "ORGAN", 135, 141], ["opioids", "TREATMENT", 8, 15], ["coughing", "PROBLEM", 44, 52], ["opioids", "TREATMENT", 86, 93]]], ["The choice and dose of anesthetics should be determined on a case-by-case basis, with the patient\u2019s hemodynamic stability, severity of illness, and mental status taken into consideration.", [["illness", "DISEASE", 135, 142], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["anesthetics", "TREATMENT", 23, 34], ["illness", "PROBLEM", 135, 142]]], ["Vasoactive drugs should be readily available to treat extreme cardiovascular reactions.", [["cardiovascular", "ANATOMY", 62, 76], ["cardiovascular reactions", "DISEASE", 62, 86], ["cardiovascular", "ANATOMICAL_SYSTEM", 62, 76], ["Vasoactive drugs", "TREATMENT", 0, 16], ["extreme cardiovascular reactions", "PROBLEM", 54, 86]]], ["Ventilation through a patent airway and using a small tidal volume should be continued throughout the induction process until the patient is intubated.", [["airway", "ANATOMY", 29, 35], ["airway", "MULTI-TISSUE_STRUCTURE", 29, 35], ["patient", "ORGANISM", 130, 137], ["patient", "SPECIES", 130, 137], ["Ventilation", "TREATMENT", 0, 11], ["a patent airway", "TREATMENT", 20, 35], ["a small tidal volume", "TREATMENT", 46, 66], ["intubated", "TREATMENT", 141, 150], ["patent", "OBSERVATION", 22, 28], ["airway", "ANATOMY", 29, 35], ["small", "OBSERVATION_MODIFIER", 48, 53], ["tidal volume", "OBSERVATION", 54, 66]]], ["The goal is to have the patient intubated within 60 s after administration of muscle relaxants.9 The rationale behind modified rapid sequence induction in China is to shorten the period of potentially ineffective ventilation, from the moment of losing consciousness to the moment of successful endotracheal intubation, in critically ill patients with minimal to no oxygen reserve due to COVID-19.Intubation and ExtubationThe approach of using modified rapid sequence induction in this patient population may be criticized, as some providers may prefer to proceed with slow and controlled induction if there is no immediate aspiration risk.", [["muscle", "ANATOMY", 78, 84], ["endotracheal", "ANATOMY", 294, 306], ["critically ill", "DISEASE", 322, 336], ["oxygen", "CHEMICAL", 365, 371], ["COVID-19", "CHEMICAL", 387, 395], ["oxygen", "CHEMICAL", 365, 371], ["COVID-19", "CHEMICAL", 387, 395], ["patient", "ORGANISM", 24, 31], ["muscle", "ORGAN", 78, 84], ["patients", "ORGANISM", 337, 345], ["oxygen", "SIMPLE_CHEMICAL", 365, 371], ["patient", "ORGANISM", 485, 492], ["patient", "SPECIES", 24, 31], ["patients", "SPECIES", 337, 345], ["patient", "SPECIES", 485, 492], ["intubated", "TREATMENT", 32, 41], ["muscle relaxants", "TREATMENT", 78, 94], ["modified rapid sequence induction", "TREATMENT", 118, 151], ["ineffective ventilation", "TREATMENT", 201, 224], ["losing consciousness", "PROBLEM", 245, 265], ["successful endotracheal intubation", "TREATMENT", 283, 317], ["oxygen reserve", "TREATMENT", 365, 379], ["COVID", "TEST", 387, 392], ["Intubation", "TREATMENT", 396, 406], ["Extubation", "TREATMENT", 411, 421], ["modified rapid sequence induction", "TREATMENT", 443, 476], ["slow and controlled induction", "TREATMENT", 568, 597], ["immediate aspiration risk", "PROBLEM", 613, 638], ["muscle", "ANATOMY", 78, 84], ["ineffective ventilation", "OBSERVATION", 201, 224], ["endotracheal intubation", "OBSERVATION", 294, 317], ["no", "UNCERTAINTY", 610, 612]]], ["They may argue that maximizing oxygen reserve, immediately after anesthetic induction but before endotracheal intubation, is warranted in patients with acute hypoxemic respiratory failure.", [["endotracheal", "ANATOMY", 97, 109], ["respiratory", "ANATOMY", 168, 179], ["oxygen", "CHEMICAL", 31, 37], ["hypoxemic respiratory failure", "DISEASE", 158, 187], ["oxygen", "CHEMICAL", 31, 37], ["oxygen", "SIMPLE_CHEMICAL", 31, 37], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 138, 146], ["maximizing oxygen reserve", "TREATMENT", 20, 45], ["anesthetic induction", "TREATMENT", 65, 85], ["endotracheal intubation", "TREATMENT", 97, 120], ["acute hypoxemic respiratory failure", "PROBLEM", 152, 187], ["acute", "OBSERVATION_MODIFIER", 152, 157], ["hypoxemic", "OBSERVATION_MODIFIER", 158, 167], ["respiratory failure", "OBSERVATION", 168, 187]]], ["They may also argue that immediately administering muscle relaxants after anesthesia induction, without testing the effectiveness of bag valve mask ventilation, is not well advised.", [["muscle", "ANATOMY", 51, 57], ["valve", "ANATOMY", 137, 142], ["muscle", "ORGAN", 51, 57], ["muscle relaxants", "TREATMENT", 51, 67], ["anesthesia induction", "TREATMENT", 74, 94], ["bag valve mask ventilation", "TREATMENT", 133, 159], ["bag valve", "OBSERVATION", 133, 142]]], ["We recognize this potential difference in approaches and leave it open for further discussion.Intubation and ExtubationPatient coughing during intubation can generate aerosols and should be avoided.", [["Intubation", "TREATMENT", 94, 104], ["ExtubationPatient coughing", "PROBLEM", 109, 135], ["intubation", "TREATMENT", 143, 153], ["aerosols", "TREATMENT", 167, 175]]], ["Gentle airway manipulation is warranted.", [["airway", "ANATOMY", 7, 13], ["airway", "MULTI-TISSUE_STRUCTURE", 7, 13], ["Gentle airway manipulation", "TREATMENT", 0, 26], ["airway", "ANATOMY", 7, 13]]], ["It is prudent to use video laryngoscopy rather than direct laryngoscopy for intubation because the former increases the distance between the healthcare worker\u2019s face and the patient\u2019s face, which may minimize the risk of contamination (fig. 8).", [["patient", "ORGANISM", 174, 181], ["patient", "SPECIES", 174, 181], ["video laryngoscopy", "TEST", 21, 39], ["direct laryngoscopy", "TEST", 52, 71], ["intubation", "TREATMENT", 76, 86], ["contamination", "PROBLEM", 221, 234], ["contamination", "OBSERVATION", 221, 234]]], ["Videoscopes also allow assistants to visualize the airway so that they can better facilitate the procedure.", [["airway", "ANATOMY", 51, 57], ["airway", "MULTI-TISSUE_STRUCTURE", 51, 57], ["the procedure", "TREATMENT", 93, 106], ["airway", "ANATOMY", 51, 57]]], ["In Wuhan, chest auscultation after intubation is not recommended, unless absolutely needed, due to concerns of contamination.", [["chest", "ANATOMY", 10, 15], ["chest", "ORGAN", 10, 15], ["chest auscultation", "TEST", 10, 28], ["intubation", "TREATMENT", 35, 45], ["contamination", "PROBLEM", 111, 124], ["chest", "ANATOMY", 10, 15], ["contamination", "OBSERVATION", 111, 124]]], ["Capnography, fogging inside of the endotracheal tube, chest movement, Spo2, the color of the patient\u2019s skin and mucous membrane, and vigilance are used to differentiate between a failed and successful intubation.Intubation and ExtubationThe same precautions should be considered during extubation.", [["endotracheal tube", "ANATOMY", 35, 52], ["chest", "ANATOMY", 54, 59], ["skin", "ANATOMY", 103, 107], ["mucous membrane", "ANATOMY", 112, 127], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 35, 52], ["patient", "ORGANISM", 93, 100], ["skin", "ORGAN", 103, 107], ["mucous membrane", "MULTI-TISSUE_STRUCTURE", 112, 127], ["patient", "SPECIES", 93, 100], ["Capnography", "TEST", 0, 11], ["the endotracheal tube", "TREATMENT", 31, 52], ["chest movement", "TEST", 54, 68], ["Spo2", "TEST", 70, 74], ["the color", "TEST", 76, 85], ["successful intubation", "TREATMENT", 190, 211], ["Intubation", "TREATMENT", 212, 222], ["Extubation", "TREATMENT", 227, 237], ["The same precautions", "TREATMENT", 237, 257], ["endotracheal tube", "OBSERVATION", 35, 52], ["chest", "ANATOMY", 54, 59], ["skin", "ANATOMY", 103, 107], ["mucous membrane", "ANATOMY", 112, 127]]], ["Measures to prevent patient agitation, coughing, and bucking should be applied.", [["agitation", "DISEASE", 28, 37], ["coughing", "DISEASE", 39, 47], ["patient", "ORGANISM", 20, 27], ["patient", "SPECIES", 20, 27], ["patient agitation", "PROBLEM", 20, 37], ["coughing", "PROBLEM", 39, 47], ["agitation", "OBSERVATION_MODIFIER", 28, 37]]], ["Appropriate levels of sedation, such as dexmedetomidine (0.4 mcg \u00b7 kg-1 \u00b7 h-1)23 or remifentanil (1 to 4 ng/ml target organ concentration)24 infusion, should be considered.", [["organ", "ANATOMY", 118, 123], ["dexmedetomidine", "CHEMICAL", 40, 55], ["remifentanil", "CHEMICAL", 84, 96], ["dexmedetomidine", "CHEMICAL", 40, 55], ["h-1)23", "CHEMICAL", 74, 80], ["remifentanil", "CHEMICAL", 84, 96], ["dexmedetomidine", "SIMPLE_CHEMICAL", 40, 55], ["h-1)23", "SIMPLE_CHEMICAL", 74, 80], ["remifentanil", "SIMPLE_CHEMICAL", 84, 96], ["organ", "ORGAN", 118, 123], ["sedation", "TREATMENT", 22, 30], ["dexmedetomidine", "TREATMENT", 40, 55], ["remifentanil", "TREATMENT", 84, 96], ["organ concentration)", "TREATMENT", 118, 138]]], ["Intravenous lidocaine (1 to 1.5 mg/kg) is effective for cough reduction.25,26 Alfentanil (15 mcg/kg) is also effective in decreasing coughing and agitation during anesthesia emergence.27Ventilation ManagementMechanical ventilation, though vital in supporting respiratory function in patients with acute hypoxemic respiratory failure or ARDS, may promote lung damage, a phenomenon known as ventilator-induced lung injury.28 Currently, we lack any guidelines or evidence to help us manage invasive mechanical ventilation in critically ill patients with COVID-19.", [["Intravenous", "ANATOMY", 0, 11], ["respiratory", "ANATOMY", 259, 270], ["respiratory", "ANATOMY", 313, 324], ["lung", "ANATOMY", 354, 358], ["lung", "ANATOMY", 408, 412], ["lidocaine", "CHEMICAL", 12, 21], ["cough reduction", "DISEASE", 56, 71], ["Alfentanil", "CHEMICAL", 78, 88], ["coughing", "DISEASE", 133, 141], ["agitation", "DISEASE", 146, 155], ["hypoxemic respiratory failure", "DISEASE", 303, 332], ["ARDS", "DISEASE", 336, 340], ["lung damage", "DISEASE", 354, 365], ["ventilator-induced lung injury", "DISEASE", 389, 419], ["critically ill", "DISEASE", 522, 536], ["lidocaine", "CHEMICAL", 12, 21], ["Alfentanil", "CHEMICAL", 78, 88], ["COVID-19", "CHEMICAL", 551, 559], ["lidocaine", "SIMPLE_CHEMICAL", 12, 21], ["Alfentanil", "SIMPLE_CHEMICAL", 78, 88], ["patients", "ORGANISM", 283, 291], ["lung", "ORGAN", 354, 358], ["lung", "ORGAN", 408, 412], ["patients", "ORGANISM", 537, 545], ["patients", "SPECIES", 283, 291], ["patients", "SPECIES", 537, 545], ["Intravenous lidocaine", "TREATMENT", 0, 21], ["cough reduction", "TREATMENT", 56, 71], ["Alfentanil", "TREATMENT", 78, 88], ["decreasing coughing", "PROBLEM", 122, 141], ["agitation", "PROBLEM", 146, 155], ["anesthesia emergence", "TREATMENT", 163, 183], ["27Ventilation Management", "TREATMENT", 184, 208], ["Mechanical ventilation", "TREATMENT", 208, 230], ["acute hypoxemic respiratory failure", "PROBLEM", 297, 332], ["ARDS", "PROBLEM", 336, 340], ["lung damage", "PROBLEM", 354, 365], ["a phenomenon", "PROBLEM", 367, 379], ["ventilator", "TREATMENT", 389, 399], ["lung injury", "PROBLEM", 408, 419], ["invasive mechanical ventilation", "TREATMENT", 487, 518], ["COVID", "TEST", 551, 556], ["decreasing", "OBSERVATION_MODIFIER", 122, 132], ["coughing", "OBSERVATION", 133, 141], ["Mechanical ventilation", "OBSERVATION", 208, 230], ["acute", "OBSERVATION_MODIFIER", 297, 302], ["hypoxemic", "OBSERVATION_MODIFIER", 303, 312], ["respiratory failure", "OBSERVATION", 313, 332], ["ARDS", "OBSERVATION", 336, 340], ["lung", "ANATOMY", 354, 358], ["damage", "OBSERVATION", 359, 365], ["lung", "ANATOMY", 408, 412], ["injury", "OBSERVATION", 413, 419]]], ["It is well advised to adopt the guidelines established for patients with ARDS,29,30 with appropriate modifications based on the firsthand patient care experience in Wuhan (table 5).", [["ARDS", "DISEASE", 73, 77], ["patients", "ORGANISM", 59, 67], ["patient", "ORGANISM", 138, 145], ["patients", "SPECIES", 59, 67], ["patient", "SPECIES", 138, 145], ["ARDS", "PROBLEM", 73, 77]]], ["This is justified as 67% of the ICU patients developed ARDS based on the recent report.3Ventilation ManagementThe ARDS lung-protective ventilation guidelines emphasize: (1) a tidal volume less than or equal to 6 ml/kg predicted body weight; (2) a respiratory rate less than or equal to 35 breaths/min; (3) a plateau airway pressure less than or equal to 30 cm H2O; and (4) a positive end-expiratory pressure (PEEP) greater than or equal to 5 cm H2O.31,32 The tidal volume can be started at 8 ml/kg and then lowered with an ultimate goal of 6 ml/kg.", [["lung", "ANATOMY", 119, 123], ["body", "ANATOMY", 228, 232], ["respiratory", "ANATOMY", 247, 258], ["airway", "ANATOMY", 316, 322], ["ARDS", "DISEASE", 55, 59], ["ARDS", "DISEASE", 114, 118], ["H2O", "CHEMICAL", 360, 363], ["H2O", "CHEMICAL", 445, 448], ["H2O", "CHEMICAL", 360, 363], ["H2O", "CHEMICAL", 445, 448], ["patients", "ORGANISM", 36, 44], ["lung", "ORGAN", 119, 123], ["body", "ORGANISM_SUBDIVISION", 228, 232], ["airway", "MULTI-TISSUE_STRUCTURE", 316, 322], ["patients", "SPECIES", 36, 44], ["ARDS", "PROBLEM", 55, 59], ["Ventilation Management", "TREATMENT", 88, 110], ["The ARDS lung", "TREATMENT", 110, 123], ["a tidal volume", "TEST", 173, 187], ["body weight", "TEST", 228, 239], ["a respiratory rate", "TEST", 245, 263], ["a plateau airway pressure", "TEST", 306, 331], ["expiratory pressure", "TEST", 388, 407], ["PEEP", "TEST", 409, 413], ["The tidal volume", "TREATMENT", 455, 471], ["ARDS", "OBSERVATION", 55, 59], ["lung", "ANATOMY", 119, 123], ["airway", "ANATOMY", 316, 322], ["pressure", "OBSERVATION_MODIFIER", 323, 331], ["tidal volume", "OBSERVATION", 459, 471]]], ["Some clinicians believe that, as long as the plateau pressure can be maintained at less than or equal to 30 cm H2O, it may be safe to ventilate the patient with tidal volumes greater than 6 ml/kg predicted body weight.33 The precise tidal volume for an individual patient should be adjusted according to the patient\u2019s plateau pressure, selected PEEP, thoracoabdominal compliance, and breathing effort.29 It is advantageous to have a driving pressure (plateau pressure minus PEEP) below 12 to 15 cm H2O via tidal volume and PEEP adjustments in patients who are not spontaneously breathing.34Ventilation ManagementIn Wuhan, patients with acute hypoxemic respiratory failure due to COVID-19 have a poor tolerance to high PEEP, likely as the result of the direct and severe lung damage by the virus and inflammatory reactions.", [["body", "ANATOMY", 206, 210], ["thoracoabdominal", "ANATOMY", 351, 367], ["respiratory", "ANATOMY", 652, 663], ["lung", "ANATOMY", 770, 774], ["H2O", "CHEMICAL", 111, 114], ["H2O", "CHEMICAL", 498, 501], ["hypoxemic respiratory failure", "DISEASE", 642, 671], ["COVID-19", "CHEMICAL", 679, 687], ["lung damage", "DISEASE", 770, 781], ["H2O", "CHEMICAL", 111, 114], ["H2O", "CHEMICAL", 498, 501], ["COVID-19", "CHEMICAL", 679, 687], ["patient", "ORGANISM", 148, 155], ["body", "ORGANISM_SUBDIVISION", 206, 210], ["patient", "ORGANISM", 264, 271], ["patient", "ORGANISM", 308, 315], ["patients", "ORGANISM", 543, 551], ["patients", "ORGANISM", 622, 630], ["lung", "ORGAN", 770, 774], ["patient", "SPECIES", 148, 155], ["patient", "SPECIES", 264, 271], ["patient", "SPECIES", 308, 315], ["patients", "SPECIES", 543, 551], ["patients", "SPECIES", 622, 630], ["the plateau pressure", "TEST", 41, 61], ["tidal volumes", "TEST", 161, 174], ["body weight", "TEST", 206, 217], ["The precise tidal volume", "TEST", 221, 245], ["plateau pressure", "TEST", 318, 334], ["selected PEEP", "TREATMENT", 336, 349], ["thoracoabdominal compliance", "TREATMENT", 351, 378], ["a driving pressure (plateau pressure minus PEEP", "TREATMENT", 431, 478], ["tidal volume", "TEST", 506, 518], ["PEEP adjustments", "TREATMENT", 523, 539], ["acute hypoxemic respiratory failure", "PROBLEM", 636, 671], ["COVID", "TEST", 679, 684], ["high PEEP", "TREATMENT", 713, 722], ["the direct and severe lung damage", "PROBLEM", 748, 781], ["the virus", "PROBLEM", 785, 794], ["inflammatory reactions", "PROBLEM", 799, 821], ["30 cm", "OBSERVATION_MODIFIER", 105, 110], ["tidal volume", "OBSERVATION", 233, 245], ["thoracoabdominal", "ANATOMY", 351, 367], ["tidal volume", "OBSERVATION", 506, 518], ["acute", "OBSERVATION_MODIFIER", 636, 641], ["hypoxemic", "OBSERVATION_MODIFIER", 642, 651], ["respiratory failure", "OBSERVATION", 652, 671], ["high PEEP", "OBSERVATION", 713, 722], ["severe", "OBSERVATION_MODIFIER", 763, 769], ["lung", "ANATOMY", 770, 774], ["damage", "OBSERVATION", 775, 781], ["inflammatory", "OBSERVATION_MODIFIER", 799, 811]]], ["The plateau pressure reaches 40 to 50 cm H2O when the PEEP is set at 18 cm H2O, Fio2 at 100%, and the tidal volume at 6 ml/kg according to the Fio2 and PEEP table.32 The widely used practice in Wuhan, after lung recruitment maneuvers, is to set PEEP at 20 cm H2O and titrate down in a decrement of 2 to 3 cm H2O each time until the goals of oxygenation, plateau pressure, and compliance are all achieved.", [["lung", "ANATOMY", 207, 211], ["H2O", "CHEMICAL", 41, 44], ["H2O", "CHEMICAL", 75, 78], ["H2O", "CHEMICAL", 259, 262], ["H2O", "CHEMICAL", 308, 311], ["H2O", "CHEMICAL", 41, 44], ["H2O", "CHEMICAL", 75, 78], ["H2O", "CHEMICAL", 259, 262], ["H2O", "CHEMICAL", 308, 311], ["lung", "ORGAN", 207, 211], ["The plateau pressure", "TEST", 0, 20], ["the PEEP", "TEST", 50, 58], ["Fio2", "TREATMENT", 80, 84], ["the tidal volume", "TREATMENT", 98, 114], ["the Fio2", "TEST", 139, 147], ["lung recruitment maneuvers", "TREATMENT", 207, 233], ["PEEP", "TREATMENT", 245, 249], ["oxygenation, plateau pressure", "TEST", 341, 370], ["plateau", "OBSERVATION_MODIFIER", 4, 11], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["widely", "OBSERVATION_MODIFIER", 170, 176], ["lung", "ANATOMY", 207, 211], ["recruitment", "OBSERVATION", 212, 223], ["plateau pressure", "OBSERVATION", 354, 370]]], ["The commonly used PEEP in this patient population is less than 10 cm H2O.Ventilation ManagementNo mode of ventilation has been suggested to be superior to others.35 There is literature suggesting that high-frequency oscillatory ventilation may be an option for viral-induced lung injury.36 However, it may be best to avoid high-frequency oscillatory ventilation in patients with COVID-19 due to concerns of aerosol generation.19,37,383637 High-frequency oscillatory ventilation has not been used amid this outbreak in Wuhan.", [["lung", "ANATOMY", 275, 279], ["H2O", "CHEMICAL", 69, 72], ["lung injury", "DISEASE", 275, 286], ["H2O", "CHEMICAL", 69, 72], ["patient", "ORGANISM", 31, 38], ["lung", "ORGAN", 275, 279], ["patients", "ORGANISM", 365, 373], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 365, 373], ["PEEP", "TREATMENT", 18, 22], ["Ventilation", "TREATMENT", 73, 84], ["ventilation", "TREATMENT", 106, 117], ["high-frequency oscillatory ventilation", "TREATMENT", 201, 239], ["viral-induced lung injury", "PROBLEM", 261, 286], ["high-frequency oscillatory ventilation", "TREATMENT", 323, 361], ["COVID", "TEST", 379, 384], ["aerosol generation", "PROBLEM", 407, 425], ["High-frequency oscillatory ventilation", "TREATMENT", 439, 477], ["high", "OBSERVATION_MODIFIER", 201, 205], ["oscillatory ventilation", "OBSERVATION", 216, 239], ["lung", "ANATOMY", 275, 279], ["injury", "OBSERVATION", 280, 286], ["oscillatory ventilation", "OBSERVATION", 338, 361], ["aerosol generation", "OBSERVATION", 407, 425]]], ["Pressure-regulated volume control ventilation, although increasingly popular in the perioperative arena, has not gained momentum in ICUs due to the lack of evidence for its outcome benefits.", [["Pressure-regulated volume control ventilation", "TREATMENT", 0, 45], ["regulated", "OBSERVATION_MODIFIER", 9, 18], ["volume", "OBSERVATION_MODIFIER", 19, 25], ["control ventilation", "OBSERVATION", 26, 45], ["increasingly", "OBSERVATION_MODIFIER", 56, 68], ["popular", "OBSERVATION_MODIFIER", 69, 76]]], ["In patients with acute lung injury or ARDS, the tidal volume can markedly exceed the lung-protective ventilation target during pressure-regulated volume control ventilation,39 which is not desirable.", [["lung", "ANATOMY", 23, 27], ["lung", "ANATOMY", 85, 89], ["acute lung injury", "DISEASE", 17, 34], ["ARDS", "DISEASE", 38, 42], ["patients", "ORGANISM", 3, 11], ["lung", "ORGAN", 23, 27], ["lung", "ORGAN", 85, 89], ["patients", "SPECIES", 3, 11], ["acute lung injury", "PROBLEM", 17, 34], ["ARDS", "PROBLEM", 38, 42], ["the tidal volume", "TEST", 44, 60], ["the lung", "TEST", 81, 89], ["pressure-regulated volume control ventilation", "TREATMENT", 127, 172], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["lung", "ANATOMY", 23, 27], ["injury", "OBSERVATION", 28, 34], ["ARDS", "OBSERVATION", 38, 42], ["tidal volume", "OBSERVATION", 48, 60], ["lung", "ANATOMY", 85, 89], ["ventilation target", "OBSERVATION", 101, 119]]], ["Pressure-regulated volume control is not the preferred mode of ventilation in Wuhan.Ventilation ManagementVentilation in the prone position improves lung mechanics and gas exchange and is currently recommended by the guidelines.29,3029 The prone position, if planned, should not be a desperate final attempt but should be considered in the early stages of the disease,40 as the evidence suggests that the early application of prolonged ventilation in the prone position decreases 28- and 90-day mortality in patients with severe ARDS.41 Prone position ventilation is currently widely used for critically ill patients in Wuhan (fig. 9).", [["lung", "ANATOMY", 149, 153], ["ARDS", "DISEASE", 529, 533], ["critically ill", "DISEASE", 593, 607], ["lung", "ORGAN", 149, 153], ["patients", "ORGANISM", 508, 516], ["patients", "ORGANISM", 608, 616], ["patients", "SPECIES", 508, 516], ["patients", "SPECIES", 608, 616], ["Pressure-regulated volume control", "TREATMENT", 0, 33], ["Ventilation Management", "TREATMENT", 84, 106], ["Ventilation", "TREATMENT", 106, 117], ["lung mechanics", "TREATMENT", 149, 163], ["gas exchange", "TEST", 168, 180], ["the disease", "PROBLEM", 356, 367], ["prolonged ventilation", "TREATMENT", 426, 447], ["severe ARDS", "PROBLEM", 522, 533], ["Prone position ventilation", "TREATMENT", 537, 563], ["volume control", "OBSERVATION", 19, 33], ["lung", "ANATOMY", 149, 153], ["mechanics", "OBSERVATION", 154, 163], ["gas exchange", "OBSERVATION", 168, 180], ["disease", "OBSERVATION", 360, 367], ["early", "OBSERVATION_MODIFIER", 405, 410], ["prolonged ventilation", "OBSERVATION", 426, 447], ["severe", "OBSERVATION_MODIFIER", 522, 528], ["ARDS", "OBSERVATION", 529, 533]]], ["Lung recruitment maneuvers, via transient elevations in airway pressure applied during mechanical ventilation, can open collapsed alveoli and thus increase the number of alveoli available for gas exchange.", [["Lung", "ANATOMY", 0, 4], ["airway", "ANATOMY", 56, 62], ["alveoli", "ANATOMY", 130, 137], ["alveoli", "ANATOMY", 170, 177], ["Lung", "ORGAN", 0, 4], ["airway", "MULTI-TISSUE_STRUCTURE", 56, 62], ["alveoli", "MULTI-TISSUE_STRUCTURE", 130, 137], ["alveoli", "MULTI-TISSUE_STRUCTURE", 170, 177], ["Lung recruitment maneuvers", "TREATMENT", 0, 26], ["transient elevations", "PROBLEM", 32, 52], ["airway pressure", "TREATMENT", 56, 71], ["mechanical ventilation", "TREATMENT", 87, 109], ["open collapsed alveoli", "PROBLEM", 115, 137], ["gas exchange", "TEST", 192, 204], ["recruitment maneuvers", "OBSERVATION", 5, 26], ["transient", "OBSERVATION_MODIFIER", 32, 41], ["elevations", "OBSERVATION_MODIFIER", 42, 52], ["airway", "ANATOMY", 56, 62], ["pressure", "OBSERVATION_MODIFIER", 63, 71], ["mechanical ventilation", "OBSERVATION", 87, 109], ["collapsed", "OBSERVATION_MODIFIER", 120, 129], ["alveoli", "OBSERVATION", 130, 137], ["increase", "OBSERVATION_MODIFIER", 147, 155]]], ["Lung recruitment maneuvers do not significantly reduce mortality but may improve oxygenation and shorten the length of hospital stay in ARDS patients.42 Overall, recruitment maneuvers are not supported by high-quality evidence,43 and caution should be exercised when using it because it can be irritating, incite coughing, and generate aerosols.Ventilation ManagementAdjunct therapies can be considered.", [["Lung", "ANATOMY", 0, 4], ["ARDS", "DISEASE", 136, 140], ["coughing", "DISEASE", 313, 321], ["Lung", "ORGAN", 0, 4], ["patients", "ORGANISM", 141, 149], ["patients", "SPECIES", 141, 149], ["Lung recruitment maneuvers", "TREATMENT", 0, 26], ["recruitment maneuvers", "TREATMENT", 162, 183], ["incite coughing", "PROBLEM", 306, 321], ["Ventilation Management", "TREATMENT", 345, 367], ["Adjunct therapies", "TREATMENT", 367, 384], ["recruitment", "OBSERVATION", 5, 16], ["recruitment maneuvers", "OBSERVATION", 162, 183]]], ["Many patients with acute hypoxemic respiratory failure due to COVID-19 have breathing overdrive.", [["respiratory", "ANATOMY", 35, 46], ["hypoxemic respiratory failure", "DISEASE", 25, 54], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["acute hypoxemic respiratory failure", "PROBLEM", 19, 54], ["COVID", "TEST", 62, 67], ["breathing overdrive", "PROBLEM", 76, 95], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["hypoxemic", "OBSERVATION_MODIFIER", 25, 34], ["respiratory failure", "OBSERVATION", 35, 54]]], ["Appropriate sedation and analgesia, such as dexmedetomidine, propofol and remifentanil infusion, are warranted.", [["dexmedetomidine", "CHEMICAL", 44, 59], ["propofol", "CHEMICAL", 61, 69], ["remifentanil", "CHEMICAL", 74, 86], ["dexmedetomidine", "CHEMICAL", 44, 59], ["propofol", "CHEMICAL", 61, 69], ["remifentanil", "CHEMICAL", 74, 86], ["dexmedetomidine", "SIMPLE_CHEMICAL", 44, 59], ["propofol", "SIMPLE_CHEMICAL", 61, 69], ["remifentanil", "SIMPLE_CHEMICAL", 74, 86], ["Appropriate sedation", "TREATMENT", 0, 20], ["analgesia", "TREATMENT", 25, 34], ["dexmedetomidine", "TREATMENT", 44, 59], ["propofol", "TREATMENT", 61, 69], ["remifentanil infusion", "TREATMENT", 74, 95]]], ["The outcome evidence related to the use of muscle relaxants has been controversial.44,4544 A recent meta-analysis concluded that muscle relaxants improve oxygenation after 48 h, but do not reduce mortality in moderate and severe ARDS patients.46 Nonetheless, muscle relaxation should be considered in cases of breathing overdrive, patient\u2013ventilator dyssynchrony, and inability to achieve the targeted tidal volume and plateau pressure.", [["muscle", "ANATOMY", 43, 49], ["muscle", "ANATOMY", 129, 135], ["muscle", "ANATOMY", 259, 265], ["ARDS", "DISEASE", 229, 233], ["muscle relaxation", "DISEASE", 259, 276], ["muscle", "ORGAN", 43, 49], ["muscle", "ORGAN", 129, 135], ["patients", "ORGANISM", 234, 242], ["muscle", "ORGAN", 259, 265], ["patients", "SPECIES", 234, 242], ["muscle relaxants", "TREATMENT", 43, 59], ["A recent meta-analysis", "TEST", 91, 113], ["muscle relaxants", "TREATMENT", 129, 145], ["moderate and severe ARDS patients", "PROBLEM", 209, 242], ["muscle relaxation", "TREATMENT", 259, 276], ["breathing overdrive", "PROBLEM", 310, 329], ["patient\u2013ventilator dyssynchrony", "PROBLEM", 331, 362], ["the targeted tidal volume", "TEST", 389, 414], ["plateau pressure", "TEST", 419, 435], ["muscle", "ANATOMY", 129, 135], ["moderate", "OBSERVATION_MODIFIER", 209, 217], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["ARDS", "OBSERVATION", 229, 233], ["muscle", "ANATOMY", 259, 265], ["tidal volume", "OBSERVATION", 402, 414], ["plateau pressure", "OBSERVATION", 419, 435]]], ["It is appropriate to be conservative with intravenous fluids in patients with severe lung injury if there are no signs of tissue hypoperfusion.29 Conservative fluid therapy is the strategy used in Wuhan.", [["intravenous", "ANATOMY", 42, 53], ["lung", "ANATOMY", 85, 89], ["tissue", "ANATOMY", 122, 128], ["fluid", "ANATOMY", 159, 164], ["lung injury", "DISEASE", 85, 96], ["hypoperfusion", "DISEASE", 129, 142], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 42, 53], ["patients", "ORGANISM", 64, 72], ["lung", "ORGAN", 85, 89], ["tissue", "TISSUE", 122, 128], ["patients", "SPECIES", 64, 72], ["intravenous fluids", "TREATMENT", 42, 60], ["severe lung injury", "PROBLEM", 78, 96], ["tissue hypoperfusion", "PROBLEM", 122, 142], ["Conservative fluid therapy", "TREATMENT", 146, 172], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["lung", "ANATOMY", 85, 89], ["injury", "OBSERVATION", 90, 96], ["no signs of", "UNCERTAINTY", 110, 121], ["tissue", "ANATOMY", 122, 128], ["hypoperfusion", "OBSERVATION", 129, 142], ["fluid therapy", "OBSERVATION", 159, 172]]], ["It is important to avoid corticosteroid treatment, given that this treatment has been shown to increase mortality and hospital-acquired infections in patients with severe influenza.47\u201349 However, the most recent study suggested that early dexamethasone administration may reduce overall mortality and mechanical ventilation duration in ARDS patients.50 Corticosteroid treatment is currently used in selected patients with severe inflammatory lung injury in Wuhan.", [["lung", "ANATOMY", 442, 446], ["infections", "DISEASE", 136, 146], ["influenza", "DISEASE", 171, 180], ["dexamethasone", "CHEMICAL", 239, 252], ["ARDS", "DISEASE", 336, 340], ["inflammatory lung injury", "DISEASE", 429, 453], ["dexamethasone", "CHEMICAL", 239, 252], ["corticosteroid", "SIMPLE_CHEMICAL", 25, 39], ["patients", "ORGANISM", 150, 158], ["dexamethasone", "SIMPLE_CHEMICAL", 239, 252], ["patients", "ORGANISM", 341, 349], ["patients", "ORGANISM", 408, 416], ["lung", "ORGAN", 442, 446], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 341, 349], ["patients", "SPECIES", 408, 416], ["corticosteroid treatment", "TREATMENT", 25, 49], ["this treatment", "TREATMENT", 62, 76], ["hospital-acquired infections", "PROBLEM", 118, 146], ["severe influenza", "PROBLEM", 164, 180], ["the most recent study", "TEST", 196, 217], ["early dexamethasone administration", "TREATMENT", 233, 267], ["mechanical ventilation duration", "TREATMENT", 301, 332], ["ARDS", "PROBLEM", 336, 340], ["Corticosteroid treatment", "TREATMENT", 353, 377], ["severe inflammatory lung injury", "PROBLEM", 422, 453], ["severe", "OBSERVATION_MODIFIER", 164, 170], ["influenza", "OBSERVATION", 171, 180], ["mechanical ventilation", "OBSERVATION", 301, 323], ["severe", "OBSERVATION_MODIFIER", 422, 428], ["inflammatory", "OBSERVATION_MODIFIER", 429, 441], ["lung", "ANATOMY", 442, 446], ["injury", "OBSERVATION", 447, 453]]], ["Disconnecting the patient from the ventilator results in loss of PEEP and atelectasis, and it should be avoided.", [["atelectasis", "DISEASE", 74, 85], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["the ventilator", "TREATMENT", 31, 45], ["PEEP", "TREATMENT", 65, 69], ["atelectasis", "PROBLEM", 74, 85], ["loss", "OBSERVATION_MODIFIER", 57, 61], ["atelectasis", "OBSERVATION", 74, 85]]], ["In-line catheters for airway suctioning and endotracheal tube clamping are recommended before disconnecting breathing circuits.Ventilation ManagementExtracorporeal membrane oxygenation was successfully used in patients with severe influenza5051 and may play an important role in select patients.", [["airway", "ANATOMY", 22, 28], ["endotracheal tube", "ANATOMY", 44, 61], ["Extracorporeal membrane", "ANATOMY", 149, 172], ["influenza5051", "CHEMICAL", 231, 244], ["influenza5051", "CHEMICAL", 231, 244], ["airway", "MULTI-TISSUE_STRUCTURE", 22, 28], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 44, 61], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 149, 172], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 286, 294], ["In-line catheters", "TREATMENT", 0, 17], ["airway suctioning", "TREATMENT", 22, 39], ["endotracheal tube clamping", "TREATMENT", 44, 70], ["disconnecting breathing circuits", "TREATMENT", 94, 126], ["Ventilation Management", "TREATMENT", 127, 149], ["Extracorporeal membrane oxygenation", "TREATMENT", 149, 184], ["severe influenza5051", "PROBLEM", 224, 244], ["line catheters", "OBSERVATION", 3, 17], ["airway", "ANATOMY", 22, 28], ["suctioning", "OBSERVATION", 29, 39], ["endotracheal", "OBSERVATION", 44, 56], ["tube clamping", "OBSERVATION", 57, 70]]], ["A recent review concluded that the potential of extracorporeal membrane oxygenation in reducing mortality in patients with ARDS due to H1N1 infection was apparent and that extracorporeal membrane oxygenation should be used as a salvage option in severely hypoxemic ARDS patients.52 The Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) trial showed that there is a potential role for extracorporeal membrane oxygenation\u2013based management protocols in patients with severe but potentially reversible respiratory failure, and these protocols may improve survival without causing severe disabilities.53 The ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial showed that extracorporeal membrane oxygenation was not able to significantly reduce 60-day mortality in patients with very severe ARDS;54 however, the post hoc Bayesian analysis suggested a potential mortality benefit under a broad set of assumptions.55 Extracorporeal membrane oxygenation has been used in some critically ill patients with COVID-19 in Wuhan.", [["extracorporeal membrane", "ANATOMY", 48, 71], ["extracorporeal membrane", "ANATOMY", 172, 195], ["extracorporeal membrane", "ANATOMY", 412, 435], ["respiratory", "ANATOMY", 526, 537], ["Lung", "ANATOMY", 646, 650], ["extracorporeal membrane", "ANATOMY", 699, 722], ["Extracorporeal membrane", "ANATOMY", 942, 965], ["ARDS", "DISEASE", 123, 127], ["infection", "DISEASE", 140, 149], ["ARDS", "DISEASE", 265, 269], ["Respiratory Failure", "DISEASE", 336, 355], ["respiratory failure", "DISEASE", 526, 545], ["Lung Injury", "DISEASE", 646, 657], ["ARDS", "DISEASE", 668, 672], ["ARDS", "DISEASE", 818, 822], ["critically ill", "DISEASE", 1000, 1014], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 48, 71], ["patients", "ORGANISM", 109, 117], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 172, 195], ["patients", "ORGANISM", 270, 278], ["patients", "ORGANISM", 478, 486], ["Lung", "ORGAN", 646, 650], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 699, 722], ["patients", "ORGANISM", 792, 800], ["Extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 942, 965], ["patients", "ORGANISM", 1015, 1023], ["patients", "SPECIES", 109, 117], ["patients", "SPECIES", 270, 278], ["patients", "SPECIES", 478, 486], ["patients", "SPECIES", 792, 800], ["patients", "SPECIES", 1015, 1023], ["extracorporeal membrane oxygenation", "TREATMENT", 48, 83], ["ARDS", "PROBLEM", 123, 127], ["H1N1 infection", "PROBLEM", 135, 149], ["extracorporeal membrane oxygenation", "TREATMENT", 172, 207], ["a salvage option", "TREATMENT", 226, 242], ["severely hypoxemic ARDS patients", "PROBLEM", 246, 278], ["The Conventional Ventilation", "TREATMENT", 282, 310], ["ECMO", "TREATMENT", 314, 318], ["Severe Adult Respiratory Failure", "PROBLEM", 323, 355], ["extracorporeal membrane oxygenation\u2013based management protocols", "TREATMENT", 412, 474], ["potentially reversible respiratory failure", "PROBLEM", 503, 545], ["these protocols", "TREATMENT", 551, 566], ["severe disabilities", "PROBLEM", 604, 623], ["The ECMO", "TREATMENT", 627, 635], ["Rescue Lung Injury", "PROBLEM", 639, 657], ["Severe ARDS", "PROBLEM", 661, 672], ["extracorporeal membrane oxygenation", "TREATMENT", 699, 734], ["very severe ARDS", "PROBLEM", 806, 822], ["hoc Bayesian analysis", "TEST", 844, 865], ["Extracorporeal membrane oxygenation", "TREATMENT", 942, 977], ["COVID", "TEST", 1029, 1034], ["extracorporeal membrane oxygenation", "OBSERVATION", 48, 83], ["infection", "OBSERVATION", 140, 149], ["hypoxemic", "OBSERVATION_MODIFIER", 255, 264], ["ARDS", "OBSERVATION", 265, 269], ["Severe", "OBSERVATION_MODIFIER", 323, 329], ["Respiratory Failure", "OBSERVATION", 336, 355], ["reversible", "OBSERVATION_MODIFIER", 515, 525], ["respiratory failure", "OBSERVATION", 526, 545], ["Lung", "ANATOMY", 646, 650], ["Injury", "OBSERVATION", 651, 657], ["Severe", "OBSERVATION_MODIFIER", 661, 667], ["ARDS", "OBSERVATION", 668, 672], ["extracorporeal membrane", "OBSERVATION", 699, 722], ["severe", "OBSERVATION_MODIFIER", 811, 817], ["ARDS", "OBSERVATION", 818, 822], ["membrane oxygenation", "OBSERVATION", 957, 977]]], ["More than 40 extracorporeal membrane oxygenation cases (combined) have been treated in Zhongnan Hospital, Jin Yin Tan Hospital, and Lung Hospital in Wuhan.", [["extracorporeal membrane", "ANATOMY", 13, 36], ["Lung", "ANATOMY", 132, 136], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 13, 36], ["40 extracorporeal membrane oxygenation cases", "TREATMENT", 10, 54], ["Lung", "ANATOMY", 132, 136]]], ["The outcomes of these patients remain to be analyzed.SummaryThe COVID-19 outbreak is a sweeping and unprecedented challenge in China.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID-19", "SPECIES", 64, 72]]], ["Its impacts are currently rapidly unfolding outside of China.", [["impacts", "OBSERVATION_MODIFIER", 4, 11], ["rapidly", "OBSERVATION_MODIFIER", 26, 33], ["unfolding", "OBSERVATION", 34, 43]]], ["As of March 4, 2020, COVID-19 was confirmed in 80,409 patients and led to 3,012 deaths in mainland China.", [["deaths", "DISEASE", 80, 86], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["COVID", "TEST", 21, 26]]], ["Approximately 3.2% of patients with COVID-19 received intubation and invasive ventilation support.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 36, 41], ["intubation", "TREATMENT", 54, 64], ["invasive ventilation support", "TREATMENT", 69, 97], ["ventilation support", "OBSERVATION", 78, 97]]], ["How to provide the best practices of intubation and ventilation amid this mass medical emergency is a real but unprecedented question.", [["intubation", "TREATMENT", 37, 47], ["ventilation", "TREATMENT", 52, 63]]], ["In this article, we summarize the firsthand experience pertinent to intubation and ventilation management from the physicians who are taking care of the critically ill patients with COVID-19 in Wuhan.", [["critically ill", "DISEASE", 153, 167], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["intubation", "TREATMENT", 68, 78], ["ventilation management", "TREATMENT", 83, 105], ["COVID", "TREATMENT", 182, 187]]], ["In patients with acute refractory hypoxemic respiratory failure, timely, but not premature, intubation and invasive ventilation support may be superior to high-flow oxygen therapy and bilevel positive airway pressure ventilation in boosting transpulmonary pressure, opening collapsed alveoli, improving oxygenation, decreasing oxygen debt, and offering a better chance for the lungs to heal.", [["respiratory", "ANATOMY", 44, 55], ["airway", "ANATOMY", 201, 207], ["transpulmonary", "ANATOMY", 241, 255], ["alveoli", "ANATOMY", 284, 291], ["lungs", "ANATOMY", 377, 382], ["hypoxemic respiratory failure", "DISEASE", 34, 63], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "CHEMICAL", 327, 333], ["oxygen", "CHEMICAL", 165, 171], ["oxygen", "CHEMICAL", 327, 333], ["patients", "ORGANISM", 3, 11], ["oxygen", "SIMPLE_CHEMICAL", 165, 171], ["airway", "MULTI-TISSUE_STRUCTURE", 201, 207], ["alveoli", "MULTI-TISSUE_STRUCTURE", 284, 291], ["oxygen", "SIMPLE_CHEMICAL", 327, 333], ["lungs", "ORGAN", 377, 382], ["patients", "SPECIES", 3, 11], ["acute refractory hypoxemic respiratory failure", "PROBLEM", 17, 63], ["intubation", "TREATMENT", 92, 102], ["invasive ventilation support", "TREATMENT", 107, 135], ["high-flow oxygen therapy", "TREATMENT", 155, 179], ["bilevel positive airway pressure ventilation", "TREATMENT", 184, 228], ["boosting transpulmonary pressure", "TREATMENT", 232, 264], ["opening collapsed alveoli", "PROBLEM", 266, 291], ["decreasing oxygen debt", "TREATMENT", 316, 338], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["refractory", "OBSERVATION_MODIFIER", 23, 33], ["hypoxemic", "OBSERVATION_MODIFIER", 34, 43], ["respiratory failure", "OBSERVATION", 44, 63], ["flow oxygen therapy", "OBSERVATION", 160, 179], ["airway pressure", "OBSERVATION", 201, 216], ["transpulmonary pressure", "OBSERVATION", 241, 264], ["collapsed", "OBSERVATION_MODIFIER", 274, 283], ["alveoli", "OBSERVATION_MODIFIER", 284, 291], ["improving", "OBSERVATION_MODIFIER", 293, 302], ["oxygenation", "OBSERVATION_MODIFIER", 303, 314], ["oxygen debt", "OBSERVATION", 327, 338], ["lungs", "ANATOMY", 377, 382], ["heal", "OBSERVATION", 386, 390]]], ["The invasive nature of intubation and ventilation exposes patients to an augmented risk of procedure-related mishaps.", [["patients", "ORGANISM", 58, 66], ["patients", "SPECIES", 58, 66], ["intubation", "TREATMENT", 23, 33], ["ventilation", "TREATMENT", 38, 49], ["procedure", "TREATMENT", 91, 100], ["invasive", "OBSERVATION_MODIFIER", 4, 12], ["intubation", "OBSERVATION", 23, 33]]], ["At the same time, these procedures present healthcare providers with an enhanced risk of cross-infection; thus, strict self-protection precautions are mandatory.AcknowledgmentsThis article was made possible by the generous sharing of firsthand experience from the physicians who had participated in the webinars held in February 2020.", [["cross-infection", "PROBLEM", 89, 104], ["strict self-protection precautions", "TREATMENT", 112, 146], ["cross-infection", "OBSERVATION", 89, 104]]], ["The authors thank Dr. Lize Xiong (Shanghai Fourth People\u2019s Hospital, Shanghai, China), Drs. Yuhang Ai, Qulian Guo, and Jie Meng (Central South University Xiangya Hospital, Changsha, China), Dr. Zhanggang Xue (Fudan University Zhongshan Hospital, Shanghai, China), Drs. Chunchun Zhai, Qianqian Qiao, and Wenfang Xia (Renmin Hospital of Wuhan University, Wuhan, China), Dr. Chuanyao Tong (Wake Forest University, Winston-Salem, North Carolina), and Dr. Hong Liu (University of California Davis Medical Center, Sacramento, California) for their participation in the first webinar held on February 8, 2020, discussing the preparedness of anesthesiologists and intensivists amid the COVID-19 outbreak.", [["the COVID", "TEST", 674, 683]]], ["The authors also thank Dr. Lize Xiong (Shanghai Fourth People\u2019s Hospital, Shanghai, China), Dr. Dan Liu (West China Hospital, Chengdu, China), Dr. Zhanggang Xue (Fudan University Zhongshan Hospital, Shanghai, China), Dr. Mingzhang Zuo (Beijing Hospital, Beijing, China), Dr. Wuhua Ma (The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine, Guangzhou, China), Dr. Hongfei Zhang (Guangzhou Zhujiang Hospital, Guangzhou, China), Dr. Huafeng Wei (University of Pennsylvania, Philadelphia, Pennsylvania), Dr. Liming Zhang (University of Pittsburgh, Pittsburgh, Pennsylvania), and Drs. Chunchun Zhai and Qianqian Qiao (Renmin Hospital of Wuhan University, Wuhan, China) for their participation in the second webinar held on February 15, 2020, discussing airway management amid the COVID-19 outbreak.", [["airway", "ANATOMY", 780, 786], ["airway", "MULTI-TISSUE_STRUCTURE", 780, 786], ["airway management", "TREATMENT", 780, 797], ["the COVID", "TEST", 803, 812], ["airway", "ANATOMY", 780, 786]]], ["The authors also thank Dr. Shanglong Yao (Wuhan Union Hospital, Wuhan, China), Drs. Haibo Qiu and Yi Yang (Southeast University Zhongda Hospital, Nanjing, China), Dr. Hongliang Wang (Harbin Medical University Affiliated Second Hospital, Harbin, China), Dr. Wei Fang (The Affiliated Hospital of Qingdao University, Qingdao, China), Dr. Xiuling Shang (Fujian Provincial Hospital, Fuzhou, China), Dr. Lina Zhang (Central South University Xiangya Hospital, Changsha, China), Dr. Dongxin Wang (Peking University First Hospital, Beijing, China), Dr. Zhanggang Xue (Fudan University Zhongshan Hospital, Shanghai, China), and Dr. Chuanyao Tong (Wake Forest University, Winston-Salem, North Carolina) for their participation in the third webinar held on February 22, 2020, discussing lung-protective ventilation and the goal of oxygenation amid the COVID-19 outbreak.", [["lung", "ANATOMY", 775, 779], ["lung", "ORGAN", 775, 779], ["lung-protective ventilation", "TREATMENT", 775, 802], ["the COVID", "TEST", 836, 845], ["lung", "ANATOMY", 775, 779], ["protective ventilation", "OBSERVATION", 780, 802]]], ["The authors also thank Dr. Zhaohui Tong and Dr. Xuyan Li (Beijing Chaoyang Hospital, Beijing, China), Dr. Xiaotong Hou (Beijing Anzhen Hospital, Beijing China), Dr. Ming Hu (Wuhan Pulmonary Hospital, Wuhan, China), Dr. Bo Hu (Wuhan Zhongnan Hospital, Wuhan, China), Dr. Ming Zhong (Fudan University Zhongshan Hospital, Shanghai, China), Dr. Ruiqiang Zheng (Su Bei People\u2019s Hoispital, Yangzhou, China), Drs. Haibo Qiu, Chun Pan, and Jianfeng Xie (Southeast University Zhongda Hospital, Nanjing, China), and Dr. Hong Liu (University of California David Medical Center, Sacramento, California) for their participation in the fourth webinar held on February 29, 2020, discussing extracorporeal membrane oxygenation amid the COVID-19 outbreak.", [["extracorporeal membrane", "ANATOMY", 675, 698], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 675, 698], ["extracorporeal membrane oxygenation", "TREATMENT", 675, 710], ["the COVID", "TEST", 716, 725], ["Pulmonary", "ANATOMY", 180, 189]]], ["We thank Dr. Xu Zhao (Xiangya Medical School, Central South University, Changsha, China) for his assistance with the literature search, data analysis, and manuscript preparation.Research SupportThis work was supported, in part, by research grant No. 2020YFC0843700 from the Ministry of Science and Technology of the People\u2019s Republic of China (Beijing, China; to Dr. Haibo Qiu).", [["2020YFC0843700", "CHEMICAL", 250, 264], ["data analysis", "TEST", 136, 149]]]], "PMC7123067": [["Aetiology and Pathogenesis ::: MalariaAfter the Anopheles mosquito aspirates with gametocytes infected blood, the gametocytes develop to gamete in the mosquito\u2019s intestines.", [["aspirates", "ANATOMY", 67, 76], ["blood", "ANATOMY", 103, 108], ["gametocytes", "ANATOMY", 114, 125], ["gamete", "ANATOMY", 137, 143], ["intestines", "ANATOMY", 162, 172], ["Anopheles mosquito", "ORGANISM", 48, 66], ["gametocytes", "CELL", 82, 93], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["gametocytes", "CELL", 114, 125], ["mosquito", "ORGANISM", 151, 159], ["intestines", "ORGAN", 162, 172], ["the Anopheles mosquito aspirates", "PROBLEM", 44, 76], ["gametocytes infected blood", "PROBLEM", 82, 108], ["the gametocytes", "PROBLEM", 110, 125], ["intestines", "ANATOMY", 162, 172]]], ["In the blood of the mosquito, the microgametes (male) penetrate the macrogametes (female), forming zygotes.", [["blood", "ANATOMY", 7, 12], ["microgametes", "ANATOMY", 34, 46], ["macrogametes", "ANATOMY", 68, 80], ["zygotes", "ANATOMY", 99, 106], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["mosquito", "ORGANISM", 20, 28], ["zygotes", "CELL", 99, 106]]], ["Then cells are changed to an elongated, motile ookinete.", [["cells", "ANATOMY", 5, 10], ["ookinete", "ANATOMY", 47, 55], ["cells", "CELL", 5, 10], ["ookinete", "CELL", 47, 55], ["elongated", "OBSERVATION_MODIFIER", 29, 38], ["motile ookinete", "OBSERVATION", 40, 55]]], ["This evolves into an oocyst.", [["oocyst", "ANATOMY", 21, 27], ["an oocyst", "PROBLEM", 18, 27], ["oocyst", "OBSERVATION", 21, 27]]], ["After the oocyst bursts, sporozoites are released and get in the saliva of the mosquito.", [["sporozoites", "ANATOMY", 25, 36], ["saliva", "ANATOMY", 65, 71], ["sporozoites", "CELL", 25, 36], ["saliva", "ORGANISM_SUBSTANCE", 65, 71], ["the oocyst bursts", "PROBLEM", 6, 23], ["sporozoites", "PROBLEM", 25, 36], ["oocyst", "OBSERVATION_MODIFIER", 10, 16], ["bursts", "OBSERVATION_MODIFIER", 17, 23]]], ["If sporozoites enter the human bloodstream through the saliva of the mosquito, liver cells via the bloodstream get infected.", [["sporozoites", "ANATOMY", 3, 14], ["bloodstream", "ANATOMY", 31, 42], ["saliva", "ANATOMY", 55, 61], ["liver cells", "ANATOMY", 79, 90], ["bloodstream", "ANATOMY", 99, 110], ["sporozoites", "CELL", 3, 14], ["human", "ORGANISM", 25, 30], ["saliva", "ORGANISM_SUBSTANCE", 55, 61], ["liver cells", "CELL", 79, 90], ["liver cells", "CELL_TYPE", 79, 90], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["sporozoites", "PROBLEM", 3, 14], ["infected", "PROBLEM", 115, 123], ["liver", "ANATOMY", 79, 84], ["bloodstream", "ANATOMY", 99, 110], ["infected", "OBSERVATION", 115, 123]]], ["They penetrate liver cells and turn into schizonts (exo-erythrocytes cycle).", [["liver cells", "ANATOMY", 15, 26], ["schizonts", "ANATOMY", 41, 50], ["erythrocytes", "ANATOMY", 56, 68], ["liver cells", "CELL", 15, 26], ["schizonts", "CELL", 41, 50], ["erythrocytes", "CELL", 56, 68], ["liver cells", "CELL_TYPE", 15, 26], ["schizonts (exo-erythrocytes cycle", "TEST", 41, 74], ["liver", "ANATOMY", 15, 20]]], ["With the exception of P. oval, merozoites are released in the bloodstream after the liver cycle (exoerythrocytic cycle).", [["merozoites", "ANATOMY", 31, 41], ["bloodstream", "ANATOMY", 62, 73], ["liver", "ANATOMY", 84, 89], ["P.", "ORGANISM", 22, 24], ["merozoites", "CELL", 31, 41], ["liver", "ORGAN", 84, 89], ["P. oval", "PROBLEM", 22, 29], ["merozoites", "PROBLEM", 31, 41], ["the liver cycle", "TEST", 80, 95], ["oval", "OBSERVATION_MODIFIER", 25, 29], ["liver", "ANATOMY", 84, 89]]], ["P. vivax and P. ovale produce hypnozoites, which can stay dormant in liver cells.", [["liver cells", "ANATOMY", 69, 80], ["P. vivax", "DISEASE", 0, 8], ["P. vivax", "ORGANISM", 0, 8], ["P. ovale", "ORGANISM", 13, 21], ["hypnozoites", "GENE_OR_GENE_PRODUCT", 30, 41], ["liver cells", "CELL", 69, 80], ["liver cells", "CELL_TYPE", 69, 80], ["P. vivax", "SPECIES", 0, 8], ["P. vivax", "SPECIES", 0, 8], ["P. ovale", "SPECIES", 13, 21], ["vivax", "PROBLEM", 3, 8], ["hypnozoites", "PROBLEM", 30, 41], ["liver", "ANATOMY", 69, 74]]], ["Merozoites enter red blood cells and multiply there asexually.", [["Merozoites", "ANATOMY", 0, 10], ["red blood cells", "ANATOMY", 17, 32], ["Merozoites", "CELL", 0, 10], ["red blood cells", "CELL", 17, 32], ["Merozoites", "CELL_TYPE", 0, 10], ["red blood cells", "CELL_TYPE", 17, 32], ["Merozoites", "TREATMENT", 0, 10], ["red blood cells", "TEST", 17, 32], ["red blood cells", "OBSERVATION", 17, 32]]], ["By rupturing erythrocytes, merozoites are released, which some of them are infecting other erythrocytes.", [["erythrocytes", "ANATOMY", 13, 25], ["merozoites", "ANATOMY", 27, 37], ["erythrocytes", "ANATOMY", 91, 103], ["erythrocytes", "CELL", 13, 25], ["merozoites", "CELL", 27, 37], ["erythrocytes", "CELL", 91, 103], ["erythrocytes", "CELL_TYPE", 13, 25], ["merozoites", "CELL_TYPE", 27, 37], ["erythrocytes", "CELL_TYPE", 91, 103], ["rupturing erythrocytes", "PROBLEM", 3, 25], ["merozoites", "PROBLEM", 27, 37], ["rupturing erythrocytes", "OBSERVATION", 3, 25], ["merozoites", "OBSERVATION_MODIFIER", 27, 37]]], ["The blood stage parasites are responsible of the typical malaria symptoms.", [["blood", "ANATOMY", 4, 9], ["malaria", "DISEASE", 57, 64], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["The blood stage parasites", "PROBLEM", 0, 25], ["the typical malaria symptoms", "PROBLEM", 45, 73], ["blood stage", "OBSERVATION_MODIFIER", 4, 15], ["parasites", "OBSERVATION", 16, 25], ["typical", "OBSERVATION_MODIFIER", 49, 56], ["malaria", "OBSERVATION", 57, 64]]], ["Some merozoites differentiate into gametocytes, after being aspirated by the mosquitoes.", [["merozoites", "ANATOMY", 5, 15], ["gametocytes", "ANATOMY", 35, 46], ["merozoites", "CELL", 5, 15], ["gametocytes", "CELL", 35, 46], ["gametocytes", "CELL_TYPE", 35, 46], ["Some merozoites", "PROBLEM", 0, 15], ["merozoites", "OBSERVATION", 5, 15], ["gametocytes", "OBSERVATION_MODIFIER", 35, 46]]], ["Again, in a mosquito infected with the pathogen, transfer of the parasite to someone else is possible (\u25d8 Table 32.2, \u25d8 Fig. 32.1).Symptoms ::: MalariaSymptoms of malaria appear after the incubation period.", [["mosquito infected", "DISEASE", 12, 29], ["malaria", "DISEASE", 162, 169], ["the pathogen", "PROBLEM", 35, 47], ["Symptoms", "PROBLEM", 130, 138], ["malaria", "PROBLEM", 162, 169], ["malaria", "OBSERVATION", 162, 169]]], ["The incubation period varies depending on the pathogen.", [["the pathogen", "PROBLEM", 42, 54]]], ["It can be between a few weeks and also takes up to several months or even a year (P. vivax or occasionally P. ovale).", [["P. vivax or occasionally P. ovale", "DISEASE", 82, 115], ["P. vivax", "ORGANISM", 82, 90], ["P. ovale", "ORGANISM", 107, 115], ["P. vivax", "SPECIES", 82, 90], ["P. vivax", "SPECIES", 82, 90]]], ["Malaria can be divided in three different forms:Malaria tertiana: Pathogen: P. vivax and P. ovale; fever every second day with one day without fever, spontaneous remission after max.", [["Malaria", "DISEASE", 0, 7], ["P. vivax and P. ovale", "DISEASE", 76, 97], ["fever", "DISEASE", 99, 104], ["fever", "DISEASE", 143, 148], ["P. vivax", "ORGANISM", 76, 84], ["P. ovale", "ORGANISM", 89, 97], ["P. vivax", "SPECIES", 76, 84], ["P. ovale", "SPECIES", 89, 97], ["P. vivax", "SPECIES", 76, 84], ["P. ovale", "SPECIES", 89, 97], ["Malaria", "PROBLEM", 0, 7], ["vivax", "PROBLEM", 79, 84], ["fever", "PROBLEM", 99, 104], ["fever", "PROBLEM", 143, 148], ["spontaneous remission", "PROBLEM", 150, 171]]], ["5 yearsMalaria quartana: Pathogen: P. malaria; fever every third day with 2 days without fever, no spontaneous remissionMalaria tropica: Pathogen: P. falciparum, irregular fevers due to the lack of synchronisation of the parasite reproduction, severe form of malaria (Malaria maligna) with high fatality, recurrence up to 2 yearsSymptoms ::: MalariaThe fever has a specific pattern.", [["P. malaria", "DISEASE", 35, 45], ["fever", "DISEASE", 47, 52], ["fever", "DISEASE", 89, 94], ["Malaria tropica", "DISEASE", 120, 135], ["P. falciparum", "DISEASE", 147, 160], ["irregular fevers", "DISEASE", 162, 178], ["parasite reproduction", "DISEASE", 221, 242], ["malaria", "DISEASE", 259, 266], ["Malaria maligna", "DISEASE", 268, 283], ["Malaria", "DISEASE", 342, 349], ["fever", "DISEASE", 353, 358], ["P. malaria", "ORGANISM", 35, 45], ["P. falciparum", "ORGANISM", 147, 160], ["Malaria", "ORGANISM", 342, 349], ["P. falciparum", "SPECIES", 147, 160], ["P. falciparum", "SPECIES", 147, 160], ["malaria", "PROBLEM", 38, 45], ["fever", "PROBLEM", 47, 52], ["fever", "PROBLEM", 89, 94], ["spontaneous remissionMalaria tropica", "PROBLEM", 99, 135], ["P. falciparum", "PROBLEM", 147, 160], ["irregular fevers", "PROBLEM", 162, 178], ["the parasite reproduction", "PROBLEM", 217, 242], ["malaria (Malaria maligna", "PROBLEM", 259, 283], ["high fatality", "PROBLEM", 290, 303], ["recurrence", "PROBLEM", 305, 315], ["Malaria", "PROBLEM", 342, 349], ["The fever", "PROBLEM", 349, 358], ["no", "UNCERTAINTY", 96, 98], ["severe", "OBSERVATION_MODIFIER", 244, 250], ["malaria", "OBSERVATION", 259, 266], ["fever", "OBSERVATION", 353, 358]]], ["In the first hour, strong rigors and increasing fever typically develop.", [["fever", "DISEASE", 48, 53], ["strong rigors", "PROBLEM", 19, 32], ["increasing fever", "PROBLEM", 37, 53], ["strong", "OBSERVATION_MODIFIER", 19, 25], ["rigors", "OBSERVATION", 26, 32], ["increasing", "OBSERVATION_MODIFIER", 37, 47], ["fever", "OBSERVATION", 48, 53]]], ["The fever can reach 40 \u00b0C and more for duration of about 4 h.", [["fever", "DISEASE", 4, 9], ["The fever", "PROBLEM", 0, 9], ["fever", "OBSERVATION", 4, 9]]], ["It is often associated with flushing, vomiting and nausea.", [["flushing", "DISEASE", 28, 36], ["vomiting", "DISEASE", 38, 46], ["nausea", "DISEASE", 51, 57], ["flushing", "PROBLEM", 28, 36], ["vomiting", "PROBLEM", 38, 46], ["nausea", "PROBLEM", 51, 57], ["flushing", "OBSERVATION", 28, 36]]], ["The fever stage is followed by an approximately 3-h stage of severe sweating with decreasing fever.", [["fever", "DISEASE", 4, 9], ["sweating", "DISEASE", 68, 76], ["fever", "DISEASE", 93, 98], ["The fever stage", "PROBLEM", 0, 15], ["severe sweating", "PROBLEM", 61, 76], ["decreasing fever", "PROBLEM", 82, 98], ["fever", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["sweating", "OBSERVATION", 68, 76], ["decreasing", "OBSERVATION_MODIFIER", 82, 92], ["fever", "OBSERVATION", 93, 98]]], ["Severe forms of malaria can be fatal in within few days.", [["malaria", "DISEASE", 16, 23], ["malaria", "PROBLEM", 16, 23], ["malaria", "OBSERVATION", 16, 23]]], ["Causes of death are cerebral malaria, respiratory failure with ADRS and kidney failure.", [["cerebral", "ANATOMY", 20, 28], ["respiratory", "ANATOMY", 38, 49], ["kidney", "ANATOMY", 72, 78], ["death", "DISEASE", 10, 15], ["cerebral malaria", "DISEASE", 20, 36], ["respiratory failure", "DISEASE", 38, 57], ["ADRS", "DISEASE", 63, 67], ["kidney failure", "DISEASE", 72, 86], ["cerebral", "ORGAN", 20, 28], ["kidney", "ORGAN", 72, 78], ["death", "PROBLEM", 10, 15], ["cerebral malaria", "PROBLEM", 20, 36], ["respiratory failure", "PROBLEM", 38, 57], ["ADRS", "PROBLEM", 63, 67], ["kidney failure", "PROBLEM", 72, 86], ["cerebral", "ANATOMY", 20, 28], ["malaria", "OBSERVATION", 29, 36], ["respiratory failure", "OBSERVATION", 38, 57], ["kidney", "ANATOMY", 72, 78], ["failure", "OBSERVATION", 79, 86]]], ["The main reason of these complications is the cyto-adherence (\u201cbonding\u201d) of the erythrocytes.", [["erythrocytes", "ANATOMY", 80, 92], ["erythrocytes", "CELL", 80, 92], ["erythrocytes", "CELL_TYPE", 80, 92], ["these complications", "PROBLEM", 19, 38], ["the erythrocytes", "PROBLEM", 76, 92], ["main", "OBSERVATION_MODIFIER", 4, 8], ["complications", "OBSERVATION", 25, 38], ["erythrocytes", "ANATOMY", 80, 92]]], ["It results in a failure of the microcirculation followed by ischaemia of vital organs.Diagnosis ::: MalariaIn case of pyrexia of unknown origin, the patient always should be asked about previous stays overseas.", [["organs", "ANATOMY", 79, 85], ["ischaemia", "DISEASE", 60, 69], ["pyrexia", "DISEASE", 118, 125], ["organs", "ORGAN", 79, 85], ["patient", "ORGANISM", 149, 156], ["patient", "SPECIES", 149, 156], ["a failure of the microcirculation", "PROBLEM", 14, 47], ["ischaemia of vital organs", "PROBLEM", 60, 85], ["pyrexia", "PROBLEM", 118, 125], ["failure", "OBSERVATION", 16, 23], ["ischaemia", "OBSERVATION", 60, 69], ["pyrexia", "OBSERVATION", 118, 125], ["unknown origin", "OBSERVATION_MODIFIER", 129, 143]]], ["Additionally to the symptoms, a blood test is the most important diagnostic tool.", [["blood", "ANATOMY", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["the symptoms", "PROBLEM", 16, 28], ["a blood test", "TEST", 30, 42]]], ["The parasite can be demonstrated using a blood smear and thick drop.", [["blood", "ANATOMY", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 41, 46], ["a blood smear", "TEST", 39, 52], ["thick drop", "PROBLEM", 57, 67], ["parasite", "OBSERVATION", 4, 12]]], ["A single negative smear does not exclude malaria.", [["malaria", "DISEASE", 41, 48], ["A single negative smear", "TEST", 0, 23], ["malaria", "PROBLEM", 41, 48], ["does not exclude", "UNCERTAINTY", 24, 40], ["malaria", "OBSERVATION", 41, 48]]], ["A negative smear should be repeated three times within 12\u201324 h.", [["A negative smear", "TEST", 0, 16], ["negative", "OBSERVATION", 2, 10]]], ["In the thick drop, existing parasites with a low count can be accumulated and detected.", [["the thick drop", "PROBLEM", 3, 17], ["existing parasites", "PROBLEM", 19, 37], ["a low count", "PROBLEM", 43, 54], ["thick", "OBSERVATION_MODIFIER", 7, 12], ["drop", "OBSERVATION_MODIFIER", 13, 17], ["parasites", "OBSERVATION", 28, 37], ["low count", "OBSERVATION_MODIFIER", 45, 54]]], ["After a positive test, the number of parasites in the erythrocytes should be calculated.", [["erythrocytes", "ANATOMY", 54, 66], ["erythrocytes", "CELL", 54, 66], ["erythrocytes", "CELL_TYPE", 54, 66], ["a positive test", "TEST", 6, 21], ["parasites in the erythrocytes", "PROBLEM", 37, 66], ["parasites", "OBSERVATION", 37, 46]]], ["A parasite count >2% might be an indication for complicated malaria.", [["malaria", "DISEASE", 60, 67], ["A parasite count", "TEST", 0, 16], ["complicated malaria", "PROBLEM", 48, 67], ["malaria", "OBSERVATION", 60, 67]]], ["A PCR-test for Plasmodium DNA is a good diagnostic tool and commonly used.", [["Plasmodium", "ORGANISM", 15, 25], ["DNA", "CELLULAR_COMPONENT", 26, 29], ["Plasmodium DNA", "DNA", 15, 29], ["A PCR", "TEST", 0, 5], ["Plasmodium DNA", "PROBLEM", 15, 29]]], ["It is slightly more sensitive than the blood smear.", [["blood", "ANATOMY", 39, 44], ["blood", "ORGANISM_SUBSTANCE", 39, 44], ["the blood smear", "TEST", 35, 50], ["slightly", "OBSERVATION_MODIFIER", 6, 14], ["more sensitive", "OBSERVATION_MODIFIER", 15, 29]]], ["It also allows a discrimination of the malaria species.", [["malaria", "DISEASE", 39, 46], ["the malaria species", "PROBLEM", 35, 54], ["malaria", "OBSERVATION", 39, 46]]], ["Another test is the antigen detection.", [["Another test", "TEST", 0, 12], ["the antigen detection", "TEST", 16, 37]]], ["These immunologic tests often use a dipstick or cassette format and provide results within 2\u201315 min.", [["These immunologic tests", "TEST", 0, 23], ["a dipstick", "TEST", 34, 44]]], ["RDTs should be followed up by microscopy.", [["RDTs", "TEST", 0, 4]]], ["RDTs and smear microscopy currently provide the best results in testing for malaria.", [["malaria", "DISEASE", 76, 83], ["RDTs", "TEST", 0, 4], ["smear microscopy", "TEST", 9, 25], ["malaria", "PROBLEM", 76, 83]]], ["The Plasmodium antibody test is not suitable in the initial phase, as antibodies only can be detected after 6\u201310 days.", [["Plasmodium", "ORGANISM", 4, 14], ["antibodies", "PROTEIN", 70, 80], ["The Plasmodium antibody test", "TEST", 0, 28], ["Plasmodium antibody", "OBSERVATION", 4, 23]]], ["It is only to retrospectively confirm a previous infection.", [["infection", "DISEASE", 49, 58], ["a previous infection", "PROBLEM", 38, 58], ["infection", "OBSERVATION", 49, 58]]], ["Regular monitoring of the blood count and renal function and a careful fluid balance is necessary during the treatment of malaria.", [["blood", "ANATOMY", 26, 31], ["renal", "ANATOMY", 42, 47], ["fluid", "ANATOMY", 71, 76], ["malaria", "DISEASE", 122, 129], ["blood", "ORGANISM_SUBSTANCE", 26, 31], ["renal", "ORGAN", 42, 47], ["Regular monitoring", "TEST", 0, 18], ["the blood count", "TEST", 22, 37], ["renal function", "TEST", 42, 56], ["a careful fluid balance", "TEST", 61, 84], ["malaria", "PROBLEM", 122, 129], ["renal", "ANATOMY", 42, 47], ["malaria", "OBSERVATION", 122, 129]]], ["A CXR may be necessary, if respiratory symptoms are present.Treatment ::: MalariaThe treatment depends on the severity and the pathogen.", [["respiratory", "ANATOMY", 27, 38], ["Malaria", "DISEASE", 74, 81], ["Malaria", "ORGANISM", 74, 81], ["CXR", "PROTEIN", 2, 5], ["A CXR", "TEST", 0, 5], ["respiratory symptoms", "PROBLEM", 27, 47], ["Malaria", "PROBLEM", 74, 81], ["The treatment", "TREATMENT", 81, 94], ["the severity", "PROBLEM", 106, 118], ["the pathogen", "PROBLEM", 123, 135]]], ["In complicated malaria, admission to the intensive care should be considered, if more than one of the following criteria exists:Inability of the oral intake of medicationParasite load of erythrocytes >2%Severe symptoms of malaria (see table above)Treatment ::: MalariaThe treatment options of complicated malaria are:Artesunate (allowed only in some countries): 2.4 mg/kg/bw iv; first dose on admission, repeated after 12 and 24 h, minimum duration of therapy 24 h and then once a day, till oral therapy is tolerated.orCombination of quinine + doxycycline or clindamycin.Quinine:First dose: 20 mg/kg/bw iv over 4 h or 7 mg/kg/bw iv over 30 min with subsequent administration of 10 mg/kg/bw iv over 4 h.Maintenance therapy: 10 mg/kg/bw iv over 4 h three times a day, beginning 4 h after the completion of the first dose.Exemption: if the patient received three or more doses of quinine in the last 48 h or had an Mefloquine prophylaxis in the last 24 h or received a Mefloquine treatment in the last 3 days.+", [["oral", "ANATOMY", 145, 149], ["erythrocytes", "ANATOMY", 187, 199], ["oral", "ANATOMY", 491, 495], ["malaria", "DISEASE", 15, 22], ["malaria", "DISEASE", 222, 229], ["Malaria", "DISEASE", 261, 268], ["malaria", "DISEASE", 305, 312], ["Artesunate", "CHEMICAL", 317, 327], ["quinine", "CHEMICAL", 534, 541], ["doxycycline", "CHEMICAL", 544, 555], ["clindamycin", "CHEMICAL", 559, 570], ["Quinine", "CHEMICAL", 571, 578], ["quinine", "CHEMICAL", 877, 884], ["Mefloquine", "CHEMICAL", 912, 922], ["Mefloquine", "CHEMICAL", 966, 976], ["Artesunate", "CHEMICAL", 317, 327], ["quinine", "CHEMICAL", 534, 541], ["doxycycline", "CHEMICAL", 544, 555], ["clindamycin", "CHEMICAL", 559, 570], ["Quinine", "CHEMICAL", 571, 578], ["quinine", "CHEMICAL", 877, 884], ["Mefloquine", "CHEMICAL", 912, 922], ["Mefloquine", "CHEMICAL", 966, 976], ["oral", "ORGANISM_SUBDIVISION", 145, 149], ["erythrocytes", "CELL", 187, 199], ["Artesunate", "SIMPLE_CHEMICAL", 317, 327], ["oral", "ORGANISM_SUBDIVISION", 491, 495], ["quinine", "SIMPLE_CHEMICAL", 534, 541], ["doxycycline", "SIMPLE_CHEMICAL", 544, 555], ["clindamycin", "SIMPLE_CHEMICAL", 559, 570], ["Quinine", "SIMPLE_CHEMICAL", 571, 578], ["patient", "ORGANISM", 837, 844], ["quinine", "SIMPLE_CHEMICAL", 877, 884], ["Mefloquine", "SIMPLE_CHEMICAL", 912, 922], ["Mefloquine", "SIMPLE_CHEMICAL", 966, 976], ["erythrocytes", "CELL_TYPE", 187, 199], ["patient", "SPECIES", 837, 844], ["complicated malaria", "PROBLEM", 3, 22], ["medicationParasite load of erythrocytes", "TREATMENT", 160, 199], ["Severe symptoms", "PROBLEM", 203, 218], ["malaria", "PROBLEM", 222, 229], ["Malaria", "PROBLEM", 261, 268], ["complicated malaria", "PROBLEM", 293, 312], ["Artesunate", "TREATMENT", 317, 327], ["therapy", "TREATMENT", 452, 459], ["oral therapy", "TREATMENT", 491, 503], ["quinine", "TREATMENT", 534, 541], ["doxycycline", "TREATMENT", 544, 555], ["clindamycin", "TREATMENT", 559, 570], ["Quinine", "TREATMENT", 571, 578], ["quinine", "TREATMENT", 877, 884], ["an Mefloquine prophylaxis", "TREATMENT", 909, 934], ["a Mefloquine treatment", "TREATMENT", 964, 986], ["complicated", "OBSERVATION_MODIFIER", 3, 14], ["malaria", "OBSERVATION", 15, 22], ["malaria", "OBSERVATION", 222, 229], ["Malaria", "OBSERVATION", 261, 268], ["complicated", "OBSERVATION_MODIFIER", 293, 304], ["malaria", "OBSERVATION", 305, 312]]]], "c0a83e7c032d27c3d27f4eea5f1ddcb37af1fd35": [["IntroductionThe deregulation of the nuclear import and export machinery is a key marker of various diseases [1,2].", [["nuclear", "ANATOMY", 36, 43], ["nuclear", "CELLULAR_COMPONENT", 36, 43], ["various diseases", "PROBLEM", 91, 107]]], ["For example, many tumor suppressor transcription factors show cytoplasmic sequestration ablating their nuclear functions allowing, for example, uncontrolled cell division [3] .", [["tumor", "ANATOMY", 18, 23], ["cytoplasmic", "ANATOMY", 62, 73], ["nuclear", "ANATOMY", 103, 110], ["cell", "ANATOMY", 157, 161], ["tumor", "DISEASE", 18, 23], ["tumor", "CANCER", 18, 23], ["cytoplasmic", "ORGANISM_SUBSTANCE", 62, 73], ["nuclear", "CELLULAR_COMPONENT", 103, 110], ["cell", "CELL", 157, 161], ["tumor suppressor transcription factors", "PROTEIN", 18, 56], ["many tumor suppressor transcription factors", "PROBLEM", 13, 56], ["cytoplasmic sequestration", "PROBLEM", 62, 87], ["uncontrolled cell division", "PROBLEM", 144, 170], ["many", "OBSERVATION_MODIFIER", 13, 17], ["tumor", "OBSERVATION", 18, 23], ["cytoplasmic sequestration", "OBSERVATION", 62, 87]]], ["The aberrant localization of onco-proteins can also lead to their inadequate activation.", [["onco-proteins", "GENE_OR_GENE_PRODUCT", 29, 42], ["onco-proteins", "PROTEIN", 29, 42], ["their inadequate activation", "PROBLEM", 60, 87], ["aberrant", "OBSERVATION_MODIFIER", 4, 12]]], ["Examples of aberrant nucleo-cytoplasmic shuttling that correlates with tumor formation, progression or resistance to treatment include p53, FOXO3a, p27, BRCA1, APC, nucleophosmin retinoblastoma, b-catenin, nuclear factor-jB (NF-jB), survivin and cyclin D1 [3] [4] [5] .", [["cytoplasmic", "ANATOMY", 28, 39], ["tumor", "ANATOMY", 71, 76], ["tumor", "DISEASE", 71, 76], ["cytoplasmic", "ORGANISM_SUBSTANCE", 28, 39], ["tumor", "CANCER", 71, 76], ["p53", "GENE_OR_GENE_PRODUCT", 135, 138], ["FOXO3a", "GENE_OR_GENE_PRODUCT", 140, 146], ["p27", "GENE_OR_GENE_PRODUCT", 148, 151], ["BRCA1", "GENE_OR_GENE_PRODUCT", 153, 158], ["APC", "GENE_OR_GENE_PRODUCT", 160, 163], ["nucleophosmin retinoblastoma", "GENE_OR_GENE_PRODUCT", 165, 193], ["b-catenin", "GENE_OR_GENE_PRODUCT", 195, 204], ["nuclear factor-jB", "GENE_OR_GENE_PRODUCT", 206, 223], ["NF-jB", "GENE_OR_GENE_PRODUCT", 225, 230], ["survivin", "GENE_OR_GENE_PRODUCT", 233, 241], ["cyclin D1 [3] [4] [5]", "SIMPLE_CHEMICAL", 246, 267], ["p53", "PROTEIN", 135, 138], ["FOXO3a", "PROTEIN", 140, 146], ["p27", "PROTEIN", 148, 151], ["BRCA1", "PROTEIN", 153, 158], ["APC", "PROTEIN", 160, 163], ["nucleophosmin retinoblastoma", "PROTEIN", 165, 193], ["b-catenin", "PROTEIN", 195, 204], ["nuclear factor-jB", "PROTEIN", 206, 223], ["NF", "PROTEIN", 225, 227], ["jB", "PROTEIN", 228, 230], ["survivin", "PROTEIN", 233, 241], ["cyclin D1", "PROTEIN", 246, 255], ["aberrant nucleo-cytoplasmic shuttling", "PROBLEM", 12, 49], ["tumor formation", "PROBLEM", 71, 86], ["treatment", "TREATMENT", 117, 126], ["p53", "TEST", 135, 138], ["FOXO3a", "TEST", 140, 146], ["BRCA1", "PROBLEM", 153, 158], ["APC", "PROBLEM", 160, 163], ["nucleophosmin retinoblastoma", "PROBLEM", 165, 193], ["b-catenin", "TEST", 195, 204], ["nuclear factor", "TEST", 206, 220], ["survivin and cyclin D1", "TREATMENT", 233, 255], ["cytoplasmic shuttling", "OBSERVATION", 28, 49], ["tumor", "OBSERVATION", 71, 76], ["nucleophosmin retinoblastoma", "OBSERVATION", 165, 193]]], ["Beyond cancer, many viruses including human HIV-1, influenza A, dengue, respiratory syncytial virus, rabies, Rift Valley fever virus and Venezuelan equine encephalitis virus rely on the transport of specific viral proteins into the host cell nucleus to perturb the anti-viral response.", [["cancer", "ANATOMY", 7, 13], ["cell nucleus", "ANATOMY", 237, 249], ["cancer", "DISEASE", 7, 13], ["HIV-1", "DISEASE", 44, 49], ["influenza A", "DISEASE", 51, 62], ["dengue", "DISEASE", 64, 70], ["respiratory syncytial virus", "DISEASE", 72, 99], ["rabies", "DISEASE", 101, 107], ["Rift Valley fever", "DISEASE", 109, 126], ["Venezuelan equine encephalitis", "DISEASE", 137, 167], ["cancer", "CANCER", 7, 13], ["human", "ORGANISM", 38, 43], ["HIV-1", "ORGANISM", 44, 49], ["influenza A", "ORGANISM", 51, 62], ["dengue,", "ORGANISM", 64, 71], ["respiratory syncytial virus", "ORGANISM", 72, 99], ["rabies", "ORGANISM", 101, 107], ["Rift Valley fever virus", "ORGANISM", 109, 132], ["Venezuelan equine encephalitis virus", "ORGANISM", 137, 173], ["cell nucleus", "CELLULAR_COMPONENT", 237, 249], ["viral proteins", "PROTEIN", 208, 222], ["human", "SPECIES", 38, 43], ["HIV-1", "SPECIES", 44, 49], ["influenza A", "SPECIES", 51, 62], ["respiratory syncytial virus", "SPECIES", 72, 99], ["Rift Valley fever virus", "SPECIES", 109, 132], ["Venezuelan equine encephalitis virus", "SPECIES", 137, 173], ["human HIV-1", "SPECIES", 38, 49], ["respiratory syncytial virus", "SPECIES", 72, 99], ["Rift Valley fever virus", "SPECIES", 109, 132], ["Venezuelan equine encephalitis virus", "SPECIES", 137, 173], ["cancer", "PROBLEM", 7, 13], ["many viruses", "PROBLEM", 15, 27], ["human HIV", "TEST", 38, 47], ["influenza A", "PROBLEM", 51, 62], ["dengue", "PROBLEM", 64, 70], ["respiratory syncytial virus", "PROBLEM", 72, 99], ["rabies", "PROBLEM", 101, 107], ["Rift Valley fever virus", "PROBLEM", 109, 132], ["Venezuelan equine encephalitis virus", "PROBLEM", 137, 173], ["cancer", "OBSERVATION", 7, 13], ["viruses", "OBSERVATION", 20, 27], ["respiratory syncytial", "ANATOMY", 72, 93], ["host cell nucleus", "OBSERVATION", 232, 249], ["anti-viral response", "OBSERVATION", 265, 284]]], ["Therefore, inhibiting the nuclear trafficking of viral proteins has been proposed as a viable therapeutic strategy [6] .", [["nuclear", "ANATOMY", 26, 33], ["nuclear", "CELLULAR_COMPONENT", 26, 33], ["viral proteins", "PROTEIN", 49, 63], ["viral proteins", "PROBLEM", 49, 63]]], ["Over the last decade, the research community has acquired a critical mass of significant knowledge on the constituents of the nuclear transport machinery.", [["nuclear", "ANATOMY", 126, 133], ["nuclear", "CELLULAR_COMPONENT", 126, 133], ["mass", "OBSERVATION", 69, 73]]], ["The emerging picture, while intriguingly complex, suggests that there is an availability of a broad range of molecular targets enabling specific therapeutic interventions.", [["specific therapeutic interventions", "TREATMENT", 136, 170]]], ["The transport of cargo proteins is mediated by several distinct types of transport signals that are recognized by specific transport receptors or via a variety of adaptor proteins.", [["cargo proteins", "PROTEIN", 17, 31], ["transport receptors", "PROTEIN", 123, 142], ["adaptor proteins", "PROTEIN", 163, 179], ["cargo proteins", "TREATMENT", 17, 31], ["transport signals", "TEST", 73, 90], ["adaptor proteins", "TREATMENT", 163, 179]]], ["These transport receptors can then interact with components of the nuclear pore complex (NPC) and with the Ras family GTPase Ran.", [["nuclear pore complex", "ANATOMY", 67, 87], ["NPC", "ANATOMY", 89, 92], ["nuclear pore complex", "GENE_OR_GENE_PRODUCT", 67, 87], ["NPC", "CANCER", 89, 92], ["Ras", "GENE_OR_GENE_PRODUCT", 107, 110], ["Ran", "GENE_OR_GENE_PRODUCT", 125, 128], ["transport receptors", "PROTEIN", 6, 25], ["nuclear pore complex", "PROTEIN", 67, 87], ["NPC", "PROTEIN", 89, 92], ["Ras family GTPase", "PROTEIN", 107, 124], ["Ran", "PROTEIN", 125, 128]]], ["Many of the steps within this process have the potential to be therapeutically targeted for innovative anti-cancer and anti-viral therapies.IntroductionThe nuclear envelope and the nuclear pore complexIntroductionThe nucleus is surrounded by an envelope composed of two phospholipidic membranes: an outer and an inner nuclear membrane that are 30 nm apart.", [["nuclear envelope", "ANATOMY", 156, 172], ["nuclear pore", "ANATOMY", 181, 193], ["nucleus", "ANATOMY", 217, 224], ["phospholipidic membranes", "ANATOMY", 270, 294], ["outer", "ANATOMY", 299, 304], ["inner nuclear membrane", "ANATOMY", 312, 334], ["anti-cancer", "CANCER", 103, 114], ["nuclear", "CELLULAR_COMPONENT", 156, 163], ["nuclear", "CELLULAR_COMPONENT", 181, 188], ["nucleus", "CELLULAR_COMPONENT", 217, 224], ["phospholipidic membranes", "CELLULAR_COMPONENT", 270, 294], ["outer", "CELLULAR_COMPONENT", 299, 304], ["inner nuclear membrane", "CELLULAR_COMPONENT", 312, 334], ["nuclear pore complex", "PROTEIN", 181, 201], ["innovative anti-cancer", "TREATMENT", 92, 114], ["anti-viral therapies", "TREATMENT", 119, 139], ["nucleus", "ANATOMY_MODIFIER", 217, 224], ["envelope", "OBSERVATION_MODIFIER", 245, 253], ["two", "OBSERVATION_MODIFIER", 266, 269], ["phospholipidic membranes", "OBSERVATION", 270, 294], ["outer", "ANATOMY_MODIFIER", 299, 304], ["inner", "ANATOMY_MODIFIER", 312, 317], ["nuclear membrane", "ANATOMY", 318, 334], ["30 nm", "OBSERVATION_MODIFIER", 344, 349]]], ["The nuclear envelope (NE) provides a much stronger physical barrier than the single cordon of the plasma membrane.", [["nuclear envelope", "ANATOMY", 4, 20], ["plasma membrane", "ANATOMY", 98, 113], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["NE", "CELLULAR_COMPONENT", 22, 24], ["plasma membrane", "CELLULAR_COMPONENT", 98, 113], ["NE", "PROTEIN", 22, 24], ["plasma membrane", "ANATOMY", 98, 113]]], ["The outer nuclear membrane is continuous with the endoplasmic reticulum [7] , whereas the inner nuclear membrane is associated with a network of intermediate filaments composed of lamin called the nuclear lamina.", [["outer nuclear membrane", "ANATOMY", 4, 26], ["endoplasmic reticulum", "ANATOMY", 50, 71], ["inner nuclear membrane", "ANATOMY", 90, 112], ["filaments", "ANATOMY", 158, 167], ["nuclear lamina", "ANATOMY", 197, 211], ["outer nuclear membrane", "CELLULAR_COMPONENT", 4, 26], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 50, 71], ["inner nuclear membrane", "CELLULAR_COMPONENT", 90, 112], ["intermediate filaments", "CELLULAR_COMPONENT", 145, 167], ["lamin", "GENE_OR_GENE_PRODUCT", 180, 185], ["nuclear lamina", "CELLULAR_COMPONENT", 197, 211], ["lamin", "PROTEIN", 180, 185], ["outer", "ANATOMY_MODIFIER", 4, 9], ["nuclear membrane", "OBSERVATION", 10, 26], ["endoplasmic reticulum", "OBSERVATION", 50, 71], ["inner", "ANATOMY_MODIFIER", 90, 95], ["nuclear membrane", "ANATOMY", 96, 112], ["intermediate filaments", "OBSERVATION", 145, 167], ["nuclear lamina", "ANATOMY", 197, 211]]], ["This acts as a site of attachment for chromosomes and as a shield for the nucleus [8] .", [["chromosomes", "ANATOMY", 38, 49], ["nucleus", "ANATOMY", 74, 81], ["chromosomes", "CELLULAR_COMPONENT", 38, 49], ["nucleus", "CELLULAR_COMPONENT", 74, 81], ["chromosomes", "DNA", 38, 49]]], ["The NE functions like a selectively permeable barrier allowing macromolecules to move between the nucleus and the cytoplasm via a gatekeeper, the NPC.", [["nucleus", "ANATOMY", 98, 105], ["cytoplasm", "ANATOMY", 114, 123], ["NPC", "ANATOMY", 146, 149], ["NPC", "DISEASE", 146, 149], ["NE", "SIMPLE_CHEMICAL", 4, 6], ["nucleus", "CELLULAR_COMPONENT", 98, 105], ["cytoplasm", "ORGANISM_SUBSTANCE", 114, 123], ["NPC", "CANCER", 146, 149], ["NE", "PROTEIN", 4, 6], ["NPC", "PROTEIN", 146, 149], ["nucleus", "ANATOMY", 98, 105], ["NPC", "ANATOMY", 146, 149]]], ["The NPC is a huge protein complex that fuses the internal and external nuclear membrane to form an aqueous channel (Fig. 1) .", [["NPC", "ANATOMY", 4, 7], ["nuclear membrane", "ANATOMY", 71, 87], ["aqueous channel", "ANATOMY", 99, 114], ["NPC", "CANCER", 4, 7], ["nuclear membrane", "CELLULAR_COMPONENT", 71, 87], ["NPC", "PROTEIN", 4, 7], ["protein complex", "PROTEIN", 18, 33], ["a huge protein complex", "TREATMENT", 11, 33], ["NPC", "ANATOMY", 4, 7], ["internal", "ANATOMY_MODIFIER", 49, 57], ["external nuclear membrane", "ANATOMY", 62, 87], ["aqueous channel", "OBSERVATION", 99, 114]]], ["The NPC is cylindrical measuring 100-150 nm in diameter and 50-70 nm in thickness [9] and is broadly conserved in eukaryotes [10, 11] .", [["NPC", "ANATOMY", 4, 7], ["NPC", "CANCER", 4, 7], ["NPC", "PROTEIN", 4, 7], ["thickness", "TEST", 72, 81], ["NPC", "ANATOMY", 4, 7], ["cylindrical", "OBSERVATION_MODIFIER", 11, 22], ["150 nm", "OBSERVATION_MODIFIER", 37, 43]]], ["The molecular mass of the NPC is approximately 125 000 kDa and the number of NPCs per nucleus is highly variable among organisms.", [["NPC", "ANATOMY", 26, 29], ["NPCs", "ANATOMY", 77, 81], ["nucleus", "ANATOMY", 86, 93], ["NPC", "CANCER", 26, 29], ["NPCs", "CELL", 77, 81], ["nucleus", "CELLULAR_COMPONENT", 86, 93], ["NPC", "PROTEIN", 26, 29], ["NPCs", "CELL_TYPE", 77, 81], ["The molecular mass of the NPC", "PROBLEM", 0, 29], ["molecular", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 14, 18], ["NPC", "ANATOMY", 26, 29], ["approximately", "OBSERVATION_MODIFIER", 33, 46], ["125 000 kDa", "OBSERVATION_MODIFIER", 47, 58], ["nucleus", "ANATOMY", 86, 93]]], ["The average number of NPCs within a vertebrate cell is between 2000 and 5000 [12] and has been extensively studied by electron microscopy (EM).", [["NPCs", "ANATOMY", 22, 26], ["cell", "ANATOMY", 47, 51], ["NPCs", "CELL", 22, 26], ["cell", "CELL", 47, 51], ["NPCs", "CELL_TYPE", 22, 26], ["electron microscopy", "TEST", 118, 137], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["vertebrate cell", "OBSERVATION", 36, 51]]], ["In particular the development of cryo-EM and cryo-electron tomography (cryo-ET) allowed structural preservation to be enhanced and purification steps to be minimized and as a consequence the detailed and artifact-free analysis of the NPC [12-15].", [["NPC", "ANATOMY", 234, 237], ["NPC", "PROTEIN", 234, 237], ["cryo-electron tomography", "TEST", 45, 69], ["the NPC", "TEST", 230, 237]]], ["These EM-based studies revealed a highly modular and dynamic structure with a doughnut-shaped central core with an eightfold rotational symmetry [16] .", [["These EM-based studies", "TEST", 0, 22], ["a highly modular and dynamic structure", "PROBLEM", 32, 70], ["highly", "OBSERVATION_MODIFIER", 34, 40], ["modular", "OBSERVATION_MODIFIER", 41, 48], ["dynamic structure", "OBSERVATION", 53, 70], ["doughnut", "OBSERVATION_MODIFIER", 78, 86], ["shaped", "OBSERVATION_MODIFIER", 87, 93], ["central", "OBSERVATION_MODIFIER", 94, 101], ["core", "OBSERVATION_MODIFIER", 102, 106], ["eightfold", "OBSERVATION_MODIFIER", 115, 124], ["rotational symmetry", "OBSERVATION", 125, 144]]], ["A central channel is surrounded by three ring-like structures, namely the cytoplasmic ring, the central spoke ring and the nuclear ring.", [["cytoplasmic ring", "ANATOMY", 74, 90], ["nuclear ring", "ANATOMY", 123, 135], ["cytoplasmic ring", "CELLULAR_COMPONENT", 74, 90], ["nuclear ring", "CELLULAR_COMPONENT", 123, 135], ["cytoplasmic ring", "PROTEIN", 74, 90], ["central spoke ring", "PROTEIN", 96, 114], ["nuclear ring", "PROTEIN", 123, 135], ["three ring-like structures", "PROBLEM", 35, 61], ["the cytoplasmic ring", "TREATMENT", 70, 90], ["central channel", "OBSERVATION", 2, 17], ["three", "OBSERVATION_MODIFIER", 35, 40], ["ring", "OBSERVATION_MODIFIER", 41, 45], ["-", "ANATOMY_MODIFIER", 45, 46], ["like structures", "OBSERVATION", 46, 61], ["cytoplasmic ring", "OBSERVATION", 74, 90], ["central", "OBSERVATION_MODIFIER", 96, 103], ["spoke ring", "OBSERVATION", 104, 114], ["nuclear ring", "OBSERVATION", 123, 135]]], ["Attached to this core structure are eight protein filaments on the cyto-plasmic side and eight protein filaments on the nuclear side that converge to a ring-like structure termed the nuclear basket.IntroductionThe NPC is composed of 30 different proteins termed nucleoporins (Nups) [17] that are organized into several sub-complexes, each of which is present in multiple copies, resulting in approximately 500-1000 individual proteins in the fully assembled NPC [18] .", [["nuclear", "ANATOMY", 120, 127], ["nuclear basket", "ANATOMY", 183, 197], ["NPC", "ANATOMY", 214, 217], ["NPC", "ANATOMY", 458, 461], ["nuclear", "CELLULAR_COMPONENT", 183, 190], ["NPC", "CANCER", 214, 217], ["Nups", "GENE_OR_GENE_PRODUCT", 276, 280], ["protein filaments", "PROTEIN", 95, 112], ["ring-like structure", "PROTEIN", 152, 171], ["NPC", "PROTEIN", 214, 217], ["nucleoporins", "PROTEIN", 262, 274], ["Nups", "PROTEIN", 276, 280], ["sub-complexes", "PROTEIN", 319, 332], ["NPC", "PROTEIN", 458, 461], ["The NPC", "TREATMENT", 210, 217], ["eight", "OBSERVATION_MODIFIER", 36, 41], ["protein filaments", "OBSERVATION", 42, 59], ["ring", "OBSERVATION_MODIFIER", 152, 156], ["nuclear basket", "OBSERVATION", 183, 197]]], ["The transport of salts, nucleotides, small molecules/ proteins and components required for the syntheses of DNA and RNA occurs passively by diffusion through the NPC.", [["NPC", "ANATOMY", 162, 165], ["salts", "CHEMICAL", 17, 22], ["nucleotides", "CHEMICAL", 24, 35], ["salts", "SIMPLE_CHEMICAL", 17, 22], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["NPC", "CANCER", 162, 165], ["NPC", "PROTEIN", 162, 165], ["nucleotides", "TREATMENT", 24, 35], ["small molecules/ proteins", "PROBLEM", 37, 62], ["DNA and RNA", "PROBLEM", 108, 119], ["small", "OBSERVATION_MODIFIER", 37, 42], ["NPC", "ANATOMY", 162, 165]]], ["In contrast, proteins larger than 40-65 kDa must be transported into the nucleus through the NPC with the assistance of transport receptors.", [["nucleus", "ANATOMY", 73, 80], ["NPC", "ANATOMY", 93, 96], ["nucleus", "CELLULAR_COMPONENT", 73, 80], ["NPC", "CANCER", 93, 96], ["NPC", "PROTEIN", 93, 96], ["transport receptors", "PROTEIN", 120, 139], ["transport receptors", "TREATMENT", 120, 139], ["larger", "OBSERVATION_MODIFIER", 22, 28]]], ["These receptors recognize the transport signals that are present on cargo proteins allowing their import (reviewed in [19] ).IntroductionThe key function of the NPC is to form a diffusion barrier between the cytoplasm and the nuclear compartment and to enable the nucleo-cytoplasmic traffic of macromolecules.", [["NPC", "ANATOMY", 161, 164], ["cytoplasm", "ANATOMY", 208, 217], ["nuclear compartment", "ANATOMY", 226, 245], ["cytoplasmic", "ANATOMY", 271, 282], ["NPC", "CANCER", 161, 164], ["cytoplasm", "ORGANISM_SUBSTANCE", 208, 217], ["nuclear compartment", "CELLULAR_COMPONENT", 226, 245], ["cytoplasmic", "ORGANISM_SUBSTANCE", 271, 282], ["cargo proteins", "PROTEIN", 68, 82], ["NPC", "PROTEIN", 161, 164], ["a diffusion barrier between the cytoplasm and the nuclear compartment", "PROBLEM", 176, 245], ["nuclear compartment", "ANATOMY", 226, 245]]], ["In addition, the NPC is also involved in other nuclear processes that include DNANucleoporin proteinsDespite its enormous dimensions, the NPC is built from a surprisingly small number of proteins called nucleoporins (Nups) [18] .", [["NPC", "ANATOMY", 17, 20], ["nuclear", "ANATOMY", 47, 54], ["NPC", "ANATOMY", 138, 141], ["NPC", "CANCER", 17, 20], ["DNANucleoporin", "GENE_OR_GENE_PRODUCT", 78, 92], ["NPC", "CANCER", 138, 141], ["nucleoporins", "GENE_OR_GENE_PRODUCT", 203, 215], ["NPC", "PROTEIN", 17, 20], ["DNANucleoporin proteins", "PROTEIN", 78, 101], ["NPC", "PROTEIN", 138, 141], ["nucleoporins", "PROTEIN", 203, 215], ["Nups", "PROTEIN", 217, 221], ["the NPC", "PROBLEM", 13, 20], ["DNANucleoporin proteins", "TREATMENT", 78, 101], ["the NPC", "PROBLEM", 134, 141], ["NPC", "OBSERVATION", 17, 20]]], ["The NPC displays a high degree of internal symmetry and can be divided into a symmetric part, enclosed in the nuclear membrane, and an asymmetric part, with extensions into the nucleus or cytoplasm (Fig. 1) .", [["NPC", "ANATOMY", 4, 7], ["nuclear membrane", "ANATOMY", 110, 126], ["nucleus", "ANATOMY", 177, 184], ["cytoplasm", "ANATOMY", 188, 197], ["NPC", "CANCER", 4, 7], ["nuclear membrane", "CELLULAR_COMPONENT", 110, 126], ["nucleus", "CELLULAR_COMPONENT", 177, 184], ["cytoplasm", "ORGANISM_SUBSTANCE", 188, 197], ["NPC", "PROTEIN", 4, 7], ["The NPC", "TREATMENT", 0, 7], ["a high degree of internal symmetry", "PROBLEM", 17, 51], ["high degree", "OBSERVATION_MODIFIER", 19, 30], ["internal symmetry", "OBSERVATION", 34, 51], ["symmetric", "OBSERVATION_MODIFIER", 78, 87], ["part", "OBSERVATION_MODIFIER", 88, 92], ["nuclear membrane", "ANATOMY", 110, 126], ["asymmetric", "OBSERVATION_MODIFIER", 135, 145], ["part", "OBSERVATION_MODIFIER", 146, 150], ["nucleus", "ANATOMY", 177, 184], ["cytoplasm", "OBSERVATION_MODIFIER", 188, 197], ["Fig", "OBSERVATION_MODIFIER", 199, 202]]], ["Nups from the symmetric part of the NPC are generally classified into three categories: membrane-anchored (POMs, part of the nuclear envelope), scaffold (coat Nups and adaptor Nups) and channel (barrier Nups).", [["NPC", "ANATOMY", 36, 39], ["membrane", "ANATOMY", 88, 96], ["POMs", "ANATOMY", 107, 111], ["nuclear", "ANATOMY", 125, 132], ["NPC", "DISEASE", 36, 39], ["NPC", "CANCER", 36, 39], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["nuclear", "CELLULAR_COMPONENT", 125, 132], ["NPC", "PROTEIN", 36, 39], ["POMs", "PROTEIN", 107, 111], ["coat Nups", "PROTEIN", 154, 163], ["adaptor Nups", "PROTEIN", 168, 180], ["channel", "PROTEIN", 186, 193], ["barrier Nups", "PROTEIN", 195, 207], ["scaffold (coat Nups and adaptor Nups", "TREATMENT", 144, 180], ["channel (barrier Nups", "TREATMENT", 186, 207], ["symmetric", "OBSERVATION_MODIFIER", 14, 23]]], ["Each category has unique structural features that are essential to execute specific functions.", [["unique structural features", "PROBLEM", 18, 44]]], ["The Nups that form the asymmetric part of the NPC are called nuclear basket Nups and cytoplasmic filament Nups.Membrane NupsMembrane Nups (POMs) anchor the symmetric part of the NPC to the pore membrane where the inner and outer nuclear membranes fuse to form the nuclear pore binding the assembly complex to the NE.", [["NPC", "ANATOMY", 46, 49], ["nuclear basket Nups", "ANATOMY", 61, 80], ["cytoplasmic", "ANATOMY", 85, 96], ["Membrane", "ANATOMY", 111, 119], ["NPC", "ANATOMY", 178, 181], ["pore membrane", "ANATOMY", 189, 202], ["inner", "ANATOMY", 213, 218], ["nuclear membranes", "ANATOMY", 229, 246], ["nuclear pore", "ANATOMY", 264, 276], ["NPC", "DISEASE", 46, 49], ["Nups", "GENE_OR_GENE_PRODUCT", 4, 8], ["NPC", "CANCER", 46, 49], ["nuclear", "CELLULAR_COMPONENT", 61, 68], ["basket Nups", "CELLULAR_COMPONENT", 69, 80], ["cytoplasmic", "ORGANISM_SUBSTANCE", 85, 96], ["NPC", "CANCER", 178, 181], ["pore membrane", "CELLULAR_COMPONENT", 189, 202], ["inner", "CELLULAR_COMPONENT", 213, 218], ["outer nuclear membranes", "CELLULAR_COMPONENT", 223, 246], ["nuclear pore", "CELLULAR_COMPONENT", 264, 276], ["NE", "CELLULAR_COMPONENT", 313, 315], ["Nups", "PROTEIN", 4, 8], ["NPC", "PROTEIN", 46, 49], ["nuclear basket Nups", "PROTEIN", 61, 80], ["cytoplasmic filament Nups", "PROTEIN", 85, 110], ["Membrane NupsMembrane Nups", "PROTEIN", 111, 137], ["POMs", "PROTEIN", 139, 143], ["NPC", "PROTEIN", 178, 181], ["assembly complex", "PROTEIN", 289, 305], ["NE", "PROTEIN", 313, 315], ["the NPC to the pore membrane", "TREATMENT", 174, 202], ["the inner and outer nuclear membranes", "TREATMENT", 209, 246], ["asymmetric", "OBSERVATION_MODIFIER", 23, 33], ["NPC", "ANATOMY", 46, 49], ["symmetric", "OBSERVATION_MODIFIER", 156, 165], ["NPC", "ANATOMY", 178, 181], ["pore membrane", "ANATOMY_MODIFIER", 189, 202], ["inner", "ANATOMY_MODIFIER", 213, 218], ["outer", "ANATOMY_MODIFIER", 223, 228], ["nuclear membranes", "ANATOMY", 229, 246]]], ["Membrane Nups contain transmembrane a-helices that allow the protein to anchor onto the membrane while large regions extend toward the luminal and pore sides of the membrane [27,28].Scaffold NupsThe scaffold Nups (coat Nups and adaptor Nups) form the skeleton of the NPC connecting the membrane Nups to the barrier Nups.", [["Membrane", "ANATOMY", 0, 8], ["transmembrane", "ANATOMY", 22, 35], ["membrane", "ANATOMY", 88, 96], ["luminal", "ANATOMY", 135, 142], ["pore sides", "ANATOMY", 147, 157], ["membrane", "ANATOMY", 165, 173], ["NPC", "ANATOMY", 267, 270], ["membrane Nups", "ANATOMY", 286, 299], ["luminal", "CHEMICAL", 135, 142], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["transmembrane", "CELLULAR_COMPONENT", 22, 35], ["membrane", "CELLULAR_COMPONENT", 88, 96], ["luminal", "MULTI-TISSUE_STRUCTURE", 135, 142], ["pore sides", "CELLULAR_COMPONENT", 147, 157], ["membrane", "CELLULAR_COMPONENT", 165, 173], ["NPC", "CANCER", 267, 270], ["membrane", "CELLULAR_COMPONENT", 286, 294], ["Nups", "PROTEIN", 9, 13], ["transmembrane a-helices", "PROTEIN", 22, 45], ["Nups", "PROTEIN", 208, 212], ["coat Nups", "PROTEIN", 214, 223], ["adaptor Nups", "PROTEIN", 228, 240], ["NPC", "PROTEIN", 267, 270], ["membrane Nups", "PROTEIN", 286, 299], ["Membrane Nups", "TREATMENT", 0, 13], ["transmembrane a-helices", "PROBLEM", 22, 45], ["The scaffold Nups (coat Nups and adaptor Nups)", "TREATMENT", 195, 241], ["the NPC", "TREATMENT", 263, 270], ["transmembrane a-helices", "OBSERVATION", 22, 45], ["large", "OBSERVATION_MODIFIER", 103, 108], ["luminal", "ANATOMY_MODIFIER", 135, 142], ["pore sides", "ANATOMY_MODIFIER", 147, 157], ["membrane", "ANATOMY_MODIFIER", 165, 173], ["skeleton", "ANATOMY", 251, 259], ["NPC", "ANATOMY", 267, 270]]], ["The scaffold Nups contain mainly a-solenoid and b-propeller folds and are classified into outer ring Nups, inner ring Nups and linker Nups according to their location and function.", [["outer ring", "ANATOMY", 90, 100], ["inner ring", "ANATOMY", 107, 117], ["a-solenoid", "CHEMICAL", 33, 43], ["a-solenoid", "SIMPLE_CHEMICAL", 33, 43], ["a-solenoid and b-propeller folds", "PROTEIN", 33, 65], ["linker Nups", "PROTEIN", 127, 138], ["The scaffold Nups", "TREATMENT", 0, 17], ["a-solenoid and b-propeller folds", "TREATMENT", 33, 65], ["inner ring Nups and linker Nups", "TREATMENT", 107, 138], ["scaffold Nups", "OBSERVATION", 4, 17], ["mainly", "OBSERVATION_MODIFIER", 26, 32], ["a-solenoid", "OBSERVATION", 33, 43], ["b-propeller folds", "OBSERVATION", 48, 65], ["outer", "ANATOMY_MODIFIER", 90, 95], ["ring", "ANATOMY_MODIFIER", 96, 100], ["Nups", "ANATOMY", 101, 105], ["inner", "OBSERVATION_MODIFIER", 107, 112], ["ring Nups", "OBSERVATION", 113, 122]]], ["The high flexibility of the outer ring Nup components allows for conformational changes of the scaffold that enable large cargo to pass through the central channel [29] .Barrier NupsBarrier Nups (channel Nups) are phenylalanineglycine Nups (FG-Nups) and form the innermost cylindrical layer that acts as a selective gatekeeper for nuclear transport regulation.", [["outer ring", "ANATOMY", 28, 38], ["nuclear", "ANATOMY", 331, 338], ["phenylalanineglycine", "CHEMICAL", 214, 234], ["FG-Nups", "CHEMICAL", 241, 248], ["phenylalanineglycine", "CHEMICAL", 214, 234], ["phenylalanineglycine Nups", "SIMPLE_CHEMICAL", 214, 239], ["FG-Nups", "SIMPLE_CHEMICAL", 241, 248], ["nuclear", "CELLULAR_COMPONENT", 331, 338], ["outer ring Nup components", "PROTEIN", 28, 53], ["the outer ring Nup components", "TREATMENT", 24, 53], ["conformational changes of the scaffold", "PROBLEM", 65, 103], ["Barrier NupsBarrier Nups (channel Nups)", "TREATMENT", 170, 209], ["phenylalanineglycine Nups (FG-Nups)", "TREATMENT", 214, 249], ["the innermost cylindrical layer", "TREATMENT", 259, 290], ["nuclear transport regulation", "TREATMENT", 331, 359], ["high", "OBSERVATION_MODIFIER", 4, 8], ["flexibility", "OBSERVATION_MODIFIER", 9, 20]]], ["FG-Nups contain multiple stretches of FG sequences that form intrinsically disordered regions.", [["FG-Nups", "SIMPLE_CHEMICAL", 0, 7], ["FG", "PROTEIN", 0, 2], ["Nups", "DNA", 3, 7], ["FG sequences", "DNA", 38, 50], ["FG", "TEST", 0, 2], ["FG sequences", "TEST", 38, 50], ["intrinsically disordered regions", "PROBLEM", 61, 93], ["multiple", "OBSERVATION_MODIFIER", 16, 24], ["stretches", "OBSERVATION_MODIFIER", 25, 34], ["intrinsically", "OBSERVATION_MODIFIER", 61, 74], ["disordered", "OBSERVATION", 75, 85]]], ["These motifs are present in about one-third of Nups forming an unstructured meshwork lining the central channel.", [["Nups", "GENE_OR_GENE_PRODUCT", 47, 51], ["meshwork", "TISSUE", 76, 84], ["unstructured meshwork", "OBSERVATION", 63, 84], ["central channel", "OBSERVATION", 96, 111]]], ["The tentacle-like structures provide several low affinity, high specificity interactions with transport receptors that escort cargo proteins through the nuclear pore.", [["tentacle-like structures", "ANATOMY", 4, 28], ["nuclear pore", "ANATOMY", 153, 165], ["nuclear pore", "CELLULAR_COMPONENT", 153, 165], ["transport receptors", "PROTEIN", 94, 113], ["cargo proteins", "PROTEIN", 126, 140], ["several low affinity", "PROBLEM", 37, 57], ["tentacle", "ANATOMY_MODIFIER", 4, 12], ["low affinity", "OBSERVATION_MODIFIER", 45, 57]]], ["Collectively, FG-rich regions build the diffusion barrier of the NPC.Asymmetric NupsAsymmetric Nups (formed by nuclear basket Nups and cytoplasmic filament Nups) are key components in establishing the directionality of the nucleo-cytoplas- In this model, the NPC is divided into several groups according to their location and structural characteristics.", [["NPC", "ANATOMY", 65, 68], ["nuclear", "ANATOMY", 111, 118], ["cytoplasmic", "ANATOMY", 135, 146], ["NPC", "ANATOMY", 259, 262], ["NPC", "DISEASE", 65, 68], ["NPC", "CANCER", 65, 68], ["nuclear", "CELLULAR_COMPONENT", 111, 118], ["cytoplasmic", "ORGANISM_SUBSTANCE", 135, 146], ["NPC", "CANCER", 259, 262], ["FG-rich regions", "PROTEIN", 14, 29], ["NPC", "PROTEIN", 65, 68], ["NupsAsymmetric Nups", "PROTEIN", 80, 99], ["nuclear basket Nups", "PROTEIN", 111, 130], ["cytoplasmic filament Nups", "PROTEIN", 135, 160], ["nucleo-cytoplas", "PROTEIN", 223, 238], ["NPC", "PROTEIN", 259, 262], ["Asymmetric NupsAsymmetric Nups", "PROBLEM", 69, 99], ["the NPC", "TREATMENT", 255, 262], ["diffusion barrier", "OBSERVATION", 40, 57], ["NPC", "ANATOMY", 65, 68], ["NupsAsymmetric Nups", "OBSERVATION", 80, 99]]], ["The symmetrical core is composed of membrane-anchored POMS (transmembrane ring), channel Nups (central FG-Nups) and scaffold Nups composed by adaptor Nups (inner and linker Nups) and coat Nups (outer ring).", [["membrane", "ANATOMY", 36, 44], ["transmembrane ring", "ANATOMY", 60, 78], ["inner", "ANATOMY", 156, 161], ["outer ring", "ANATOMY", 194, 204], ["membrane", "CELLULAR_COMPONENT", 36, 44], ["inner", "TISSUE", 156, 161], ["membrane-anchored POMS", "PROTEIN", 36, 58], ["transmembrane ring", "PROTEIN", 60, 78], ["channel Nups", "PROTEIN", 81, 93], ["FG", "PROTEIN", 103, 105], ["Nups", "PROTEIN", 106, 110], ["scaffold Nups", "PROTEIN", 116, 129], ["adaptor Nups", "PROTEIN", 142, 154], ["inner and linker Nups", "PROTEIN", 156, 177], ["coat Nups", "PROTEIN", 183, 192], ["outer ring", "PROTEIN", 194, 204], ["membrane-anchored POMS (transmembrane ring)", "TREATMENT", 36, 79], ["channel Nups (central FG-Nups)", "TREATMENT", 81, 111], ["scaffold Nups", "TREATMENT", 116, 129], ["inner and linker Nups)", "TREATMENT", 156, 178], ["coat Nups (outer ring)", "TREATMENT", 183, 205], ["symmetrical", "OBSERVATION_MODIFIER", 4, 15], ["core", "OBSERVATION_MODIFIER", 16, 20]]], ["Asymmetric parts of the pore are the nuclear FG-Nups and the basket plus the cytoplasmic FG-Nups and filaments.", [["pore", "ANATOMY", 24, 28], ["nuclear", "ANATOMY", 37, 44], ["basket", "ANATOMY", 61, 67], ["cytoplasmic", "ANATOMY", 77, 88], ["filaments", "ANATOMY", 101, 110], ["pore", "CELLULAR_COMPONENT", 24, 28], ["nuclear", "CELLULAR_COMPONENT", 37, 44], ["cytoplasmic", "ORGANISM_SUBSTANCE", 77, 88], ["filaments", "CELLULAR_COMPONENT", 101, 110], ["nuclear FG-Nups", "PROTEIN", 37, 52], ["cytoplasmic FG", "PROTEIN", 77, 91], ["Nups", "PROTEIN", 92, 96], ["parts", "OBSERVATION_MODIFIER", 11, 16], ["pore", "OBSERVATION_MODIFIER", 24, 28]]], ["(C) The yeast and vertebrate homolog Nups that are known to constitute each NPC substructure are listed.", [["NPC", "ANATOMY", 76, 79], ["Nups", "GENE_OR_GENE_PRODUCT", 37, 41], ["NPC", "CANCER", 76, 79], ["Nups", "PROTEIN", 37, 41], ["yeast", "SPECIES", 8, 13], ["yeast", "SPECIES", 8, 13], ["The yeast and vertebrate homolog Nups", "PROBLEM", 4, 41], ["homolog Nups", "OBSERVATION", 29, 41]]], ["Symmetric Nups are equally distributed on the cytoplasmic and nucleoplasmic parts of the NPC and form the core region.", [["cytoplasmic", "ANATOMY", 46, 57], ["nucleoplasmic parts", "ANATOMY", 62, 81], ["NPC", "ANATOMY", 89, 92], ["Nups", "GENE_OR_GENE_PRODUCT", 10, 14], ["cytoplasmic", "ORGANISM_SUBSTANCE", 46, 57], ["nucleoplasmic", "ORGANISM_SUBSTANCE", 62, 75], ["NPC", "CANCER", 89, 92], ["cytoplasmic and nucleoplasmic parts", "PROTEIN", 46, 81], ["NPC", "PROTEIN", 89, 92], ["Nups", "OBSERVATION", 10, 14], ["equally", "OBSERVATION_MODIFIER", 19, 26], ["distributed", "OBSERVATION_MODIFIER", 27, 38], ["NPC", "ANATOMY", 89, 92], ["core", "ANATOMY_MODIFIER", 106, 110], ["region", "ANATOMY_MODIFIER", 111, 117]]], ["Asymmetric Nups form the nuclear basket and the cytoplasmic filaments.", [["nuclear basket", "ANATOMY", 25, 39], ["cytoplasmic filaments", "ANATOMY", 48, 69], ["Nups", "GENE_OR_GENE_PRODUCT", 11, 15], ["nuclear", "CELLULAR_COMPONENT", 25, 32], ["cytoplasmic filaments", "CELLULAR_COMPONENT", 48, 69], ["Nups", "PROTEIN", 11, 15], ["cytoplasmic filaments", "PROTEIN", 48, 69], ["Nups", "OBSERVATION", 11, 15], ["cytoplasmic filaments", "OBSERVATION", 48, 69]]], ["They serve as docking sites for transport factors and include associated mRNA export factors.", [["transport factors", "PROTEIN", 32, 49], ["mRNA export factors", "PROTEIN", 73, 92], ["associated mRNA export factors", "PROBLEM", 62, 92]]], ["See the main text for more information.Asymmetric Nupsmic transport process.", [["Asymmetric Nupsmic transport process", "PROBLEM", 39, 75], ["Nupsmic", "OBSERVATION", 50, 57], ["transport process", "OBSERVATION", 58, 75]]], ["These structures mediate specific interactions with transport complexes and several asymmetric Nups that contain FG repeats serving as binding sites with important roles in cargo-NPC interactions.The transport signalsFor nuclear import and export, macromolecules generally require specific transport signals, namely a nuclear localization signal (NLS) or a nuclear export signal (NES) (Fig. 2) .", [["NPC", "ANATOMY", 179, 182], ["nuclear", "ANATOMY", 221, 228], ["nuclear", "ANATOMY", 318, 325], ["nuclear", "ANATOMY", 357, 364], ["Nups", "GENE_OR_GENE_PRODUCT", 95, 99], ["FG repeats", "CELLULAR_COMPONENT", 113, 123], ["NPC", "GENE_OR_GENE_PRODUCT", 179, 182], ["nuclear", "CELLULAR_COMPONENT", 221, 228], ["nuclear", "CELLULAR_COMPONENT", 318, 325], ["NLS", "CELLULAR_COMPONENT", 347, 350], ["nuclear", "CELLULAR_COMPONENT", 357, 364], ["transport complexes", "PROTEIN", 52, 71], ["Nups", "PROTEIN", 95, 99], ["FG repeats", "PROTEIN", 113, 123], ["NPC", "PROTEIN", 179, 182], ["nuclear localization signal", "PROTEIN", 318, 345], ["NLS", "PROTEIN", 347, 350], ["nuclear export signal", "PROTEIN", 357, 378], ["NES", "PROTEIN", 380, 383], ["transport complexes", "TREATMENT", 52, 71], ["several asymmetric Nups", "PROBLEM", 76, 99], ["specific transport signals", "TEST", 281, 307], ["a nuclear localization signal", "TEST", 316, 345], ["asymmetric", "OBSERVATION_MODIFIER", 84, 94], ["Nups", "OBSERVATION", 95, 99]]], ["Soluble transport receptors of the karyopherin family of proteins (known as importins and exportins) recognize these sequences within macromolecules.", [["karyopherin", "GENE_OR_GENE_PRODUCT", 35, 46], ["importins", "GENE_OR_GENE_PRODUCT", 76, 85], ["exportins", "GENE_OR_GENE_PRODUCT", 90, 99], ["Soluble transport receptors", "PROTEIN", 0, 27], ["karyopherin family", "PROTEIN", 35, 53], ["importins", "PROTEIN", 76, 85], ["exportins", "PROTEIN", 90, 99]]], ["NLS and NES can be defined as sequences within proteins that are necessary and sufficient for their import/export (summarized in Table 1 ).", [["NLS", "GENE_OR_GENE_PRODUCT", 0, 3], ["NES", "GENE_OR_GENE_PRODUCT", 8, 11], ["NLS", "PROTEIN", 0, 3], ["NES", "PROTEIN", 8, 11]]], ["These sequences bind transport receptors either directly or via adaptor molecules and enable the release of the transport complex at the end of the translocation process [30] .", [["transport receptors", "PROTEIN", 21, 40], ["adaptor molecules", "PROTEIN", 64, 81], ["transport complex", "PROTEIN", 112, 129]]], ["The transport signals that interact with importin-a (Imp-a), importin-b (Imp-b), CRM1 (chromosome region maintenance 1, also known as expor-tin1 or Xpo1) and transportin-1 (also known as karyopherin-b2) are well described but they remain to be determined for the other 16 human karyopherin-bs [31] [32] [33] [34] [35] .", [["chromosome region", "ANATOMY", 87, 104], ["importin", "GENE_OR_GENE_PRODUCT", 41, 49], ["Imp-a", "GENE_OR_GENE_PRODUCT", 53, 58], ["importin-b", "GENE_OR_GENE_PRODUCT", 61, 71], ["Imp-b", "GENE_OR_GENE_PRODUCT", 73, 78], ["CRM1 (chromosome region maintenance 1", "GENE_OR_GENE_PRODUCT", 81, 118], ["expor-tin1", "GENE_OR_GENE_PRODUCT", 134, 144], ["Xpo1", "GENE_OR_GENE_PRODUCT", 148, 152], ["transportin-1", "GENE_OR_GENE_PRODUCT", 158, 171], ["karyopherin-b2", "GENE_OR_GENE_PRODUCT", 187, 201], ["human", "ORGANISM", 272, 277], ["karyopherin-bs [31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 278, 317], ["importin", "PROTEIN", 41, 49], ["Imp", "PROTEIN", 53, 56], ["importin-b", "PROTEIN", 61, 71], ["Imp", "PROTEIN", 73, 76], ["b", "PROTEIN", 77, 78], ["CRM1", "PROTEIN", 81, 85], ["chromosome region maintenance 1", "PROTEIN", 87, 118], ["expor-tin1", "PROTEIN", 134, 144], ["Xpo1", "PROTEIN", 148, 152], ["transportin-1", "PROTEIN", 158, 171], ["karyopherin", "PROTEIN", 187, 198], ["b2", "DNA", 199, 201], ["human", "SPECIES", 272, 277], ["human", "SPECIES", 272, 277], ["importin-b (Imp-b)", "TREATMENT", 61, 79], ["CRM1 (chromosome region maintenance", "TREATMENT", 81, 116]]], ["The known NLSs can be classified into either classical NLSs or non-classical NLSs.", [["NLSs", "CELLULAR_COMPONENT", 10, 14], ["NLSs", "PROTEIN", 10, 14], ["NLSs", "PROTEIN", 55, 59], ["non-classical NLSs", "PROTEIN", 63, 81], ["The known NLSs", "PROBLEM", 0, 14], ["NLSs", "OBSERVATION", 10, 14]]], ["The classical NLSs can be further divided into monopartite or bipartite NLSs.", [["NLSs", "PROTEIN", 14, 18], ["monopartite or bipartite NLSs", "PROTEIN", 47, 76], ["The classical NLSs", "PROBLEM", 0, 18]]], ["The non-classical NLSs include proline-tyrosine NLSs (PY-NLSs) that allow the cargo protein to bind to karyopherin-b2 that mediates the direct interaction with Imp-b.", [["proline", "CHEMICAL", 31, 38], ["tyrosine", "CHEMICAL", 39, 47], ["proline", "CHEMICAL", 31, 38], ["tyrosine", "CHEMICAL", 39, 47], ["proline-tyrosine NLSs", "GENE_OR_GENE_PRODUCT", 31, 52], ["PY-NLSs", "GENE_OR_GENE_PRODUCT", 54, 61], ["karyopherin-b2", "GENE_OR_GENE_PRODUCT", 103, 117], ["Imp", "GENE_OR_GENE_PRODUCT", 160, 163], ["NLSs", "PROTEIN", 18, 22], ["proline-tyrosine NLSs", "PROTEIN", 31, 52], ["PY", "PROTEIN", 54, 56], ["NLSs", "PROTEIN", 57, 61], ["cargo protein", "PROTEIN", 78, 91], ["karyopherin", "PROTEIN", 103, 114], ["b2", "PROTEIN", 115, 117], ["Imp", "PROTEIN", 160, 163], ["proline-tyrosine NLSs", "TREATMENT", 31, 52], ["the cargo protein", "TREATMENT", 74, 91], ["karyopherin", "TREATMENT", 103, 114]]], ["For nuclear export, the leucine-rich NES (recognized by CRM1) is the most extensively characterized export signal while the structure of the CRM1-snurportin1 and RanGTP complex has been elucidated [36,37].Classical NLSsThe first nuclear transport signals were described in the SV40 large T antigen and nucleoplasmin in the early 1980s comprising a short lysine-rich sequence classified as classical NLSs [31, 38] .", [["nuclear", "ANATOMY", 4, 11], ["nuclear", "ANATOMY", 229, 236], ["leucine", "CHEMICAL", 24, 31], ["leucine", "CHEMICAL", 24, 31], ["lysine", "CHEMICAL", 354, 360], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["leucine", "AMINO_ACID", 24, 31], ["-rich NES", "GENE_OR_GENE_PRODUCT", 31, 40], ["CRM1", "GENE_OR_GENE_PRODUCT", 56, 60], ["CRM1", "GENE_OR_GENE_PRODUCT", 141, 145], ["snurportin1", "GENE_OR_GENE_PRODUCT", 146, 157], ["RanGTP", "GENE_OR_GENE_PRODUCT", 162, 168], ["nuclear", "CELLULAR_COMPONENT", 229, 236], ["SV40", "ORGANISM", 277, 281], ["large T antigen", "GENE_OR_GENE_PRODUCT", 282, 297], ["nucleoplasmin", "GENE_OR_GENE_PRODUCT", 302, 315], ["leucine-rich NES", "PROTEIN", 24, 40], ["CRM1", "PROTEIN", 56, 60], ["CRM1", "PROTEIN", 141, 145], ["snurportin1", "PROTEIN", 146, 157], ["RanGTP complex", "PROTEIN", 162, 176], ["NLSs", "PROTEIN", 215, 219], ["SV40 large T antigen", "PROTEIN", 277, 297], ["nucleoplasmin", "PROTEIN", 302, 315], ["lysine-rich sequence", "PROTEIN", 354, 374], ["NLSs", "PROTEIN", 399, 403], ["nuclear export", "TEST", 4, 18], ["RanGTP complex", "PROBLEM", 162, 176], ["the SV40 large T antigen", "TEST", 273, 297], ["a short lysine-rich sequence", "TREATMENT", 346, 374], ["classical NLSs", "TEST", 389, 403]]], ["These bind the armadillo (ARM) domain in the C terminus of Imp-a.", [["Imp", "GENE_OR_GENE_PRODUCT", 59, 62], ["armadillo (ARM) domain", "PROTEIN", 15, 37], ["C terminus", "PROTEIN", 45, 55], ["Imp", "PROTEIN", 59, 62], ["These bind the armadillo (ARM) domain", "TREATMENT", 0, 37], ["ARM", "ANATOMY", 26, 29]]], ["The adaptor protein Imp-a also binds the transport receptor Imp-b through its N-terminal aIBB domain forming a ternary complex [39] .", [["N", "CHEMICAL", 78, 79], ["Imp", "GENE_OR_GENE_PRODUCT", 20, 23], ["Imp-b", "GENE_OR_GENE_PRODUCT", 60, 65], ["Imp", "PROTEIN", 20, 23], ["transport receptor Imp-b", "PROTEIN", 41, 65], ["N-terminal aIBB domain", "PROTEIN", 78, 100], ["ternary complex", "PROTEIN", 111, 126]]], ["The small size and relatively simple sequence patterns of these basic NLSs have facilitated identification of similar signals in many proteins.", [["basic NLSs", "PROTEIN", 64, 74], ["The small size", "PROBLEM", 0, 14], ["these basic NLSs", "PROBLEM", 58, 74], ["similar signals in many proteins", "PROBLEM", 110, 142], ["small", "OBSERVATION_MODIFIER", 4, 9], ["size", "OBSERVATION_MODIFIER", 10, 14], ["relatively", "OBSERVATION_MODIFIER", 19, 29], ["simple", "OBSERVATION_MODIFIER", 30, 36], ["similar signals", "OBSERVATION", 110, 125]]], ["The classical NLSs contain one or two clusters of positively charged amino acids, typically lysine or arginine, and are divided into two classes, monopartite and bipartite classical NLSs [40] .", [["amino acids", "CHEMICAL", 69, 80], ["lysine", "CHEMICAL", 92, 98], ["arginine", "CHEMICAL", 102, 110], ["amino acids", "CHEMICAL", 69, 80], ["lysine", "CHEMICAL", 92, 98], ["arginine", "CHEMICAL", 102, 110], ["amino acids", "AMINO_ACID", 69, 80], ["lysine", "AMINO_ACID", 92, 98], ["arginine", "AMINO_ACID", 102, 110], ["monopartite", "SIMPLE_CHEMICAL", 146, 157], ["NLSs", "PROTEIN", 14, 18], ["NLSs", "PROTEIN", 182, 186], ["charged amino acids", "TREATMENT", 61, 80], ["one", "OBSERVATION_MODIFIER", 27, 30], ["amino acids", "OBSERVATION", 69, 80]]], ["The monopartite classical NLS is a short and highly basic signal.", [["monopartite classical NLS", "PROTEIN", 4, 29], ["a short and highly basic signal", "PROBLEM", 33, 64], ["monopartite", "OBSERVATION_MODIFIER", 4, 15], ["NLS", "OBSERVATION", 26, 29], ["short", "OBSERVATION_MODIFIER", 35, 40]]], ["The two stretches of basic amino acids within a bipartite classical NLS are separated by a linker region that is usually 10-12 residues long, although longer linker sequences have been reported [41] .", [["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "AMINO_ACID", 27, 38], ["NLS", "GENE_OR_GENE_PRODUCT", 68, 71], ["bipartite classical NLS", "PROTEIN", 48, 71], ["linker region", "PROTEIN", 91, 104], ["linker sequences", "PROTEIN", 158, 174], ["basic amino acids", "TEST", 21, 38], ["a bipartite classical NLS", "PROBLEM", 46, 71], ["longer linker sequences", "PROBLEM", 151, 174], ["two", "OBSERVATION_MODIFIER", 4, 7], ["stretches", "OBSERVATION_MODIFIER", 8, 17], ["amino acids", "OBSERVATION", 27, 38]]], ["In addition, several atypical NLSs that bind to classical NLS binding sites in Imp-a have been characterized, including the hydrophobic NLS from phospholipid scramblase 1 [40].Non-classical NLSsSome cargo proteins bypass the requirement for an adaptor protein and bind directly to transport receptors through non-classical NLSs.", [["NLSs", "GENE_OR_GENE_PRODUCT", 30, 34], ["NLS", "GENE_OR_GENE_PRODUCT", 58, 61], ["Imp-a", "GENE_OR_GENE_PRODUCT", 79, 84], ["phospholipid scramblase 1", "GENE_OR_GENE_PRODUCT", 145, 170], ["NLSs", "PROTEIN", 30, 34], ["NLS binding sites", "PROTEIN", 58, 75], ["Imp", "PROTEIN", 79, 82], ["hydrophobic NLS", "PROTEIN", 124, 139], ["NLSs", "PROTEIN", 190, 194], ["cargo proteins", "PROTEIN", 199, 213], ["adaptor protein", "PROTEIN", 244, 259], ["transport receptors", "PROTEIN", 281, 300], ["non-classical NLSs", "PROTEIN", 309, 327], ["several atypical NLSs", "PROBLEM", 13, 34], ["classical NLS binding sites", "PROBLEM", 48, 75], ["the hydrophobic NLS", "PROBLEM", 120, 139], ["phospholipid scramblase", "TEST", 145, 168], ["Non-classical NLSs", "PROBLEM", 176, 194], ["cargo proteins bypass", "TREATMENT", 199, 220], ["an adaptor protein", "TREATMENT", 241, 259], ["atypical", "OBSERVATION_MODIFIER", 21, 29], ["NLSs", "OBSERVATION", 30, 34], ["cargo proteins bypass", "OBSERVATION", 199, 220]]], ["Proteins that are directly recognized by Imp-b include ribosomal proteins, CREB, the human immunodeficiency virus (HIV) Rev and Tat, SREBP-2, the human T-cell leukemia virus type 1 (HTLV-1) protein Rex, PTHrP, cyclin B1, Smad3, TRF and SRY [40] .", [["ribosomal", "ANATOMY", 55, 64], ["human immunodeficiency virus", "DISEASE", 85, 113], ["Imp-b", "GENE_OR_GENE_PRODUCT", 41, 46], ["ribosomal", "CELLULAR_COMPONENT", 55, 64], ["CREB", "GENE_OR_GENE_PRODUCT", 75, 79], ["human immunodeficiency virus", "ORGANISM", 85, 113], ["HIV", "ORGANISM", 115, 118], ["Rev", "GENE_OR_GENE_PRODUCT", 120, 123], ["Tat", "GENE_OR_GENE_PRODUCT", 128, 131], ["SREBP-2", "GENE_OR_GENE_PRODUCT", 133, 140], ["human T-cell leukemia virus type 1", "ORGANISM", 146, 180], ["HTLV-1", "ORGANISM", 182, 188], ["Rex", "GENE_OR_GENE_PRODUCT", 198, 201], ["PTHrP", "GENE_OR_GENE_PRODUCT", 203, 208], ["cyclin B1", "GENE_OR_GENE_PRODUCT", 210, 219], ["Smad3", "GENE_OR_GENE_PRODUCT", 221, 226], ["TRF", "GENE_OR_GENE_PRODUCT", 228, 231], ["SRY [40", "GENE_OR_GENE_PRODUCT", 236, 243], ["Imp", "PROTEIN", 41, 44], ["ribosomal proteins", "PROTEIN", 55, 73], ["CREB", "PROTEIN", 75, 79], ["Rev", "PROTEIN", 120, 123], ["Tat", "PROTEIN", 128, 131], ["SREBP-2", "PROTEIN", 133, 140], ["human T-cell leukemia virus type 1 (HTLV-1) protein", "PROTEIN", 146, 197], ["Rex", "PROTEIN", 198, 201], ["PTHrP", "PROTEIN", 203, 208], ["cyclin B1", "PROTEIN", 210, 219], ["Smad3", "PROTEIN", 221, 226], ["TRF", "PROTEIN", 228, 231], ["SRY", "PROTEIN", 236, 239], ["human immunodeficiency virus", "SPECIES", 85, 113], ["human", "SPECIES", 146, 151], ["T-cell leukemia virus type 1", "SPECIES", 152, 180], ["HTLV-1", "SPECIES", 182, 188], ["human immunodeficiency virus", "SPECIES", 85, 113], ["HIV", "SPECIES", 115, 118], ["human T-cell leukemia virus type 1", "SPECIES", 146, 180], ["HTLV-1", "SPECIES", 182, 188], ["Imp", "TEST", 41, 44], ["ribosomal proteins", "TEST", 55, 73], ["the human immunodeficiency virus", "PROBLEM", 81, 113], ["Tat", "TEST", 128, 131], ["SREBP", "TEST", 133, 138], ["the human T-cell leukemia virus type", "TEST", 142, 178], ["HTLV", "TEST", 182, 186], ["protein Rex", "TEST", 190, 201], ["PTHrP", "TEST", 203, 208], ["cyclin B1", "TREATMENT", 210, 219], ["cell leukemia", "OBSERVATION", 154, 167]]], ["In contrast to the interaction between classical NLS and Imp-a, proteins that bind to Imp-b directly do not obey strict rules and the NLSs that confer Imp-b recognition vary significantly in both size and charge [40] .Non-classical NLSsMany proteins that are imported into the nucleus can bind directly to the transport receptor transportin-1.", [["nucleus", "ANATOMY", 277, 284], ["NLS", "GENE_OR_GENE_PRODUCT", 49, 52], ["Imp", "GENE_OR_GENE_PRODUCT", 57, 60], ["Imp-b", "GENE_OR_GENE_PRODUCT", 86, 91], ["Imp-b", "GENE_OR_GENE_PRODUCT", 151, 156], ["nucleus", "CELLULAR_COMPONENT", 277, 284], ["transportin-1", "GENE_OR_GENE_PRODUCT", 329, 342], ["NLS", "PROTEIN", 49, 52], ["Imp", "PROTEIN", 57, 60], ["Imp", "PROTEIN", 86, 89], ["NLSs", "PROTEIN", 134, 138], ["Imp", "PROTEIN", 151, 154], ["NLSs", "PROTEIN", 232, 236], ["transport receptor transportin-1", "PROTEIN", 310, 342], ["Non-classical NLSsMany proteins", "PROBLEM", 218, 249], ["size", "OBSERVATION_MODIFIER", 196, 200]]], ["Common characteristics between the apparently disparate signals recognized by transportin-1 were described unifying them into a new class of NLS termed PY-NLS [34] .", [["transportin-1", "GENE_OR_GENE_PRODUCT", 78, 91], ["NLS", "GENE_OR_GENE_PRODUCT", 141, 144], ["transportin-1", "PROTEIN", 78, 91], ["NLS", "PROTEIN", 141, 144], ["PY", "PROTEIN", 152, 154], ["NLS", "PROTEIN", 155, 158]]], ["The consensus motif of PY-NLS consists of a loose N-terminal hydrophobic motif, a central arginine residue and a C-terminal PY sequence [42] .", [["arginine", "CHEMICAL", 90, 98], ["N", "CHEMICAL", 50, 51], ["arginine", "CHEMICAL", 90, 98], ["C", "CHEMICAL", 113, 114], ["arginine", "AMINO_ACID", 90, 98], ["PY", "PROTEIN", 23, 25], ["NLS", "PROTEIN", 26, 29], ["loose N-terminal hydrophobic motif", "PROTEIN", 44, 78], ["C-terminal PY sequence", "PROTEIN", 113, 135], ["a loose N-terminal hydrophobic motif", "PROBLEM", 42, 78], ["a central arginine residue", "PROBLEM", 80, 106], ["a C-terminal PY sequence", "TREATMENT", 111, 135]]], ["The physical rules that describe the PY-NLSs as structurally disordered in free cargoes, positively charged and with weak consensus motifs predicted approximately 100 candidate transportin-1 cargoes [34] .", [["transportin-1", "GENE_OR_GENE_PRODUCT", 177, 190], ["PY", "PROTEIN", 37, 39], ["NLSs", "PROTEIN", 40, 44], ["consensus motifs", "PROTEIN", 122, 138], ["transportin", "PROTEIN", 177, 188], ["structurally disordered in free cargoes", "PROBLEM", 48, 87], ["weak consensus motifs", "PROBLEM", 117, 138]]], ["Interestingly, arginine-glycine-rich NLSs known as RG-NLSs in the yeast proteins Hrp1 and Nab2 and the 38 amino acid long NLS of the hnRNP A1 protein, designated M9, were also shown to have the same characteristics as the PY-NLS [42, 45] .", [["arginine", "CHEMICAL", 15, 23], ["glycine", "CHEMICAL", 24, 31], ["amino acid", "CHEMICAL", 106, 116], ["arginine", "CHEMICAL", 15, 23], ["glycine", "CHEMICAL", 24, 31], ["amino acid", "CHEMICAL", 106, 116], ["arginine", "AMINO_ACID", 15, 23], ["glycine", "AMINO_ACID", 24, 31], ["RG-NLSs", "GENE_OR_GENE_PRODUCT", 51, 58], ["Hrp1", "GENE_OR_GENE_PRODUCT", 81, 85], ["Nab2", "GENE_OR_GENE_PRODUCT", 90, 94], ["amino acid", "AMINO_ACID", 106, 116], ["hnRNP A1", "GENE_OR_GENE_PRODUCT", 133, 141], ["arginine-glycine-rich NLSs", "PROTEIN", 15, 41], ["RG", "PROTEIN", 51, 53], ["NLSs", "PROTEIN", 54, 58], ["yeast proteins", "PROTEIN", 66, 80], ["Hrp1", "PROTEIN", 81, 85], ["Nab2", "PROTEIN", 90, 94], ["38 amino acid long NLS", "PROTEIN", 103, 125], ["hnRNP A1 protein", "PROTEIN", 133, 149], ["M9", "PROTEIN", 162, 164], ["NLS", "PROTEIN", 225, 228], ["yeast", "SPECIES", 66, 71], ["yeast", "SPECIES", 66, 71], ["arginine", "TEST", 15, 23], ["RG", "TEST", 51, 53], ["the yeast proteins Hrp1", "TEST", 62, 85], ["Nab2", "TEST", 90, 94], ["the 38 amino acid", "TEST", 99, 116], ["the hnRNP A1 protein", "TEST", 129, 149], ["the PY-NLS", "TEST", 218, 228]]], ["Recently other non-classical NLSs such as the extensive coiled-coil domain of STAT5a [46] have been characterized.", [["STAT5a", "GENE_OR_GENE_PRODUCT", 78, 84], ["NLSs", "PROTEIN", 29, 33], ["coiled-coil domain", "PROTEIN", 56, 74], ["STAT5a [46]", "PROTEIN", 78, 89], ["Recently other non-classical NLSs", "PROBLEM", 0, 33], ["the extensive coiled-coil domain of STAT5a", "TREATMENT", 42, 84], ["NLSs", "OBSERVATION", 29, 33], ["extensive", "OBSERVATION_MODIFIER", 46, 55], ["coiled", "OBSERVATION", 56, 62]]], ["Furthermore, a number of proteins have been identified that contain both classical and nonclassical NLS motifs that can interact directly with both Imp-a and Imp-b family members.Leucine-rich NESs containing cargoesThe first signals that direct the nuclear export of a protein were identified in HIV Rev and protein kinase .", [["nuclear", "ANATOMY", 249, 256], ["Leucine", "CHEMICAL", 179, 186], ["Leucine", "CHEMICAL", 179, 186], ["Imp", "GENE_OR_GENE_PRODUCT", 148, 151], ["Imp-b", "GENE_OR_GENE_PRODUCT", 158, 163], ["Leucine-rich NESs", "SIMPLE_CHEMICAL", 179, 196], ["nuclear", "CELLULAR_COMPONENT", 249, 256], ["HIV", "ORGANISM", 296, 299], ["Rev", "GENE_OR_GENE_PRODUCT", 300, 303], ["protein kinase", "GENE_OR_GENE_PRODUCT", 308, 322], ["NLS motifs", "PROTEIN", 100, 110], ["Imp", "PROTEIN", 148, 151], ["Imp-b family members", "PROTEIN", 158, 178], ["Leucine-rich NESs", "PROTEIN", 179, 196], ["HIV Rev", "PROTEIN", 296, 303], ["protein kinase", "PROTEIN", 308, 322], ["HIV", "SPECIES", 296, 299], ["Leucine-rich NESs containing cargoes", "TREATMENT", 179, 215], ["a protein", "TEST", 267, 276], ["HIV Rev and protein kinase", "TEST", 296, 322]]], ["The consensus sequence for NES is /1-X (2-3) -/2-X (2-3) -/3-X-/4 (where / represents one of the hydrophobic residues L, V, I, F or M, and X can be any amino acid but preferentially is charged, polar or a small amino acid) [47-49].Leucine-rich NESs containing cargoesMore complex export signatures incorporate the three-dimensional features of the whole protein that are recognized and targeted for export [50, 51] .", [["amino acid", "CHEMICAL", 152, 162], ["amino acid", "CHEMICAL", 211, 221], ["Leucine", "CHEMICAL", 231, 238], ["amino acid", "CHEMICAL", 152, 162], ["amino acid", "CHEMICAL", 211, 221], ["Leucine", "CHEMICAL", 231, 238], ["2-3) -/2-X (2-3) -/3-X-/4", "SIMPLE_CHEMICAL", 40, 65], ["amino acid", "AMINO_ACID", 152, 162], ["amino acid", "AMINO_ACID", 211, 221], ["Leucine-rich NESs", "SIMPLE_CHEMICAL", 231, 248], ["consensus sequence", "DNA", 4, 22], ["NES", "PROTEIN", 27, 30], ["X", "PROTEIN", 139, 140], ["Leucine-rich NESs", "PROTEIN", 231, 248], ["The consensus sequence", "TEST", 0, 22], ["NES", "TEST", 27, 30], ["the hydrophobic residues", "PROBLEM", 93, 117], ["any amino acid", "PROBLEM", 148, 162], ["a small amino acid", "TEST", 203, 221], ["Leucine-rich NESs containing cargoes", "TREATMENT", 231, 267], ["the whole protein", "TEST", 344, 361]]], ["Proteins containing these NESs are recognized and exported by CRM1 [52-55] (Fig. 2) .", [["NESs", "GENE_OR_GENE_PRODUCT", 26, 30], ["CRM1", "GENE_OR_GENE_PRODUCT", 62, 66], ["NESs", "PROTEIN", 26, 30], ["CRM1", "PROTEIN", 62, 66], ["CRM1", "TEST", 62, 66]]], ["G\u20ac uttler et al. showed that CRM1 contains five pockets for binding the conserved hydrophobic residues of NESs.", [["CRM1", "GENE_OR_GENE_PRODUCT", 29, 33], ["NESs", "PATHOLOGICAL_FORMATION", 106, 110], ["CRM1", "PROTEIN", 29, 33], ["NESs", "PROTEIN", 106, 110], ["CRM1 contains five pockets", "PROBLEM", 29, 55], ["CRM1", "OBSERVATION", 29, 33], ["five", "OBSERVATION_MODIFIER", 43, 47], ["pockets", "OBSERVATION_MODIFIER", 48, 55], ["hydrophobic residues", "OBSERVATION", 82, 102]]], ["Accordingly, a structure-based NES consensus with an additional hydrophobic position (five instead of four) has been proposed [56].", [["NES consensus", "DNA", 31, 44], ["an additional hydrophobic position", "TREATMENT", 50, 84]]], ["Kosugi et al. generated a large number of NES peptides in a random peptide library screen and delineated multiple distinct consensus sequences that described more than 80% of known functional NESs [57] .", [["consensus sequences", "DNA", 123, 142], ["NES peptides", "PROBLEM", 42, 54], ["a random peptide library screen", "TEST", 58, 89], ["multiple distinct consensus sequences", "PROBLEM", 105, 142], ["large", "OBSERVATION_MODIFIER", 26, 31], ["NES peptides", "OBSERVATION", 42, 54]]], ["A predictor, NESsential, that uses sequence derived meta-features, such as predicted disorder and solvent accessibility, in addition to a primary sequence that can identify promising NES-containing candidate proteins [58, 59] , http://validness.ym.edu.tw/index.php.", [["disorder", "DISEASE", 85, 93], ["NES", "PROTEIN", 183, 186], ["candidate proteins", "PROTEIN", 198, 216], ["predicted disorder", "PROBLEM", 75, 93]]], ["Other recently developed NES predictor tools include WREGEX, which uses position-specific scoring matrices for motif prediction [60] , and NESMAPPER (http://sourceforge.net/projects/nesmapper), which has been developed based on the activity profile of all classes of NESs [61] .Nuclear transport receptorsProteins larger than 40 kDa are transported through the NPC by soluble nuclear transport receptors (NTRs).", [["Nuclear", "ANATOMY", 278, 285], ["NPC", "ANATOMY", 361, 364], ["nuclear", "ANATOMY", 376, 383], ["Nuclear transport receptors", "GENE_OR_GENE_PRODUCT", 278, 305], ["NPC", "CANCER", 361, 364], ["nuclear transport receptors", "GENE_OR_GENE_PRODUCT", 376, 403], ["NTRs", "GENE_OR_GENE_PRODUCT", 405, 409], ["NES", "PROTEIN", 25, 28], ["Nuclear transport receptors", "PROTEIN", 278, 305], ["NPC", "PROTEIN", 361, 364], ["soluble nuclear transport receptors", "PROTEIN", 368, 403], ["NTRs", "PROTEIN", 405, 409], ["motif prediction", "TEST", 111, 127], ["Nuclear transport receptors", "TEST", 278, 305], ["Proteins", "TEST", 305, 313], ["larger", "OBSERVATION_MODIFIER", 314, 320]]], ["NTRs continuously shuttle between the nucleus and the cytoplasm, bind their cargo on one side of the nucleus and release it on the other side.", [["nucleus", "ANATOMY", 38, 45], ["cytoplasm", "ANATOMY", 54, 63], ["nucleus", "ANATOMY", 101, 108], ["NTRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleus", "CELLULAR_COMPONENT", 38, 45], ["cytoplasm", "ORGANISM_SUBSTANCE", 54, 63], ["nucleus", "CELLULAR_COMPONENT", 101, 108], ["NTRs", "PROTEIN", 0, 4], ["NTRs", "TREATMENT", 0, 4], ["nucleus", "ANATOMY", 38, 45], ["nucleus", "ANATOMY", 101, 108]]], ["The majority of the nuclear-cytoplasmic transport receptors are members of the b-karyopherin protein family with each member recognizing a unique group of cargo proteins or RNAs (summarized in Table 2 ) [62] .", [["nuclear", "ANATOMY", 20, 27], ["cytoplasmic", "ANATOMY", 28, 39], ["nuclear", "CELLULAR_COMPONENT", 20, 27], ["cytoplasmic", "ORGANISM_SUBSTANCE", 28, 39], ["b-karyopherin", "GENE_OR_GENE_PRODUCT", 79, 92], ["nuclear-cytoplasmic transport receptors", "PROTEIN", 20, 59], ["b-karyopherin protein family", "PROTEIN", 79, 107], ["cargo proteins", "PROTEIN", 155, 169], ["RNAs", "RNA", 173, 177]]], ["There are 22 putative members of the karyopherin family in humans [63] that share only modest sequence homology with the greatest homology noted within their Ran-binding domain [64] .", [["karyopherin", "GENE_OR_GENE_PRODUCT", 37, 48], ["humans", "ORGANISM", 59, 65], ["karyopherin family", "PROTEIN", 37, 55], ["Ran-binding domain", "PROTEIN", 158, 176], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65]]], ["A specific architecture within the karyopherin family is the tandem HEAT repeat fold formed by anti-parallel helices that are linked by a short intra-repeat loop [65] .", [["karyopherin", "GENE_OR_GENE_PRODUCT", 35, 46], ["karyopherin family", "PROTEIN", 35, 53], ["anti-parallel helices", "PROTEIN", 95, 116], ["a short intra-repeat loop", "TREATMENT", 136, 161]]], ["Karyopherin-b proteins can either directly or indirectly, through adaptors, interact with their cargo.", [["Karyopherin-b proteins", "GENE_OR_GENE_PRODUCT", 0, 22], ["Karyopherin-b proteins", "PROTEIN", 0, 22], ["adaptors", "PROTEIN", 66, 74], ["Karyopherin-b proteins", "TREATMENT", 0, 22]]], ["In addition there are six homologs of adaptor proteins that belong to the Imp-a protein family that have been identified in humans which adds a further level of complexity to this process [67] .", [["Imp", "GENE_OR_GENE_PRODUCT", 74, 77], ["humans", "ORGANISM", 124, 130], ["adaptor proteins", "PROTEIN", 38, 54], ["Imp", "PROTEIN", 74, 77], ["protein family", "PROTEIN", 80, 94], ["humans", "SPECIES", 124, 130], ["humans", "SPECIES", 124, 130], ["adaptor proteins", "TREATMENT", 38, 54]]], ["For example, Imp-b mediated nuclear import of the uridine-rich small nuclear RNPs involves a different adaptor protein called snuportin-1 and, as in the case of Imp-a, snuportin-1 binds Imp-b through an IBB domain.", [["nuclear", "ANATOMY", 28, 35], ["nuclear RNPs", "ANATOMY", 69, 81], ["uridine", "CHEMICAL", 50, 57], ["uridine", "CHEMICAL", 50, 57], ["Imp-b", "GENE_OR_GENE_PRODUCT", 13, 18], ["nuclear", "CELLULAR_COMPONENT", 28, 35], ["uridine", "SIMPLE_CHEMICAL", 50, 57], ["snuportin-1", "GENE_OR_GENE_PRODUCT", 126, 137], ["Imp", "GENE_OR_GENE_PRODUCT", 161, 164], ["snuportin-1", "GENE_OR_GENE_PRODUCT", 168, 179], ["Imp-b", "GENE_OR_GENE_PRODUCT", 186, 191], ["Imp-b", "PROTEIN", 13, 18], ["uridine-rich small nuclear RNPs", "PROTEIN", 50, 81], ["adaptor protein", "PROTEIN", 103, 118], ["snuportin-1", "PROTEIN", 126, 137], ["Imp", "PROTEIN", 161, 164], ["snuportin-1", "PROTEIN", 168, 179], ["Imp", "PROTEIN", 186, 189], ["IBB domain", "PROTEIN", 203, 213], ["the uridine", "TREATMENT", 46, 57], ["an IBB domain", "TREATMENT", 200, 213], ["small", "OBSERVATION_MODIFIER", 63, 68], ["nuclear RNPs", "OBSERVATION", 69, 81]]], ["The karyopherin-b proteins are multi-domain transport factors that contain a cargo binding domain, an NPC binding domain [68] and a binding domain for the small Ras-like GTPase Ran [69, 70] .", [["NPC", "ANATOMY", 102, 105], ["karyopherin-b", "GENE_OR_GENE_PRODUCT", 4, 17], ["NPC", "CANCER", 102, 105], ["Ras-", "GENE_OR_GENE_PRODUCT", 161, 165], ["Ran", "GENE_OR_GENE_PRODUCT", 177, 180], ["karyopherin-b proteins", "PROTEIN", 4, 26], ["multi-domain transport factors", "PROTEIN", 31, 61], ["cargo binding domain", "PROTEIN", 77, 97], ["NPC binding domain", "PROTEIN", 102, 120], ["binding domain", "PROTEIN", 132, 146], ["small Ras-like GTPase", "PROTEIN", 155, 176], ["Ran", "PROTEIN", 177, 180], ["The karyopherin-b proteins", "TREATMENT", 0, 26], ["multi-domain transport factors", "PROBLEM", 31, 61], ["a cargo binding domain", "PROBLEM", 75, 97], ["a binding domain", "TEST", 130, 146], ["the small Ras-", "TEST", 151, 165], ["cargo binding", "OBSERVATION", 77, 90], ["small", "OBSERVATION_MODIFIER", 155, 160]]], ["Family members contain both import and export receptors; however, only a few of them have been functionally characterized in higher eukaryotes (indicated in Table 2 ).Import receptorsA protein that contains a classical NLS is bound by the NLS binding pocket formed by the armadillo repeats within the Imp-a adaptor protein.", [["receptorsA", "GENE_OR_GENE_PRODUCT", 174, 184], ["NLS", "GENE_OR_GENE_PRODUCT", 219, 222], ["Imp", "GENE_OR_GENE_PRODUCT", 301, 304], ["export receptors", "PROTEIN", 39, 55], ["receptorsA protein", "PROTEIN", 174, 192], ["NLS", "PROTEIN", 219, 222], ["NLS binding pocket", "PROTEIN", 239, 257], ["armadillo repeats", "PROTEIN", 272, 289], ["Imp", "PROTEIN", 301, 304], ["adaptor protein", "PROTEIN", 307, 322], ["a classical NLS", "PROBLEM", 207, 222], ["the NLS binding pocket", "PROBLEM", 235, 257], ["the armadillo repeats", "TEST", 268, 289]]], ["The transport receptor Imp-b binds to Imp-a and then targets the NLS-containing protein into and through the NPC.", [["NPC", "ANATOMY", 109, 112], ["Imp-b", "GENE_OR_GENE_PRODUCT", 23, 28], ["Imp", "GENE_OR_GENE_PRODUCT", 38, 41], ["NLS", "GENE_OR_GENE_PRODUCT", 65, 68], ["NPC", "CANCER", 109, 112], ["transport receptor Imp-b", "PROTEIN", 4, 28], ["Imp", "PROTEIN", 38, 41], ["NLS", "PROTEIN", 65, 68], ["NPC", "PROTEIN", 109, 112], ["NPC", "ANATOMY", 109, 112]]], ["Intriguingly, Imp-b has been shown to contain two binding sites for FG-rich motifs that are located away from the cargo binding site [71] .", [["Imp-b", "GENE_OR_GENE_PRODUCT", 14, 19], ["Imp-b", "PROTEIN", 14, 19], ["FG-rich motifs", "PROTEIN", 68, 82], ["cargo binding site", "PROTEIN", 114, 132], ["two binding sites", "PROBLEM", 46, 63], ["FG-rich motifs", "TREATMENT", 68, 82]]], ["Most karyopherin-b proteins do not rely on adaptors to bind to cargoes as they can directly interact with basic NLSs of core histones and ribosomal proteins or arginine-glycine-rich NLSs of some RNA binding proteins.CRM1 (chromosome region maintenance 1)The most extensively characterized export receptor is chromosome region maintenance 1 (CRM1), a member of the karyopherin-b family of receptor proteins.", [["ribosomal", "ANATOMY", 138, 147], ["chromosome region", "ANATOMY", 222, 239], ["chromosome region", "ANATOMY", 308, 325], ["arginine", "CHEMICAL", 160, 168], ["glycine", "CHEMICAL", 169, 176], ["arginine", "CHEMICAL", 160, 168], ["glycine", "CHEMICAL", 169, 176], ["karyopherin-b", "GENE_OR_GENE_PRODUCT", 5, 18], ["histones", "CELLULAR_COMPONENT", 125, 133], ["ribosomal", "CELLULAR_COMPONENT", 138, 147], ["arginine", "AMINO_ACID", 160, 168], ["glycine", "AMINO_ACID", 169, 176], ["RNA binding proteins", "GENE_OR_GENE_PRODUCT", 195, 215], ["CRM1", "GENE_OR_GENE_PRODUCT", 216, 220], ["chromosome region", "CELLULAR_COMPONENT", 222, 239], ["chromosome region maintenance 1", "GENE_OR_GENE_PRODUCT", 308, 339], ["CRM1", "GENE_OR_GENE_PRODUCT", 341, 345], ["karyopherin-b", "GENE_OR_GENE_PRODUCT", 364, 377], ["karyopherin-b proteins", "PROTEIN", 5, 27], ["basic NLSs", "PROTEIN", 106, 116], ["core histones", "PROTEIN", 120, 133], ["ribosomal proteins", "PROTEIN", 138, 156], ["arginine-glycine-rich NLSs", "PROTEIN", 160, 186], ["RNA binding proteins", "PROTEIN", 195, 215], ["CRM1", "PROTEIN", 216, 220], ["chromosome region", "DNA", 222, 239], ["export receptor", "PROTEIN", 289, 304], ["chromosome region maintenance 1", "DNA", 308, 339], ["CRM1", "PROTEIN", 341, 345], ["karyopherin-b family", "PROTEIN", 364, 384], ["receptor proteins", "PROTEIN", 388, 405], ["core histones", "PROBLEM", 120, 133], ["ribosomal proteins", "PROBLEM", 138, 156], ["arginine-glycine", "TREATMENT", 160, 176], ["some RNA binding proteins", "PROBLEM", 190, 215], ["CRM1 (chromosome region maintenance", "TREATMENT", 216, 251], ["receptor proteins", "TREATMENT", 388, 405]]], ["CRM1 exports proteins that contain leucine-rich NESs from the nucleus into the cytoplasm [53,55].", [["nucleus", "ANATOMY", 62, 69], ["cytoplasm", "ANATOMY", 79, 88], ["leucine", "CHEMICAL", 35, 42], ["leucine", "CHEMICAL", 35, 42], ["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["leucine", "AMINO_ACID", 35, 42], ["nucleus", "CELLULAR_COMPONENT", 62, 69], ["cytoplasm", "ORGANISM_SUBSTANCE", 79, 88], ["CRM1", "PROTEIN", 0, 4], ["leucine-rich NESs", "PROTEIN", 35, 52], ["CRM1 exports proteins", "TEST", 0, 21], ["leucine", "TEST", 35, 42], ["leucine", "OBSERVATION_MODIFIER", 35, 42], ["nucleus", "ANATOMY", 62, 69], ["cytoplasm", "OBSERVATION_MODIFIER", 79, 88]]], ["CRM1 has 20 HEAT domains that allow RanGTP to bind.", [["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["RanGTP", "GENE_OR_GENE_PRODUCT", 36, 42], ["CRM1", "PROTEIN", 0, 4], ["20 HEAT domains", "PROTEIN", 9, 24], ["RanGTP", "PROTEIN", 36, 42], ["CRM1", "PROBLEM", 0, 4], ["20 HEAT domains", "PROBLEM", 9, 24], ["20 HEAT", "OBSERVATION_MODIFIER", 9, 16]]], ["Cargo binding takes place outside of this HEAT domain ring in a hydrophobic cleft producing a generic NES docking site [56] .", [["HEAT domain ring", "PROTEIN", 42, 58], ["NES docking site", "PROTEIN", 102, 118], ["Cargo binding", "PROBLEM", 0, 13], ["this HEAT domain ring", "TREATMENT", 37, 58], ["a hydrophobic cleft", "PROBLEM", 62, 81], ["hydrophobic cleft", "OBSERVATION", 64, 81]]], ["CRM1 recognizes NESs that are present in a large range of proteins that are structurally unrelated [72] .", [["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["NESs", "GENE_OR_GENE_PRODUCT", 16, 20], ["CRM1", "PROTEIN", 0, 4], ["NESs", "PROTEIN", 16, 20], ["large", "OBSERVATION_MODIFIER", 43, 48]]], ["CRM1 can also be recruited by adaptor molecules in situations where it does not bind directly to a protein that is to be exported from the nucleus (e.g. Exp5 cooperates with CRM1 to export large ribosomal subunits [73] ).", [["nucleus", "ANATOMY", 139, 146], ["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["nucleus", "CELLULAR_COMPONENT", 139, 146], ["Exp5", "GENE_OR_GENE_PRODUCT", 153, 157], ["CRM1", "GENE_OR_GENE_PRODUCT", 174, 178], ["CRM1", "PROTEIN", 0, 4], ["adaptor molecules", "PROTEIN", 30, 47], ["Exp5", "PROTEIN", 153, 157], ["CRM1", "PROTEIN", 174, 178], ["ribosomal subunits", "PROTEIN", 195, 213], ["CRM1", "PROBLEM", 0, 4], ["large ribosomal subunits", "TREATMENT", 189, 213], ["nucleus", "ANATOMY", 139, 146]]], ["CRM1 also participates in the export of the 40s and 60s pre-ribosomal subunits as well as essential RNPs Another key function of CRM1 is its role in SPN1 recycling (an adaptor for U snRNPs) back to the cytoplasm [51] .", [["cytoplasm", "ANATOMY", 202, 211], ["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CRM1", "GENE_OR_GENE_PRODUCT", 129, 133], ["SPN1", "GENE_OR_GENE_PRODUCT", 149, 153], ["U snRNPs", "GENE_OR_GENE_PRODUCT", 180, 188], ["cytoplasm", "ORGANISM_SUBSTANCE", 202, 211], ["CRM1", "PROTEIN", 0, 4], ["40s and 60s pre-ribosomal subunits", "PROTEIN", 44, 78], ["RNPs", "PROTEIN", 100, 104], ["CRM1", "PROTEIN", 129, 133], ["SPN1", "PROTEIN", 149, 153], ["adaptor for U snRNPs", "PROTEIN", 168, 188], ["60s pre-ribosomal subunits", "TREATMENT", 52, 78], ["an adaptor for U snRNPs", "TREATMENT", 165, 188]]], ["Intriguingly, overexpression of CRM1 has been reported in various tumor types and has beenAlternative nuclear transport pathwaysWhile most proteins are transported through the NPC by conventional karyopherin-b mediated mechanisms, alternative nuclear transport pathways have been described for a number of proteins.", [["tumor", "ANATOMY", 66, 71], ["nuclear", "ANATOMY", 102, 109], ["NPC", "ANATOMY", 176, 179], ["nuclear", "ANATOMY", 243, 250], ["tumor", "DISEASE", 66, 71], ["CRM1", "GENE_OR_GENE_PRODUCT", 32, 36], ["tumor", "CANCER", 66, 71], ["NPC", "CANCER", 176, 179], ["karyopherin-b", "GENE_OR_GENE_PRODUCT", 196, 209], ["nuclear", "CELLULAR_COMPONENT", 243, 250], ["CRM1", "PROTEIN", 32, 36], ["NPC", "PROTEIN", 176, 179], ["karyopherin", "PROTEIN", 196, 207], ["overexpression of CRM1", "PROBLEM", 14, 36], ["the NPC", "TREATMENT", 172, 179], ["conventional karyopherin-b mediated mechanisms", "TREATMENT", 183, 229], ["CRM1", "OBSERVATION", 32, 36], ["various", "OBSERVATION_MODIFIER", 58, 65], ["tumor", "OBSERVATION", 66, 71]]], ["These karyopherin-b-independent pathways include transport by alternative carriers such as the calcium-binding proteins calmodulin and calreticulin and translocation that seems to be mediated by direct interaction with NPC components, independent of carrier molecules.", [["NPC", "ANATOMY", 219, 222], ["calcium", "CHEMICAL", 95, 102], ["calcium", "CHEMICAL", 95, 102], ["karyopherin-b", "GENE_OR_GENE_PRODUCT", 6, 19], ["calcium", "SIMPLE_CHEMICAL", 95, 102], ["calmodulin", "GENE_OR_GENE_PRODUCT", 120, 130], ["calreticulin", "GENE_OR_GENE_PRODUCT", 135, 147], ["NPC", "GENE_OR_GENE_PRODUCT", 219, 222], ["karyopherin", "PROTEIN", 6, 17], ["calcium-binding proteins", "PROTEIN", 95, 119], ["calmodulin", "PROTEIN", 120, 130], ["calreticulin", "PROTEIN", 135, 147], ["NPC components", "PROTEIN", 219, 233], ["carrier molecules", "PROTEIN", 250, 267], ["the calcium-binding proteins calmodulin", "TREATMENT", 91, 130], ["NPC components", "TREATMENT", 219, 233]]], ["Importantly, many proteins are transported by more than one mechanism.", [["proteins", "OBSERVATION", 18, 26]]], ["It has been suggested that these seemingly redundant pathways may ensure the maintenance of cellular functions under conditions in which one pathway is inhibited [104] .", [["cellular", "ANATOMY", 92, 100], ["cellular", "CELL", 92, 100]]], ["Calmodulin has been shown to facilitate the nuclear import of the transcription factors SRY and SOX9 by binding to specific sequences in a way similar to NLS binding by karyopherin-b [105] .", [["nuclear", "ANATOMY", 44, 51], ["Calmodulin", "CHEMICAL", 0, 10], ["Calmodulin", "GENE_OR_GENE_PRODUCT", 0, 10], ["nuclear", "CELLULAR_COMPONENT", 44, 51], ["SRY", "GENE_OR_GENE_PRODUCT", 88, 91], ["SOX9", "GENE_OR_GENE_PRODUCT", 96, 100], ["NLS", "GENE_OR_GENE_PRODUCT", 154, 157], ["Calmodulin", "PROTEIN", 0, 10], ["transcription factors", "PROTEIN", 66, 87], ["SRY", "PROTEIN", 88, 91], ["SOX9", "PROTEIN", 96, 100], ["NLS", "PROTEIN", 154, 157], ["karyopherin", "PROTEIN", 169, 180], ["Calmodulin", "TREATMENT", 0, 10]]], ["The nuclear import of these transcription factors is regulated by calcium.", [["nuclear", "ANATOMY", 4, 11], ["calcium", "CHEMICAL", 66, 73], ["calcium", "CHEMICAL", 66, 73], ["nuclear", "CELLULAR_COMPONENT", 4, 11], ["calcium", "SIMPLE_CHEMICAL", 66, 73], ["transcription factors", "PROTEIN", 28, 49], ["calcium", "TEST", 66, 73]]], ["Similarly, calreticulin exports the glucocorticoid receptor from the nucleus in a calcium-dependent manner [106] .", [["nucleus", "ANATOMY", 69, 76], ["calcium", "CHEMICAL", 82, 89], ["calcium", "CHEMICAL", 82, 89], ["calreticulin", "GENE_OR_GENE_PRODUCT", 11, 23], ["glucocorticoid receptor", "GENE_OR_GENE_PRODUCT", 36, 59], ["nucleus", "CELLULAR_COMPONENT", 69, 76], ["calcium", "SIMPLE_CHEMICAL", 82, 89], ["calreticulin", "PROTEIN", 11, 23], ["glucocorticoid receptor", "PROTEIN", 36, 59], ["calreticulin", "OBSERVATION", 11, 23], ["glucocorticoid receptor", "OBSERVATION", 36, 59], ["nucleus", "ANATOMY", 69, 76]]], ["In addition, calreticulin is involved in the nuclear export of thyroid hormone receptor a1 and viral proteins [107] [108] [109] .", [["nuclear", "ANATOMY", 45, 52], ["calreticulin", "GENE_OR_GENE_PRODUCT", 13, 25], ["nuclear", "CELLULAR_COMPONENT", 45, 52], ["thyroid hormone receptor a1", "GENE_OR_GENE_PRODUCT", 63, 90], ["calreticulin", "PROTEIN", 13, 25], ["thyroid hormone receptor a1", "PROTEIN", 63, 90], ["viral proteins", "PROTEIN", 95, 109], ["viral proteins", "TEST", 95, 109], ["calreticulin", "OBSERVATION", 13, 25], ["thyroid", "ANATOMY", 63, 70]]], ["Some proteins can enter the nucleus without requiring receptor proteins and there is growing evidence that receptor-independent nuclear import can be mediated by the direct binding of the transport cargo to FG-containing Nups.", [["nucleus", "ANATOMY", 28, 35], ["nuclear", "ANATOMY", 128, 135], ["nucleus", "CELLULAR_COMPONENT", 28, 35], ["nuclear", "CELLULAR_COMPONENT", 128, 135], ["FG", "SIMPLE_CHEMICAL", 207, 209], ["Nups", "GENE_OR_GENE_PRODUCT", 221, 225], ["receptor proteins", "PROTEIN", 54, 71], ["FG", "PROTEIN", 207, 209], ["Nups", "PROTEIN", 221, 225], ["Some proteins", "PROBLEM", 0, 13], ["receptor proteins", "TREATMENT", 54, 71], ["nucleus", "ANATOMY", 28, 35]]], ["It has been suggested that proteins with armadillo repeats such as b-catenin, that are structurally related to karyopherin transport receptors, can directly bind to the NPC and are imported into the nucleus independently of conventional NTRs of the karyopherin-b type.", [["NPC", "ANATOMY", 169, 172], ["nucleus", "ANATOMY", 199, 206], ["b-catenin", "GENE_OR_GENE_PRODUCT", 67, 76], ["karyopherin transport receptors", "GENE_OR_GENE_PRODUCT", 111, 142], ["NPC", "CANCER", 169, 172], ["nucleus", "CELLULAR_COMPONENT", 199, 206], ["NTRs", "GENE_OR_GENE_PRODUCT", 237, 241], ["karyopherin-b type", "GENE_OR_GENE_PRODUCT", 249, 267], ["armadillo repeats", "PROTEIN", 41, 58], ["b-catenin", "PROTEIN", 67, 76], ["karyopherin transport receptors", "PROTEIN", 111, 142], ["NPC", "PROTEIN", 169, 172], ["NTRs", "PROTEIN", 237, 241], ["karyopherin", "PROTEIN", 249, 260], ["proteins with armadillo repeats", "PROBLEM", 27, 58], ["b-catenin", "TREATMENT", 67, 76], ["karyopherin transport receptors", "TREATMENT", 111, 142], ["NPC", "ANATOMY", 169, 172]]], ["Other proteins such as the tumor suppressor proteins SMAD3 and 4 and the transcription factor PU.1 utilize direct binding to FG-Nups to cross the NPC.", [["tumor", "ANATOMY", 27, 32], ["NPC", "ANATOMY", 146, 149], ["tumor", "DISEASE", 27, 32], ["tumor", "CANCER", 27, 32], ["SMAD3", "GENE_OR_GENE_PRODUCT", 53, 58], ["4", "GENE_OR_GENE_PRODUCT", 63, 64], ["PU.1", "GENE_OR_GENE_PRODUCT", 94, 98], ["FG-Nups", "GENE_OR_GENE_PRODUCT", 125, 132], ["NPC", "CANCER", 146, 149], ["tumor suppressor proteins", "PROTEIN", 27, 52], ["SMAD3 and 4", "PROTEIN", 53, 64], ["transcription factor", "PROTEIN", 73, 93], ["PU.1", "PROTEIN", 94, 98], ["FG", "PROTEIN", 125, 127], ["Nups", "PROTEIN", 128, 132], ["NPC", "PROTEIN", 146, 149], ["Other proteins", "PROBLEM", 0, 14], ["the tumor suppressor proteins SMAD3", "TREATMENT", 23, 58], ["tumor", "OBSERVATION", 27, 32], ["NPC", "ANATOMY", 146, 149]]], ["Conversely, some proteins can be transported through their interaction with proteins that contain a functional NLS known as a 'piggyback' mechanism.", [["NLS", "GENE_OR_GENE_PRODUCT", 111, 114], ["NLS", "PROTEIN", 111, 114], ["a 'piggyback' mechanism", "TREATMENT", 124, 147]]], ["Recently, Speese et al. reported a novel NPC-independent mechanism for the nuclear export of RNP by nuclear envelope budding akin to nuclear egress of herpes-type viruses [110] .", [["NPC", "ANATOMY", 41, 44], ["nuclear", "ANATOMY", 75, 82], ["nuclear", "ANATOMY", 100, 107], ["nuclear", "ANATOMY", 133, 140], ["herpes-type viruses", "DISEASE", 151, 170], ["NPC", "CANCER", 41, 44], ["nuclear", "CELLULAR_COMPONENT", 75, 82], ["RNP", "CELLULAR_COMPONENT", 93, 96], ["nuclear", "CELLULAR_COMPONENT", 100, 107], ["nuclear", "CELLULAR_COMPONENT", 133, 140], ["herpes-type viruses", "ORGANISM", 151, 170], ["NPC", "PROTEIN", 41, 44], ["RNP", "PROTEIN", 93, 96], ["a novel NPC", "PROBLEM", 33, 44], ["herpes", "PROBLEM", 151, 157], ["type viruses", "PROBLEM", 158, 170]]], ["During this mechanism, RNP granules bud into the perinuclear space in a manner dependent on lamin C.The Ran systemThe nucleo-cytoplasmic transport process mediated by members of the karyopherin protein family requires metabolic energy.", [["RNP granules", "ANATOMY", 23, 35], ["perinuclear space", "ANATOMY", 49, 66], ["cytoplasmic", "ANATOMY", 125, 136], ["RNP granules", "CELLULAR_COMPONENT", 23, 35], ["perinuclear space", "CELLULAR_COMPONENT", 49, 66], ["Ran", "GENE_OR_GENE_PRODUCT", 104, 107], ["cytoplasmic", "ORGANISM_SUBSTANCE", 125, 136], ["karyopherin", "GENE_OR_GENE_PRODUCT", 182, 193], ["Ran", "PROTEIN", 104, 107], ["karyopherin protein family", "PROTEIN", 182, 208], ["RNP granules bud into the perinuclear space", "PROBLEM", 23, 66], ["RNP", "OBSERVATION", 23, 26], ["granules bud", "OBSERVATION", 27, 39], ["perinuclear space", "OBSERVATION", 49, 66], ["metabolic energy", "OBSERVATION", 218, 234]]], ["The loading and unloading of transport receptors with cargo molecules is controlled by the small Ras-like GTPase Ran and requires GTP hydrolysis [111] .", [["GTP", "CHEMICAL", 130, 133], ["GTP", "CHEMICAL", 130, 133], ["Ras-", "GENE_OR_GENE_PRODUCT", 97, 101], ["Ran", "GENE_OR_GENE_PRODUCT", 113, 116], ["GTP", "SIMPLE_CHEMICAL", 130, 133], ["transport receptors", "PROTEIN", 29, 48], ["cargo molecules", "PROTEIN", 54, 69], ["small Ras-like GTPase", "PROTEIN", 91, 112], ["Ran", "PROTEIN", 113, 116], ["The loading and unloading of transport receptors", "TREATMENT", 0, 48], ["cargo molecules", "PROBLEM", 54, 69], ["GTP hydrolysis", "TREATMENT", 130, 144], ["cargo molecules", "OBSERVATION", 54, 69], ["small", "OBSERVATION_MODIFIER", 91, 96]]], ["Ran is a 25 kDa protein that exists in two different nucleotide-bound states: RanGDP and RanGTP [112, 113] .", [["nucleotide", "CHEMICAL", 53, 63], ["nucleotide", "CHEMICAL", 53, 63], ["Ran", "GENE_OR_GENE_PRODUCT", 0, 3], ["RanGDP", "SIMPLE_CHEMICAL", 78, 84], ["RanGTP", "GENE_OR_GENE_PRODUCT", 89, 95], ["Ran", "PROTEIN", 0, 3], ["25 kDa protein", "PROTEIN", 9, 23], ["nucleotide-bound states", "PROTEIN", 53, 76], ["RanGDP", "PROTEIN", 78, 84], ["RanGTP", "PROTEIN", 89, 95], ["a 25 kDa protein", "TEST", 7, 23], ["RanGDP", "TEST", 78, 84], ["RanGTP", "TEST", 89, 95], ["25 kDa", "OBSERVATION_MODIFIER", 9, 15]]], ["Ran hydrolyzes GTP very slowly and interacts with regulatory proteins including Ran-GAP1 (Ran GTPase activating protein 1) and RanBP1 that significantly increase GTP hydrolysis by Ran [114] .", [["GTP", "CHEMICAL", 15, 18], ["GTP", "CHEMICAL", 162, 165], ["GTP", "CHEMICAL", 15, 18], ["GTP", "CHEMICAL", 162, 165], ["Ran", "GENE_OR_GENE_PRODUCT", 0, 3], ["GTP", "SIMPLE_CHEMICAL", 15, 18], ["Ran-GAP1", "GENE_OR_GENE_PRODUCT", 80, 88], ["Ran GTPase activating protein 1", "GENE_OR_GENE_PRODUCT", 90, 121], ["RanBP1", "GENE_OR_GENE_PRODUCT", 127, 133], ["GTP", "SIMPLE_CHEMICAL", 162, 165], ["Ran [114]", "GENE_OR_GENE_PRODUCT", 180, 189], ["Ran", "PROTEIN", 0, 3], ["regulatory proteins", "PROTEIN", 50, 69], ["Ran-GAP1", "PROTEIN", 80, 88], ["Ran GTPase activating protein 1", "PROTEIN", 90, 121], ["RanBP1", "PROTEIN", 127, 133], ["Ran", "PROTEIN", 180, 183], ["Ran hydrolyzes GTP", "PROBLEM", 0, 18], ["Ran-GAP1 (Ran GTPase activating protein", "TREATMENT", 80, 119], ["RanBP1", "TREATMENT", 127, 133], ["GTP hydrolysis", "TREATMENT", 162, 176]]], ["Conversely, the Ran regulatory protein RanGTP exchange factor (RanGEF, also termed RCC1 in human cells) accelerates the exchange of nucleotides restoring the pool of the RanGTP.", [["cells", "ANATOMY", 97, 102], ["nucleotides", "CHEMICAL", 132, 143], ["Ran", "GENE_OR_GENE_PRODUCT", 16, 19], ["RanGTP", "GENE_OR_GENE_PRODUCT", 39, 45], ["RanGEF", "GENE_OR_GENE_PRODUCT", 63, 69], ["RCC1", "GENE_OR_GENE_PRODUCT", 83, 87], ["human", "ORGANISM", 91, 96], ["cells", "CELL", 97, 102], ["RanGTP", "GENE_OR_GENE_PRODUCT", 170, 176], ["Ran regulatory protein", "PROTEIN", 16, 38], ["RanGTP exchange factor", "PROTEIN", 39, 61], ["RanGEF", "PROTEIN", 63, 69], ["RCC1", "PROTEIN", 83, 87], ["human cells", "CELL_TYPE", 91, 102], ["RanGTP", "PROTEIN", 170, 176], ["human", "SPECIES", 91, 96], ["human", "SPECIES", 91, 96], ["the Ran regulatory protein RanGTP exchange factor", "PROBLEM", 12, 61], ["RCC1 in human cells", "TREATMENT", 83, 102], ["the exchange of nucleotides", "TREATMENT", 116, 143], ["protein RanGTP", "OBSERVATION", 31, 45], ["RanGTP", "OBSERVATION_MODIFIER", 170, 176]]], ["RanGAP1 is exclusively cytoplasmic [115] and RanBP1 is predominantly localized in the cytoplasm [116] whereas RanGEF is nuclear.", [["cytoplasmic", "ANATOMY", 23, 34], ["cytoplasm", "ANATOMY", 86, 95], ["nuclear", "ANATOMY", 120, 127], ["RanGAP1", "GENE_OR_GENE_PRODUCT", 0, 7], ["cytoplasmic", "ORGANISM_SUBSTANCE", 23, 34], ["[115]", "GENE_OR_GENE_PRODUCT", 35, 40], ["RanBP1", "GENE_OR_GENE_PRODUCT", 45, 51], ["cytoplasm", "ORGANISM_SUBSTANCE", 86, 95], ["RanGEF", "GENE_OR_GENE_PRODUCT", 110, 116], ["nuclear", "CELLULAR_COMPONENT", 120, 127], ["RanGAP1", "PROTEIN", 0, 7], ["RanBP1", "PROTEIN", 45, 51], ["RanGEF", "PROTEIN", 110, 116], ["RanBP1", "TEST", 45, 51], ["predominantly", "OBSERVATION_MODIFIER", 55, 68], ["localized", "OBSERVATION_MODIFIER", 69, 78]]], ["As a consequence of this strict nuclear localization of RanGEF and cytoplasmic RanGAP1, Ran in complex with GTP is localized mostly in the nucleus and RanGDP (Ran in complex with GDP) in the cytoplasm [62] .", [["nuclear", "ANATOMY", 32, 39], ["cytoplasmic", "ANATOMY", 67, 78], ["nucleus", "ANATOMY", 139, 146], ["cytoplasm", "ANATOMY", 191, 200], ["GTP", "CHEMICAL", 108, 111], ["GTP", "CHEMICAL", 108, 111], ["GDP", "CHEMICAL", 179, 182], ["nuclear", "CELLULAR_COMPONENT", 32, 39], ["RanGEF", "GENE_OR_GENE_PRODUCT", 56, 62], ["cytoplasmic", "ORGANISM_SUBSTANCE", 67, 78], ["RanGAP1", "GENE_OR_GENE_PRODUCT", 79, 86], ["Ran", "GENE_OR_GENE_PRODUCT", 88, 91], ["GTP", "SIMPLE_CHEMICAL", 108, 111], ["nucleus", "CELLULAR_COMPONENT", 139, 146], ["RanGDP", "GENE_OR_GENE_PRODUCT", 151, 157], ["Ran in complex with", "GENE_OR_GENE_PRODUCT", 159, 178], ["GDP", "SIMPLE_CHEMICAL", 179, 182], ["cytoplasm", "ORGANISM_SUBSTANCE", 191, 200], ["RanGEF", "PROTEIN", 56, 62], ["cytoplasmic RanGAP1", "PROTEIN", 67, 86], ["Ran", "PROTEIN", 88, 91], ["GTP", "PROTEIN", 108, 111], ["RanGDP", "PROTEIN", 151, 157], ["Ran", "PROTEIN", 159, 162], ["GDP", "PROTEIN", 179, 182], ["cytoplasmic RanGAP1", "TEST", 67, 86], ["nucleus", "ANATOMY", 139, 146]]], ["This RanGTP gradient provides directionality to nuclear-cytoplasmic transport because importins and exportins differ in the way they utilize the RanGTP gradient [117] .", [["nuclear", "ANATOMY", 48, 55], ["cytoplasmic", "ANATOMY", 56, 67], ["RanGTP", "GENE_OR_GENE_PRODUCT", 5, 11], ["nuclear", "CELLULAR_COMPONENT", 48, 55], ["cytoplasmic", "ORGANISM_SUBSTANCE", 56, 67], ["importins", "GENE_OR_GENE_PRODUCT", 86, 95], ["exportins", "GENE_OR_GENE_PRODUCT", 100, 109], ["RanGTP", "GENE_OR_GENE_PRODUCT", 145, 151], ["RanGTP", "PROTEIN", 5, 11], ["importins", "PROTEIN", 86, 95], ["exportins", "PROTEIN", 100, 109], ["RanGTP", "PROTEIN", 145, 151], ["This RanGTP gradient", "PROBLEM", 0, 20], ["the RanGTP gradient", "TEST", 141, 160], ["RanGTP gradient", "OBSERVATION", 5, 20]]], ["Import complexes are dissociated by RanGTP binding in contrast to export complexes which are formed by association with RanGTP.", [["RanGTP", "GENE_OR_GENE_PRODUCT", 36, 42], ["RanGTP", "GENE_OR_GENE_PRODUCT", 120, 126], ["RanGTP", "PROTEIN", 36, 42], ["export complexes", "PROTEIN", 66, 82], ["RanGTP", "PROTEIN", 120, 126], ["RanGTP binding", "OBSERVATION", 36, 50]]], ["Both importins and exportins bind RanGTP directly [52, 118, 119] and use the metabolic energy supplied by the RanGTPase system for directional transport [120, 121] .", [["importins", "GENE_OR_GENE_PRODUCT", 5, 14], ["exportins", "GENE_OR_GENE_PRODUCT", 19, 28], ["RanGTP", "GENE_OR_GENE_PRODUCT", 34, 40], ["RanGTPase", "GENE_OR_GENE_PRODUCT", 110, 119], ["importins", "PROTEIN", 5, 14], ["exportins", "PROTEIN", 19, 28], ["RanGTP", "PROTEIN", 34, 40], ["RanGTPase", "PROTEIN", 110, 119], ["directional transport", "TEST", 131, 152]]], ["Importins bind their cargo at low RanGTP level (in the cytoplasm) and traverse the NPC as dimeric complexes transporting cargo (Fig. 2 ) [118, 119] .", [["cytoplasm", "ANATOMY", 55, 64], ["NPC", "ANATOMY", 83, 86], ["Importins", "GENE_OR_GENE_PRODUCT", 0, 9], ["RanGTP", "GENE_OR_GENE_PRODUCT", 34, 40], ["cytoplasm", "ORGANISM_SUBSTANCE", 55, 64], ["NPC", "CANCER", 83, 86], ["Importins", "PROTEIN", 0, 9], ["RanGTP", "PROTEIN", 34, 40], ["NPC", "PROTEIN", 83, 86], ["dimeric complexes", "PROTEIN", 90, 107], ["NPC", "ANATOMY", 83, 86]]], ["Exportins act in an opposite manner, recruiting their cargo at high RanGTP levels in the nucleus (Fig. 2) [84,88] .", [["nucleus", "ANATOMY", 89, 96], ["Exportins", "GENE_OR_GENE_PRODUCT", 0, 9], ["RanGTP", "GENE_OR_GENE_PRODUCT", 68, 74], ["nucleus", "CELLULAR_COMPONENT", 89, 96], ["Exportins", "PROTEIN", 0, 9], ["RanGTP", "PROTEIN", 68, 74], ["nucleus", "ANATOMY", 89, 96]]], ["The RanGTP-exportin-cargo complex crosses the NPC into the cytoplasm where it disassembles following GTPase activation releasing the transported cargo.", [["NPC", "ANATOMY", 46, 49], ["cytoplasm", "ANATOMY", 59, 68], ["RanGTP", "GENE_OR_GENE_PRODUCT", 4, 10], ["exportin", "GENE_OR_GENE_PRODUCT", 11, 19], ["NPC", "CANCER", 46, 49], ["cytoplasm", "ORGANISM_SUBSTANCE", 59, 68], ["GTPase", "GENE_OR_GENE_PRODUCT", 101, 107], ["cargo", "CELLULAR_COMPONENT", 145, 150], ["RanGTP", "PROTEIN", 4, 10], ["exportin", "PROTEIN", 11, 19], ["cargo complex", "PROTEIN", 20, 33], ["NPC", "PROTEIN", 46, 49], ["GTPase", "PROTEIN", 101, 107], ["The RanGTP", "TEST", 0, 10], ["GTPase activation", "TREATMENT", 101, 118], ["NPC", "ANATOMY", 46, 49]]], ["The free export in translocates back into the nucleus to mediate another round of export.Trafficking of macromolecules through the NPCA number of models have been proposed to describe the molecular mechanism of selective gating through the NPC.", [["nucleus", "ANATOMY", 46, 53], ["NPC", "ANATOMY", 240, 243], ["nucleus", "CELLULAR_COMPONENT", 46, 53], ["NPC", "CANCER", 240, 243], ["NPC", "PROTEIN", 240, 243], ["selective gating through the NPC", "PROBLEM", 211, 243], ["free export", "OBSERVATION", 4, 15], ["nucleus", "ANATOMY", 46, 53], ["round", "OBSERVATION_MODIFIER", 73, 78], ["export", "OBSERVATION", 82, 88], ["macromolecules", "OBSERVATION", 104, 118], ["NPC", "ANATOMY", 240, 243]]], ["The polymer brush model suggests that movements of the unfolded FG-Nups sweep away macromolecules [11, 122, 123] .", [["The polymer brush model", "TEST", 0, 23], ["the unfolded FG", "TEST", 51, 66], ["movements", "OBSERVATION_MODIFIER", 38, 47]]], ["Conversely, the collapse model, based on atomic force microscopy data [124, 125] , suggests that regions of FG repeats may collapse following the binding of transport factors.", [["FG repeats", "PROTEIN", 108, 118], ["transport factors", "PROTEIN", 157, 174], ["the collapse model", "PROBLEM", 12, 30], ["atomic force microscopy data", "TEST", 41, 69], ["FG repeats", "TEST", 108, 118], ["collapse", "PROBLEM", 123, 131], ["collapse", "OBSERVATION", 16, 24], ["collapse", "OBSERVATION", 123, 131]]], ["These transport factors would open up their own passage through the central tube when they pass the meshwork of FG repeats.", [["meshwork", "ANATOMY", 100, 108], ["tube", "TISSUE", 76, 80], ["meshwork", "TISSUE", 100, 108], ["FG repeats", "CELLULAR_COMPONENT", 112, 122], ["transport factors", "PROTEIN", 6, 23], ["FG repeats", "PROTEIN", 112, 122], ["the central tube", "TREATMENT", 64, 80], ["FG repeats", "TEST", 112, 122], ["central tube", "OBSERVATION", 68, 80]]], ["The 'hydrophobic gel' model [126] , also called 'saturated model' [127, 128] , proposed that the phenylalanines in the FG repeat regions are crosslinked with each other and form a dense gel of FG repeat filaments.", [["FG repeat", "ANATOMY", 119, 128], ["filaments", "ANATOMY", 203, 212], ["phenylalanines", "CHEMICAL", 97, 111], ["phenylalanines", "CHEMICAL", 97, 111], ["phenylalanines", "SIMPLE_CHEMICAL", 97, 111], ["FG repeat filaments", "CELLULAR_COMPONENT", 193, 212], ["FG repeat regions", "DNA", 119, 136], ["The 'hydrophobic gel' model", "TREATMENT", 0, 27], ["the phenylalanines", "TREATMENT", 93, 111], ["dense", "OBSERVATION_MODIFIER", 180, 185]]], ["Transport factors bind to these FG repeats, dissolve the crosslinks and facilitate passage through the nuclear pore.", [["nuclear pore", "ANATOMY", 103, 115], ["nuclear pore", "CELLULAR_COMPONENT", 103, 115], ["FG repeats", "PROTEIN", 32, 42], ["these FG repeats", "TEST", 26, 42], ["the crosslinks", "TREATMENT", 53, 67]]], ["Another model suggested that the FG repeat regions form a layer coating the inner walls of the central tube where non-binding molecules can only pass through the narrow FG-Nup-free middle and where the transport factors enter this layer through binding giving them full access to the tube volume [129] .", [["inner walls", "ANATOMY", 76, 87], ["tube", "ANATOMY", 284, 288], ["central tube", "TISSUE", 95, 107], ["tube", "TISSUE", 284, 288], ["FG repeat regions", "DNA", 33, 50], ["non-binding molecules", "PROTEIN", 114, 135], ["FG", "PROTEIN", 169, 171], ["Nup", "PROTEIN", 172, 175], ["transport factors", "PROTEIN", 202, 219], ["the FG repeat regions", "PROBLEM", 29, 50], ["a layer coating the inner walls of the central tube", "TREATMENT", 56, 107], ["non-binding molecules", "PROBLEM", 114, 135], ["the tube volume", "TEST", 280, 295], ["layer", "OBSERVATION_MODIFIER", 58, 63], ["inner", "ANATOMY_MODIFIER", 76, 81], ["walls", "ANATOMY_MODIFIER", 82, 87], ["central tube", "OBSERVATION", 95, 107], ["narrow", "OBSERVATION_MODIFIER", 162, 168], ["middle", "ANATOMY_MODIFIER", 181, 187]]], ["Melc ak et al. proposed a model of pore dilatation by intermolecular sliding of Nup58/45 tetramers to adjust the diameter of the transport channel for the passage of cargo [130] .Nuclear importThe recognition of NLSs by Imp-a and heterodimerization with Imp-b initiates the process of nuclear import.", [["pore", "ANATOMY", 35, 39], ["Nuclear", "ANATOMY", 179, 186], ["nuclear", "ANATOMY", 285, 292], ["Nuclear", "CELLULAR_COMPONENT", 179, 186], ["NLSs", "GENE_OR_GENE_PRODUCT", 212, 216], ["Imp", "GENE_OR_GENE_PRODUCT", 220, 223], ["Imp-b", "GENE_OR_GENE_PRODUCT", 254, 259], ["nuclear", "CELLULAR_COMPONENT", 285, 292], ["Nup58", "PROTEIN", 80, 85], ["45 tetramers", "PROTEIN", 86, 98], ["NLSs", "PROTEIN", 212, 216], ["Imp", "PROTEIN", 220, 223], ["Imp-b", "PROTEIN", 254, 259], ["a model of pore dilatation", "TREATMENT", 24, 50], ["intermolecular sliding of Nup58/45 tetramers", "TREATMENT", 54, 98], ["the transport channel", "TREATMENT", 125, 146], ["Nuclear import", "TEST", 179, 193], ["pore", "OBSERVATION_MODIFIER", 35, 39], ["dilatation", "OBSERVATION", 40, 50]]], ["The import complex, consisting of the cargo protein and the Imp-a/b complex, localizes to the nuclear envelope, binds RanGDP and docks at the nuclear pore.", [["nuclear envelope", "ANATOMY", 94, 110], ["nuclear pore", "ANATOMY", 142, 154], ["Imp-a/b complex", "GENE_OR_GENE_PRODUCT", 60, 75], ["nuclear", "CELLULAR_COMPONENT", 94, 101], ["RanGDP", "GENE_OR_GENE_PRODUCT", 118, 124], ["nuclear pore", "CELLULAR_COMPONENT", 142, 154], ["import complex", "PROTEIN", 4, 18], ["cargo protein", "PROTEIN", 38, 51], ["Imp-a/b complex", "PROTEIN", 60, 75], ["RanGDP", "PROTEIN", 118, 124], ["nuclear pore", "OBSERVATION_MODIFIER", 142, 154]]], ["The Imp-a/b complex mediates the binding to and translocation through the NPC.", [["NPC", "ANATOMY", 74, 77], ["Imp-a/b", "GENE_OR_GENE_PRODUCT", 4, 11], ["NPC", "CANCER", 74, 77], ["Imp-a/b complex", "PROTEIN", 4, 19], ["NPC", "PROTEIN", 74, 77], ["NPC", "ANATOMY", 74, 77]]], ["Once trans-location through the pore is executed, dissociation of the import complex is stimulated by RanGTP in the nucleus.", [["pore", "ANATOMY", 32, 36], ["nucleus", "ANATOMY", 116, 123], ["pore", "CELLULAR_COMPONENT", 32, 36], ["RanGTP", "GENE_OR_GENE_PRODUCT", 102, 108], ["nucleus", "CELLULAR_COMPONENT", 116, 123], ["import complex", "PROTEIN", 70, 84], ["RanGTP", "PROTEIN", 102, 108], ["nucleus", "ANATOMY", 116, 123]]], ["Importin-a is recycled back to the cytoplasm through the nuclear exporter CAS, whereas Imp-b is separately transported back to the cytoplasm together with RanGTP.", [["cytoplasm", "ANATOMY", 35, 44], ["nuclear", "ANATOMY", 57, 64], ["cytoplasm", "ANATOMY", 131, 140], ["Importin-a", "GENE_OR_GENE_PRODUCT", 0, 10], ["cytoplasm", "ORGANISM_SUBSTANCE", 35, 44], ["nuclear", "CELLULAR_COMPONENT", 57, 64], ["Imp-b", "GENE_OR_GENE_PRODUCT", 87, 92], ["cytoplasm", "ORGANISM_SUBSTANCE", 131, 140], ["RanGTP", "GENE_OR_GENE_PRODUCT", 155, 161], ["Importin", "PROTEIN", 0, 8], ["nuclear exporter CAS", "PROTEIN", 57, 77], ["Imp-b", "PROTEIN", 87, 92], ["RanGTP", "PROTEIN", 155, 161]]], ["RanGAP1-facilitated GTP hydrolysis of Ran on the cytoplasmic side causes the release of Imp-b for the next cycle.Nuclear exportThe process of nuclear export is carried out according to principles which are analogous to those of nuclear import, using specific nuclear export receptors like CRM1 that recognize NES sequences on cargo proteins [131, 132] .", [["cytoplasmic", "ANATOMY", 49, 60], ["Nuclear", "ANATOMY", 113, 120], ["nuclear", "ANATOMY", 142, 149], ["nuclear", "ANATOMY", 228, 235], ["nuclear", "ANATOMY", 259, 266], ["RanGAP1", "CHEMICAL", 0, 7], ["GTP", "CHEMICAL", 20, 23], ["GTP", "CHEMICAL", 20, 23], ["RanGAP1", "GENE_OR_GENE_PRODUCT", 0, 7], ["GTP", "SIMPLE_CHEMICAL", 20, 23], ["Ran", "GENE_OR_GENE_PRODUCT", 38, 41], ["cytoplasmic", "ORGANISM_SUBSTANCE", 49, 60], ["Imp-b", "GENE_OR_GENE_PRODUCT", 88, 93], ["Nuclear", "CELLULAR_COMPONENT", 113, 120], ["nuclear", "CELLULAR_COMPONENT", 142, 149], ["nuclear", "CELLULAR_COMPONENT", 228, 235], ["nuclear", "CELLULAR_COMPONENT", 259, 266], ["CRM1", "GENE_OR_GENE_PRODUCT", 289, 293], ["NES", "GENE_OR_GENE_PRODUCT", 309, 312], ["RanGAP1", "PROTEIN", 0, 7], ["Ran", "PROTEIN", 38, 41], ["Imp", "PROTEIN", 88, 91], ["nuclear export receptors", "PROTEIN", 259, 283], ["CRM1", "PROTEIN", 289, 293], ["NES sequences", "PROTEIN", 309, 322], ["cargo proteins", "PROTEIN", 326, 340], ["RanGAP1", "TEST", 0, 7], ["GTP hydrolysis", "TREATMENT", 20, 34], ["Nuclear export", "TEST", 113, 127], ["export", "OBSERVATION", 121, 127]]], ["The affinity of CRM1 for most NESs is low and formation of the export complex is promoted by RanBP3 which links CRM1 to the chromatin binding protein RCC1 [133, 134] and increases the active concentration of RanGTP.", [["chromatin", "ANATOMY", 124, 133], ["CRM1", "GENE_OR_GENE_PRODUCT", 16, 20], ["NESs", "GENE_OR_GENE_PRODUCT", 30, 34], ["RanBP3", "GENE_OR_GENE_PRODUCT", 93, 99], ["CRM1", "GENE_OR_GENE_PRODUCT", 112, 116], ["chromatin", "CELLULAR_COMPONENT", 124, 133], ["RCC1", "GENE_OR_GENE_PRODUCT", 150, 154], ["RanGTP", "GENE_OR_GENE_PRODUCT", 208, 214], ["CRM1", "PROTEIN", 16, 20], ["NESs", "PROTEIN", 30, 34], ["export complex", "PROTEIN", 63, 77], ["RanBP3", "PROTEIN", 93, 99], ["CRM1", "PROTEIN", 112, 116], ["chromatin binding protein", "PROTEIN", 124, 149], ["RCC1", "PROTEIN", 150, 154], ["RanGTP", "PROTEIN", 208, 214], ["The affinity of CRM1", "PROBLEM", 0, 20], ["protein RCC1", "TEST", 142, 154], ["active", "OBSERVATION_MODIFIER", 184, 190], ["concentration", "OBSERVATION_MODIFIER", 191, 204]]], ["This promotes the affinity of the NES cargo for the export receptor [135, 136] .", [["NES", "GENE_OR_GENE_PRODUCT", 34, 37], ["NES cargo", "PROTEIN", 34, 43], ["export receptor", "PROTEIN", 52, 67]]], ["This complex moves through the NPC via the interaction with FG repeat proteins [137] .", [["NPC", "ANATOMY", 31, 34], ["NPC", "CANCER", 31, 34], ["NPC", "PROTEIN", 31, 34], ["FG repeat proteins", "PROTEIN", 60, 78], ["FG repeat proteins", "TEST", 60, 78], ["NPC", "ANATOMY", 31, 34]]], ["Within the cytoplasm, the CRM1 complex binds to the cytoplasmic filament complex (Nup88, Nup214 and Nup358 [84, [138] [139] [140] [141] ) and interacts with RanGAP causing the hydrolysis of GTP which promotes the dissociation of the protein complex.", [["cytoplasm", "ANATOMY", 11, 20], ["cytoplasmic filament", "ANATOMY", 52, 72], ["GTP", "CHEMICAL", 190, 193], ["Nup358", "CHEMICAL", 100, 106], ["GTP", "CHEMICAL", 190, 193], ["cytoplasm", "ORGANISM_SUBSTANCE", 11, 20], ["CRM1", "GENE_OR_GENE_PRODUCT", 26, 30], ["cytoplasmic", "ORGANISM_SUBSTANCE", 52, 63], ["Nup88", "GENE_OR_GENE_PRODUCT", 82, 87], ["Nup214", "GENE_OR_GENE_PRODUCT", 89, 95], ["RanGAP", "GENE_OR_GENE_PRODUCT", 157, 163], ["GTP", "SIMPLE_CHEMICAL", 190, 193], ["CRM1 complex", "PROTEIN", 26, 38], ["cytoplasmic filament complex", "PROTEIN", 52, 80], ["Nup88", "PROTEIN", 82, 87], ["Nup214", "PROTEIN", 89, 95], ["Nup358", "PROTEIN", 100, 106], ["RanGAP", "PROTEIN", 157, 163], ["protein complex", "PROTEIN", 233, 248], ["the cytoplasmic filament complex", "TEST", 48, 80], ["Nup214", "TEST", 89, 95], ["Nup358", "TEST", 100, 106], ["RanGAP", "TEST", 157, 163], ["the hydrolysis of GTP", "PROBLEM", 172, 193], ["the dissociation of the protein complex", "PROBLEM", 209, 248], ["cytoplasm", "ANATOMY_MODIFIER", 11, 20], ["cytoplasmic", "OBSERVATION_MODIFIER", 52, 63], ["filament", "OBSERVATION_MODIFIER", 64, 72]]], ["Following this dissociation, the cargo is released in the cytoplasm [36, 142] .Export of RNAsRNAs transcribed in the nucleus have to be exported, either to fulfill their function in protein synthesis or to mature into functional particles [143] .", [["cytoplasm", "ANATOMY", 58, 67], ["nucleus", "ANATOMY", 117, 124], ["cargo", "CELLULAR_COMPONENT", 33, 38], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["RNAsRNAs", "GENE_OR_GENE_PRODUCT", 89, 97], ["nucleus", "CELLULAR_COMPONENT", 117, 124], ["RNAsRNAs", "PROTEIN", 89, 97], ["nucleus", "ANATOMY", 117, 124]]], ["The pre-mRNA is processed and packaged into messenger ribonucleoprotein (mRNP) complexes to be exported through bulk or specific export.", [["mRNP", "CELLULAR_COMPONENT", 73, 77], ["pre-mRNA", "RNA", 4, 12], ["messenger ribonucleoprotein (mRNP) complexes", "PROTEIN", 44, 88]]], ["The majority of poly-A transcripts are exported via the non-karyopherin heterodimer Nxf1/Nxt1 independently of the RanGTP gradient.", [["poly-A", "GENE_OR_GENE_PRODUCT", 16, 22], ["Nxf1", "GENE_OR_GENE_PRODUCT", 84, 88], ["Nxt1", "GENE_OR_GENE_PRODUCT", 89, 93], ["RanGTP", "GENE_OR_GENE_PRODUCT", 115, 121], ["poly-A transcripts", "RNA", 16, 34], ["non-karyopherin heterodimer", "PROTEIN", 56, 83], ["Nxf1", "PROTEIN", 84, 88], ["Nxt1", "PROTEIN", 89, 93], ["RanGTP", "PROTEIN", 115, 121], ["RanGTP gradient", "OBSERVATION", 115, 130]]], ["Conversely, a specific subset of endogenous transcripts is exported from the nucleus via CRM1.", [["nucleus", "ANATOMY", 77, 84], ["nucleus", "CELLULAR_COMPONENT", 77, 84], ["CRM1", "GENE_OR_GENE_PRODUCT", 89, 93], ["endogenous transcripts", "RNA", 33, 55], ["CRM1", "PROTEIN", 89, 93], ["endogenous transcripts", "OBSERVATION", 33, 55], ["nucleus", "ANATOMY", 77, 84]]], ["For efficient export, RNAs must undergo processing that includes splicing, 3 0 -end formation of the poly-A tail and the addition of a methyl-7-guanosine (m7G) cap structure to their 5 0 -ends [144] [145] [146] .", [["poly-A", "CHEMICAL", 101, 107], ["methyl-7-guanosine", "CHEMICAL", 135, 153], ["m7G", "CHEMICAL", 155, 158], ["methyl-7-guanosine", "CHEMICAL", 135, 153], ["m7G", "CHEMICAL", 155, 158], ["methyl-7-guanosine", "SIMPLE_CHEMICAL", 135, 153], ["m7G", "SIMPLE_CHEMICAL", 155, 158], ["RNAs", "RNA", 22, 26], ["poly-A tail", "PROTEIN", 101, 112], ["methyl-7-guanosine (m7G) cap structure", "PROTEIN", 135, 173], ["a methyl-7-guanosine (m7G) cap structure", "TREATMENT", 133, 173], ["tail", "ANATOMY", 108, 112]]], ["For the majority of transcripts, the m7G cap recruits the CBC, which then activates export factors that allow the export mRNPs to bind to the NPC and traverse the hydrophobic central channel.", [["NPC", "ANATOMY", 142, 145], ["m7G", "GENE_OR_GENE_PRODUCT", 37, 40], ["CBC", "GENE_OR_GENE_PRODUCT", 58, 61], ["NPC", "CANCER", 142, 145], ["m7G cap", "PROTEIN", 37, 44], ["CBC", "PROTEIN", 58, 61], ["export factors", "PROTEIN", 84, 98], ["NPC", "PROTEIN", 142, 145], ["hydrophobic central channel", "PROTEIN", 163, 190], ["the m7G cap", "TREATMENT", 33, 44], ["the CBC", "TEST", 54, 61], ["NPC", "ANATOMY", 142, 145], ["hydrophobic", "OBSERVATION", 163, 174], ["central channel", "ANATOMY_MODIFIER", 175, 190]]], ["Nxf1 (also known as TAP) [147] ) is the major driver of interaction between the export mRNP and the NPC.", [["mRNP", "ANATOMY", 87, 91], ["NPC", "ANATOMY", 100, 103], ["Nxf1", "GENE_OR_GENE_PRODUCT", 0, 4], ["TAP) [147]", "GENE_OR_GENE_PRODUCT", 20, 30], ["mRNP", "CELLULAR_COMPONENT", 87, 91], ["NPC", "CANCER", 100, 103], ["Nxf1", "PROTEIN", 0, 4], ["TAP", "PROTEIN", 20, 23], ["export mRNP", "PROTEIN", 80, 91], ["NPC", "PROTEIN", 100, 103], ["mRNP", "OBSERVATION", 87, 91], ["NPC", "ANATOMY", 100, 103]]], ["The Nxf1/Nxt1 hete-rodimer is recruited to the mRNP via the transcription-export (TREX) complex [79, 144, 145, [148] [149] [150] .", [["mRNP", "ANATOMY", 47, 51], ["Nxf1", "GENE_OR_GENE_PRODUCT", 4, 8], ["Nxt1", "GENE_OR_GENE_PRODUCT", 9, 13], ["mRNP", "CELLULAR_COMPONENT", 47, 51], ["Nxf1", "PROTEIN", 4, 8], ["Nxt1", "PROTEIN", 9, 13], ["hete", "PROTEIN", 14, 18], ["rodimer", "PROTEIN", 19, 26], ["mRNP", "PROTEIN", 47, 51], ["transcription-export (TREX) complex", "PROTEIN", 60, 95], ["The Nxf1", "TEST", 0, 8]]], ["The TREX complex consists of UAP56, REF/a Aly, CIP29 and THO multi-subunit complex composed of THOC1/Hpr1, hTho2, THOC5, THOC6, THOC7 and Tex1 [144, [151] [152] [153] .", [["TREX", "GENE_OR_GENE_PRODUCT", 4, 8], ["UAP56", "GENE_OR_GENE_PRODUCT", 29, 34], ["REF", "GENE_OR_GENE_PRODUCT", 36, 39], ["Aly", "GENE_OR_GENE_PRODUCT", 42, 45], ["CIP29", "GENE_OR_GENE_PRODUCT", 47, 52], ["THO", "GENE_OR_GENE_PRODUCT", 57, 60], ["THOC1", "GENE_OR_GENE_PRODUCT", 95, 100], ["Hpr1", "GENE_OR_GENE_PRODUCT", 101, 105], ["hTho2", "GENE_OR_GENE_PRODUCT", 107, 112], ["THOC5", "GENE_OR_GENE_PRODUCT", 114, 119], ["THOC6", "GENE_OR_GENE_PRODUCT", 121, 126], ["THOC7", "GENE_OR_GENE_PRODUCT", 128, 133], ["TREX complex", "PROTEIN", 4, 16], ["UAP56", "PROTEIN", 29, 34], ["REF", "PROTEIN", 36, 39], ["Aly", "PROTEIN", 42, 45], ["CIP29", "PROTEIN", 47, 52], ["THO multi-subunit complex", "PROTEIN", 57, 82], ["THOC1", "PROTEIN", 95, 100], ["Hpr1", "PROTEIN", 101, 105], ["hTho2", "PROTEIN", 107, 112], ["THOC5", "PROTEIN", 114, 119], ["THOC6", "PROTEIN", 121, 126], ["THOC7", "PROTEIN", 128, 133], ["Tex1", "PROTEIN", 138, 142], ["THOC1", "TEST", 95, 100], ["Hpr1", "TEST", 101, 105], ["hTho2", "TEST", 107, 112], ["Tex1", "TEST", 138, 142]]], ["REF/Aly and THO complexes promote the interaction of cargo mRNAs with the Nxf1 receptor [144, 151] that associates mRNPs with the nuclear basket via the ribonucleic acid export protein Rae1 and Nup98 to permit passage through the central channel (Fig. 2) [154, 155] .", [["mRNPs", "ANATOMY", 115, 120], ["nuclear basket", "ANATOMY", 130, 144], ["ribonucleic acid", "CHEMICAL", 153, 169], ["REF", "GENE_OR_GENE_PRODUCT", 0, 3], ["Aly", "GENE_OR_GENE_PRODUCT", 4, 7], ["THO", "GENE_OR_GENE_PRODUCT", 12, 15], ["Nxf1 receptor", "GENE_OR_GENE_PRODUCT", 74, 87], ["mRNPs", "CELLULAR_COMPONENT", 115, 120], ["nuclear", "CELLULAR_COMPONENT", 130, 137], ["Rae1", "GENE_OR_GENE_PRODUCT", 185, 189], ["Nup98", "GENE_OR_GENE_PRODUCT", 194, 199], ["REF", "PROTEIN", 0, 3], ["Aly", "PROTEIN", 4, 7], ["THO complexes", "PROTEIN", 12, 25], ["cargo mRNAs", "RNA", 53, 64], ["Nxf1 receptor", "PROTEIN", 74, 87], ["ribonucleic acid export protein", "PROTEIN", 153, 184], ["Rae1", "PROTEIN", 185, 189], ["Nup98", "PROTEIN", 194, 199], ["Nup98", "TREATMENT", 194, 199]]], ["At the cytoplasmic face, the cargo mRNPs are released and the export factors are recycled.", [["cytoplasmic face", "ANATOMY", 7, 23], ["mRNPs", "ANATOMY", 35, 40], ["cytoplasmic", "ORGANISM_SUBSTANCE", 7, 18], ["cargo mRNPs", "PROTEIN", 29, 40], ["export factors", "PROTEIN", 62, 76], ["cytoplasmic", "OBSERVATION_MODIFIER", 7, 18], ["face", "ANATOMY_MODIFIER", 19, 23], ["cargo mRNPs", "OBSERVATION", 29, 40]]], ["RanBP2 associates with Nup88 and Nup214 [141] and plays a very important role in cargo release and recycling after bulk mRNA export.Export of RNAsAn alternative to the Nxf1-driven export pathway involves the serine-and arginine-rich SR proteins SRp20 and 9G8 that mediate the export of H2a mRNA and of some spliced transcripts [156, 157] .", [["arginine", "CHEMICAL", 219, 227], ["serine", "CHEMICAL", 208, 214], ["arginine", "CHEMICAL", 219, 227], ["RanBP2", "GENE_OR_GENE_PRODUCT", 0, 6], ["Nup88", "GENE_OR_GENE_PRODUCT", 23, 28], ["Nup214 [141]", "GENE_OR_GENE_PRODUCT", 33, 45], ["cargo", "CELLULAR_COMPONENT", 81, 86], ["RNAsAn", "GENE_OR_GENE_PRODUCT", 142, 148], ["Nxf1", "GENE_OR_GENE_PRODUCT", 168, 172], ["serine", "AMINO_ACID", 208, 214], ["arginine", "AMINO_ACID", 219, 227], ["SRp20", "GENE_OR_GENE_PRODUCT", 245, 250], ["9G8", "GENE_OR_GENE_PRODUCT", 255, 258], ["H2a", "GENE_OR_GENE_PRODUCT", 286, 289], ["RanBP2", "PROTEIN", 0, 6], ["Nup88", "PROTEIN", 23, 28], ["RNAsAn", "PROTEIN", 142, 148], ["Nxf1", "PROTEIN", 168, 172], ["serine-and arginine-rich SR proteins", "PROTEIN", 208, 244], ["SRp20", "PROTEIN", 245, 250], ["9G8", "PROTEIN", 255, 258], ["H2a mRNA", "RNA", 286, 294], ["the serine", "TEST", 204, 214]]], ["Although the majority of mRNAs use the Nxf1 receptor to cross the NPC, subsets of transcripts are exported via the general CRM1 pathway.", [["NPC", "ANATOMY", 66, 69], ["Nxf1 receptor", "GENE_OR_GENE_PRODUCT", 39, 52], ["NPC", "CANCER", 66, 69], ["CRM1", "GENE_OR_GENE_PRODUCT", 123, 127], ["mRNAs", "RNA", 25, 30], ["Nxf1 receptor", "PROTEIN", 39, 52], ["NPC", "PROTEIN", 66, 69], ["CRM1", "PROTEIN", 123, 127], ["the Nxf1 receptor", "TREATMENT", 35, 52], ["NPC", "ANATOMY", 66, 69]]], ["Additionally, through protein cofactors, CRM1 is involved in the export of specific types of mRNAs, small nuclear RNAs (U snRNAs) and ribosomal RNAs.", [["CRM1", "GENE_OR_GENE_PRODUCT", 41, 45], ["U snRNAs", "GENE_OR_GENE_PRODUCT", 120, 128], ["ribosomal", "CELLULAR_COMPONENT", 134, 143], ["protein cofactors", "PROTEIN", 22, 39], ["CRM1", "PROTEIN", 41, 45], ["mRNAs", "RNA", 93, 98], ["small nuclear RNAs", "RNA", 100, 118], ["U snRNAs", "RNA", 120, 128], ["ribosomal RNAs", "RNA", 134, 148], ["small nuclear RNAs (U snRNAs)", "PROBLEM", 100, 129], ["ribosomal RNAs", "PROBLEM", 134, 148], ["small", "OBSERVATION_MODIFIER", 100, 105], ["nuclear RNAs", "OBSERVATION", 106, 118], ["ribosomal RNAs", "OBSERVATION", 134, 148]]], ["CRM1 does not bind RNA directly but via NES-containing adaptor proteins that bind to RNA or other RNA binding proteins [148] .", [["CRM1", "GENE_OR_GENE_PRODUCT", 0, 4], ["NES", "GENE_OR_GENE_PRODUCT", 40, 43], ["CRM1", "PROTEIN", 0, 4], ["NES", "PROTEIN", 40, 43], ["adaptor proteins", "PROTEIN", 55, 71], ["RNA", "RNA", 85, 88], ["RNA binding proteins", "PROTEIN", 98, 118], ["adaptor proteins", "TREATMENT", 55, 71], ["other RNA binding proteins", "TEST", 92, 118]]], ["Once this step is completed, CRM1-cargo complexes dissociate, permitting the RNA to enter the cytoplasm and to recycle export factors [148] .", [["cytoplasm", "ANATOMY", 94, 103], ["CRM1", "GENE_OR_GENE_PRODUCT", 29, 33], ["cytoplasm", "ORGANISM_SUBSTANCE", 94, 103], ["CRM1", "PROTEIN", 29, 33], ["cargo complexes", "PROTEIN", 34, 49]]], ["As in bulk mRNA export, Nup88, Nup214 and RanBP2 play critical roles in the recycling and release steps for CRM1-dependent export [138, 158] .Regulation of the nucleo-cytoplasmic traffickingThe nucleo-cytoplasmic transport processes are regulated by cellular signaling systems via cargo protein modification(s) and the transport machinery, including the transport receptors, the NPC and the Ran system.", [["cytoplasmic", "ANATOMY", 167, 178], ["cytoplasmic", "ANATOMY", 201, 212], ["cellular", "ANATOMY", 250, 258], ["NPC", "ANATOMY", 379, 382], ["Nup88", "GENE_OR_GENE_PRODUCT", 24, 29], ["Nup214", "GENE_OR_GENE_PRODUCT", 31, 37], ["RanBP2", "GENE_OR_GENE_PRODUCT", 42, 48], ["CRM1", "GENE_OR_GENE_PRODUCT", 108, 112], ["cytoplasmic", "ORGANISM_SUBSTANCE", 167, 178], ["cytoplasmic", "ORGANISM_SUBSTANCE", 201, 212], ["cellular", "CELL", 250, 258], ["NPC", "CANCER", 379, 382], ["Ran", "GENE_OR_GENE_PRODUCT", 391, 394], ["Nup88", "PROTEIN", 24, 29], ["Nup214", "PROTEIN", 31, 37], ["RanBP2", "PROTEIN", 42, 48], ["CRM1", "PROTEIN", 108, 112], ["transport receptors", "PROTEIN", 354, 373], ["NPC", "PROTEIN", 379, 382], ["Ran", "PROTEIN", 391, 394], ["the nucleo", "TEST", 156, 166], ["cargo protein modification", "TREATMENT", 281, 307], ["the transport machinery", "TREATMENT", 315, 338], ["the transport receptors", "TREATMENT", 350, 373], ["the NPC", "TREATMENT", 375, 382], ["cytoplasmic trafficking", "OBSERVATION", 167, 190], ["NPC", "ANATOMY", 379, 382]]], ["Indeed targeting nucleo-cytoplasmic transport has directed the development of new exciting therapeutic avenues to treat cancers that display aberrant protein subcellular localization [159, 160] .Modification of the cargo proteinsImportin-NLS/exportin-NES interactions can be modulated by conformational changes in both NLS/ NES regions and in the substrate binding site of karyopherins [161] .", [["cytoplasmic", "ANATOMY", 24, 35], ["cancers", "ANATOMY", 120, 127], ["subcellular", "ANATOMY", 158, 169], ["cancers", "DISEASE", 120, 127], ["cytoplasmic", "ORGANISM_SUBSTANCE", 24, 35], ["cancers", "CANCER", 120, 127], ["Importin", "GENE_OR_GENE_PRODUCT", 229, 237], ["NLS", "GENE_OR_GENE_PRODUCT", 238, 241], ["exportin", "GENE_OR_GENE_PRODUCT", 242, 250], ["NES", "GENE_OR_GENE_PRODUCT", 251, 254], ["NLS", "GENE_OR_GENE_PRODUCT", 319, 322], ["cargo proteins", "PROTEIN", 215, 229], ["Importin", "PROTEIN", 229, 237], ["NLS", "PROTEIN", 238, 241], ["exportin", "PROTEIN", 242, 250], ["NES", "PROTEIN", 251, 254], ["NLS", "PROTEIN", 319, 322], ["NES regions", "PROTEIN", 324, 335], ["substrate binding site", "PROTEIN", 347, 369], ["cancers", "PROBLEM", 120, 127], ["aberrant protein subcellular localization", "PROBLEM", 141, 182], ["the cargo proteinsImportin", "TREATMENT", 211, 237], ["conformational changes in both NLS/ NES regions", "PROBLEM", 288, 335], ["new", "OBSERVATION_MODIFIER", 78, 81]]], ["In some cases the three-dimen-sional structure of a protein masks its own transport signal as in the case of p105 [161] , the precursor p50 subunit of NF-jB.", [["p50", "GENE_OR_GENE_PRODUCT", 136, 139], ["NF-jB.", "GENE_OR_GENE_PRODUCT", 151, 157], ["p50 subunit", "PROTEIN", 136, 147], ["NF", "PROTEIN", 151, 153], ["a protein masks", "TREATMENT", 50, 65], ["the precursor p50", "TEST", 122, 139]]], ["Upon stimulation, p105 is phosphorylated, the C-terminal part of the protein is degraded and the NLS becomes accessible allowing the p50 protein to be recognized by the Imp-a/Imp-b complex [162] .", [["p105", "GENE_OR_GENE_PRODUCT", 18, 22], ["NLS", "GENE_OR_GENE_PRODUCT", 97, 100], ["p50", "GENE_OR_GENE_PRODUCT", 133, 136], ["Imp-b", "GENE_OR_GENE_PRODUCT", 175, 180], ["p105", "PROTEIN", 18, 22], ["C-terminal part", "PROTEIN", 46, 61], ["NLS", "PROTEIN", 97, 100], ["p50 protein", "PROTEIN", 133, 144], ["Imp", "PROTEIN", 169, 172], ["Imp", "PROTEIN", 175, 178], ["phosphorylated", "PROBLEM", 26, 40], ["the C-terminal part of the protein", "PROBLEM", 42, 76], ["the p50 protein", "TEST", 129, 144]]], ["Furthermore, phosphorylation within or close to the NLS/NES can promote intramolecular masking.", [["NLS", "GENE_OR_GENE_PRODUCT", 52, 55], ["NES", "GENE_OR_GENE_PRODUCT", 56, 59], ["NLS", "PROTEIN", 52, 55], ["NES", "PROTEIN", 56, 59], ["phosphorylation", "TREATMENT", 13, 28], ["intramolecular masking", "OBSERVATION", 72, 94]]], ["In the case of Hog1p (high osmolarity glycerol pathway-signaling protein) phosphorylation at Thr174 and Tyr176 renders Hog1p-NES inaccessible for binding to CRM1 and prevents its export from the nucleus [163] .", [["nucleus", "ANATOMY", 195, 202], ["glycerol", "CHEMICAL", 38, 46], ["glycerol", "CHEMICAL", 38, 46], ["Thr", "CHEMICAL", 93, 96], ["Tyr176", "CHEMICAL", 104, 110], ["Hog1p", "GENE_OR_GENE_PRODUCT", 15, 20], ["high osmolarity glycerol pathway-signaling protein", "GENE_OR_GENE_PRODUCT", 22, 72], ["Thr174", "AMINO_ACID", 93, 99], ["Tyr176", "AMINO_ACID", 104, 110], ["Hog1p-NES", "GENE_OR_GENE_PRODUCT", 119, 128], ["CRM1", "GENE_OR_GENE_PRODUCT", 157, 161], ["nucleus", "CELLULAR_COMPONENT", 195, 202], ["Hog1p", "PROTEIN", 15, 20], ["signaling protein", "PROTEIN", 55, 72], ["Hog1p", "PROTEIN", 119, 124], ["NES", "PROTEIN", 125, 128], ["CRM1", "PROTEIN", 157, 161], ["Hog1p (high osmolarity glycerol pathway", "TREATMENT", 15, 54], ["phosphorylation", "TEST", 74, 89], ["binding to CRM1", "PROBLEM", 146, 161], ["nucleus", "ANATOMY", 195, 202]]], ["Similarly NF-AT2 (nuclear factor of activated T cell 2) contains two NLSs that can be masked by phosphorylation at a low calcium concentration.", [["calcium", "CHEMICAL", 121, 128], ["calcium", "CHEMICAL", 121, 128], ["NF-AT2", "GENE_OR_GENE_PRODUCT", 10, 16], ["nuclear factor of activated T cell 2", "GENE_OR_GENE_PRODUCT", 18, 54], ["calcium", "SIMPLE_CHEMICAL", 121, 128], ["NF-AT2", "PROTEIN", 10, 16], ["nuclear factor of activated T cell 2", "PROTEIN", 18, 54], ["NLSs", "PROTEIN", 69, 73], ["activated T cell", "PROBLEM", 36, 52], ["two NLSs", "PROBLEM", 65, 73], ["a low calcium concentration", "TREATMENT", 115, 142]]], ["Following a calcium concentration increase, calcineurin is dephosphorylated and NF-AT2 is imported into the nucleus [164] [165] [166] .", [["nucleus", "ANATOMY", 108, 115], ["calcium", "CHEMICAL", 12, 19], ["calcium", "CHEMICAL", 12, 19], ["calcium", "SIMPLE_CHEMICAL", 12, 19], ["calcineurin", "GENE_OR_GENE_PRODUCT", 44, 55], ["NF-AT2", "GENE_OR_GENE_PRODUCT", 80, 86], ["nucleus", "CELLULAR_COMPONENT", 108, 115], ["calcineurin", "PROTEIN", 44, 55], ["NF-AT2", "PROTEIN", 80, 86], ["a calcium concentration increase", "TREATMENT", 10, 42], ["calcineurin", "TREATMENT", 44, 55], ["nucleus", "ANATOMY", 108, 115]]], ["In the canonical NF-jB pathway, I-jB masks the NLS sequence of NF-jB p65 [167] .", [["NF-jB", "GENE_OR_GENE_PRODUCT", 17, 22], ["I-jB", "GENE_OR_GENE_PRODUCT", 32, 36], ["NF-jB p65", "GENE_OR_GENE_PRODUCT", 63, 72], ["NF", "PROTEIN", 17, 19], ["jB", "PROTEIN", 20, 22], ["I-jB", "PROTEIN", 32, 36], ["NLS sequence", "PROTEIN", 47, 59], ["NF-jB p65", "PROTEIN", 63, 72]]], ["In resting conditions, I-jB is phosphorylated, ubiquitinated and degraded by proteasome resulting in NLS unmasking and NF-jB p65 nuclear import [168, 169] .", [["nuclear", "ANATOMY", 129, 136], ["-jB", "GENE_OR_GENE_PRODUCT", 24, 27], ["NLS", "GENE_OR_GENE_PRODUCT", 101, 104], ["NF-jB p65", "GENE_OR_GENE_PRODUCT", 119, 128], ["I-jB", "PROTEIN", 23, 27], ["proteasome", "PROTEIN", 77, 87], ["NLS", "PROTEIN", 101, 104], ["NF-jB p65", "PROTEIN", 119, 128]]], ["One of the multiple regulatory mechanisms of p53 is its homo-tetramerization that masks one of its NES sequences.", [["p53", "GENE_OR_GENE_PRODUCT", 45, 48], ["p53", "PROTEIN", 45, 48], ["NES sequences", "DNA", 99, 112], ["multiple", "OBSERVATION_MODIFIER", 11, 19]]], ["Dissociation of this tetramer is required for its nuclear export [170] .", [["nuclear", "ANATOMY", 50, 57], ["nuclear", "CELLULAR_COMPONENT", 50, 57], ["this tetramer", "TREATMENT", 16, 29]]], ["Binding of proteins to RNA and DNA can also modulate the intermolecular masking of localization signal.", [["DNA", "CELLULAR_COMPONENT", 31, 34], ["Binding of proteins to RNA", "PROBLEM", 0, 26], ["DNA", "PROBLEM", 31, 34], ["intermolecular masking", "OBSERVATION", 57, 79], ["localization signal", "OBSERVATION", 83, 102]]], ["For example, the NLS of the Rev protein, implicated in HIV mRNA translocation, is masked when Rev is linked to mRNA and recycling of Rev is possible only after release of the transported mRNA [171] .", [["NLS", "GENE_OR_GENE_PRODUCT", 17, 20], ["Rev", "GENE_OR_GENE_PRODUCT", 28, 31], ["HIV", "ORGANISM", 55, 58], ["Rev", "GENE_OR_GENE_PRODUCT", 94, 97], ["Rev", "GENE_OR_GENE_PRODUCT", 133, 136], ["NLS", "PROTEIN", 17, 20], ["Rev protein", "PROTEIN", 28, 39], ["HIV mRNA", "RNA", 55, 63], ["Rev", "PROTEIN", 94, 97], ["mRNA", "RNA", 111, 115], ["Rev", "PROTEIN", 133, 136], ["HIV", "SPECIES", 55, 58], ["HIV mRNA translocation", "PROBLEM", 55, 77], ["HIV mRNA", "OBSERVATION", 55, 63]]], ["Conversely, nucleo-cytoplasmic transport can be enhanced by phosphorylation of SV40 virus large T antigen [172] or Pho4 factor [173] increasing the affinity of their NLS/NES signals to the corresponding karyopherin receptors [172] .Viral regulation of nucleo-cytoplasmic traffickingMany viruses have evolved elegant strategies to exploit the host nucleo-cytoplasmic transport pathways to evade the cellular anti-viral response or to facilitate viral replication.", [["cytoplasmic", "ANATOMY", 19, 30], ["cytoplasmic", "ANATOMY", 259, 270], ["cytoplasmic", "ANATOMY", 354, 365], ["cellular", "ANATOMY", 398, 406], ["cytoplasmic", "ORGANISM_SUBSTANCE", 19, 30], ["SV40 virus", "ORGANISM", 79, 89], ["large T antigen", "GENE_OR_GENE_PRODUCT", 90, 105], ["Pho4 factor", "GENE_OR_GENE_PRODUCT", 115, 126], ["NLS", "GENE_OR_GENE_PRODUCT", 166, 169], ["NES", "GENE_OR_GENE_PRODUCT", 170, 173], ["karyopherin", "GENE_OR_GENE_PRODUCT", 203, 214], ["cytoplasmic", "ORGANISM_SUBSTANCE", 259, 270], ["cytoplasmic", "ORGANISM_SUBSTANCE", 354, 365], ["cellular", "CELL", 398, 406], ["Pho4 factor", "PROTEIN", 115, 126], ["NLS", "PROTEIN", 166, 169], ["NES", "PROTEIN", 170, 173], ["karyopherin receptors", "PROTEIN", 203, 224], ["SV40 virus", "SPECIES", 79, 89], ["SV40 virus large T antigen", "TEST", 79, 105], ["Pho4 factor", "TEST", 115, 126], ["nucleo", "TEST", 252, 258], ["cytoplasmic trafficking", "PROBLEM", 259, 282], ["the cellular anti-viral response", "PROBLEM", 394, 426], ["viral replication", "TREATMENT", 444, 461]]], ["Some viruses such as the vesicular stomatitis virus interact with Nups to inhibit the export of host mRNAs that encode anti-viral factors and make the translation machinery available for expression of viral mRNAs [174] .", [["vesicular stomatitis", "DISEASE", 25, 45], ["vesicular stomatitis virus", "ORGANISM", 25, 51], ["Nups", "GENE_OR_GENE_PRODUCT", 66, 70], ["Nups", "PROTEIN", 66, 70], ["host mRNAs", "RNA", 96, 106], ["anti-viral factors", "PROTEIN", 119, 137], ["viral mRNAs", "RNA", 201, 212], ["vesicular stomatitis virus", "SPECIES", 25, 51], ["vesicular stomatitis virus", "SPECIES", 25, 51], ["Some viruses", "PROBLEM", 0, 12], ["the vesicular stomatitis virus", "PROBLEM", 21, 51], ["anti-viral factors", "TREATMENT", 119, 137], ["viral mRNAs", "PROBLEM", 201, 212], ["viruses", "OBSERVATION", 5, 12], ["vesicular stomatitis", "OBSERVATION", 25, 45]]], ["Similarly, the ICP27 protein of herpes simplex virus interacts with Nup62 and blocks nuclear import of proteins via Imp-a/b1 and Imp-b2 pathways [175, 176] .", [["nuclear", "ANATOMY", 85, 92], ["herpes simplex", "DISEASE", 32, 46], ["ICP27", "GENE_OR_GENE_PRODUCT", 15, 20], ["herpes simplex virus", "ORGANISM", 32, 52], ["Nup62", "GENE_OR_GENE_PRODUCT", 68, 73], ["nuclear", "CELLULAR_COMPONENT", 85, 92], ["Imp-a/b1", "GENE_OR_GENE_PRODUCT", 116, 124], ["Imp-b2", "GENE_OR_GENE_PRODUCT", 129, 135], ["ICP27 protein", "PROTEIN", 15, 28], ["Nup62", "PROTEIN", 68, 73], ["Imp", "PROTEIN", 116, 119], ["b1", "PROTEIN", 122, 124], ["Imp", "PROTEIN", 129, 132], ["b2", "PROTEIN", 133, 135], ["herpes simplex virus", "SPECIES", 32, 52], ["herpes simplex virus", "SPECIES", 32, 52], ["the ICP27 protein", "TEST", 11, 28], ["herpes simplex virus interacts", "PROBLEM", 32, 62], ["Nup62", "TREATMENT", 68, 73], ["Imp-b2 pathways", "TEST", 129, 144], ["herpes simplex virus", "OBSERVATION", 32, 52]]], ["Conversely, poliovirus and human rhinovirus block the nuclear import of proteins via the Imp-a/b1 and Imp-b2 pathways by viral-mediated proteolytic cleavage of specific Nups [21, [177] [178] [179] [180] [181] [182] [183] .", [["nuclear", "ANATOMY", 54, 61], ["poliovirus", "ORGANISM", 12, 22], ["human rhinovirus", "ORGANISM", 27, 43], ["nuclear", "CELLULAR_COMPONENT", 54, 61], ["Imp-a", "GENE_OR_GENE_PRODUCT", 89, 94], ["b1", "GENE_OR_GENE_PRODUCT", 95, 97], ["Imp-b2", "GENE_OR_GENE_PRODUCT", 102, 108], ["Imp-a", "PROTEIN", 89, 94], ["b1", "PROTEIN", 95, 97], ["Imp", "PROTEIN", 102, 105], ["b2", "PROTEIN", 106, 108], ["human", "SPECIES", 27, 32], ["rhinovirus", "SPECIES", 33, 43], ["human rhinovirus", "SPECIES", 27, 43], ["poliovirus", "PROBLEM", 12, 22], ["human rhinovirus block", "PROBLEM", 27, 49], ["the Imp-a/b1", "TEST", 85, 97], ["Imp-b2 pathways", "TEST", 102, 117]]], ["Other viruses inhibit the nuclear import of the STAT proteins that are known to be key regulators of the cell anti-virus response.", [["nuclear", "ANATOMY", 26, 33], ["cell", "ANATOMY", 105, 109], ["nuclear", "CELLULAR_COMPONENT", 26, 33], ["STAT", "GENE_OR_GENE_PRODUCT", 48, 52], ["cell", "CELL", 105, 109], ["STAT proteins", "PROTEIN", 48, 61], ["Other viruses", "PROBLEM", 0, 13], ["the STAT proteins", "TEST", 44, 61], ["viruses", "OBSERVATION", 6, 13]]], ["Furthermore, the severe acute respiratory syndrome (SARS) virus disrupts the nuclear import of STAT1 by tethering the tyrosine-phosphorylated STAT1-Imp-a/ Imp-b complex to endoplasmic reticulum/Golgi membranes [184] [185] [186] [187] .", [["nuclear", "ANATOMY", 77, 84], ["endoplasmic reticulum", "ANATOMY", 172, 193], ["Golgi membranes", "ANATOMY", 194, 209], ["acute respiratory syndrome", "DISEASE", 24, 50], ["SARS", "DISEASE", 52, 56], ["tyrosine", "CHEMICAL", 118, 126], ["tyrosine", "CHEMICAL", 118, 126], ["nuclear", "CELLULAR_COMPONENT", 77, 84], ["STAT1", "GENE_OR_GENE_PRODUCT", 95, 100], ["tyrosine", "AMINO_ACID", 118, 126], ["STAT1", "GENE_OR_GENE_PRODUCT", 142, 147], ["Imp", "GENE_OR_GENE_PRODUCT", 148, 151], ["Imp-b complex", "GENE_OR_GENE_PRODUCT", 155, 168], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 172, 193], ["Golgi membranes", "CELLULAR_COMPONENT", 194, 209], ["STAT1", "PROTEIN", 95, 100], ["STAT1", "PROTEIN", 142, 147], ["Imp", "PROTEIN", 148, 151], ["Imp-b complex", "PROTEIN", 155, 168], ["severe acute respiratory syndrome (SARS) virus", "SPECIES", 17, 63], ["the severe acute respiratory syndrome", "PROBLEM", 13, 50], ["SARS) virus", "PROBLEM", 52, 63], ["the tyrosine", "TEST", 114, 126], ["phosphorylated STAT1", "TEST", 127, 147], ["Imp", "TEST", 148, 151], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["respiratory syndrome", "OBSERVATION", 30, 50]]], ["Yet another way exploited by viruses to prevent STAT1 nuclear localization is to bind viral proteins to import receptors.", [["nuclear", "ANATOMY", 54, 61], ["STAT1", "GENE_OR_GENE_PRODUCT", 48, 53], ["STAT1", "PROTEIN", 48, 53], ["viral proteins", "PROTEIN", 86, 100], ["import receptors", "PROTEIN", 104, 120], ["STAT1 nuclear localization", "PROBLEM", 48, 74], ["viruses", "OBSERVATION", 29, 36]]], ["The Ebola virus VP24 protein binds Imp-a to block its interaction with phosphorylated STAT1 and hnRNP C1/C2 [188] [189] [190] .", [["Ebola virus", "ORGANISM", 4, 15], ["VP24", "GENE_OR_GENE_PRODUCT", 16, 20], ["Imp-a", "GENE_OR_GENE_PRODUCT", 35, 40], ["STAT1", "GENE_OR_GENE_PRODUCT", 86, 91], ["hnRNP C1", "GENE_OR_GENE_PRODUCT", 96, 104], ["Ebola virus VP24 protein", "PROTEIN", 4, 28], ["Imp", "PROTEIN", 35, 38], ["phosphorylated STAT1", "PROTEIN", 71, 91], ["hnRNP C1", "PROTEIN", 96, 104], ["Ebola virus", "SPECIES", 4, 15], ["Ebola virus", "SPECIES", 4, 15], ["The Ebola virus", "TEST", 0, 15], ["Imp", "TEST", 35, 38], ["hnRNP C1/C2", "TEST", 96, 107]]], ["The L1 protein of the human papilloma virus type 11 binds Imp-b2/b3 and disrupts cargo import.", [["human papilloma virus type 11", "ORGANISM", 22, 51], ["Imp-b2", "GENE_OR_GENE_PRODUCT", 58, 64], ["b3", "GENE_OR_GENE_PRODUCT", 65, 67], ["cargo", "GENE_OR_GENE_PRODUCT", 81, 86], ["L1 protein", "PROTEIN", 4, 14], ["Imp", "PROTEIN", 58, 61], ["b2", "PROTEIN", 62, 64], ["b3", "PROTEIN", 65, 67], ["human papilloma virus", "SPECIES", 22, 43], ["human papilloma virus type 11", "SPECIES", 22, 51], ["L1", "ANATOMY", 4, 6], ["human", "ANATOMY", 22, 27], ["papilloma virus", "OBSERVATION", 28, 43]]], ["Encephalomyocarditis virus exerts its inhibitory effect on the nuclear protein import of infected cells via its L protein that hyper-phosphorylates Nups and binds Ran [191] [192] [193] .", [["nuclear", "ANATOMY", 63, 70], ["cells", "ANATOMY", 98, 103], ["Encephalomyocarditis", "DISEASE", 0, 20], ["Encephalomyocarditis virus", "ORGANISM", 0, 26], ["nuclear", "CELLULAR_COMPONENT", 63, 70], ["cells", "CELL", 98, 103], ["Nups", "GENE_OR_GENE_PRODUCT", 148, 152], ["Ran", "GENE_OR_GENE_PRODUCT", 163, 166], ["infected cells", "CELL_TYPE", 89, 103], ["L protein", "PROTEIN", 112, 121], ["Nups", "PROTEIN", 148, 152], ["Ran", "PROTEIN", 163, 166], ["Encephalomyocarditis virus", "SPECIES", 0, 26], ["Encephalomyocarditis virus", "PROBLEM", 0, 26], ["infected cells", "PROBLEM", 89, 103], ["its L protein", "TEST", 108, 121], ["inhibitory effect", "OBSERVATION_MODIFIER", 38, 55], ["infected cells", "OBSERVATION", 89, 103]]], ["In addition herpes viruses and HIV promote viral mRNA export by reprogramming the cellular transport pathways.", [["cellular", "ANATOMY", 82, 90], ["herpes viruses", "DISEASE", 12, 26], ["herpes viruses", "ORGANISM", 12, 26], ["HIV", "ORGANISM", 31, 34], ["cellular", "CELL", 82, 90], ["viral mRNA", "RNA", 43, 53], ["HIV", "SPECIES", 31, 34], ["HIV", "SPECIES", 31, 34], ["herpes viruses", "PROBLEM", 12, 26], ["HIV", "PROBLEM", 31, 34], ["herpes viruses", "OBSERVATION", 12, 26], ["viral mRNA", "OBSERVATION", 43, 53]]], ["The HIV-1 Rev protein facilitates nuclear export of unspliced or partially spliced viral mRNAs through the Rev-responsive element, an RNA signature within these viral mRNAs [85, 194, 195] .", [["nuclear", "ANATOMY", 34, 41], ["HIV-1", "ORGANISM", 4, 9], ["Rev", "GENE_OR_GENE_PRODUCT", 10, 13], ["nuclear", "CELLULAR_COMPONENT", 34, 41], ["HIV-1 Rev protein", "PROTEIN", 4, 21], ["viral mRNAs", "RNA", 83, 94], ["Rev-responsive element", "DNA", 107, 129], ["viral mRNAs", "RNA", 161, 172], ["HIV-1", "SPECIES", 4, 9], ["HIV-1", "SPECIES", 4, 9], ["The HIV", "TEST", 0, 7], ["partially spliced viral mRNAs", "PROBLEM", 65, 94], ["an RNA signature", "TEST", 131, 147], ["these viral mRNAs", "TEST", 155, 172], ["viral mRNAs", "OBSERVATION", 83, 94]]], ["As a result, Rev-bound viral RNA binds to CRM1 and RanGTP and is transported through the NPC.ConclusionsThe nuclear transport processes within our cells are governed by several types of protein-protein interactions (e.g. adaptor protein-cargo, adaptor proteintransport receptor, transport receptor-cargo, transport receptor-Ran, transport receptor-Nup), yet only one enzymatic reaction occurs, namely the hydrolysis of GTP by Ran GTPase.", [["NPC", "ANATOMY", 89, 92], ["nuclear", "ANATOMY", 108, 115], ["cells", "ANATOMY", 147, 152], ["GTP", "CHEMICAL", 419, 422], ["GTP", "CHEMICAL", 419, 422], ["CRM1", "GENE_OR_GENE_PRODUCT", 42, 46], ["RanGTP", "GENE_OR_GENE_PRODUCT", 51, 57], ["NPC", "CANCER", 89, 92], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["cells", "CELL", 147, 152], ["adaptor proteintransport receptor", "GENE_OR_GENE_PRODUCT", 244, 277], ["Ran", "GENE_OR_GENE_PRODUCT", 324, 327], ["GTP", "SIMPLE_CHEMICAL", 419, 422], ["Ran", "GENE_OR_GENE_PRODUCT", 426, 429], ["Rev-bound viral RNA", "RNA", 13, 32], ["CRM1", "PROTEIN", 42, 46], ["RanGTP", "PROTEIN", 51, 57], ["NPC", "PROTEIN", 89, 92], ["adaptor protein", "PROTEIN", 221, 236], ["cargo", "PROTEIN", 237, 242], ["adaptor proteintransport receptor", "PROTEIN", 244, 277], ["transport receptor", "PROTEIN", 279, 297], ["cargo", "PROTEIN", 298, 303], ["transport receptor", "PROTEIN", 305, 323], ["Ran", "PROTEIN", 324, 327], ["transport receptor", "PROTEIN", 329, 347], ["Nup", "PROTEIN", 348, 351], ["Ran GTPase", "PROTEIN", 426, 436], ["Rev-bound viral RNA binds", "PROBLEM", 13, 38], ["protein-protein interactions", "TREATMENT", 186, 214], ["adaptor protein", "TREATMENT", 221, 236], ["adaptor proteintransport receptor", "TREATMENT", 244, 277], ["one enzymatic reaction", "PROBLEM", 363, 385], ["the hydrolysis of GTP", "PROBLEM", 401, 422], ["NPC", "ANATOMY", 89, 92]]], ["While pharmacological targeting of protein-protein interactions has historically been considered challenging, the development of nuclear export inhibitors proves the viability of this approach.", [["nuclear", "ANATOMY", 129, 136], ["nuclear", "CELLULAR_COMPONENT", 129, 136], ["protein-protein interactions", "PROBLEM", 35, 63], ["nuclear export inhibitors", "TREATMENT", 129, 154], ["this approach", "TREATMENT", 179, 192]]], ["Therapeutic agents that attempt to normalize or to target protein localization are aimed at various regulatory components within the transport process, including the upstream regulatory components, the cargo proteins, the transport receptors, the Ran regulators and the NPC itself.", [["NPC", "ANATOMY", 270, 273], ["Ran", "GENE_OR_GENE_PRODUCT", 247, 250], ["NPC", "CANCER", 270, 273], ["upstream regulatory components", "PROTEIN", 166, 196], ["cargo proteins", "PROTEIN", 202, 216], ["transport receptors", "PROTEIN", 222, 241], ["Ran regulators", "PROTEIN", 247, 261], ["NPC", "PROTEIN", 270, 273], ["Therapeutic agents", "TREATMENT", 0, 18], ["target protein localization", "PROBLEM", 51, 78], ["NPC", "ANATOMY", 270, 273]]], ["In some cases, compounds have been developed to successfully influence subcellular protein distribution in disease states, including CRM1 and Imp-a/b inhibitors.", [["subcellular", "ANATOMY", 71, 82], ["CRM1", "GENE_OR_GENE_PRODUCT", 133, 137], ["Imp-a/b", "GENE_OR_GENE_PRODUCT", 142, 149], ["CRM1", "PROTEIN", 133, 137], ["Imp", "PROTEIN", 142, 145], ["subcellular protein distribution in disease states", "PROBLEM", 71, 121], ["CRM1", "TEST", 133, 137], ["Imp-a/b inhibitors", "TREATMENT", 142, 160], ["protein distribution", "OBSERVATION", 83, 103]]], ["Continued and intensified research efforts aimed at better understanding the nuclear transport mechanisms, and how they relate to pathogenesis, will probably reveal the identity of novel targets for the treatment of cancer and to subvert viral infections.", [["nuclear", "ANATOMY", 77, 84], ["cancer", "ANATOMY", 216, 222], ["cancer", "DISEASE", 216, 222], ["viral infections", "DISEASE", 238, 254], ["nuclear", "CELLULAR_COMPONENT", 77, 84], ["cancer", "CANCER", 216, 222], ["pathogenesis", "PROBLEM", 130, 142], ["cancer", "PROBLEM", 216, 222], ["subvert viral infections", "PROBLEM", 230, 254], ["cancer", "OBSERVATION", 216, 222], ["viral", "OBSERVATION_MODIFIER", 238, 243], ["infections", "OBSERVATION", 244, 254]]]], "9e586a5a00c01925558b496dd59e6bf675813a17": [["the profession is becoming ethnically more diverse, there are still significant issues.", [["still significant issues", "PROBLEM", 62, 86], ["ethnically", "OBSERVATION_MODIFIER", 27, 37], ["more diverse", "OBSERVATION_MODIFIER", 38, 50], ["significant", "OBSERVATION_MODIFIER", 68, 79], ["issues", "OBSERVATION", 80, 86]]], ["But only 1% of registered dentists identify as being Black British 4 which is a significant departure from the representation of 3% in the UK population.", [["significant", "OBSERVATION_MODIFIER", 80, 91], ["departure", "OBSERVATION", 92, 101]]], ["5 In addition, those of a BAME background are less likely to enter clinical teaching or academic roles.", [["less likely", "UNCERTAINTY", 46, 57]]], ["That is, women or BAME persons in a position will act as role models for future generations entering those positions.", [["women", "ORGANISM", 9, 14], ["women", "SPECIES", 9, 14], ["persons", "SPECIES", 23, 30]]], ["In a diverse society, diversity in dentistry is desirable, as it can remove barriers for access to unrepresented groups and help understand the unique challenges of overlooked patient cohorts.", [["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 176, 183], ["diverse", "OBSERVATION_MODIFIER", 5, 12], ["society", "OBSERVATION", 13, 20], ["diversity", "OBSERVATION_MODIFIER", 22, 31]]]], "68edb38e367d4befd04d88bd8b4661ff03ef8d06": [["IntroductionOral factor-Xa inhibitors (FXaI) have become widely used for both venous thromboembolism (VTE) treatment and prophylaxis, as well as stroke prevention in non-valvular atrial fibrillation.IntroductionSeveral large-scale clinical trials have shown that edoxaban, apixaban, and rivaroxaban are as or more effective than warfarin with a more favorable bleeding profile.", [["venous", "ANATOMY", 78, 84], ["atrial", "ANATOMY", 179, 185], ["venous thromboembolism", "DISEASE", 78, 100], ["VTE", "DISEASE", 102, 105], ["stroke", "DISEASE", 145, 151], ["atrial fibrillation", "DISEASE", 179, 198], ["edoxaban", "CHEMICAL", 263, 271], ["apixaban", "CHEMICAL", 273, 281], ["rivaroxaban", "CHEMICAL", 287, 298], ["warfarin", "CHEMICAL", 329, 337], ["bleeding", "DISEASE", 360, 368], ["edoxaban", "CHEMICAL", 263, 271], ["apixaban", "CHEMICAL", 273, 281], ["rivaroxaban", "CHEMICAL", 287, 298], ["warfarin", "CHEMICAL", 329, 337], ["IntroductionOral factor-Xa", "GENE_OR_GENE_PRODUCT", 0, 26], ["FXaI", "SIMPLE_CHEMICAL", 39, 43], ["venous", "MULTI-TISSUE_STRUCTURE", 78, 84], ["edoxaban", "SIMPLE_CHEMICAL", 263, 271], ["apixaban", "SIMPLE_CHEMICAL", 273, 281], ["rivaroxaban", "SIMPLE_CHEMICAL", 287, 298], ["warfarin", "SIMPLE_CHEMICAL", 329, 337], ["IntroductionOral factor-Xa inhibitors", "TREATMENT", 0, 37], ["FXaI)", "TREATMENT", 39, 44], ["both venous thromboembolism", "PROBLEM", 73, 100], ["VTE) treatment", "TREATMENT", 102, 116], ["prophylaxis", "TREATMENT", 121, 132], ["stroke prevention", "TREATMENT", 145, 162], ["non-valvular atrial fibrillation", "PROBLEM", 166, 198], ["Several large-scale clinical trials", "TREATMENT", 211, 246], ["edoxaban", "TREATMENT", 263, 271], ["apixaban", "TREATMENT", 273, 281], ["rivaroxaban", "TREATMENT", 287, 298], ["warfarin", "TREATMENT", 329, 337], ["a more favorable bleeding profile", "PROBLEM", 343, 376], ["venous", "ANATOMY", 78, 84], ["thromboembolism", "OBSERVATION", 85, 100], ["non-valvular atrial", "ANATOMY", 166, 185], ["fibrillation", "OBSERVATION", 186, 198], ["large", "OBSERVATION_MODIFIER", 219, 224]]], ["[1] [2] [3] [4] [5] Attributes owing to their widespread use include minimal drug-drug interactions (DDI), tolerability, and lack of routine laboratory monitoring requirements.", [["[1] [2] [3] [4] [5", "SIMPLE_CHEMICAL", 0, 18], ["routine laboratory monitoring requirements", "TEST", 133, 175]]], ["6 Liquid chromatography (LC)-mass spectrometry (MS) can accurately quantify FXaI plasma concentrations and is considered the gold standard of assessing FXaI plasma concentrations, 7 however not all laboratories have 24-hour access to perform this type of analysis.", [["plasma", "ANATOMY", 81, 87], ["plasma", "ANATOMY", 157, 163], ["FXaI", "CHEMICAL", 76, 80], ["FXaI", "CHEMICAL", 152, 156], ["FXaI", "SIMPLE_CHEMICAL", 76, 80], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["FXaI", "SIMPLE_CHEMICAL", 152, 156], ["plasma", "ORGANISM_SUBSTANCE", 157, 163], ["Liquid chromatography", "TEST", 2, 23], ["mass spectrometry", "PROBLEM", 29, 46], ["FXaI plasma concentrations", "TEST", 152, 178], ["analysis", "TEST", 255, 263]]], ["Commercially available anti-Xa chromogenic assays may be utilized for FXaI levels with appropriate drug calibrators, 8, 9 and have demonstrated good correlation between plasma FXaI concentration and anti-factor Xa activity across a range of plasma concentrations.", [["plasma", "ANATOMY", 169, 175], ["plasma", "ANATOMY", 241, 247], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 23, 30], ["FXaI", "SIMPLE_CHEMICAL", 70, 74], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["FXaI", "SIMPLE_CHEMICAL", 176, 180], ["anti-factor Xa", "GENE_OR_GENE_PRODUCT", 199, 213], ["plasma", "ORGANISM_SUBSTANCE", 241, 247], ["FXaI", "PROTEIN", 70, 74], ["FXaI", "PROTEIN", 176, 180], ["anti-factor Xa", "PROTEIN", 199, 213], ["anti-Xa chromogenic assays", "TEST", 23, 49], ["FXaI levels", "TEST", 70, 81], ["appropriate drug calibrators", "TEST", 87, 115], ["plasma FXaI concentration", "TREATMENT", 169, 194], ["anti-factor Xa activity", "TREATMENT", 199, 222], ["plasma concentrations", "TREATMENT", 241, 262]]], ["10 Some researchers have attempted to establish \"on therapy\" anti-Xa level ranges for apixaban and rivaroxaban in a pragmatic setting, 11 whereas other pharmacokinetic studies conducted in healthy volunteers suggest expected plasma levels based on FXaI type, dose, and time since last dose.", [["plasma", "ANATOMY", 225, 231], ["apixaban", "CHEMICAL", 86, 94], ["rivaroxaban", "CHEMICAL", 99, 110], ["apixaban", "CHEMICAL", 86, 94], ["rivaroxaban", "CHEMICAL", 99, 110], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 61, 68], ["apixaban", "SIMPLE_CHEMICAL", 86, 94], ["rivaroxaban", "SIMPLE_CHEMICAL", 99, 110], ["volunteers", "ORGANISM", 197, 207], ["plasma", "ORGANISM_SUBSTANCE", 225, 231], ["therapy", "TREATMENT", 52, 59], ["anti", "TREATMENT", 61, 65], ["apixaban", "TREATMENT", 86, 94], ["rivaroxaban", "TREATMENT", 99, 110], ["other pharmacokinetic studies", "TEST", 146, 175], ["plasma levels", "TEST", 225, 238]]], ["12, 13 Certain clinical scenarios such as breakthrough thrombosis, bleeding events, and hepatic and renal insufficiency may warrant assessment of physiologically relevant FXaI concentrations, [14] [15] [16] [17] [18] and there is some evidence correlating plasma concentrations of certain direct oral anticoagulants (DOAC) such as dabigatran and edoxaban with bleeding events.", [["hepatic", "ANATOMY", 88, 95], ["renal", "ANATOMY", 100, 105], ["plasma", "ANATOMY", 256, 262], ["oral", "ANATOMY", 296, 300], ["thrombosis", "DISEASE", 55, 65], ["bleeding", "DISEASE", 67, 75], ["hepatic and renal insufficiency", "DISEASE", 88, 119], ["[14] [15] [16] [17", "CHEMICAL", 192, 210], ["DOAC", "CHEMICAL", 317, 321], ["dabigatran", "CHEMICAL", 331, 341], ["edoxaban", "CHEMICAL", 346, 354], ["bleeding", "DISEASE", 360, 368], ["FXaI", "CHEMICAL", 171, 175], ["dabigatran", "CHEMICAL", 331, 341], ["edoxaban", "CHEMICAL", 346, 354], ["hepatic", "MULTI-TISSUE_STRUCTURE", 88, 95], ["renal", "ORGAN", 100, 105], ["FXaI", "SIMPLE_CHEMICAL", 171, 175], ["[14] [15] [16] [17] [18]", "SIMPLE_CHEMICAL", 192, 216], ["plasma", "ORGANISM_SUBSTANCE", 256, 262], ["oral", "ORGANISM_SUBDIVISION", 296, 300], ["anticoagulants", "SIMPLE_CHEMICAL", 301, 315], ["DOAC", "SIMPLE_CHEMICAL", 317, 321], ["dabigatran", "SIMPLE_CHEMICAL", 331, 341], ["edoxaban", "SIMPLE_CHEMICAL", 346, 354], ["breakthrough thrombosis", "PROBLEM", 42, 65], ["bleeding events", "PROBLEM", 67, 82], ["hepatic and renal insufficiency", "PROBLEM", 88, 119], ["assessment", "TEST", 132, 142], ["plasma concentrations", "TEST", 256, 277], ["direct oral anticoagulants", "TREATMENT", 289, 315], ["DOAC", "TREATMENT", 317, 321], ["dabigatran", "TREATMENT", 331, 341], ["edoxaban", "TREATMENT", 346, 354], ["bleeding events", "PROBLEM", 360, 375], ["thrombosis", "OBSERVATION", 55, 65], ["bleeding", "OBSERVATION", 67, 75], ["hepatic", "ANATOMY", 88, 95], ["renal", "ANATOMY", 100, 105], ["insufficiency", "OBSERVATION", 106, 119]]], ["19, 20 However, there is a paucity of data describing the relationship between FXaI anti-Xa levels and clinical outcomes in patients taking apixaban and rivaroxaban in a real-world setting.", [["apixaban", "CHEMICAL", 140, 148], ["rivaroxaban", "CHEMICAL", 153, 164], ["apixaban", "CHEMICAL", 140, 148], ["rivaroxaban", "CHEMICAL", 153, 164], ["FXaI anti-Xa", "GENE_OR_GENE_PRODUCT", 79, 91], ["patients", "ORGANISM", 124, 132], ["apixaban", "SIMPLE_CHEMICAL", 140, 148], ["rivaroxaban", "SIMPLE_CHEMICAL", 153, 164], ["FXaI anti", "PROTEIN", 79, 88], ["Xa", "PROTEIN", 89, 91], ["patients", "SPECIES", 124, 132], ["FXaI anti-Xa levels", "TREATMENT", 79, 98], ["apixaban", "TREATMENT", 140, 148], ["rivaroxaban", "TREATMENT", 153, 164]]], ["The objective of this study was to evaluate anti-Xa levels for apixaban and rivaroxaban and their association with major bleeding events.Study DesignThis retrospective, observational cohort study was approved by the Houston Methodist Research Institute Institutional Review Board (IRB).", [["apixaban", "CHEMICAL", 63, 71], ["rivaroxaban", "CHEMICAL", 76, 87], ["bleeding", "DISEASE", 121, 129], ["apixaban", "CHEMICAL", 63, 71], ["rivaroxaban", "CHEMICAL", 76, 87], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 44, 51], ["apixaban", "SIMPLE_CHEMICAL", 63, 71], ["rivaroxaban", "SIMPLE_CHEMICAL", 76, 87], ["this study", "TEST", 17, 27], ["anti-Xa levels", "TREATMENT", 44, 58], ["apixaban", "TREATMENT", 63, 71], ["rivaroxaban", "TREATMENT", 76, 87], ["major bleeding events", "PROBLEM", 115, 136], ["observational cohort study", "TEST", 169, 195], ["bleeding", "OBSERVATION", 121, 129]]], ["All anti-Xa levels for apixaban and rivaroxaban ordered at Houston Methodist, a seven-hospital system, from May 2016 to September 2019 were evaluated regardless of whether there was a documented inpatient dose of apixaban or rivaroxaban.", [["apixaban", "CHEMICAL", 23, 31], ["rivaroxaban", "CHEMICAL", 36, 47], ["apixaban", "CHEMICAL", 213, 221], ["rivaroxaban", "CHEMICAL", 225, 236], ["apixaban", "CHEMICAL", 23, 31], ["rivaroxaban", "CHEMICAL", 36, 47], ["apixaban", "CHEMICAL", 213, 221], ["rivaroxaban", "CHEMICAL", 225, 236], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 4, 11], ["apixaban", "SIMPLE_CHEMICAL", 23, 31], ["rivaroxaban", "SIMPLE_CHEMICAL", 36, 47], ["apixaban", "SIMPLE_CHEMICAL", 213, 221], ["rivaroxaban", "SIMPLE_CHEMICAL", 225, 236], ["Xa levels", "TEST", 9, 18], ["apixaban", "TREATMENT", 23, 31], ["rivaroxaban", "TREATMENT", 36, 47], ["apixaban", "TREATMENT", 213, 221], ["rivaroxaban", "TREATMENT", 225, 236]]], ["Of note, all anti-Xa level tests for FXaI were performed at one laboratory in the Texas Medical Center Hospital.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 13, 20], ["FXaI", "SIMPLE_CHEMICAL", 37, 41], ["Xa", "PROTEIN", 18, 20], ["Xa level tests", "TEST", 18, 32], ["FXaI", "TEST", 37, 41]]], ["Levels were excluded if any of the following factors were identified: unfractionated heparin (UFH) or low molecular weight heparin (LMWH) product administration within 24 hours prior to an anti-Xa level being drawn; the level was deemed to be ordered in error (i.e., incorrect assay ordered based on drug exposure or the patient was not taking a FXaI); or critical information was missing from the electronic health record (EHR).", [["heparin", "CHEMICAL", 85, 92], ["UFH", "CHEMICAL", 94, 97], ["heparin", "CHEMICAL", 123, 130], ["LMWH", "CHEMICAL", 132, 136], ["unfractionated heparin", "SIMPLE_CHEMICAL", 70, 92], ["UFH", "SIMPLE_CHEMICAL", 94, 97], ["low molecular weight heparin", "SIMPLE_CHEMICAL", 102, 130], ["LMWH", "SIMPLE_CHEMICAL", 132, 136], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 189, 196], ["patient", "ORGANISM", 321, 328], ["Xa", "PROTEIN", 194, 196], ["patient", "SPECIES", 321, 328], ["Levels", "TEST", 0, 6], ["unfractionated heparin", "TREATMENT", 70, 92], ["UFH", "TREATMENT", 94, 97], ["low molecular weight heparin (LMWH) product administration", "TREATMENT", 102, 160], ["an anti-Xa level", "TEST", 186, 202], ["incorrect assay", "TEST", 267, 282]]], ["The EHR was also queried for patient demographic information, baseline laboratory values, and all FXaI administrations.", [["FXaI", "CHEMICAL", 98, 102], ["patient", "ORGANISM", 29, 36], ["patient", "SPECIES", 29, 36], ["all FXaI administrations", "TREATMENT", 94, 118]]], ["Reasons for anti-Xa level ordering and clinical decisions regarding FXaI were chart reviewed by two investigators (NJ and AD).", [["AD", "DISEASE", 122, 124], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 12, 19], ["FXaI", "SIMPLE_CHEMICAL", 68, 72], ["Xa", "PROTEIN", 17, 19], ["anti-Xa level ordering", "TEST", 12, 34]]], ["If patients had multiple levels obtained during the same encounter, only initial levels were included in final analyses.Study EndpointsThe primary endpoint of this study was the prevalence of major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH) which included bleeding that was fatal, located in a critical area or organ (i.e., intracranial, intraspinal, retroperitoneal, intraocular, pericardial, or intramuscular), caused a drop in hemoglobin of \u2265 2 g/dL, or led to the transfusion of two or more units of blood.", [["area", "ANATOMY", 353, 357], ["organ", "ANATOMY", 361, 366], ["intracranial", "ANATOMY", 374, 386], ["intraspinal", "ANATOMY", 388, 399], ["retroperitoneal", "ANATOMY", 401, 416], ["intraocular", "ANATOMY", 418, 429], ["pericardial", "ANATOMY", 431, 442], ["intramuscular", "ANATOMY", 447, 460], ["blood", "ANATOMY", 554, 559], ["bleeding", "DISEASE", 198, 206], ["Thrombosis", "DISEASE", 257, 267], ["Haemostasis", "DISEASE", 272, 283], ["ISTH", "DISEASE", 285, 289], ["bleeding", "DISEASE", 306, 314], ["patients", "ORGANISM", 3, 11], ["organ", "ORGAN", 361, 366], ["pericardial", "ORGAN", 431, 442], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 447, 460], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 480, 490], ["blood", "ORGANISM_SUBSTANCE", 554, 559], ["hemoglobin", "PROTEIN", 480, 490], ["patients", "SPECIES", 3, 11], ["multiple levels", "TEST", 16, 31], ["initial levels", "TEST", 73, 87], ["Study Endpoints", "TEST", 120, 135], ["this study", "TEST", 159, 169], ["major bleeding events", "PROBLEM", 192, 213], ["Thrombosis", "PROBLEM", 257, 267], ["Haemostasis (ISTH)", "PROBLEM", 272, 290], ["bleeding", "PROBLEM", 306, 314], ["fatal", "PROBLEM", 324, 329], ["organ (i.e., intracranial, intraspinal, retroperitoneal, intraocular, pericardial, or intramuscular)", "PROBLEM", 361, 461], ["a drop in hemoglobin", "PROBLEM", 470, 490], ["the transfusion", "TREATMENT", 514, 529], ["blood", "TREATMENT", 554, 559], ["major", "OBSERVATION_MODIFIER", 192, 197], ["bleeding", "OBSERVATION", 198, 206], ["Thrombosis", "OBSERVATION", 257, 267], ["bleeding", "OBSERVATION", 306, 314], ["fatal", "OBSERVATION_MODIFIER", 324, 329], ["organ", "ANATOMY", 361, 366], ["intraspinal", "ANATOMY", 388, 399], ["retroperitoneal", "ANATOMY", 401, 416], ["intraocular", "ANATOMY", 418, 429], ["pericardial", "ANATOMY", 431, 442], ["drop", "OBSERVATION_MODIFIER", 472, 476]]], ["21 Major bleeding events were reviewed and adjudicated by two of the authors (NJ and AD) was confirmed either by presence of pertinent laboratory or imaging findings, as well as provider documentation for each patient.", [["bleeding", "DISEASE", 9, 17], ["AD", "DISEASE", 85, 87], ["patient", "ORGANISM", 210, 217], ["patient", "SPECIES", 210, 217], ["Major bleeding events", "PROBLEM", 3, 24], ["imaging findings", "TEST", 149, 165], ["bleeding", "OBSERVATION", 9, 17]]], ["Median anti-Xa levels were determined both in patients with and without a major bleeding event.", [["bleeding", "DISEASE", 80, 88], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 7, 14], ["patients", "ORGANISM", 46, 54], ["Xa", "PROTEIN", 12, 14], ["patients", "SPECIES", 46, 54], ["Median anti-Xa levels", "TEST", 0, 21], ["a major bleeding event", "PROBLEM", 72, 94], ["bleeding", "OBSERVATION", 80, 88]]], ["Anti-Xa J o u r n a l P r e -p r o o f levels obtained at the time of, or within 24 hours after a bleeding event, were considered to be in the context of a major bleed and categorized as such.", [["bleeding", "DISEASE", 98, 106], ["a l P r e -p r o o f levels", "TEST", 18, 45], ["a bleeding event", "PROBLEM", 96, 112], ["a major bleed", "PROBLEM", 154, 167], ["bleeding", "OBSERVATION", 98, 106], ["major", "OBSERVATION_MODIFIER", 156, 161], ["bleed", "OBSERVATION", 162, 167]]], ["Secondary endpoints consisted of reversal agent use (four-factor prothrombin complex concentrate (4F-PCC) and andexanet alfa), reasons for obtaining an anti-Xa level, changes in FXaI therapy at hospital discharge, and all anti-Xa levels following a documented inpatient dose.", [["4F-PCC", "CHEMICAL", 98, 104], ["andexanet alfa", "CHEMICAL", 110, 124], ["FXaI", "CHEMICAL", 178, 182], ["prothrombin", "GENE_OR_GENE_PRODUCT", 65, 76], ["4F-PCC", "SIMPLE_CHEMICAL", 98, 104], ["andexanet alfa", "SIMPLE_CHEMICAL", 110, 124], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 152, 159], ["FXaI", "SIMPLE_CHEMICAL", 178, 182], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 222, 229], ["4F", "PROTEIN", 98, 100], ["andexanet alfa", "PROTEIN", 110, 124], ["Xa", "PROTEIN", 157, 159], ["Xa", "PROTEIN", 227, 229], ["Secondary endpoints", "PROBLEM", 0, 19], ["reversal agent", "TREATMENT", 33, 47], ["factor prothrombin complex concentrate", "TREATMENT", 58, 96], ["andexanet alfa", "TREATMENT", 110, 124], ["an anti-Xa level", "TEST", 149, 165], ["FXaI therapy", "TREATMENT", 178, 190], ["Xa levels", "TEST", 227, 236]]], ["Pre-specified subgroup analyses were planned in order to compare patients with and without a major bleeding event on the basis of age, body mass index (BMI), baseline creatinine clearance (estimated with the Cockcroft-Gault equation), presence of AKI as defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria 22 , use of renal replacement therapy (RRT), dose appropriateness based on approved package labeling 23, 24 , and concomitant use of antiplatelet drugs or inhibitors of FXaI metabolism.Chromogenic Anti-Xa AssayApixaban and rivaroxaban anti-Xa levels were determined using a calibrated STA\u00ae -Liquid Anti-Xa Assay that is calibrated with commercial apixaban and rivaroxaban calibrators, and are available 24 hours a day, seven days a week at our institution.", [["body", "ANATOMY", 135, 139], ["renal", "ANATOMY", 339, 344], ["bleeding", "DISEASE", 99, 107], ["creatinine", "CHEMICAL", 167, 177], ["AKI", "DISEASE", 247, 250], ["AssayApixaban", "CHEMICAL", 532, 545], ["rivaroxaban", "CHEMICAL", 550, 561], ["apixaban", "CHEMICAL", 674, 682], ["rivaroxaban", "CHEMICAL", 687, 698], ["creatinine", "CHEMICAL", 167, 177], ["AssayApixaban", "CHEMICAL", 532, 545], ["rivaroxaban", "CHEMICAL", 550, 561], ["apixaban", "CHEMICAL", 674, 682], ["rivaroxaban", "CHEMICAL", 687, 698], ["patients", "ORGANISM", 65, 73], ["body", "ORGANISM_SUBDIVISION", 135, 139], ["creatinine", "SIMPLE_CHEMICAL", 167, 177], ["renal", "ORGAN", 339, 344], ["antiplatelet drugs", "SIMPLE_CHEMICAL", 460, 478], ["FXaI", "SIMPLE_CHEMICAL", 496, 500], ["Chromogenic Anti-Xa AssayApixaban", "SIMPLE_CHEMICAL", 512, 545], ["rivaroxaban", "SIMPLE_CHEMICAL", 550, 561], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 562, 569], ["apixaban", "SIMPLE_CHEMICAL", 674, 682], ["rivaroxaban", "SIMPLE_CHEMICAL", 687, 698], ["FXaI", "PROTEIN", 496, 500], ["Xa", "PROTEIN", 567, 569], ["patients", "SPECIES", 65, 73], ["Pre-specified subgroup analyses", "TEST", 0, 31], ["a major bleeding event", "PROBLEM", 91, 113], ["body mass index", "PROBLEM", 135, 150], ["baseline creatinine clearance", "TEST", 158, 187], ["AKI", "PROBLEM", 247, 250], ["the Kidney Disease", "PROBLEM", 265, 283], ["renal replacement therapy", "TREATMENT", 339, 364], ["RRT", "TREATMENT", 366, 369], ["antiplatelet drugs", "TREATMENT", 460, 478], ["inhibitors", "TREATMENT", 482, 492], ["FXaI metabolism", "TREATMENT", 496, 511], ["Chromogenic Anti-Xa AssayApixaban", "TREATMENT", 512, 545], ["rivaroxaban anti", "TREATMENT", 550, 566], ["Xa levels", "TEST", 567, 576], ["Liquid Anti-Xa Assay", "TREATMENT", 618, 638], ["commercial apixaban", "TREATMENT", 663, 682], ["rivaroxaban calibrators", "TREATMENT", 687, 710], ["bleeding", "OBSERVATION", 99, 107], ["AKI", "OBSERVATION", 247, 250], ["Kidney", "ANATOMY", 269, 275], ["Disease", "OBSERVATION", 276, 283], ["renal", "ANATOMY", 339, 344], ["replacement", "OBSERVATION", 345, 356]]], ["In this assay, exogenous factor Xa is added to a patient's plasma sample which can then complex with any present FXaI.", [["plasma sample", "ANATOMY", 59, 72], ["factor Xa", "GENE_OR_GENE_PRODUCT", 25, 34], ["patient", "ORGANISM", 49, 56], ["plasma", "ORGANISM_SUBSTANCE", 59, 65], ["FXaI", "GENE_OR_GENE_PRODUCT", 113, 117], ["exogenous factor Xa", "PROTEIN", 15, 34], ["FXaI", "PROTEIN", 113, 117], ["patient", "SPECIES", 49, 56], ["exogenous factor Xa", "PROBLEM", 15, 34], ["a patient's plasma sample", "TEST", 47, 72]]], ["A substrate that is specific for factor-Xa is then added to the sample, and the factor-Xa-substrate complex then cleaves a chromophore to produce color, with the amount of color produced being inversely proportional to FXaI presence.", [["sample", "ANATOMY", 64, 70], ["factor-Xa", "GENE_OR_GENE_PRODUCT", 33, 42], ["FXaI", "GENE_OR_GENE_PRODUCT", 219, 223], ["Xa", "PROTEIN", 40, 42], ["Xa-substrate complex", "PROTEIN", 87, 107], ["FXaI", "PROTEIN", 219, 223], ["factor-Xa", "PROBLEM", 33, 42]]], ["Expected peak levels (2-4 hours post-dose) are provided in the result details as well.", [["Expected peak levels", "TEST", 0, 20], ["peak", "OBSERVATION_MODIFIER", 9, 13]]], ["The lower limit of the reportable range of our assays for both apixaban and rivaroxaban are < 20 ng/mL, and the upper limit 451 ng/mL and 472 ng/mL for apixaban and rivaroxaban, respectively.", [["apixaban", "CHEMICAL", 63, 71], ["rivaroxaban", "CHEMICAL", 76, 87], ["apixaban", "CHEMICAL", 152, 160], ["rivaroxaban", "CHEMICAL", 165, 176], ["apixaban", "CHEMICAL", 63, 71], ["rivaroxaban", "CHEMICAL", 76, 87], ["apixaban", "CHEMICAL", 152, 160], ["rivaroxaban", "CHEMICAL", 165, 176], ["apixaban", "SIMPLE_CHEMICAL", 63, 71], ["rivaroxaban", "SIMPLE_CHEMICAL", 76, 87], ["apixaban", "SIMPLE_CHEMICAL", 152, 160], ["rivaroxaban", "SIMPLE_CHEMICAL", 165, 176], ["our assays", "TEST", 43, 53], ["both apixaban", "TREATMENT", 58, 71], ["rivaroxaban", "TREATMENT", 76, 87], ["apixaban", "TREATMENT", 152, 160], ["rivaroxaban", "TREATMENT", 165, 176], ["lower limit", "OBSERVATION_MODIFIER", 4, 15]]], ["Expected peak levels for apixaban are 16-108 ng/mL and 102-155 ng/mL following a 2.5 mg and 5 mg dose, respectively.", [["apixaban", "CHEMICAL", 25, 33], ["apixaban", "CHEMICAL", 25, 33], ["apixaban", "SIMPLE_CHEMICAL", 25, 33], ["Expected peak levels", "TEST", 0, 20], ["apixaban", "TREATMENT", 25, 33]]], ["Likewise, typically observed peak levels for rivaroxaban are 90-190 ng/mL and 180-340 ng/mL following a 10 mg J o u r n a l P r e -p r o o f and 20 mg dose, respectively.", [["rivaroxaban", "CHEMICAL", 45, 56], ["rivaroxaban", "CHEMICAL", 45, 56], ["rivaroxaban", "SIMPLE_CHEMICAL", 45, 56], ["peak levels", "TEST", 29, 40], ["rivaroxaban", "TREATMENT", 45, 56], ["a l P r e -p r o o f", "TREATMENT", 120, 140]]], ["These ranges have been adopted from previously conducted pharmacokinetic studies.", [["previously conducted pharmacokinetic studies", "TEST", 36, 80]]], ["13, 25 Statistical analysis Continuous data were reported as mean and standard deviation or median and interquartile range (IQR) as appropriate.", [["Statistical analysis", "TEST", 7, 27]]], ["Categorical data were compared with the chi-squared or Fisher's exact test.", [["Categorical data", "TEST", 0, 16], ["Fisher's exact test", "TEST", 55, 74]]], ["Differences between two groups were assessed with a student's t-test or Mann-Whitney U test depending on the data distribution, with a p-value of \u2264 0.05 indicating a statistically significant difference at the two-sided level.", [["a student's t-test", "TEST", 50, 68], ["Whitney U test", "TEST", 77, 91], ["a p-value", "TEST", 133, 142], ["significant", "OBSERVATION_MODIFIER", 180, 191], ["difference", "OBSERVATION", 192, 202], ["sided", "ANATOMY_MODIFIER", 214, 219]]], ["Binary logistic regression was performed in order to ascertain any factors that predisposed patients to increased odds of experiencing a major bleeding event.", [["bleeding", "DISEASE", 143, 151], ["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100], ["Binary logistic regression", "PROBLEM", 0, 26], ["a major bleeding event", "PROBLEM", 135, 157], ["major", "OBSERVATION_MODIFIER", 137, 142], ["bleeding", "OBSERVATION", 143, 151]]], ["A backwards stepwise selection method was implemented utilizing the following variables: age > 80 years, weight < 60 kg, baseline CrCl < 50 mL/min, AKI within 48 hours of level, strong CYP3A4 or P-gp inhibitor use, antiplatelet use, inappropriately high dosing regimen, and anti-Xa level stratified into tertiles (<100, 100-300, and >300 ng/mL).", [["AKI", "DISEASE", 148, 151], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 185, 191], ["P-gp", "GENE_OR_GENE_PRODUCT", 195, 199], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 274, 281], ["CYP3A4", "PROTEIN", 185, 191], ["Xa", "PROTEIN", 279, 281], ["A backwards stepwise selection method", "TREATMENT", 0, 37], ["weight", "TEST", 105, 111], ["CrCl", "TEST", 130, 134], ["AKI", "PROBLEM", 148, 151], ["strong CYP3A4", "PROBLEM", 178, 191], ["P-gp inhibitor", "TREATMENT", 195, 209], ["antiplatelet use", "TREATMENT", 215, 231], ["inappropriately high dosing regimen", "TREATMENT", 233, 268], ["anti-Xa level", "TEST", 274, 287]]], ["Variables with a p-value of < 0.2 were included into the final models.", [["a p-value", "TEST", 15, 24]]], ["Three models were constructed, one combining both apixaban and rivaroxaban, and two for each individual FXaI.", [["apixaban", "CHEMICAL", 50, 58], ["rivaroxaban", "CHEMICAL", 63, 74], ["apixaban", "CHEMICAL", 50, 58], ["rivaroxaban", "CHEMICAL", 63, 74], ["apixaban", "SIMPLE_CHEMICAL", 50, 58], ["rivaroxaban", "SIMPLE_CHEMICAL", 63, 74], ["FXaI", "GENE_OR_GENE_PRODUCT", 104, 108], ["FXaI", "PROTEIN", 104, 108], ["apixaban", "TREATMENT", 50, 58], ["rivaroxaban", "TREATMENT", 63, 74]]], ["Descriptive and comparative analyses were performed with GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA), and binary logistic regression was carried out using STATA version 14.2 (StataCorp, College Station, TX).Patient CharacteristicsDuring the study period, a total of 979 anti-Xa levels for apixaban and rivaroxaban were Patients who received 4F-PCC or andexanet alfa had statistically significant higher median anti-Xa levels than those who did not receive a reversal agent for apixaban (73 ng/mL vs. 153 ng/mL, p=0.0019), but not for rivaroxaban (76 ng/mL vs. 131 ng/mL, p=0.21).", [["apixaban", "CHEMICAL", 307, 315], ["rivaroxaban", "CHEMICAL", 320, 331], ["4F-PCC", "CHEMICAL", 359, 365], ["andexanet alfa", "CHEMICAL", 369, 383], ["apixaban", "CHEMICAL", 495, 503], ["rivaroxaban", "CHEMICAL", 552, 563], ["apixaban", "CHEMICAL", 307, 315], ["rivaroxaban", "CHEMICAL", 320, 331], ["4F-PCC", "CHEMICAL", 359, 365], ["apixaban", "CHEMICAL", 495, 503], ["rivaroxaban", "CHEMICAL", 552, 563], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 288, 295], ["apixaban", "SIMPLE_CHEMICAL", 307, 315], ["rivaroxaban", "SIMPLE_CHEMICAL", 320, 331], ["Patients", "ORGANISM", 337, 345], ["4F-PCC", "SIMPLE_CHEMICAL", 359, 365], ["andexanet alfa", "SIMPLE_CHEMICAL", 369, 383], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 428, 435], ["apixaban", "SIMPLE_CHEMICAL", 495, 503], ["rivaroxaban", "SIMPLE_CHEMICAL", 552, 563], ["Xa", "PROTEIN", 433, 435], ["Patient", "SPECIES", 225, 232], ["Patients", "SPECIES", 337, 345], ["comparative analyses", "TEST", 16, 36], ["GraphPad Prism version", "TEST", 57, 79], ["STATA version", "TEST", 173, 186], ["TX", "TREATMENT", 221, 223], ["anti-Xa levels", "TREATMENT", 288, 302], ["apixaban", "TREATMENT", 307, 315], ["rivaroxaban", "TREATMENT", 320, 331], ["PCC", "TREATMENT", 362, 365], ["andexanet alfa", "TREATMENT", 369, 383], ["a reversal agent", "TREATMENT", 474, 490], ["apixaban", "TREATMENT", 495, 503], ["rivaroxaban", "TREATMENT", 552, 563]]], ["There were 12 patients who received 4F-PCC (n=8) and andexanet alfa (n=4) outside the context of major bleeding.", [["4F-PCC", "CHEMICAL", 36, 42], ["andexanet alfa", "CHEMICAL", 53, 67], ["bleeding", "DISEASE", 103, 111], ["4F-PCC", "CHEMICAL", 36, 42], ["patients", "ORGANISM", 14, 22], ["4F-PCC", "SIMPLE_CHEMICAL", 36, 42], ["andexanet alfa", "SIMPLE_CHEMICAL", 53, 67], ["patients", "SPECIES", 14, 22], ["4F-PCC (n", "TREATMENT", 36, 45], ["andexanet alfa", "TREATMENT", 53, 67], ["major bleeding", "PROBLEM", 97, 111], ["major", "OBSERVATION_MODIFIER", 97, 102], ["bleeding", "OBSERVATION", 103, 111]]], ["Three patients who were given 4F-PCC also received fresh frozen plasma (FFP), and six patients received only FFP.", [["plasma", "ANATOMY", 64, 70], ["patients", "ORGANISM", 6, 14], ["4F-PCC", "SIMPLE_CHEMICAL", 30, 36], ["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["FFP", "ORGANISM_SUBSTANCE", 72, 75], ["patients", "ORGANISM", 86, 94], ["FFP", "PROTEIN", 109, 112], ["patients", "SPECIES", 6, 14], ["patients", "SPECIES", 86, 94], ["fresh frozen plasma (FFP", "TREATMENT", 51, 75], ["FFP", "TREATMENT", 109, 112]]], ["In addition, two patients received aminocaproic acid for a major bleed.Patient CharacteristicsReasons for obtaining level and changes to therapyLevels following a doseThere were 143 anti-Xa levels following an inpatient dose of apixaban and 15 anti-Xa levels following a dose of rivaroxaban (figure 4).", [["aminocaproic acid", "CHEMICAL", 35, 52], ["therapyLevels", "DISEASE", 137, 150], ["apixaban", "CHEMICAL", 228, 236], ["rivaroxaban", "CHEMICAL", 279, 290], ["aminocaproic acid", "CHEMICAL", 35, 52], ["apixaban", "CHEMICAL", 228, 236], ["rivaroxaban", "CHEMICAL", 279, 290], ["patients", "ORGANISM", 17, 25], ["aminocaproic acid", "SIMPLE_CHEMICAL", 35, 52], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 182, 189], ["apixaban", "SIMPLE_CHEMICAL", 228, 236], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 244, 251], ["rivaroxaban", "SIMPLE_CHEMICAL", 279, 290], ["Xa", "PROTEIN", 187, 189], ["Xa", "PROTEIN", 249, 251], ["patients", "SPECIES", 17, 25], ["Patient", "SPECIES", 71, 78], ["aminocaproic acid", "TREATMENT", 35, 52], ["a major bleed", "PROBLEM", 57, 70], ["therapyLevels", "TREATMENT", 137, 150], ["Xa levels", "TEST", 187, 196], ["apixaban", "TREATMENT", 228, 236], ["15 anti-Xa levels", "TREATMENT", 241, 258], ["rivaroxaban (figure", "TREATMENT", 279, 298], ["major", "OBSERVATION_MODIFIER", 59, 64], ["bleed", "OBSERVATION", 65, 70]]], ["There were 9 patients taking apixaban who still had detectable (>20 ng/mL or greater than the lower limit of assay quantification) anti-Xa levels beyond 30 hours (not depicted), all of whom had AKI or were on hemodialysis, but none had a major bleeding event.", [["apixaban", "CHEMICAL", 29, 37], ["AKI", "DISEASE", 194, 197], ["bleeding", "DISEASE", 244, 252], ["apixaban", "CHEMICAL", 29, 37], ["patients", "ORGANISM", 13, 21], ["apixaban", "SIMPLE_CHEMICAL", 29, 37], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 131, 138], ["Xa", "PROTEIN", 136, 138], ["patients", "SPECIES", 13, 21], ["apixaban", "TREATMENT", 29, 37], ["anti-Xa levels", "TEST", 131, 145], ["AKI", "PROBLEM", 194, 197], ["hemodialysis", "TREATMENT", 209, 221], ["a major bleeding event", "PROBLEM", 236, 258], ["AKI", "OBSERVATION", 194, 197], ["bleeding", "OBSERVATION", 244, 252]]], ["Median (10-90 th percentile) anti-Xa levels observed 2-4 hours after a dose of apixaban were as follows: 2.5 mg, 120 ng/mL (76-238 ng/mL); 5 mg, 200 ng/mL (78->451 ng/mL).", [["apixaban", "CHEMICAL", 79, 87], ["apixaban", "CHEMICAL", 79, 87], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 29, 36], ["apixaban", "SIMPLE_CHEMICAL", 79, 87], ["Xa", "PROTEIN", 34, 36], ["anti-Xa levels", "TEST", 29, 43], ["apixaban", "TREATMENT", 79, 87]]], ["One rivaroxaban level was drawn within 2-4 hours after a 15 mg dose (448 ng/mL), and four levels following a 20 mg dose, ranging from 51 ng/mL to >472 ng/mL.", [["rivaroxaban", "CHEMICAL", 4, 15], ["rivaroxaban", "CHEMICAL", 4, 15], ["rivaroxaban", "SIMPLE_CHEMICAL", 4, 15], ["One rivaroxaban level", "TEST", 0, 21]]], ["None of the patients with detectable anti-Xa levels for rivaroxaban beyond four hours had a major bleeding event, although three patients had AKI.J o u r n a l P r e -p r o o fSeveral studies have commented on reasons for obtaining anti-Xa levels for apixaban and rivaroxaban in clinical practice.", [["rivaroxaban", "CHEMICAL", 56, 67], ["bleeding", "DISEASE", 98, 106], ["AKI", "DISEASE", 142, 145], ["apixaban", "CHEMICAL", 251, 259], ["rivaroxaban", "CHEMICAL", 264, 275], ["rivaroxaban", "CHEMICAL", 56, 67], ["apixaban", "CHEMICAL", 251, 259], ["rivaroxaban", "CHEMICAL", 264, 275], ["patients", "ORGANISM", 12, 20], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 37, 44], ["rivaroxaban", "SIMPLE_CHEMICAL", 56, 67], ["patients", "ORGANISM", 129, 137], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 232, 239], ["apixaban", "SIMPLE_CHEMICAL", 251, 259], ["rivaroxaban", "SIMPLE_CHEMICAL", 264, 275], ["Xa", "PROTEIN", 42, 44], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 129, 137], ["Xa levels", "TEST", 42, 51], ["rivaroxaban", "TREATMENT", 56, 67], ["a major bleeding event", "PROBLEM", 90, 112], ["AKI", "PROBLEM", 142, 145], ["fSeveral studies", "TEST", 175, 191], ["anti-Xa levels", "TREATMENT", 232, 246], ["apixaban", "TREATMENT", 251, 259], ["rivaroxaban", "TREATMENT", 264, 275], ["bleeding", "OBSERVATION", 98, 106]]], ["9, 17, 26, 27 To our knowledge, this is one of the largest cohorts of patients with anti-Xa levels for both apixaban and rivaroxaban available in the context of major bleeding at the time of a bleeding event.", [["apixaban", "CHEMICAL", 108, 116], ["rivaroxaban", "CHEMICAL", 121, 132], ["bleeding", "DISEASE", 167, 175], ["bleeding", "DISEASE", 193, 201], ["apixaban", "CHEMICAL", 108, 116], ["rivaroxaban", "CHEMICAL", 121, 132], ["patients", "ORGANISM", 70, 78], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 84, 91], ["apixaban", "SIMPLE_CHEMICAL", 108, 116], ["rivaroxaban", "SIMPLE_CHEMICAL", 121, 132], ["patients", "SPECIES", 70, 78], ["anti-Xa levels", "TREATMENT", 84, 98], ["both apixaban", "TREATMENT", 103, 116], ["rivaroxaban", "TREATMENT", 121, 132], ["major bleeding", "PROBLEM", 161, 175], ["a bleeding event", "PROBLEM", 191, 207], ["bleeding", "OBSERVATION", 167, 175], ["bleeding", "OBSERVATION", 193, 201]]], ["Several other reports have attempted to describe the association between anti-Xa levels and clinical outcomes in a real-world setting.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 73, 80], ["Xa", "PROTEIN", 78, 80], ["anti-Xa levels", "TREATMENT", 73, 87]]], ["One study examined 411 C-peak anti-Xa levels for patients taking apixaban, rivaroxaban, and dabigatran for atrial fibrillation.", [["atrial", "ANATOMY", 107, 113], ["apixaban", "CHEMICAL", 65, 73], ["rivaroxaban", "CHEMICAL", 75, 86], ["dabigatran", "CHEMICAL", 92, 102], ["atrial fibrillation", "DISEASE", 107, 126], ["apixaban", "CHEMICAL", 65, 73], ["rivaroxaban", "CHEMICAL", 75, 86], ["dabigatran", "CHEMICAL", 92, 102], ["Xa", "GENE_OR_GENE_PRODUCT", 35, 37], ["patients", "ORGANISM", 49, 57], ["apixaban", "SIMPLE_CHEMICAL", 65, 73], ["rivaroxaban", "SIMPLE_CHEMICAL", 75, 86], ["dabigatran", "SIMPLE_CHEMICAL", 92, 102], ["atrial", "MULTI-TISSUE_STRUCTURE", 107, 113], ["Xa", "PROTEIN", 35, 37], ["patients", "SPECIES", 49, 57], ["One study", "TEST", 0, 9], ["C", "TEST", 23, 24], ["peak anti-Xa levels", "TEST", 25, 44], ["apixaban", "TREATMENT", 65, 73], ["rivaroxaban", "TREATMENT", 75, 86], ["dabigatran", "TREATMENT", 92, 102], ["atrial fibrillation", "PROBLEM", 107, 126], ["atrial", "ANATOMY", 107, 113], ["fibrillation", "OBSERVATION", 114, 126]]], ["28 In a multivariate regression analysis, higher C-peak plasma concentrations were significantly associated with development of bleeding events (OR=2.7, 95% CI=1.3-5.4).", [["plasma", "ANATOMY", 56, 62], ["bleeding", "DISEASE", 128, 136], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["a multivariate regression analysis", "TEST", 6, 40], ["higher C-peak plasma concentrations", "PROBLEM", 42, 77], ["bleeding events", "PROBLEM", 128, 143], ["CI", "TEST", 157, 159], ["bleeding", "OBSERVATION", 128, 136]]], ["28 Likewise, Japanese patients taking rivaroxaban for atrial fibrillation who experienced a major (n=3) or non-major (n=19) bleed had higher peak anti-Xa levels (2.40 IU/mL vs. 1.85 IU/mL, p=0.001) and lower baseline creatinine clearance (46.2 mL/min vs. 58.8 mL/min, p=0.024).", [["atrial", "ANATOMY", 54, 60], ["rivaroxaban", "CHEMICAL", 38, 49], ["atrial fibrillation", "DISEASE", 54, 73], ["creatinine", "CHEMICAL", 217, 227], ["rivaroxaban", "CHEMICAL", 38, 49], ["creatinine", "CHEMICAL", 217, 227], ["patients", "ORGANISM", 22, 30], ["rivaroxaban", "SIMPLE_CHEMICAL", 38, 49], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 146, 153], ["creatinine", "SIMPLE_CHEMICAL", 217, 227], ["Xa", "PROTEIN", 151, 153], ["patients", "SPECIES", 22, 30], ["rivaroxaban", "TREATMENT", 38, 49], ["atrial fibrillation", "PROBLEM", 54, 73], ["a major (n=3) or non-major (n=19) bleed", "PROBLEM", 90, 129], ["higher peak anti-Xa levels", "PROBLEM", 134, 160], ["lower baseline creatinine clearance", "PROBLEM", 202, 237], ["atrial", "ANATOMY", 54, 60], ["fibrillation", "OBSERVATION", 61, 73]]], ["29 Within our cohort, subgroup analyses and logistic regression models showed that advanced age was associated with major bleeding, which is in alignment with findings from other analyses of ROCKET-AF and ARISTOTLE, 30,31 but did not demonstrate that lower baseline renal function, AKI, or antiplatelet use were associated with increased odds of major bleeding.", [["renal", "ANATOMY", 266, 271], ["bleeding", "DISEASE", 122, 130], ["AF", "DISEASE", 198, 200], ["AKI", "DISEASE", 282, 285], ["bleeding", "DISEASE", 352, 360], ["renal", "ORGAN", 266, 271], ["subgroup analyses", "TEST", 22, 39], ["logistic regression models", "TEST", 44, 70], ["major bleeding", "PROBLEM", 116, 130], ["ROCKET", "TEST", 191, 197], ["AF", "PROBLEM", 198, 200], ["ARISTOTLE", "TEST", 205, 214], ["lower baseline renal function", "PROBLEM", 251, 280], ["AKI", "PROBLEM", 282, 285], ["antiplatelet use", "TREATMENT", 290, 306], ["major bleeding", "PROBLEM", 346, 360], ["major", "OBSERVATION_MODIFIER", 116, 121], ["bleeding", "OBSERVATION", 122, 130], ["renal", "ANATOMY", 266, 271], ["AKI", "OBSERVATION", 282, 285], ["major", "OBSERVATION_MODIFIER", 346, 351], ["bleeding", "OBSERVATION", 352, 360]]], ["Given that the timing of last dose was not always known, this may influence the sensitivity of these analyses specific to renal function.", [["renal", "ANATOMY", 122, 127], ["renal", "ORGAN", 122, 127], ["these analyses", "TEST", 95, 109]]], ["Moreover, increasing anti-Xa levels in our study were not necessarily associated with an increased risk of odds for major bleeding, with the exception of modest anti-Xa levels (100-300 ng/mL) for rivaroxaban.", [["bleeding", "DISEASE", 122, 130], ["rivaroxaban", "CHEMICAL", 196, 207], ["rivaroxaban", "CHEMICAL", 196, 207], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 21, 28], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 161, 168], ["rivaroxaban", "SIMPLE_CHEMICAL", 196, 207], ["Xa", "PROTEIN", 26, 28], ["Xa", "PROTEIN", 166, 168], ["increasing anti-Xa levels", "PROBLEM", 10, 35], ["our study", "TEST", 39, 48], ["major bleeding", "PROBLEM", 116, 130], ["modest anti-Xa levels", "TEST", 154, 175], ["rivaroxaban", "TREATMENT", 196, 207], ["bleeding", "OBSERVATION", 122, 130]]], ["This finding also mirrors the anti-Xa rivaroxaban levels seen in patients with acute major bleeding events who received andexanet alfa in the ANNEXA-4 trial.", [["rivaroxaban", "CHEMICAL", 38, 49], ["bleeding", "DISEASE", 91, 99], ["andexanet alfa", "CHEMICAL", 120, 134], ["rivaroxaban", "CHEMICAL", 38, 49], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 30, 37], ["rivaroxaban", "SIMPLE_CHEMICAL", 38, 49], ["patients", "ORGANISM", 65, 73], ["andexanet alfa", "SIMPLE_CHEMICAL", 120, 134], ["patients", "SPECIES", 65, 73], ["the anti-Xa rivaroxaban levels", "TEST", 26, 56], ["acute major bleeding events", "PROBLEM", 79, 106], ["andexanet alfa", "TREATMENT", 120, 134], ["acute", "OBSERVATION_MODIFIER", 79, 84], ["major", "OBSERVATION_MODIFIER", 85, 90], ["bleeding", "OBSERVATION", 91, 99]]], ["32 In addition, we identified that patients with inappropriately high-dose regimens of FXaI had increased odds of experiencing major bleeding.J o u r n a l P r e -p r o o fThis finding is not surprising, and remains in line with evidence-based recommendations to dose adjust based on patient-specific factors for certain indications when clinically indicated.", [["FXaI", "CHEMICAL", 87, 91], ["bleeding", "DISEASE", 133, 141], ["patients", "ORGANISM", 35, 43], ["FXaI", "SIMPLE_CHEMICAL", 87, 91], ["patient", "ORGANISM", 284, 291], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 284, 291], ["inappropriately high-dose regimens", "TREATMENT", 49, 83], ["FXaI", "TREATMENT", 87, 91], ["major bleeding", "PROBLEM", 127, 141], ["a l P r e -p r o o fThis finding", "TEST", 152, 184], ["major", "OBSERVATION_MODIFIER", 127, 132], ["bleeding", "OBSERVATION", 133, 141]]], ["33J o u r n a l P r e -p r o o fIn the ANEXXA-4 trial, the median anti-Xa levels for patients taking apixaban and rivaroxaban were 149.7 ng/mL and 211.8 ng/mL, respectively.", [["apixaban", "CHEMICAL", 101, 109], ["rivaroxaban", "CHEMICAL", 114, 125], ["apixaban", "CHEMICAL", 101, 109], ["rivaroxaban", "CHEMICAL", 114, 125], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 66, 73], ["patients", "ORGANISM", 85, 93], ["apixaban", "SIMPLE_CHEMICAL", 101, 109], ["rivaroxaban", "SIMPLE_CHEMICAL", 114, 125], ["Xa", "PROTEIN", 71, 73], ["patients", "SPECIES", 85, 93], ["fIn the ANEXXA", "TEST", 31, 45], ["the median anti-Xa levels", "TREATMENT", 55, 80], ["apixaban", "TREATMENT", 101, 109], ["rivaroxaban", "TREATMENT", 114, 125]]], ["32 Our study found similar median FXaI levels, many of which may be considered as abnormally elevated given that our ranges are based on levels seen 2-4 hours after a dose and many patients presented with an unknown last dose of FXaI.", [["FXaI", "CHEMICAL", 229, 233], ["FXaI", "GENE_OR_GENE_PRODUCT", 34, 38], ["patients", "ORGANISM", 181, 189], ["FXaI", "GENE_OR_GENE_PRODUCT", 229, 233], ["FXaI", "PROTEIN", 34, 38], ["patients", "SPECIES", 181, 189], ["Our study", "TEST", 3, 12], ["similar median FXaI levels", "TEST", 19, 45], ["abnormally elevated", "PROBLEM", 82, 101], ["levels", "TEST", 137, 143], ["FXaI", "TREATMENT", 229, 233], ["may be considered", "UNCERTAINTY", 61, 78], ["abnormally", "OBSERVATION_MODIFIER", 82, 92], ["elevated", "OBSERVATION", 93, 101]]], ["Interestingly, the investigators of ANNEXA-4 did not demonstrate a correlation between anti-Xa activity reduction and hemostatic efficacy with receiver operator characteristic (ROC) curve analyses.", [["ANNEXA-4", "CHEMICAL", 36, 44], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 87, 94], ["Xa", "PROTEIN", 92, 94], ["anti-Xa activity reduction", "TREATMENT", 87, 113], ["curve analyses", "TEST", 182, 196]]], ["This is an important consideration, and although anti-Xa activity reduction may not be a strong predictor of clinical response to andexanet alfa, assessment of the extent of residual anticoagulation in patients treated with FXaI's may help guide the use of other reversal strategies.", [["andexanet", "CHEMICAL", 130, 139], ["FXaI", "CHEMICAL", 224, 228], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 49, 56], ["andexanet alfa", "SIMPLE_CHEMICAL", 130, 144], ["patients", "ORGANISM", 202, 210], ["Xa", "PROTEIN", 54, 56], ["andexanet alfa", "PROTEIN", 130, 144], ["patients", "SPECIES", 202, 210], ["anti-Xa activity reduction", "TREATMENT", 49, 75], ["andexanet alfa", "TREATMENT", 130, 144], ["assessment", "TEST", 146, 156], ["residual anticoagulation", "TREATMENT", 174, 198], ["FXaI's", "TREATMENT", 224, 230], ["other reversal strategies", "TREATMENT", 257, 282], ["important consideration", "UNCERTAINTY", 11, 34], ["residual", "OBSERVATION_MODIFIER", 174, 182], ["anticoagulation", "OBSERVATION", 183, 198]]], ["Furthermore, anti-Xa levels may be useful in guiding decisions for reversal of anticoagulation in emergent settings, especially in the absence of a complete history from a patient or when the last dose of drug is unknown and they have risk factors for drug accumulation.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 13, 20], ["patient", "ORGANISM", 172, 179], ["Xa", "PROTEIN", 18, 20], ["patient", "SPECIES", 172, 179], ["anti-Xa levels", "TEST", 13, 27], ["anticoagulation", "TREATMENT", 79, 94], ["drug", "TREATMENT", 205, 209], ["drug accumulation", "PROBLEM", 252, 269]]], ["9, 34 Given that andexanet alfa is not widely accessible across all institutions, it is vital to consider the role of other reversal strategies and agents including fresh frozen plasma, blood products, and 4F-PCC.", [["plasma", "ANATOMY", 178, 184], ["blood", "ANATOMY", 186, 191], ["andexanet", "CHEMICAL", 17, 26], ["andexanet alfa", "SIMPLE_CHEMICAL", 17, 31], ["plasma", "ORGANISM_SUBSTANCE", 178, 184], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["4F-PCC", "SIMPLE_CHEMICAL", 206, 212], ["4F", "PROTEIN", 206, 208], ["andexanet alfa", "TREATMENT", 17, 31], ["other reversal strategies", "TREATMENT", 118, 143], ["agents", "TREATMENT", 148, 154], ["fresh frozen plasma", "TREATMENT", 165, 184], ["blood products", "TREATMENT", 186, 200], ["4F-PCC", "TREATMENT", 206, 212]]], ["[35] [36] [37] Some comparative data between andexanet alfa and 4F-PCC are emerging, 36 The most common reasons for obtaining an anti-Xa level in our study were similar with reports from other centers [14] [15] [16] 41 and included new bleeding, prior to a surgical procedure, and prior to heparin or fibrinolytic therapy.", [["andexanet", "CHEMICAL", 45, 54], ["bleeding", "DISEASE", 236, 244], ["heparin", "CHEMICAL", 290, 297], ["[14] [15] [16] 41", "CHEMICAL", 201, 218], ["andexanet alfa", "SIMPLE_CHEMICAL", 45, 59], ["4F-PCC", "SIMPLE_CHEMICAL", 64, 70], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 129, 136], ["[14] [15] [16] 41", "SIMPLE_CHEMICAL", 201, 218], ["heparin", "SIMPLE_CHEMICAL", 290, 297], ["4F", "PROTEIN", 64, 66], ["Xa", "PROTEIN", 134, 136], ["andexanet alfa", "TREATMENT", 45, 59], ["an anti-Xa level", "TEST", 126, 142], ["our study", "TEST", 146, 155], ["new bleeding", "PROBLEM", 232, 244], ["a surgical procedure", "TREATMENT", 255, 275], ["heparin", "TREATMENT", 290, 297], ["fibrinolytic therapy", "TREATMENT", 301, 321], ["new", "OBSERVATION_MODIFIER", 232, 235], ["bleeding", "OBSERVATION", 236, 244]]], ["One study included 102 patients taking either apixaban or rivaroxaban examined anti-Xa levels prior to cardiac ablation.", [["cardiac", "ANATOMY", 103, 110], ["apixaban", "CHEMICAL", 46, 54], ["rivaroxaban", "CHEMICAL", 58, 69], ["apixaban", "CHEMICAL", 46, 54], ["rivaroxaban", "CHEMICAL", 58, 69], ["patients", "ORGANISM", 23, 31], ["apixaban", "SIMPLE_CHEMICAL", 46, 54], ["rivaroxaban", "SIMPLE_CHEMICAL", 58, 69], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 79, 86], ["cardiac", "ORGAN", 103, 110], ["Xa", "PROTEIN", 84, 86], ["patients", "SPECIES", 23, 31], ["One study", "TEST", 0, 9], ["apixaban", "TREATMENT", 46, 54], ["rivaroxaban", "TREATMENT", 58, 69], ["Xa levels", "TEST", 84, 93], ["cardiac ablation", "TREATMENT", 103, 119], ["cardiac", "ANATOMY", 103, 110], ["ablation", "OBSERVATION", 111, 119]]], ["The investigators found detectable plasma DOAC concentration (>30 ng/mL) measured 24 hours after the last intake in 51.3% of patients.", [["plasma", "ANATOMY", 35, 41], ["DOAC", "CHEMICAL", 42, 46], ["DOAC", "CHEMICAL", 42, 46], ["plasma", "ORGANISM_SUBSTANCE", 35, 41], ["DOAC", "SIMPLE_CHEMICAL", 42, 46], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["plasma DOAC concentration", "TREATMENT", 35, 60]]], ["42 In more severely ill patients, residual anticoagulation resulting from decreased drug clearance may have important implications, especially when transitioning patients to parenteral anticoagulants.", [["parenteral", "ANATOMY", 174, 184], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 162, 170], ["parenteral anticoagulants", "SIMPLE_CHEMICAL", 174, 199], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 162, 170], ["residual anticoagulation", "TREATMENT", 34, 58], ["decreased drug clearance", "PROBLEM", 74, 98], ["parenteral anticoagulants", "TREATMENT", 174, 199], ["severely", "OBSERVATION_MODIFIER", 11, 19], ["ill", "OBSERVATION_MODIFIER", 20, 23], ["residual", "OBSERVATION_MODIFIER", 34, 42], ["anticoagulation", "OBSERVATION", 43, 58], ["decreased", "OBSERVATION_MODIFIER", 74, 83]]], ["43 Anti-Xa levels were frequently utilized to assess for residual anticoagulation or potential drug accumulation in our study, and we similarly observed some patients with detectable anti-Xa levels beyond 24 hours after a dose, most often with concomitant renal impairment.", [["renal", "ANATOMY", 256, 261], ["renal impairment", "DISEASE", 256, 272], ["Anti-Xa", "GENE_OR_GENE_PRODUCT", 3, 10], ["patients", "ORGANISM", 158, 166], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 183, 190], ["renal", "ORGAN", 256, 261], ["Xa", "PROTEIN", 8, 10], ["Xa", "PROTEIN", 188, 190], ["patients", "SPECIES", 158, 166], ["Anti-Xa levels", "TEST", 3, 17], ["residual anticoagulation", "PROBLEM", 57, 81], ["potential drug accumulation", "PROBLEM", 85, 112], ["our study", "TEST", 116, 125], ["detectable anti-Xa levels", "PROBLEM", 172, 197], ["concomitant renal impairment", "PROBLEM", 244, 272], ["drug accumulation", "OBSERVATION", 95, 112], ["renal", "ANATOMY", 256, 261], ["impairment", "OBSERVATION", 262, 272]]], ["The addition of strong inhibitors of FXaI metabolism may warrant the checking of anti-Xa levels to assess drug exposure.", [["FXaI", "SIMPLE_CHEMICAL", 37, 41], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 81, 88], ["Xa", "PROTEIN", 86, 88], ["strong inhibitors", "TREATMENT", 16, 33], ["FXaI metabolism", "PROBLEM", 37, 52], ["anti-Xa levels", "TEST", 81, 95], ["drug exposure", "PROBLEM", 106, 119]]], ["This was evidenced in a study including 12 hospitalized patients being treated for novel coronavirus infection COVID-19, where lopinavir/ritonavir administration resulted in an average 6.14-fold increase in trough plasma concentrations of apixaban and rivaroxaban.", [["plasma", "ANATOMY", 214, 220], ["coronavirus infection", "DISEASE", 89, 110], ["lopinavir/ritonavir", "CHEMICAL", 127, 146], ["apixaban", "CHEMICAL", 239, 247], ["rivaroxaban", "CHEMICAL", 252, 263], ["lopinavir", "CHEMICAL", 127, 136], ["ritonavir", "CHEMICAL", 137, 146], ["apixaban", "CHEMICAL", 239, 247], ["rivaroxaban", "CHEMICAL", 252, 263], ["patients", "ORGANISM", 56, 64], ["coronavirus", "ORGANISM", 89, 100], ["lopinavir", "SIMPLE_CHEMICAL", 127, 136], ["ritonavir", "SIMPLE_CHEMICAL", 137, 146], ["plasma", "ORGANISM_SUBSTANCE", 214, 220], ["apixaban", "SIMPLE_CHEMICAL", 239, 247], ["rivaroxaban", "SIMPLE_CHEMICAL", 252, 263], ["patients", "SPECIES", 56, 64], ["a study", "TEST", 22, 29], ["novel coronavirus infection COVID", "PROBLEM", 83, 116], ["lopinavir/ritonavir administration", "TREATMENT", 127, 161], ["trough plasma concentrations", "TREATMENT", 207, 235], ["apixaban", "TREATMENT", 239, 247], ["rivaroxaban", "TREATMENT", 252, 263], ["coronavirus infection", "OBSERVATION", 89, 110]]], ["44 Our analysis did not show an association of potential drug interactions and adverse events, however overall exposure for unique drugs was low and impact of different dosing regimens was not assessed.", [["Our analysis", "TEST", 3, 15], ["potential drug interactions", "PROBLEM", 47, 74], ["adverse events", "PROBLEM", 79, 93], ["unique drugs", "TREATMENT", 124, 136], ["different dosing regimens", "TREATMENT", 159, 184]]], ["Further investigation is warranted into exploring the impact of drug interactions on adverse events on a larger scale.J o u r n a l P r e -p r o o fCurrently no guidelines endorse changes in therapy in response to anti-Xa levels for apixaban and rivaroxaban, however there were instances in our cohort where changes to FXaI therapy were in part due to an anti-Xa level in addition to the overall clinical context.", [["apixaban", "CHEMICAL", 233, 241], ["rivaroxaban", "CHEMICAL", 246, 257], ["FXaI", "CHEMICAL", 319, 323], ["apixaban", "CHEMICAL", 233, 241], ["rivaroxaban", "CHEMICAL", 246, 257], ["FXaI", "CHEMICAL", 319, 323], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 214, 221], ["apixaban", "SIMPLE_CHEMICAL", 233, 241], ["rivaroxaban", "SIMPLE_CHEMICAL", 246, 257], ["FXaI", "SIMPLE_CHEMICAL", 319, 323], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 355, 362], ["Xa", "PROTEIN", 219, 221], ["Xa", "PROTEIN", 360, 362], ["Further investigation", "TEST", 0, 21], ["drug interactions", "PROBLEM", 64, 81], ["adverse events", "PROBLEM", 85, 99], ["a larger scale", "TREATMENT", 103, 117], ["therapy", "TREATMENT", 191, 198], ["anti-Xa levels", "TREATMENT", 214, 228], ["apixaban", "TREATMENT", 233, 241], ["rivaroxaban", "TREATMENT", 246, 257], ["FXaI therapy", "TREATMENT", 319, 331], ["an anti-Xa level", "TEST", 352, 368]]], ["Our results for all anti-Xa levels following a documented dose of FXaI underscores the importance that peak levels have a large inter-patient variability, which may be partly due to differences in anti-Xa assays and reagents used across different laboratories.", [["FXaI", "CHEMICAL", 66, 70], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 20, 27], ["FXaI", "SIMPLE_CHEMICAL", 66, 70], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 197, 204], ["Xa", "PROTEIN", 25, 27], ["Xa", "PROTEIN", 202, 204], ["all anti-Xa levels", "TEST", 16, 34], ["FXaI", "TREATMENT", 66, 70], ["peak levels", "TEST", 103, 114], ["a large inter-patient variability", "PROBLEM", 120, 153], ["anti-Xa assays", "TEST", 197, 211], ["large", "OBSERVATION_MODIFIER", 122, 127], ["inter-patient variability", "OBSERVATION", 128, 153], ["may be partly due to", "UNCERTAINTY", 161, 181]]], ["Despite the fact that the expected level ranges currently utilized at our institution were derived from pharmacokinetic studies in healthy J o u r n a l P r e -p r o o f volunteers, growing evidence illustrates that in a real-world setting patient exhibit a wide range of levels after a given dose.", [["patient", "ORGANISM", 240, 247], ["patient", "SPECIES", 240, 247], ["pharmacokinetic studies", "TEST", 104, 127], ["volunteers", "PROBLEM", 170, 180], ["wide", "OBSERVATION_MODIFIER", 258, 262]]], ["For example, in a study of Korean patients, median peak levels for a 5 mg and 2.5 mg dose of apixaban were 202 ng/mL and 151 ng/mL, respectively.", [["apixaban", "CHEMICAL", 93, 101], ["apixaban", "CHEMICAL", 93, 101], ["patients", "ORGANISM", 34, 42], ["apixaban", "SIMPLE_CHEMICAL", 93, 101], ["patients", "SPECIES", 34, 42], ["median peak levels", "TEST", 44, 62], ["apixaban", "TREATMENT", 93, 101]]], ["18 The peak anti-Xa levels seen in our patients differed from those studies from which our expected level ranges were derived, highlighting the importance that hospitals may opt to develop and validate institution-specific ranges if anti-Xa levels are utilized on a consistent basis.J o u r n a l P r e -p r o o fThis study has several important limitations to consider, a major limitation being that anti-Xa testing was done in the clinical context of the patient, and not by randomization.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 12, 19], ["patients", "ORGANISM", 39, 47], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 233, 240], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 401, 408], ["patient", "ORGANISM", 457, 464], ["Xa", "PROTEIN", 17, 19], ["Xa", "PROTEIN", 238, 240], ["Xa", "PROTEIN", 406, 408], ["patients", "SPECIES", 39, 47], ["patient", "SPECIES", 457, 464], ["The peak anti-Xa levels", "TEST", 3, 26], ["those studies", "TEST", 62, 75], ["anti-Xa levels", "TEST", 233, 247], ["fThis study", "TEST", 312, 323], ["anti-Xa testing", "TEST", 401, 416]]], ["The decision to assess anti-Xa levels for specific FXaI was therefore patient-and provider-specific, and it is possible that routine anti-Xa testing in unselected patients may yield different results.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 23, 30], ["FXaI", "GENE_OR_GENE_PRODUCT", 51, 55], ["patient", "ORGANISM", 70, 77], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 133, 140], ["patients", "ORGANISM", 163, 171], ["Xa", "PROTEIN", 28, 30], ["FXaI", "PROTEIN", 51, 55], ["Xa", "PROTEIN", 138, 140], ["patient", "SPECIES", 70, 77], ["patients", "SPECIES", 163, 171], ["anti-Xa levels", "TEST", 23, 37], ["Xa testing", "TEST", 138, 148]]], ["Second, the inherent limitations of a retrospective cohort study cannot be ignored, and although outcomes and changes to therapy were carefully chart reviewed in an objective manner, there may have been other contributing factors that were not captured.", [["a retrospective cohort study", "TEST", 36, 64], ["therapy", "TREATMENT", 121, 128]]], ["Third, certain risk factors that may predispose patients to develop bleeding (i.e., history of prior bleeding, concomitant comorbidities, and bleeding risk calculator tools such as HAS-BLED scores) were not included in our baseline demographic information.", [["bleeding", "DISEASE", 68, 76], ["bleeding", "DISEASE", 101, 109], ["bleeding", "DISEASE", 142, 150], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["bleeding", "PROBLEM", 68, 76], ["prior bleeding", "PROBLEM", 95, 109], ["concomitant comorbidities", "PROBLEM", 111, 136], ["bleeding risk calculator tools", "PROBLEM", 142, 172], ["bleeding", "OBSERVATION", 68, 76]]], ["Therefore, it is uncertain how these risk factors may influence the odds of bleeding irrespective of corresponding anti-Xa levels within our patient population.", [["bleeding", "DISEASE", 76, 84], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 115, 122], ["patient", "ORGANISM", 141, 148], ["Xa", "PROTEIN", 120, 122], ["patient", "SPECIES", 141, 148], ["bleeding", "PROBLEM", 76, 84], ["Xa levels", "TEST", 120, 129], ["bleeding", "OBSERVATION", 76, 84]]], ["Additionally, the majority of anti-Xa levels obtained in this study would be considered peak or random levels based on the time that they were drawn.", [["anti-Xa", "GENE_OR_GENE_PRODUCT", 30, 37], ["Xa", "PROTEIN", 35, 37], ["anti-Xa levels", "TEST", 30, 44], ["this study", "TEST", 57, 67], ["random levels", "TEST", 96, 109]]], ["Therefore, we cannot make any observations regarding trough levels which have been described in other studies and may display less inter-patient variability.", [["trough levels", "TEST", 53, 66], ["other studies", "TEST", 96, 109]]], ["Lastly, the reported upper limit of our institution's anti-Xa assay for apixaban and rivaroxaban is 451 ng/mL and 472 ng/mL, respectively.", [["apixaban", "CHEMICAL", 72, 80], ["rivaroxaban", "CHEMICAL", 85, 96], ["apixaban", "CHEMICAL", 72, 80], ["rivaroxaban", "CHEMICAL", 85, 96], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 54, 61], ["apixaban", "SIMPLE_CHEMICAL", 72, 80], ["rivaroxaban", "SIMPLE_CHEMICAL", 85, 96], ["apixaban", "TREATMENT", 72, 80], ["rivaroxaban", "TREATMENT", 85, 96], ["upper limit", "OBSERVATION_MODIFIER", 21, 32]]], ["It is not typical practice at our institution to further dilute samples that exceed this upper limit, therefore the full extent of FXaI exposure may be underestimated in certain patients.J o u r n a l P r e -p r o o fJournal Pre-proofConclusionIn conclusion, this study captured FXaI-specific anti-Xa levels in patients taking apixaban and rivaroxaban who experienced a major bleeding event.", [["samples", "ANATOMY", 64, 71], ["FXaI", "CHEMICAL", 131, 135], ["apixaban", "CHEMICAL", 327, 335], ["rivaroxaban", "CHEMICAL", 340, 351], ["bleeding", "DISEASE", 376, 384], ["FXaI", "CHEMICAL", 131, 135], ["apixaban", "CHEMICAL", 327, 335], ["rivaroxaban", "CHEMICAL", 340, 351], ["upper", "ORGANISM_SUBDIVISION", 89, 94], ["FXaI", "GENE_OR_GENE_PRODUCT", 131, 135], ["patients", "ORGANISM", 178, 186], ["FXaI", "SIMPLE_CHEMICAL", 279, 283], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 293, 300], ["patients", "ORGANISM", 311, 319], ["apixaban", "SIMPLE_CHEMICAL", 327, 335], ["rivaroxaban", "SIMPLE_CHEMICAL", 340, 351], ["FXaI", "PROTEIN", 279, 283], ["Xa", "PROTEIN", 298, 300], ["patients", "SPECIES", 178, 186], ["patients", "SPECIES", 311, 319], ["further dilute samples", "TEST", 49, 71], ["FXaI exposure", "PROBLEM", 131, 144], ["this study", "TEST", 259, 269], ["FXaI", "TEST", 279, 283], ["Xa levels", "TEST", 298, 307], ["apixaban", "TREATMENT", 327, 335], ["rivaroxaban", "TREATMENT", 340, 351], ["a major bleeding event", "PROBLEM", 368, 390], ["upper limit", "OBSERVATION_MODIFIER", 89, 100], ["bleeding", "OBSERVATION", 376, 384]]], ["Both patients with and without major bleeding events exhibited levels that indicated circulating drug, however higher levels were not necessarily associated with increased odds of major bleeding within our cohort.", [["bleeding", "DISEASE", 37, 45], ["bleeding", "DISEASE", 186, 194], ["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["major bleeding events", "PROBLEM", 31, 52], ["circulating drug", "PROBLEM", 85, 101], ["higher levels", "PROBLEM", 111, 124], ["major bleeding", "PROBLEM", 180, 194], ["major", "OBSERVATION_MODIFIER", 180, 185], ["bleeding", "OBSERVATION", 186, 194]]], ["We did identify advanced age, inappropriately high dosing regimens, and modest peak anti-Xa rivaroxaban levels as being associated with major bleeding.", [["rivaroxaban", "CHEMICAL", 92, 103], ["bleeding", "DISEASE", 142, 150], ["rivaroxaban", "CHEMICAL", 92, 103], ["anti-Xa rivaroxaban", "GENE_OR_GENE_PRODUCT", 84, 103], ["inappropriately high dosing regimens", "TREATMENT", 30, 66], ["modest peak anti-Xa rivaroxaban levels", "TREATMENT", 72, 110], ["major bleeding", "PROBLEM", 136, 150], ["major", "OBSERVATION_MODIFIER", 136, 141], ["bleeding", "OBSERVATION", 142, 150]]], ["Management of selected patients with major bleeding events included the use of reversal agents such as 4F-PCC and andexanet alfa, and those who received a reversal agent tended to have higher anti-Xa levels than those who did not.", [["bleeding", "DISEASE", 43, 51], ["4F-PCC", "CHEMICAL", 103, 109], ["andexanet alfa", "CHEMICAL", 114, 128], ["4F-PCC", "CHEMICAL", 103, 109], ["patients", "ORGANISM", 23, 31], ["4F-PCC", "SIMPLE_CHEMICAL", 103, 109], ["andexanet alfa", "SIMPLE_CHEMICAL", 114, 128], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 192, 199], ["Xa", "PROTEIN", 197, 199], ["patients", "SPECIES", 23, 31], ["major bleeding events", "PROBLEM", 37, 58], ["reversal agents", "TREATMENT", 79, 94], ["4F-PCC", "TREATMENT", 103, 109], ["andexanet alfa", "TREATMENT", 114, 128], ["a reversal agent", "TREATMENT", 153, 169], ["bleeding", "OBSERVATION", 43, 51]]], ["The most common reason for obtaining anti-Xa levels seen in our cohort included confirmed or suspected bleeding, heparin or fibrinolysis clearance, and clearance for a procedure.", [["bleeding", "DISEASE", 103, 111], ["heparin", "CHEMICAL", 113, 120], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 37, 44], ["heparin", "SIMPLE_CHEMICAL", 113, 120], ["Xa", "PROTEIN", 42, 44], ["anti-Xa levels", "TEST", 37, 51], ["bleeding", "PROBLEM", 103, 111], ["heparin", "TREATMENT", 113, 120], ["fibrinolysis clearance", "TREATMENT", 124, 146], ["a procedure", "TREATMENT", 166, 177], ["bleeding", "OBSERVATION", 103, 111]]], ["While our study may highlight the utility of anti-Xa levels for apixaban and rivaroxaban in certain clinical situations including confirmed or suspected bleeding, clearance for heparin or fibrinolytic therapy, and prior to a surgical procedure, changes to FXaI therapy should always be made in the context of each patient and take into account other factors.", [["apixaban", "CHEMICAL", 64, 72], ["rivaroxaban", "CHEMICAL", 77, 88], ["bleeding", "DISEASE", 153, 161], ["heparin", "CHEMICAL", 177, 184], ["FXaI", "CHEMICAL", 256, 260], ["apixaban", "CHEMICAL", 64, 72], ["rivaroxaban", "CHEMICAL", 77, 88], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 45, 52], ["apixaban", "SIMPLE_CHEMICAL", 64, 72], ["rivaroxaban", "SIMPLE_CHEMICAL", 77, 88], ["heparin", "SIMPLE_CHEMICAL", 177, 184], ["FXaI", "SIMPLE_CHEMICAL", 256, 260], ["patient", "ORGANISM", 314, 321], ["patient", "SPECIES", 314, 321], ["our study", "TEST", 6, 15], ["anti-Xa levels", "TREATMENT", 45, 59], ["apixaban", "TREATMENT", 64, 72], ["rivaroxaban", "TREATMENT", 77, 88], ["bleeding", "PROBLEM", 153, 161], ["heparin", "TREATMENT", 177, 184], ["fibrinolytic therapy", "TREATMENT", 188, 208], ["a surgical procedure", "TREATMENT", 223, 243], ["FXaI therapy", "TREATMENT", 256, 268], ["bleeding", "OBSERVATION", 153, 161]]], ["J o u r n a l P r e -p r o o f A p ix a b a n 5 m g A p ix a b a n 2 .5 m g A 5 m g e x p e c te d r a n g e 2 .5 m g e x p e c te d r a n g e R iv a ro x a b a n 1 5 m g R iv a ro x a b a n 2 0 m g B 1 0 m g e x p e c te d r a n g e 2 0 m g e x p e c te d r a n g eConclusionThe peak anti-Xa levels in the above figure are following a documented dose of apixaban or rivaroxaban.", [["apixaban", "CHEMICAL", 355, 363], ["rivaroxaban", "CHEMICAL", 367, 378], ["apixaban", "CHEMICAL", 355, 363], ["rivaroxaban", "CHEMICAL", 367, 378], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 285, 292], ["apixaban", "SIMPLE_CHEMICAL", 355, 363], ["rivaroxaban", "SIMPLE_CHEMICAL", 367, 378], ["Xa", "PROTEIN", 290, 292], ["J", "TEST", 0, 1], ["ix", "TEST", 35, 37], ["ix", "TEST", 56, 58], ["A", "TEST", 76, 77], ["d", "TEST", 131, 132], ["a ro", "TEST", 176, 180], ["B", "TEST", 199, 200], ["g", "TEST", 207, 208], ["c", "TEST", 217, 218], ["te", "TEST", 219, 221], ["d", "TEST", 222, 223], ["e", "TEST", 232, 233], ["g e", "TEST", 240, 243], ["e c", "TEST", 248, 251], ["The peak anti", "TEST", 276, 289], ["Xa levels", "TEST", 290, 299], ["apixaban", "TREATMENT", 355, 363], ["rivaroxaban", "TREATMENT", 367, 378]]], ["The expected peak levels boxes refer to the expected anti-Xa levels seen 2-4 hours after a given dose of FXaI and are adopted from previously conducted studies.Conclusion\uf0b7 Quantification and assessment of anticoagulation can be accomplished with factor Xa inhibitor (FXaI) specific anti-Xa levels \uf0b7 Patients on oral FXaI who are elderly and have inappropriately high dosing regimens may be at an elevated risk for major bleeding \uf0b7 It remains to be determined if elevated anti-Xa levels for apixaban and rivaroxaban may confer a direct increased risk for bleeding in the absence of other factors \uf0b7 Anti-Xa levels may be useful in the inpatient setting for confirmed or suspected bleeding, clearance for parenteral anticoagulation, and prior to an emergent procedure J o u r n a l P r e -p r o o f Journal Pre-proof", [["oral", "ANATOMY", 311, 315], ["parenteral", "ANATOMY", 702, 712], ["FXaI", "CHEMICAL", 105, 109], ["bleeding", "DISEASE", 420, 428], ["apixaban", "CHEMICAL", 490, 498], ["rivaroxaban", "CHEMICAL", 503, 514], ["bleeding", "DISEASE", 554, 562], ["bleeding", "DISEASE", 678, 686], ["FXaI", "CHEMICAL", 105, 109], ["apixaban", "CHEMICAL", 490, 498], ["rivaroxaban", "CHEMICAL", 503, 514], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 53, 60], ["FXaI", "SIMPLE_CHEMICAL", 105, 109], ["factor Xa inhibitor", "GENE_OR_GENE_PRODUCT", 246, 265], ["FXaI", "SIMPLE_CHEMICAL", 267, 271], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 282, 289], ["Patients", "ORGANISM", 299, 307], ["oral", "ORGANISM_SUBDIVISION", 311, 315], ["anti-Xa", "GENE_OR_GENE_PRODUCT", 471, 478], ["apixaban", "SIMPLE_CHEMICAL", 490, 498], ["rivaroxaban", "SIMPLE_CHEMICAL", 503, 514], ["Anti-Xa", "GENE_OR_GENE_PRODUCT", 597, 604], ["Xa", "PROTEIN", 58, 60], ["Xa", "PROTEIN", 476, 478], ["Xa", "PROTEIN", 602, 604], ["Patients", "SPECIES", 299, 307], ["The expected peak levels boxes", "PROBLEM", 0, 30], ["Xa levels", "TEST", 58, 67], ["FXaI", "TREATMENT", 105, 109], ["previously conducted studies", "TEST", 131, 159], ["Quantification", "TEST", 172, 186], ["assessment", "TEST", 191, 201], ["anticoagulation", "TREATMENT", 205, 220], ["factor Xa inhibitor", "TREATMENT", 246, 265], ["specific anti-Xa levels", "TEST", 273, 296], ["oral FXaI", "TREATMENT", 311, 320], ["inappropriately high dosing regimens", "TREATMENT", 346, 382], ["an elevated risk", "PROBLEM", 393, 409], ["major bleeding", "PROBLEM", 414, 428], ["elevated anti-Xa levels", "PROBLEM", 462, 485], ["apixaban", "TREATMENT", 490, 498], ["rivaroxaban", "TREATMENT", 503, 514], ["bleeding", "PROBLEM", 554, 562], ["Anti-Xa levels", "TEST", 597, 611], ["bleeding", "PROBLEM", 678, 686], ["parenteral anticoagulation", "TREATMENT", 702, 728], ["an emergent procedure", "TREATMENT", 743, 764], ["bleeding", "OBSERVATION", 420, 428], ["bleeding", "OBSERVATION", 554, 562], ["bleeding", "OBSERVATION", 678, 686]]]], "5a6feb5681fada705e8116050a1811061c80688c": [["INTRODUCTIONCOVID-19 is an infection caused by the SARS-CoV-2 coronavirus [1] .", [["infection", "DISEASE", 27, 36], ["SARS-CoV-2 coronavirus", "ORGANISM", 51, 73], ["CoV-2 coronavirus", "SPECIES", 56, 73], ["SARS-CoV-2 coronavirus", "SPECIES", 51, 73], ["an infection", "PROBLEM", 24, 36], ["the SARS", "PROBLEM", 47, 55], ["infection", "OBSERVATION", 27, 36]]], ["On March 11, 2020 , WHO characterised the COVID-19 outbreak as a pandemic [1] .INTRODUCTIONWhile the majority of cases result in mild symptoms, some might progress to pneumonia, acute respiratory distress syndrome and death [4] , [5] , [6] .", [["respiratory", "ANATOMY", 184, 195], ["pneumonia", "DISEASE", 167, 176], ["acute respiratory distress syndrome", "DISEASE", 178, 213], ["death", "DISEASE", 218, 223], ["the COVID", "TEST", 38, 47], ["mild symptoms", "PROBLEM", 129, 142], ["pneumonia", "PROBLEM", 167, 176], ["acute respiratory distress syndrome", "PROBLEM", 178, 213], ["death", "PROBLEM", 218, 223], ["mild", "OBSERVATION_MODIFIER", 129, 133], ["symptoms", "OBSERVATION", 134, 142], ["pneumonia", "OBSERVATION", 167, 176], ["acute", "OBSERVATION_MODIFIER", 178, 183], ["respiratory distress", "OBSERVATION", 184, 204]]], ["In hospitalized patients it has been reported to be higher than 10% in some centres [8] .INTRODUCTIONVitamin C is one of the most commonly used interventions to treat respiratory infections, so the interest in testing its effects in the current pandemic is not surprising.", [["respiratory", "ANATOMY", 167, 178], ["respiratory infections", "DISEASE", 167, 189], [".INTRODUCTIONVitamin C", "CHEMICAL", 88, 110], ["patients", "ORGANISM", 16, 24], [".INTRODUCTIONVitamin C", "SIMPLE_CHEMICAL", 88, 110], ["patients", "SPECIES", 16, 24], ["interventions", "TREATMENT", 144, 157], ["respiratory infections", "PROBLEM", 167, 189], ["respiratory", "ANATOMY", 167, 178], ["infections", "OBSERVATION", 179, 189]]], ["The use of vitamin C began in the early 30s, and in the 70s it became widespread when the Nobel Prize winner, Linus Pauling, concluded that the use of vitamin C could relieve the common cold [9] .", [["vitamin C", "CHEMICAL", 11, 20], ["vitamin C", "CHEMICAL", 151, 160], ["vitamin C", "CHEMICAL", 11, 20], ["vitamin C", "CHEMICAL", 151, 160], ["vitamin C", "SIMPLE_CHEMICAL", 11, 20], ["vitamin C", "SIMPLE_CHEMICAL", 151, 160], ["vitamin C", "TREATMENT", 11, 20], ["vitamin C", "TREATMENT", 151, 160]]], ["Today, vitamin C is usually perceived as an effective, harmless and inexpensive therapeutic alternative.", [["vitamin C", "CHEMICAL", 7, 16], ["vitamin C", "CHEMICAL", 7, 16], ["vitamin C", "SIMPLE_CHEMICAL", 7, 16], ["vitamin C", "TREATMENT", 7, 16]]], ["It is thought to improve the functioning of the immune system through various means, such as increasing the activity of phagocytes and lymphocytes, improving the response of T lymphocytes and augmenting interferon levels [10] .INTRODUCTIONAlthough the evidence does not show that the intake of vitamin C translates into a clinically meaningful benefit on the treatment of respiratory infections [11] , a role in critical patients, mediated by several mechanisms, has also been proposed [12] .", [["immune system", "ANATOMY", 48, 61], ["phagocytes", "ANATOMY", 120, 130], ["lymphocytes", "ANATOMY", 135, 146], ["T lymphocytes", "ANATOMY", 174, 187], ["respiratory", "ANATOMY", 372, 383], ["vitamin C", "CHEMICAL", 294, 303], ["respiratory infections", "DISEASE", 372, 394], ["vitamin C", "CHEMICAL", 294, 303], ["immune system", "ANATOMICAL_SYSTEM", 48, 61], ["phagocytes", "CELL", 120, 130], ["lymphocytes", "CELL", 135, 146], ["T lymphocytes", "CELL", 174, 187], ["interferon", "GENE_OR_GENE_PRODUCT", 203, 213], ["vitamin C", "SIMPLE_CHEMICAL", 294, 303], ["patients", "ORGANISM", 421, 429], ["phagocytes", "CELL_TYPE", 120, 130], ["lymphocytes", "CELL_TYPE", 135, 146], ["T lymphocytes", "CELL_TYPE", 174, 187], ["interferon", "PROTEIN", 203, 213], ["patients", "SPECIES", 421, 429], ["lymphocytes", "PROBLEM", 135, 146], ["augmenting interferon levels", "TREATMENT", 192, 220], ["vitamin C", "TREATMENT", 294, 303], ["respiratory infections", "PROBLEM", 372, 394], ["respiratory", "ANATOMY", 372, 383], ["infections", "OBSERVATION", 384, 394]]], ["Hence, research addressing the effect of vitamin C specifically for COVID-19 would add valuable information [13] .INTRODUCTIONUsing innovative and agile processes, taking advantage of technological tools, and resorting to the collective effort of several research groups, this living systematic review aims to provide a timely, rigorous and continuously updated summary of the evidence available on the role of vitamin C in preventing infection or treating patients with COVID-19.INTRODUCTION3 .", [["vitamin C", "CHEMICAL", 41, 50], ["vitamin C", "CHEMICAL", 411, 420], ["infection", "DISEASE", 435, 444], ["vitamin C", "CHEMICAL", 41, 50], ["COVID-19", "CHEMICAL", 68, 76], ["vitamin C", "CHEMICAL", 411, 420], ["COVID-19", "CHEMICAL", 471, 479], ["vitamin C", "SIMPLE_CHEMICAL", 41, 50], ["vitamin C", "SIMPLE_CHEMICAL", 411, 420], ["patients", "ORGANISM", 457, 465], ["patients", "SPECIES", 457, 465], ["vitamin C", "TREATMENT", 41, 50], ["COVID", "TEST", 68, 73], ["vitamin C", "TREATMENT", 411, 420], ["infection", "PROBLEM", 435, 444], ["COVID", "TEST", 471, 476], ["infection", "OBSERVATION", 435, 444]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)INTRODUCTIONThe copyright holder for this preprint this version posted May 8, 2020.Protocol and registrationThis manuscript complies with the 'Preferred Reporting Items for Systematic reviews and Meta-Analyses' (PRISMA) guidelines for reporting systematic reviews and meta-analyses [14] .Protocol and registrationA protocol stating the shared objectives and methodology of multiple evidence syntheses (systematic reviews and overviews of systematic reviews) to be conducted in parallel for different questions relevant to COVID-19 was published elsewhere [15 ] .", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 214, 234], ["Protocol", "TREATMENT", 285, 293], ["Systematic reviews", "TEST", 375, 393], ["meta-analyses", "TEST", 470, 483], ["registrationA protocol", "TREATMENT", 503, 525], ["COVID", "TEST", 724, 729], ["med", "ANATOMY", 105, 108]]], ["This protocol was adapted to the specificities of the question assessed in this review and submitted to PROSPERO (awaiting ID allocation)Electronic searchesOur literature search was devised by the team maintaining the L\u00b7OVE platform ( https://app.iloveevidence.com ) , using the following approach:Electronic searches1.", [["This protocol", "TREATMENT", 0, 13]]], ["Identification of terms relevant to the population and intervention components of the search strategy, using Word2vec technology [16] to the corpus of documents available in Epistemonikos Database.Electronic searches2.", [["intervention components", "TREATMENT", 55, 78], ["searches2", "OBSERVATION", 208, 217]]], ["Creation of a sensitive boolean strategy encompassing all the relevant terms 4.", [["a sensitive boolean strategy", "TREATMENT", 12, 40]]], ["Iterative analysis of articles missed by the boolean strategy, and refinement of the strategy accordingly.Electronic searchesOur main search source will be Epistemonikos database ( https://www.epistemonikos.org ), a comprehensive database of systematic reviews and other types of evidence [ .", [["Iterative analysis", "TEST", 0, 18], ["the boolean strategy", "TREATMENT", 41, 61], ["systematic reviews", "TEST", 242, 260]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Electronic searchesThe copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 221, 241], ["med", "ANATOMY", 105, 108]]], ["28.20083360 doi: medRxiv preprint Vitamin C for the treatment of COVID-19: A living systematic review The searches will cover from the inception date of each database until the day before submission.", [["Vitamin C", "CHEMICAL", 34, 43], ["Vitamin C", "CHEMICAL", 34, 43], ["COVID-19", "CHEMICAL", 65, 73], ["Vitamin C", "SIMPLE_CHEMICAL", 34, 43], ["medRxiv preprint Vitamin C", "TREATMENT", 17, 43]]], ["No study design, publication status or language restriction will be applied to the searches in Epistemonikos or the additional searches.Electronic searchesThe following strategy will be used to search in Epistemonikos Database.", [["study design", "TEST", 3, 15], ["language restriction", "TREATMENT", 39, 59]]], ["We will adapt it to the syntax of other databases.Electronic searches(coronavir* OR coronovirus* OR \"corona virus\" OR \"virus corona\" OR \"corono virus\" OR \"virus corono\" OR hcov* OR \"covid-19\" OR covid19* OR \"covid 19\" OR \"2019-nCoV\" OR cv19* OR \"cv-19\" OR \"cv 19\" OR \"n-cov\" OR ncov* OR \"sars-cov-2\" OR \"sars-cov2\" OR (wuhan* AND (virus OR viruses OR viral) OR coronav AND (virus OR viruses OR viral)) OR \"sars-cov\" OR \"sars cov\" OR \"sars-coronavirus\" OR \"severe acute respiratory syndrome\" OR \"mers-cov\" OR \"mers cov\" OR \"middle east respiratory syndrome\" OR \"middle-east respiratory syndrome\" OR \"covid-19-related\" OR \"SARS-CoV-2-related\" OR \"SARS-CoV2-related\" OR \"2019-nCoV-related\" OR \"cv-19-related\" OR \"n-cov-related\") AND ((\"vitamin c\" OR \"vit c\" OR \"vitamin-c\" OR \"vitamins c\" OR ascorb* OR \"l-ascorbic\"))Other sourcesIn order to identify articles that might have been missed in the el ectronic searches, we will do the following:Other sources1.", [["acute respiratory syndrome", "DISEASE", 463, 489], ["respiratory syndrome", "DISEASE", 535, 555], ["middle-east respiratory syndrome", "DISEASE", 561, 593], ["SARS", "DISEASE", 621, 625], ["SARS", "DISEASE", 645, 649], ["vitamin", "CHEMICAL", 733, 740], ["vitamin", "CHEMICAL", 759, 766], ["vitamin c", "CHEMICAL", 733, 742], ["vitamin-c", "CHEMICAL", 759, 768], ["vitamin c", "SIMPLE_CHEMICAL", 733, 742], ["vitamin-c", "SIMPLE_CHEMICAL", 759, 768], ["vitamins", "SIMPLE_CHEMICAL", 774, 782], ["coronavir* OR coronovirus* OR \"corona virus\" OR \"virus corona\" OR \"corono virus\" OR \"virus corono\" OR hcov* OR \"covid-19", "SPECIES", 70, 190], ["coronavirus\" OR \"severe acute respiratory syndrome\" OR \"mers-cov\" OR \"mers cov\" OR \"middle east respiratory syndrome\" OR \"middle-east respiratory syndrome\" OR \"covid-19", "SPECIES", 439, 607], ["corona virus", "PROBLEM", 101, 113], ["cv", "TEST", 246, 248], ["cv", "TEST", 257, 259], ["sars", "TEST", 288, 292], ["cov", "TEST", 293, 296], ["sars", "TEST", 304, 308], ["viruses", "PROBLEM", 340, 347], ["viral)", "TEST", 351, 357], ["coronav AND (virus", "PROBLEM", 361, 379], ["sars", "PROBLEM", 406, 410], ["sars", "PROBLEM", 434, 438], ["severe acute respiratory syndrome", "PROBLEM", 456, 489], ["middle east respiratory syndrome\"", "PROBLEM", 523, 556], ["east respiratory syndrome", "PROBLEM", 568, 593], ["SARS", "PROBLEM", 621, 625], ["SARS", "PROBLEM", 645, 649], ["vitamin c\"", "TREATMENT", 733, 743], ["vit c\"", "TREATMENT", 748, 754], ["vitamin-c\"", "TREATMENT", 759, 769], ["vitamins", "TREATMENT", 774, 782], ["severe", "OBSERVATION_MODIFIER", 456, 462], ["acute", "OBSERVATION_MODIFIER", 463, 468], ["respiratory syndrome", "OBSERVATION", 469, 489], ["middle", "ANATOMY_MODIFIER", 523, 529], ["respiratory syndrome", "OBSERVATION", 535, 555], ["middle", "ANATOMY_MODIFIER", 561, 567], ["respiratory syndrome", "OBSERVATION", 573, 593]]], ["Screen the reference lists of other systematic reviews, and evaluate in full text all the articles they include.Other sources2.", [["other systematic reviews", "TEST", 30, 54]]], ["Scan the reference lists of selected guidelines, narrative reviews and other documents.", [["Scan", "TEST", 0, 4]]], ["Conduct cross-citation search in Google Scholar and Microsoft Academic, using each included study as the index reference.", [["study", "TEST", 92, 97]]], ["Review websites specialised in COVID-19.", [["COVID-19", "DNA", 31, 39]]], ["Email the contact authors of all the included studies to ask for additional publications or data on their studies, and for other studies in the topic.", [["their studies", "TEST", 100, 113], ["other studies", "TEST", 123, 136]]], ["Review the reference list of each included study.5.", [["study", "TEST", 43, 48]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["28.20083360 doi: medRxiv preprintTypes of studiesWe will preferentially include randomised trials.", [["studies", "TEST", 42, 49], ["randomised trials", "TREATMENT", 80, 97]]], ["However, information from non-randomised studies will be used if there is no direct evidence from randomised trials or the certainty of evidence for the critical outcomes resulting from the randomised trials is graded as low-or very low, and the certainty provided by the non-randomised evidence grades higher than the one provided by the randomised evidence [19] .Types of studiesWe will exclude studies evaluating the effects on animal models or in vitro conditions.Types of participantsWe will include trials assessing participants with COVID-19, as defined by the authors of the trials.", [["participants", "ORGANISM", 477, 489], ["participants", "SPECIES", 477, 489], ["participants", "SPECIES", 522, 534], ["non-randomised studies", "TEST", 26, 48], ["randomised trials", "TREATMENT", 98, 115], ["the randomised trials", "TEST", 186, 207], ["studies", "TEST", 374, 381], ["studies", "TEST", 397, 404], ["higher", "OBSERVATION_MODIFIER", 303, 309]]], ["Whenever we find substantial clinical heterogeneity on how the condition was defined, we will explore it using a sensitivity analysis.Types of participantsIn case we find no direct evidence from randomised trials, or if the evidence from randomised trials provides low-or very low-certainty evidence for critical outcomes, we will include information from randomised trials evaluating vitamin C administration in other coronavirus infections, such as MERS-CoV or SARS-CoV infections [19] .Type of interventionsThe intervention of interest is vitamin C. We will not restrict our criteria to any dosage, duration, timing or route of administration.Type of interventionsThe comparison of interest will be placebo (intervention plus optimal treatment versus placebo plus optimal treatment) or no treatment plus optimal treatment versus optimal treatment.", [["vitamin C", "CHEMICAL", 385, 394], ["coronavirus infections", "DISEASE", 419, 441], ["SARS-CoV infections", "DISEASE", 463, 482], ["vitamin C.", "CHEMICAL", 542, 552], ["vitamin C", "CHEMICAL", 385, 394], ["vitamin C.", "CHEMICAL", 542, 552], ["participants", "ORGANISM", 143, 155], ["vitamin C", "SIMPLE_CHEMICAL", 385, 394], ["coronavirus", "ORGANISM", 419, 430], ["MERS-CoV", "ORGANISM", 451, 459], ["SARS-CoV", "ORGANISM", 463, 471], ["vitamin", "SIMPLE_CHEMICAL", 542, 549], ["participants", "SPECIES", 143, 155], ["MERS-CoV", "SPECIES", 451, 459], ["SARS-CoV", "SPECIES", 463, 471], ["a sensitivity analysis", "TEST", 111, 133], ["randomised trials", "TREATMENT", 195, 212], ["randomised trials", "TEST", 238, 255], ["randomised trials", "TREATMENT", 356, 373], ["vitamin C administration", "TREATMENT", 385, 409], ["other coronavirus infections", "PROBLEM", 413, 441], ["SARS", "PROBLEM", 463, 467], ["CoV infections", "PROBLEM", 468, 482], ["Type of interventions", "TREATMENT", 489, 510], ["vitamin C.", "TREATMENT", 542, 552], ["Type of interventions", "TREATMENT", 646, 667], ["placebo (intervention", "TREATMENT", 702, 723], ["optimal treatment", "TREATMENT", 729, 746], ["placebo", "TREATMENT", 754, 761], ["optimal treatment", "TREATMENT", 767, 784], ["treatment", "TREATMENT", 792, 801], ["optimal treatment", "TREATMENT", 807, 824], ["optimal treatment", "TREATMENT", 832, 849], ["substantial", "OBSERVATION_MODIFIER", 17, 28]]], ["Trials assessing vitamin C plus other drugs will be eligible if the cointerventions are identical in both intervention and comparison groups.Type of interventionsTrials evaluating vitamin C in combination with other active drugs versus placebo or no treatment will be also included.Type of outcomesWe will not use the outcomes as an inclusion criteria during the selection process.", [["vitamin C", "CHEMICAL", 17, 26], ["vitamin C", "CHEMICAL", 180, 189], ["vitamin C", "CHEMICAL", 17, 26], ["vitamin C", "CHEMICAL", 180, 189], ["vitamin C", "SIMPLE_CHEMICAL", 17, 26], ["vitamin C", "SIMPLE_CHEMICAL", 180, 189], ["vitamin C", "TREATMENT", 17, 26], ["other drugs", "TREATMENT", 32, 43], ["Type of interventions", "TREATMENT", 141, 162], ["vitamin C", "TREATMENT", 180, 189], ["other active drugs", "TREATMENT", 210, 228], ["placebo", "TREATMENT", 236, 243], ["treatment", "TREATMENT", 250, 259]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["Primary and secondary outcomes will be presented in the GRADE 'Summary of Findings' tables, and a table with all the outcomes will be presented as an appendix [22] .Selection of studiesThe results of the literature search in Epistemonikos database will be automatically incorporated into the L\u00b7OVE platform (automated retrieval), where they will be de-duplicated by an algorithm comparing unique identifiers (database ID, DOI, trial registry ID), and citation details (i.e. author names, journal, year of publication, volume, number, pages, article title and article abstract).Selection of studiesThe additional searches will be uploaded to the screening software Collaboratron\u2122 [23] .Selection of studiesIn both L\u00b7OVE platform and Collaboratron\u2122, two researchers will independently screen the titles and abstracts yielded by the search against the inclusion criteria.", [["Selection of studies", "TEST", 165, 185], ["Selection of studies", "TEST", 577, 597], ["Selection of studies", "TEST", 685, 705], ["appendix", "ANATOMY", 150, 158]]], ["We will obtain the full reports for all titles that appear to meet the inclusion criteria or require further analysis to decide about their inclusion.Selection of studiesWe will record the reasons for excluding trials in any stage of the search and outline the study selection process in a PRISMA flow diagram adapted for the purpose of this project .Selection of studies7 .", [["further analysis", "TEST", 101, 117], ["Selection of studies", "TEST", 150, 170], ["trials", "TREATMENT", 211, 217], ["a PRISMA flow diagram", "TEST", 288, 309], ["Selection of studies7", "TEST", 351, 372]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020.Extraction and management of dataUsing standardised forms, two reviewers will independently extract data from each included study.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["Extraction", "TREATMENT", 272, 282], ["study", "TEST", 396, 401], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["We will collect the following information: study design, setting, participant characteristics (including disease severity and age) and study eligibility criteria; details about the administered intervention and comparison, including dose and therapeutic scheme, duration, timing (i.e. time after diagnosis) and route of administration; the outcomes assessed and the time they were measured; the source of funding of the study and the conflicts of interest disclosed by the investigators; the risk of bias assessment for each individual study.Extraction and management of dataWe will resolve disagreements by discussion, and one arbiter will adjudicate unresolved disagreements.Risk of bias assessmentThe risk of bias for each randomised trial will be assessed using a 'risk of bias' tool (RoB 2.0: a revised tool to assess risk of bias in randomised trials) [24] .", [["the administered intervention", "TREATMENT", 177, 206], ["administration", "TREATMENT", 320, 334], ["the study", "TEST", 416, 425], ["bias assessment", "TEST", 500, 515], ["each individual study", "TEST", 520, 541], ["Extraction", "TREATMENT", 542, 552], ["management", "TREATMENT", 557, 567], ["bias assessment", "TEST", 685, 700], ["each randomised trial", "TREATMENT", 721, 742], ["bias in randomised trials", "TREATMENT", 831, 856], ["bias", "OBSERVATION", 685, 689]]], ["We will consider the effect of assignment to the intervention for this review.", [["this review", "TEST", 66, 77]]], ["These five domains are: bias due to (1) the randomisation process, (2) deviations from intended interventions (effects of assignment to interventions at baseline), (3) missing outcome data, (4) measurement of the outcome, and (5) selection of reported results.", [["the randomisation process", "PROBLEM", 40, 65], ["intended interventions", "TREATMENT", 87, 109], ["interventions", "TREATMENT", 136, 149]]], ["Answers to signalling questions and supporting information will lead to a domain-level judgement in the form of 'Low risk of bias', 'Some concerns', or 'High risk of bias'.", [["a domain-level judgement", "TREATMENT", 72, 96]]], ["We will assess the risks of bias of other study designs with the ROBINS-I tool (ROBINS-I: Risk Of Bias In Non-randomised Studies of Interventions) [25] .", [["other study", "TEST", 36, 47]]], ["We will assess the following domains: bias due to confounding, bias in selection of participants into the study, bias in classification of interventions, bias due to deviations from intended interventions (effect of assignment to intervention), bias due to missing data, bias in measurement of outcomes and bias in the selection of the reported result.", [["participants", "SPECIES", 84, 96], ["the study", "TEST", 102, 111], ["interventions", "TREATMENT", 139, 152], ["deviations", "PROBLEM", 166, 176], ["intended interventions", "TREATMENT", 182, 204], ["intervention", "TREATMENT", 230, 242], ["missing data", "PROBLEM", 257, 269]]], ["We will not consider time-varying confounding, as these confounders are not relevant in this setting [25] .Risk of bias assessmentWe will consider the following factors as baseline potential confounders:Risk of bias assessment\u2022 Age \u2022 Comorbidities (e.g. cardiovascular disease, renal disease, eye disease, liver disease) 8 .", [["cardiovascular", "ANATOMY", 254, 268], ["renal", "ANATOMY", 278, 283], ["eye", "ANATOMY", 293, 296], ["liver", "ANATOMY", 306, 311], ["cardiovascular disease, renal disease, eye disease", "DISEASE", 254, 304], ["liver disease", "DISEASE", 306, 319], ["renal", "ORGAN", 278, 283], ["eye", "ORGAN", 293, 296], ["liver", "ORGAN", 306, 311], ["bias assessment", "TEST", 115, 130], ["bias assessment", "TEST", 211, 226], ["Comorbidities (e.g. cardiovascular disease", "PROBLEM", 234, 276], ["renal disease", "PROBLEM", 278, 291], ["eye disease", "PROBLEM", 293, 304], ["liver disease)", "PROBLEM", 306, 320], ["bias", "OBSERVATION", 115, 119], ["renal", "ANATOMY", 278, 283], ["disease", "OBSERVATION", 284, 291], ["eye", "ANATOMY", 293, 296], ["disease", "OBSERVATION", 297, 304], ["liver", "ANATOMY", 306, 311], ["disease", "OBSERVATION", 312, 319]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["28.20083360 doi: medRxiv preprint \u2022 Co-interventions \u2022 Severity, as defined by the authors (i.e respiratory failure vs respiratory distress syndrome vs ICU requirement).Measures of treatment effectFor dichotomous outcomes, we will express the estimate of treatment effect of an intervention as risk ratios (RR) or odds ratios (OR) along with 95% confidence intervals (CI).Measures of treatment effectFor continuous outcomes, we will use mean difference and standard deviation (SD) to summarise the data using a 95% CI.", [["respiratory failure", "DISEASE", 96, 115], ["respiratory distress syndrome", "DISEASE", 119, 148], ["respiratory failure", "PROBLEM", 96, 115], ["respiratory distress syndrome", "PROBLEM", 119, 148], ["ICU requirement", "PROBLEM", 152, 167], ["an intervention", "TREATMENT", 275, 290], ["risk ratios", "TEST", 294, 305], ["RR", "TEST", 307, 309], ["CI", "TEST", 368, 370], ["mean difference", "PROBLEM", 437, 452], ["respiratory failure", "OBSERVATION", 96, 115], ["respiratory distress", "OBSERVATION", 119, 139]]], ["Whenever continuous outcomes are measured using different scales, the treatment effect will be expressed as a standardised mean difference (SMD) with 95% CI.", [["different scales", "TREATMENT", 48, 64]]], ["When possible, we will multiply the SMD by a standard deviation that is representative from the pooled studies, for example, the SD from a well-known scale used by several of the studies included in the analysis on which the result is based.", [["SD", "DISEASE", 129, 131], ["the pooled studies", "TEST", 92, 110], ["the studies", "TEST", 175, 186], ["the analysis", "TEST", 199, 211]]], ["In cases where the minimally important difference (MID) is known, we will also present continuous outcomes as MID units or inform the results as the difference in the proportion of patients achieving a minimal important effect between intervention and control [26] .", [["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 181, 189], ["MID units", "TREATMENT", 110, 119], ["intervention and control", "TREATMENT", 235, 259], ["minimally", "OBSERVATION_MODIFIER", 19, 28]]], ["Then, these results will be displayed on the 'Summary of Findings Table' as mean difference [26] .Strategy for data synthesisIf we include more than one trial we will conduct meta-analysis for studies clinically homogeneous using RevMan 5 [27] , using the inverse variance method with random effects model.", [["data synthesis", "TEST", 111, 125], ["studies", "TEST", 193, 200], ["the inverse variance method", "TREATMENT", 252, 279], ["random effects model", "TREATMENT", 285, 305]]], ["For any outcomes where data are insufficient to calculate an effect estimate, a narrative synthesis will be presented.Subgroup and sensitivity analysisWe will perform subgroup analysis according to the definition of severe COVID-19 infection (i.e respiratory failure vs respiratory distress syndrome vs ICU requirement).", [["respiratory", "ANATOMY", 247, 258], ["respiratory", "ANATOMY", 270, 281], ["infection", "DISEASE", 232, 241], ["respiratory failure", "DISEASE", 247, 266], ["respiratory distress syndrome", "DISEASE", 270, 299], ["a narrative synthesis", "TREATMENT", 78, 99], ["subgroup analysis", "TEST", 167, 184], ["severe COVID-19 infection", "PROBLEM", 216, 241], ["respiratory failure", "PROBLEM", 247, 266], ["respiratory distress syndrome", "PROBLEM", 270, 299], ["ICU requirement", "PROBLEM", 303, 318], ["severe", "OBSERVATION_MODIFIER", 216, 222], ["infection", "OBSERVATION", 232, 241], ["respiratory failure", "OBSERVATION", 247, 266], ["respiratory distress", "OBSERVATION", 270, 290]]], ["In case we identify significant differences between subgroups (test for interaction <0.05) we will report the results of individual subgroups separately.Subgroup and sensitivity analysisWe will perform sensitivity analysis excluding high risk of bias studies, and if non-randomised studies are used, excluding studies that did not report adjusted estimates.", [["sensitivity analysis", "TEST", 202, 222], ["bias studies", "TEST", 246, 258], ["non-randomised studies", "TEST", 267, 289], ["significant", "OBSERVATION_MODIFIER", 20, 31]]], ["In cases where the primary analysis effect estimates and the sensitivity analysis effect estimates significantly differ we will either present the low risk of bias -adjusted sensitivity analysis estimates -or present the primary analysis estimates but downgrading the certainty of the evidence because of risk of bias.9.", [["the sensitivity analysis", "TEST", 57, 81], ["the primary analysis", "TEST", 217, 237]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["28.20083360 doi: medRxiv preprintAssessment of certainty of evidenceThe certainty of the evidence for all outcomes will be judged using the Grading of Recommendations Assessment, Development and Evaluation working group methodology (GRADE Working Group) [28] , across the domains of risk of bias, consistency, directness, precision and reporting bias.", [["Evaluation", "TEST", 195, 205]]], ["Certainty will be adjudicated as high, moderate, low or very low.", [["moderate, low or very low", "PROBLEM", 39, 64], ["moderate", "OBSERVATION_MODIFIER", 39, 47], ["low", "OBSERVATION_MODIFIER", 49, 52]]], ["A SoF table with all the comparisons and outcomes will be presented as an appendix.Living evidence synthesisAn artificial intelligence algorithm deployed in the Coronavirus/COVID-19 topic of the L\u00b7OVE platform ( https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d ) will provide instant notification of articles with a high likelihood to be eligible.", [["SoF table", "DNA", 2, 11], ["appendix", "ANATOMY", 74, 82]]], ["We will consider resubmission to a journal if there is a change in the direction of the effect on the critical outcomes or a substantial modification to the certainty of the evidence.", [["substantial", "OBSERVATION_MODIFIER", 125, 136], ["modification", "OBSERVATION", 137, 149]]], ["This review is part of a larger project set up to produce multiple parallel systematic reviews relevant to COVID-19 [ 15 ] .10.", [["COVID-19 [ 15 ] .10", "DNA", 107, 126], ["COVID", "TEST", 107, 112]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 201, 221], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 105, 108]]], ["28.20083360 doi: medRxiv preprint Roles and contributions GR conceived the common protocol for all the reviews being conducted by the COVID-19 L\u00b7OVE Working Group.", [["GR", "GENE_OR_GENE_PRODUCT", 58, 60], ["GR", "PROTEIN", 58, 60]]], ["GR drafted the manuscript, and all other authors contributed to it.", [["GR", "GENE_OR_GENE_PRODUCT", 0, 2], ["GR", "PROTEIN", 0, 2]]], ["The corresponding author is the guarantor and declares that all authors meet authorship criteria and that no other authors meeting the criteria have been omitted.(which was not certified by peer review)The COVID-19 L\u00b7OVE Working Group was created by Epistemonikos and a number of expert teams in order to provide decision makers with the best evidence related to COVID-19.", [["COVID-19", "CHEMICAL", 363, 371], ["COVID-19", "DNA", 363, 371], ["The COVID", "TEST", 202, 211], ["COVID", "TEST", 363, 368]]], ["There are no other relationships or activities that could have influenced the submitted work.FundingThis project was not commissioned by any organisation and did not receive external funding.", [["external funding", "TREATMENT", 174, 190], ["no", "UNCERTAINTY", 10, 12]]], ["Epistemonikos Foundation is providing training, support and tools at no cost for all the members of the COVID-19 L\u00b7OVE Working Group.PROSPERO registrationThis protocol has been submitted (awaiting PROSPERO ID allocation).EthicsAs researchers will not access information that could lead to the identification of an individual participant, obtaining ethical approval was waived.Data sharingAll data related to the project will be available.", [["PROSPERO registration", "TREATMENT", 133, 154], ["This protocol", "TREATMENT", 154, 167], ["All data", "TEST", 388, 396]]], ["CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)11The copyright holder for this preprint this version posted May 8, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["ND", "PROBLEM", 9, 11], ["med", "ANATOMY", 105, 108]]]], "9cd6f7eef808b5362ce36f7b92a50cb28238136c": [["INTRODUCTIONPorcine epidemic diarrhea virus (PEDV) causes severe enteritis, watery diarrhea, vomiting, dehydration, and even death in suckling piglets.", [["diarrhea", "DISEASE", 29, 37], ["enteritis", "DISEASE", 65, 74], ["watery diarrhea", "DISEASE", 76, 91], ["vomiting", "DISEASE", 93, 101], ["dehydration", "DISEASE", 103, 114], ["death", "DISEASE", 125, 130], ["INTRODUCTIONPorcine epidemic diarrhea virus", "ORGANISM", 0, 43], ["piglets", "ORGANISM", 143, 150], ["diarrhea virus", "SPECIES", 29, 43], ["piglets", "SPECIES", 143, 150], ["INTRODUCTIONPorcine epidemic diarrhea virus", "SPECIES", 0, 43], ["PEDV", "SPECIES", 45, 49], ["INTRODUCTIONPorcine epidemic diarrhea virus (PEDV", "PROBLEM", 0, 49], ["severe enteritis", "PROBLEM", 58, 74], ["watery diarrhea", "PROBLEM", 76, 91], ["vomiting", "PROBLEM", 93, 101], ["dehydration", "PROBLEM", 103, 114], ["even death in suckling piglets", "PROBLEM", 120, 150], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["enteritis", "OBSERVATION", 65, 74], ["watery", "OBSERVATION_MODIFIER", 76, 82], ["diarrhea", "OBSERVATION", 83, 91]]], ["Subsequently, the virus affected many countries such as the Czech Republic, Belgium, Hungary, South Korea, Italy, and Thailand (Song and Park, 2012) .", [["the virus", "PROBLEM", 14, 23], ["virus", "OBSERVATION", 18, 23]]], ["Since 2010, a large-scale outbreak of PEDV has occurred in swine herds around China.", [["PEDV", "CHEMICAL", 38, 42], ["PEDV", "ORGANISM", 38, 42], ["swine", "SPECIES", 59, 64], ["PEDV", "SPECIES", 38, 42], ["swine", "SPECIES", 59, 64], ["PEDV", "PROBLEM", 38, 42], ["large", "OBSERVATION_MODIFIER", 14, 19], ["-scale", "OBSERVATION_MODIFIER", 19, 25], ["PEDV", "OBSERVATION", 38, 42]]], ["Then, the emergence of PEDV occurred in Ohio in the United States in 2013, which spread throughout the United States .", [["PEDV", "CHEMICAL", 23, 27], ["PEDV", "ORGANISM", 23, 27], ["PEDV", "SPECIES", 23, 27], ["PEDV", "PROBLEM", 23, 27], ["PEDV", "OBSERVATION", 23, 27]]], ["Currently, due to lack of effective vaccines, isolation and identification of new PEDV strains to develop appropriate vaccines for prevention and control of the disease have garnered great interest.INTRODUCTIONPEDV belongs to the genus Alphacoronavirus within the Coronaviridae family (Brian and Baric, 2005) .", [["PEDV strains", "ORGANISM", 82, 94], ["PEDV", "SPECIES", 82, 86], ["effective vaccines", "TREATMENT", 26, 44], ["isolation", "TREATMENT", 46, 55], ["new PEDV strains", "PROBLEM", 78, 94], ["appropriate vaccines", "TREATMENT", 106, 126], ["the disease", "PROBLEM", 157, 168]]], ["Its genome size is about 28 kb, and it possesses at least seven open reading frames (ORF): ORF1a, ORF1b, spike (S), ORF3, envelope (E), membrane (M), and nucleocapsid (N).", [["membrane", "ANATOMY", 136, 144], ["ORF1a", "GENE_OR_GENE_PRODUCT", 91, 96], ["ORF1b", "GENE_OR_GENE_PRODUCT", 98, 103], ["spike (S)", "GENE_OR_GENE_PRODUCT", 105, 114], ["ORF3, envelope (E)", "GENE_OR_GENE_PRODUCT", 116, 134], ["membrane", "CELLULAR_COMPONENT", 136, 144], ["open reading frames", "DNA", 64, 83], ["ORF", "DNA", 85, 88], ["ORF1a", "DNA", 91, 96], ["ORF1b", "DNA", 98, 103], ["spike", "DNA", 105, 110], ["S", "DNA", 112, 113], ["ORF3", "DNA", 116, 120], ["E", "DNA", 132, 133], ["ORF1a", "TEST", 91, 96], ["spike", "PROBLEM", 105, 110], ["ORF3", "PROBLEM", 116, 120], ["size", "OBSERVATION_MODIFIER", 11, 15], ["28 kb", "OBSERVATION_MODIFIER", 25, 30]]], ["PEDV S protein plays a critical role in inducing neutralization antibodies, specific receptor binding, and membrane fusion.", [["membrane", "ANATOMY", 107, 115], ["PEDV S", "GENE_OR_GENE_PRODUCT", 0, 6], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["PEDV S protein", "PROTEIN", 0, 14], ["neutralization antibodies", "PROTEIN", 49, 74], ["PEDV", "SPECIES", 0, 4], ["inducing neutralization antibodies", "PROBLEM", 40, 74], ["specific receptor binding", "PROBLEM", 76, 101], ["membrane fusion", "TREATMENT", 107, 122], ["membrane fusion", "OBSERVATION", 107, 122]]], ["In addition, the S gene has shown a high degree of genetic variability.", [["S gene", "DNA", 17, 23], ["a high degree of genetic variability", "PROBLEM", 34, 70], ["high degree", "OBSERVATION_MODIFIER", 36, 47], ["genetic variability", "OBSERVATION", 51, 70]]], ["Therefore, it is often used to analyze PEDV genetic variation.", [["PEDV", "GENE_OR_GENE_PRODUCT", 39, 43]]], ["According to phylogenetic analysis of S genes, PEDV strains have been divided into two clusters: genome I subtype and genome II subtype (Lee et al., 2010; Chen et al., 2014) .", [["PEDV strains", "ORGANISM", 47, 59], ["S genes", "DNA", 38, 45], ["PEDV strains", "DNA", 47, 59], ["genome I subtype", "DNA", 97, 113], ["PEDV", "SPECIES", 47, 51], ["phylogenetic analysis", "TEST", 13, 34], ["PEDV strains", "PROBLEM", 47, 59]]], ["Further, several variant PEDV strains have been identified, which were characterized by insertion and deletion (INDEL) in labeled (S) genes named S-INDEL PEDV.", [["PEDV", "GENE_OR_GENE_PRODUCT", 25, 29], ["INDEL", "DNA", 112, 117], ["labeled (S) genes", "DNA", 122, 139], ["S-INDEL PEDV", "DNA", 146, 158], ["several variant PEDV strains", "PROBLEM", 9, 37], ["insertion and deletion (INDEL)", "TREATMENT", 88, 118], ["PEDV strains", "OBSERVATION", 25, 37], ["insertion", "OBSERVATION_MODIFIER", 88, 97]]], ["The pathogenesis of PEDV is strain specific.", [["PEDV", "CHEMICAL", 20, 24], ["PEDV", "GENE_OR_GENE_PRODUCT", 20, 24], ["PEDV", "SPECIES", 20, 24], ["PEDV", "PROBLEM", 20, 24], ["PEDV", "OBSERVATION", 20, 24], ["strain", "OBSERVATION_MODIFIER", 28, 34], ["specific", "OBSERVATION_MODIFIER", 35, 43]]], ["Studies on its pathogenesis in piglets suggest that the PEDV non-S-INDEL strain has stronger pathogenicity compared to the PEDV S-INDEL strain (Chen et al., 2014; Yamamoto et al., 2015; .", [["INDEL", "CHEMICAL", 67, 72], ["piglets", "ORGANISM", 31, 38], ["PEDV non-S-INDEL strain", "ORGANISM", 56, 79], ["piglets", "SPECIES", 31, 38], ["PEDV", "SPECIES", 56, 60], ["PEDV", "SPECIES", 123, 127], ["the PEDV non-S-INDEL strain", "PROBLEM", 52, 79], ["stronger pathogenicity", "PROBLEM", 84, 106], ["INDEL strain", "PROBLEM", 130, 142]]], ["PEDV JS-A belongs to the non-S-INDEL strain.INTRODUCTIONUpon viral infection, the host innate immune response is the first line of defense (Moynagh, 2005) .", [["PEDV", "CHEMICAL", 0, 4], ["viral infection", "DISEASE", 61, 76], ["PEDV", "SPECIES", 0, 4], ["the non-S-INDEL strain", "PROBLEM", 21, 43], ["INTRODUCTIONUpon viral infection", "PROBLEM", 44, 76], ["viral", "OBSERVATION_MODIFIER", 61, 66], ["infection", "OBSERVATION", 67, 76]]], ["NF-\u03baB regulates expression of numerous components of the immune system, which is thought to be the hallmark of most infection, including coronaviruses (DeDiego et al., 2014) .", [["immune system", "ANATOMY", 57, 70], ["infection", "DISEASE", 116, 125], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["NF-\u03baB", "PROTEIN", 0, 5], ["most infection", "PROBLEM", 111, 125], ["coronaviruses", "PROBLEM", 137, 150], ["numerous", "OBSERVATION_MODIFIER", 30, 38], ["components", "OBSERVATION_MODIFIER", 39, 49], ["immune system", "OBSERVATION", 57, 70], ["thought to be", "UNCERTAINTY", 81, 94], ["most", "OBSERVATION_MODIFIER", 111, 115], ["infection", "OBSERVATION", 116, 125]]], ["RNA viruses interact with pattern-recognition receptors (PRRs), including Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs) .", [["pattern-recognition receptors", "GENE_OR_GENE_PRODUCT", 26, 55], ["PRRs", "GENE_OR_GENE_PRODUCT", 57, 61], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 74, 93], ["TLRs", "GENE_OR_GENE_PRODUCT", 95, 99], ["RIG-I-like receptors", "GENE_OR_GENE_PRODUCT", 105, 125], ["RLRs", "GENE_OR_GENE_PRODUCT", 127, 131], ["pattern-recognition receptors", "PROTEIN", 26, 55], ["PRRs", "PROTEIN", 57, 61], ["Toll-like receptors", "PROTEIN", 74, 93], ["TLRs", "PROTEIN", 95, 99], ["RIG-I-like receptors", "PROTEIN", 105, 125], ["RLRs", "PROTEIN", 127, 131], ["RNA viruses", "PROBLEM", 0, 11], ["viruses", "OBSERVATION", 4, 11]]], ["Several in vitro studies have been conducted to clarify the role of PEDV in innate immune responses at the cellular level.", [["cellular", "ANATOMY", 107, 115], ["PEDV", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 107, 115], ["PEDV", "PROTEIN", 68, 72], ["Several in vitro studies", "TEST", 0, 24], ["PEDV", "PROBLEM", 68, 72]]], ["Several other studies have determined that PEDV nucleocapsid protein (N) inhibits the production of type I and III interferons (IFNs) (Ding et al., 2014; Cao et al., 2015a; Shan et al., 2018) .", [["PEDV nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 43, 72], ["type I and III interferons", "GENE_OR_GENE_PRODUCT", 100, 126], ["IFNs", "GENE_OR_GENE_PRODUCT", 128, 132], ["PEDV nucleocapsid protein", "PROTEIN", 43, 68], ["N", "PROTEIN", 70, 71], ["type I and III interferons", "PROTEIN", 100, 126], ["IFNs", "PROTEIN", 128, 132], ["PEDV", "SPECIES", 43, 47], ["Several other studies", "TEST", 0, 21], ["PEDV nucleocapsid protein", "TEST", 43, 68], ["type I and III interferons (IFNs)", "PROBLEM", 100, 133]]], ["PEDV non-S-INDEL infection inhibits the induction of proinflammatory cytokines and IFN-I by down-regulating TLRs and downstream signaling molecules (Temeeyasen et al., 2018) .INTRODUCTIONNeonatal Fc receptor (FcRn) has been fully characterized to transfer maternal IgG to the fetus or newborn and protect IgG from degradation.", [["fetus", "ANATOMY", 276, 281], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 17, 26], ["PEDV", "ORGANISM", 0, 4], ["IFN-I", "GENE_OR_GENE_PRODUCT", 83, 88], ["TLRs", "GENE_OR_GENE_PRODUCT", 108, 112], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 196, 207], ["FcRn", "GENE_OR_GENE_PRODUCT", 209, 213], ["IgG", "GENE_OR_GENE_PRODUCT", 265, 268], ["fetus", "ORGAN", 276, 281], ["IgG", "GENE_OR_GENE_PRODUCT", 305, 308], ["proinflammatory cytokines", "PROTEIN", 53, 78], ["IFN-I", "PROTEIN", 83, 88], ["TLRs", "PROTEIN", 108, 112], ["downstream signaling molecules", "PROTEIN", 117, 147], ["INTRODUCTIONNeonatal Fc receptor", "PROTEIN", 175, 207], ["FcRn", "PROTEIN", 209, 213], ["maternal IgG", "PROTEIN", 256, 268], ["IgG", "PROTEIN", 305, 308], ["PEDV", "SPECIES", 0, 4], ["PEDV non-S-INDEL infection", "PROBLEM", 0, 26], ["proinflammatory cytokines", "TEST", 53, 78], ["IFN", "TEST", 83, 86], ["infection", "OBSERVATION", 17, 26]]], ["In addition to IgG, FcRn binds to albumin, which regulates liver damage (Pyzik et al., 2017) .", [["liver", "ANATOMY", 59, 64], ["liver damage", "DISEASE", 59, 71], ["IgG", "GENE_OR_GENE_PRODUCT", 15, 18], ["FcRn", "GENE_OR_GENE_PRODUCT", 20, 24], ["albumin", "GENE_OR_GENE_PRODUCT", 34, 41], ["liver", "ORGAN", 59, 64], ["IgG", "PROTEIN", 15, 18], ["FcRn", "PROTEIN", 20, 24], ["albumin", "PROTEIN", 34, 41], ["IgG", "TREATMENT", 15, 18], ["albumin", "TEST", 34, 41], ["liver", "ANATOMY", 59, 64]]], ["Transmissible gastroenteritis virus (TGEV) infection up-regulates pFcRn expression and activates the NF-\u03baB signaling pathway in IPEC-J2 cells (Guo et al., 2016a) .", [["IPEC-J2 cells", "ANATOMY", 128, 141], ["Transmissible gastroenteritis", "DISEASE", 0, 29], ["infection", "DISEASE", 43, 52], ["Transmissible gastroenteritis virus", "ORGANISM", 0, 35], ["TGEV", "ORGANISM", 37, 41], ["pFcRn", "GENE_OR_GENE_PRODUCT", 66, 71], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 101, 106], ["IPEC-J2 cells", "CELL", 128, 141], ["pFcRn", "PROTEIN", 66, 71], ["NF-\u03baB", "PROTEIN", 101, 106], ["IPEC-J2 cells", "CELL_LINE", 128, 141], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["Transmissible gastroenteritis virus", "SPECIES", 0, 35], ["TGEV", "SPECIES", 37, 41], ["Transmissible gastroenteritis virus (TGEV) infection", "PROBLEM", 0, 52], ["the NF", "TEST", 97, 103], ["gastroenteritis", "OBSERVATION", 14, 29], ["J2", "ANATOMY", 133, 135]]], ["In our study, the pathogenicity of JS-A in 5-day-old piglets was studied by clinical evaluation, quantitative analysis of virus copy number in the feces, histology, and immunohistochemistry.", [["feces", "ANATOMY", 147, 152], ["JS-A", "CHEMICAL", 35, 39], ["JS-A", "CELL", 35, 39], ["piglets", "ORGANISM", 53, 60], ["feces", "ORGANISM_SUBDIVISION", 147, 152], ["piglets", "SPECIES", 53, 60], ["our study", "TEST", 3, 12], ["clinical evaluation", "TEST", 76, 95], ["quantitative analysis", "TEST", 97, 118], ["histology", "TEST", 154, 163], ["immunohistochemistry", "TEST", 169, 189], ["JS", "ANATOMY", 35, 37], ["feces", "ANATOMY", 147, 152]]], ["We also studied the gene regulation of TLRs, RIG-I, and downstream signaling pathways in the intestinal mucosa of pigs newly infected with JS-A.", [["intestinal mucosa", "ANATOMY", 93, 110], ["TLRs", "GENE_OR_GENE_PRODUCT", 39, 43], ["RIG-I", "GENE_OR_GENE_PRODUCT", 45, 50], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 93, 110], ["pigs", "ORGANISM", 114, 118], ["TLRs", "PROTEIN", 39, 43], ["RIG-I", "PROTEIN", 45, 50], ["pigs", "SPECIES", 114, 118], ["pigs", "SPECIES", 114, 118], ["intestinal mucosa", "ANATOMY", 93, 110], ["infected", "OBSERVATION", 125, 133]]], ["The purpose of this study was to investigate the genomic characteristics and pathogenicity of JS-A and the expression of TLRs, RIG-I, NF-\u03baB, and FcRn in the intestinal mucosa of infected piglets.Clinical Samples and Virus IsolationFecal samples and intestinal contents from piglets suffering from severe watery diarrhea were collected in a pig farm from Jiangsu Province.", [["intestinal mucosa", "ANATOMY", 157, 174], ["piglets", "ANATOMY", 187, 194], ["samples", "ANATOMY", 237, 244], ["intestinal", "ANATOMY", 249, 259], ["watery diarrhea", "DISEASE", 304, 319], ["JS-A", "CELL", 94, 98], ["TLRs", "GENE_OR_GENE_PRODUCT", 121, 125], ["RIG-I", "GENE_OR_GENE_PRODUCT", 127, 132], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 134, 139], ["FcRn", "GENE_OR_GENE_PRODUCT", 145, 149], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 157, 174], ["piglets", "ORGANISM", 187, 194], ["intestinal", "ORGAN", 249, 259], ["piglets", "ORGANISM", 274, 281], ["pig", "ORGANISM", 340, 343], ["TLRs", "PROTEIN", 121, 125], ["RIG", "PROTEIN", 127, 130], ["NF-\u03baB", "PROTEIN", 134, 139], ["FcRn", "PROTEIN", 145, 149], ["piglets", "SPECIES", 187, 194], ["piglets", "SPECIES", 274, 281], ["pig", "SPECIES", 340, 343], ["pig", "SPECIES", 340, 343], ["this study", "TEST", 15, 25], ["TLRs", "TEST", 121, 125], ["RIG", "TEST", 127, 130], ["NF", "TEST", 134, 136], ["Clinical Samples", "TEST", 195, 211], ["Virus IsolationFecal samples", "TREATMENT", 216, 244], ["intestinal contents", "PROBLEM", 249, 268], ["severe watery diarrhea", "PROBLEM", 297, 319], ["intestinal mucosa", "ANATOMY", 157, 174], ["infected piglets", "OBSERVATION", 178, 194], ["intestinal", "ANATOMY", 249, 259], ["severe", "OBSERVATION_MODIFIER", 297, 303], ["watery", "OBSERVATION_MODIFIER", 304, 310], ["diarrhea", "OBSERVATION", 311, 319]]], ["PEDV-positive samples were detected by realtime polymerase chain reaction (RT-PCR), based on the N gene, as previously described (Lee et al., 2015) .", [["samples", "ANATOMY", 14, 21], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["PEDV", "PROTEIN", 0, 4], ["N gene", "DNA", 97, 103], ["PEDV", "SPECIES", 0, 4], ["PEDV", "TEST", 0, 4], ["realtime polymerase chain reaction", "TEST", 39, 73], ["RT-PCR", "TEST", 75, 81]]], ["Clinical samples were homogenized in DMEM (HyClone, Logan, UT, USA), centrifuged at 4,000 rpm/min, and filtered through a 0.22-\u03bcm filter (Millipore, MA).Clinical Samples and Virus IsolationVero (ATCC, CCL-81) cells were obtained from the China Center for Type Culture Collection (Wuhan, China) and were cultured in DMEM containing 10% fetal bovine serum (FBS, Gibco, Waltham, MA, USA).", [["samples", "ANATOMY", 9, 16], ["CCL-81) cells", "ANATOMY", 201, 214], ["fetal bovine serum", "ANATOMY", 335, 353], ["FBS", "ANATOMY", 355, 358], ["CCL-81) cells", "CELL", 201, 214], ["bovine", "ORGANISM", 341, 347], ["serum", "ORGANISM_SUBSTANCE", 348, 353], ["FBS", "ORGANISM_SUBSTANCE", 355, 358], ["Virus IsolationVero (ATCC, CCL-81) cells", "CELL_LINE", 174, 214], ["bovine", "SPECIES", 341, 347], ["Virus IsolationVero (ATCC, CCL-81", "SPECIES", 174, 207], ["bovine", "SPECIES", 341, 347], ["Clinical samples", "TEST", 0, 16], ["a 0.22-\u03bcm filter (Millipore", "TREATMENT", 120, 147], ["Clinical Samples", "TEST", 153, 169], ["Virus IsolationVero (ATCC, CCL", "TREATMENT", 174, 204], ["Type Culture Collection", "PROBLEM", 255, 278], ["fetal bovine serum", "TEST", 335, 353], ["FBS", "TEST", 355, 358], ["Gibco", "TEST", 360, 365]]], ["Vero cells were incubated with 1 mL of filtered inoculum for 2 h.", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["filtered inoculum", "TREATMENT", 39, 56]]], ["After virus adsorption, cells were maintained in DMEM containing 8 \u03bcg/mL trypsin (Gibco, USA) and antibiotics.", [["cells", "ANATOMY", 24, 29], ["cells", "CELL", 24, 29], ["virus adsorption", "TREATMENT", 6, 22], ["cells", "PROBLEM", 24, 29], ["antibiotics", "TREATMENT", 98, 109]]], ["After 2 h, the cells were maintained in DMEM containing 8 \u03bcg/mL trypsin at 37\u00b0C in 5% CO 2 until a cytopathic effect became visible.", [["cells", "ANATOMY", 15, 20], ["CO 2", "CHEMICAL", 86, 90], ["cells", "CELL", 15, 20], ["trypsin", "GENE_OR_GENE_PRODUCT", 64, 71], ["trypsin", "PROTEIN", 64, 71], ["the cells", "TREATMENT", 11, 20], ["trypsin", "TREATMENT", 64, 71], ["a cytopathic effect", "PROBLEM", 97, 116], ["cytopathic", "OBSERVATION", 99, 109]]], ["The supernatant was collected after the cytopathic effect was observed.", [["supernatant", "ANATOMY", 4, 15], ["The supernatant", "TREATMENT", 0, 15], ["the cytopathic effect", "PROBLEM", 36, 57], ["cytopathic", "OBSERVATION_MODIFIER", 40, 50]]], ["The virus was cloned and purified by plaque purification three times and tested by TCID 50 .Immunofluorescence AssayAt 24 h post-infection, cells were fixed with 4% paraformaldehyde in PBS for 15 min and permeabilized with 0.1% Triton X-100 for 10 min.", [["plaque", "ANATOMY", 37, 43], ["cells", "ANATOMY", 140, 145], ["infection", "DISEASE", 129, 138], ["paraformaldehyde", "CHEMICAL", 165, 181], ["Triton X-100", "CHEMICAL", 228, 240], ["paraformaldehyde", "CHEMICAL", 165, 181], ["cells", "CELL", 140, 145], ["paraformaldehyde", "SIMPLE_CHEMICAL", 165, 181], ["Triton X-100", "SIMPLE_CHEMICAL", 228, 240], ["The virus", "PROBLEM", 0, 9], ["plaque purification", "TREATMENT", 37, 56], ["Immunofluorescence", "TEST", 92, 110], ["infection", "PROBLEM", 129, 138], ["cells", "TEST", 140, 145], ["4% paraformaldehyde in PBS", "TREATMENT", 162, 188], ["virus", "OBSERVATION", 4, 9], ["plaque", "OBSERVATION", 37, 43], ["infection", "OBSERVATION", 129, 138]]], ["Subsequently, cells were incubated with PBST containing 5% skim milk for 1 h, followed by primary (PEDV polyclonal antibody; prepared in our laboratory) and secondary [fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG; ABclonal, China] antibodies for 1 h.", [["cells", "ANATOMY", 14, 19], ["milk", "ANATOMY", 64, 68], ["fluorescein isothiocyanate", "CHEMICAL", 168, 194], ["fluorescein isothiocyanate", "CHEMICAL", 168, 194], ["FITC", "CHEMICAL", 196, 200], ["cells", "CELL", 14, 19], ["milk", "ORGANISM_SUBSTANCE", 64, 68], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 168, 194], ["FITC", "SIMPLE_CHEMICAL", 196, 200], ["goat", "ORGANISM", 210, 214], ["PEDV polyclonal antibody", "PROTEIN", 99, 123], ["fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG; ABclonal, China] antibodies", "PROTEIN", 168, 259], ["goat", "SPECIES", 210, 214], ["anti-rabbit", "SPECIES", 215, 226], ["PEDV", "SPECIES", 99, 103], ["goat", "SPECIES", 210, 214], ["PBST", "TREATMENT", 40, 44], ["primary (PEDV polyclonal antibody", "PROBLEM", 90, 123], ["fluorescein isothiocyanate (FITC)-labeled goat anti-rabbit IgG", "TREATMENT", 168, 230]]], ["Finally, the samples were stained with DAPI for 15 min and examined using a fluorescence microscope (Olympus IX73, Japan).Western BlotAt 24 h post-infection, cells lysates were prepared for 12% SDS-PAGE, and proteins were electroblotted onto a polyvinylidene difluoride membrane (Bio-Rad, USA).", [["samples", "ANATOMY", 13, 20], ["cells lysates", "ANATOMY", 158, 171], ["infection", "DISEASE", 147, 156], ["DAPI", "CHEMICAL", 39, 43], ["polyvinylidene", "CHEMICAL", 244, 258], ["difluoride", "CHEMICAL", 259, 269], ["DAPI", "SIMPLE_CHEMICAL", 39, 43], ["cells", "CELL", 158, 163], ["lysates", "ORGANISM_SUBSTANCE", 164, 171], ["membrane", "CELLULAR_COMPONENT", 270, 278], ["the samples", "TEST", 9, 20], ["DAPI", "TREATMENT", 39, 43], ["a fluorescence microscope", "TEST", 74, 99], ["post-infection", "PROBLEM", 142, 156], ["cells lysates", "TEST", 158, 171], ["a polyvinylidene difluoride membrane", "TREATMENT", 242, 278], ["infection", "OBSERVATION", 147, 156]]], ["PEDV-N polyclonal antibody (prepared in our laboratory) was used as a primary antibody, followed by HRP-conjugated goat anti-rabbit IgG or anti-mouse IgG (ABclonal, China) as secondary antibodies.", [["HRP", "SIMPLE_CHEMICAL", 100, 103], ["goat", "ORGANISM", 115, 119], ["PEDV", "PROTEIN", 0, 4], ["N polyclonal antibody", "PROTEIN", 5, 26], ["primary antibody", "PROTEIN", 70, 86], ["HRP", "PROTEIN", 100, 103], ["conjugated goat anti-rabbit IgG", "PROTEIN", 104, 135], ["anti-mouse IgG", "PROTEIN", 139, 153], ["ABclonal", "PROTEIN", 155, 163], ["secondary antibodies", "PROTEIN", 175, 195], ["goat", "SPECIES", 115, 119], ["anti-rabbit", "SPECIES", 120, 131], ["anti-mouse", "SPECIES", 139, 149], ["goat", "SPECIES", 115, 119], ["anti-rabbit", "SPECIES", 120, 131], ["anti-mouse", "SPECIES", 139, 149], ["PEDV", "TEST", 0, 4], ["polyclonal antibody", "TEST", 7, 26], ["a primary antibody", "TEST", 68, 86], ["HRP", "TEST", 100, 103], ["conjugated goat anti-rabbit IgG", "TREATMENT", 104, 135], ["anti-mouse IgG", "TEST", 139, 153], ["secondary antibodies", "PROBLEM", 175, 195]]], ["Proteins were visualized as described previously (Guo et al., 2016b) .Electron MicroscopyPEDV-infected Vero cells were examined by electron microscopy (EM), following previously described procedures (Chen et al., 2014) .", [["Vero cells", "ANATOMY", 103, 113], ["Vero cells", "CELL", 103, 113], ["MicroscopyPEDV-infected Vero cells", "CELL_LINE", 79, 113], ["Electron MicroscopyPEDV", "TEST", 70, 93], ["infected Vero cells", "PROBLEM", 94, 113], ["infected", "OBSERVATION_MODIFIER", 94, 102], ["Vero cells", "OBSERVATION", 103, 113]]], ["These samples were negatively stained with 2% sodium phosphotungstic acid (pH 6.8) and examined using a Hitachi Model H-7650 TEM (Hitachi H-7000FA, Japan).Phylogenetic AnalysisTotal RNAs were extracted using TRIzol @ reagent (Invitrogen, Carlsbad, CA, USA), and total RNA was reverse transcribed into cDNA using reverse transcriptase (TaKaRa, Osaka, Japan).", [["samples", "ANATOMY", 6, 13], ["sodium phosphotungstic acid", "CHEMICAL", 46, 73], ["H-7650", "CHEMICAL", 118, 124], ["sodium phosphotungstic acid", "CHEMICAL", 46, 73], ["H-7650", "CHEMICAL", 118, 124], ["sodium phosphotungstic acid", "SIMPLE_CHEMICAL", 46, 73], ["cDNA", "DNA", 301, 305], ["reverse transcriptase", "PROTEIN", 312, 333], ["These samples", "TEST", 0, 13], ["2% sodium phosphotungstic acid", "TREATMENT", 43, 73], ["pH", "TEST", 75, 77], ["a Hitachi Model H", "TEST", 102, 119], ["Hitachi H", "TEST", 130, 139], ["Phylogenetic AnalysisTotal RNAs", "PROBLEM", 155, 186], ["TRIzol", "TREATMENT", 208, 214], ["Invitrogen", "TREATMENT", 226, 236], ["total RNA", "TREATMENT", 262, 271], ["reverse transcriptase (TaKaRa", "TREATMENT", 312, 341], ["AnalysisTotal RNAs", "OBSERVATION", 168, 186]]], ["The whole genome of JS-A was sequenced using 25 pairs of primers previously reported in Table 1 by Chen (Chen et al., 2012) .", [["JS-A", "CELL", 20, 24], ["JS-A", "DNA", 20, 24], ["JS-A", "SPECIES", 20, 24], ["JS", "ANATOMY", 20, 22]]], ["Phylogenetic trees with 25 strains ( Table 2 ) full-length genome and S-nucleotide sequences were generated using the distancebased adjacency method in MEGA7.Inoculation of Piglets With Porcine Epidemic Diarrhea Virus Strain JS-AThis study was implemented according to the Guide of the Scientific Ethics Committee of Huazhong Agricultural University (HZAUSW-2018-011).", [["Epidemic Diarrhea", "DISEASE", 194, 211], ["Porcine", "ORGANISM", 186, 193], ["S-nucleotide sequences", "DNA", 70, 92], ["MEGA7", "DNA", 152, 157], ["Piglets", "SPECIES", 173, 180], ["Porcine", "SPECIES", 186, 193], ["Porcine Epidemic Diarrhea Virus Strain JS-AThis", "SPECIES", 186, 233], ["Phylogenetic trees", "TEST", 0, 18], ["S-nucleotide sequences", "TEST", 70, 92], ["the distancebased adjacency method in MEGA7", "TREATMENT", 114, 157], ["Porcine Epidemic Diarrhea Virus Strain JS", "PROBLEM", 186, 227], ["Porcine", "OBSERVATION_MODIFIER", 186, 193], ["Epidemic", "OBSERVATION_MODIFIER", 194, 202]]], ["Twelve 5-day-old piglets were purchased from a commercial pig farm, both PEDV RNA and antibody negative, and were randomly divided into two groups (6 piglets/ group) in two separate rooms.", [["piglets", "ORGANISM", 17, 24], ["pig", "ORGANISM", 58, 61], ["piglets", "ORGANISM", 150, 157], ["PEDV RNA", "RNA", 73, 81], ["piglets", "SPECIES", 17, 24], ["pig", "SPECIES", 58, 61], ["pig", "SPECIES", 58, 61], ["PEDV", "SPECIES", 73, 77], ["antibody", "TEST", 86, 94]]], ["Piglets were fed a mixture of liquid milk replacer and had free access to water.", [["Piglets", "ORGANISM", 0, 7], ["milk", "ORGANISM_SUBSTANCE", 37, 41], ["Piglets", "SPECIES", 0, 7], ["a mixture of liquid milk replacer", "TREATMENT", 17, 50]]], ["After 1 day of adaptation, piglets in the challenged group received 3 \u00d7 10 5 TCID 50 PEDV JS-A orally, while piglets in the control group received 3 mL maintenance medium orally.", [["PEDV JS-A", "CHEMICAL", 85, 94], ["piglets", "ORGANISM", 27, 34], ["JS-A", "SIMPLE_CHEMICAL", 90, 94], ["piglets", "ORGANISM", 109, 116], ["piglets", "SPECIES", 27, 34], ["piglets", "SPECIES", 109, 116], ["piglets", "TREATMENT", 27, 34]]], ["The piglets were observed daily for signs of vomiting, diarrhea, lethargy, weight, and body temperature until the end of the experiment.", [["body", "ANATOMY", 87, 91], ["vomiting", "DISEASE", 45, 53], ["diarrhea", "DISEASE", 55, 63], ["lethargy", "DISEASE", 65, 73], ["piglets", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 87, 91], ["piglets", "SPECIES", 4, 11], ["The piglets", "TREATMENT", 0, 11], ["vomiting", "PROBLEM", 45, 53], ["diarrhea", "PROBLEM", 55, 63], ["lethargy", "PROBLEM", 65, 73], ["weight", "TEST", 75, 81], ["body temperature", "PROBLEM", 87, 103]]], ["Intestinal segments, including the jejunum and ileum, were collected after euthanasia of three of six piglets in each group, selected at random, at 4 dpi for histopathological and immunohistochemical examinations using the method described previously (Lee et al., 2010) .", [["Intestinal segments", "ANATOMY", 0, 19], ["jejunum", "ANATOMY", 35, 42], ["ileum", "ANATOMY", 47, 52], ["Intestinal segments", "MULTI-TISSUE_STRUCTURE", 0, 19], ["jejunum", "MULTI-TISSUE_STRUCTURE", 35, 42], ["ileum", "MULTI-TISSUE_STRUCTURE", 47, 52], ["piglets", "ORGANISM", 102, 109], ["piglets", "SPECIES", 102, 109], ["euthanasia", "TREATMENT", 75, 85], ["histopathological and immunohistochemical examinations", "TEST", 158, 212], ["segments", "ANATOMY_MODIFIER", 11, 19], ["jejunum", "ANATOMY", 35, 42], ["ileum", "ANATOMY", 47, 52]]], ["At the end of the experiment (21 dpi), the remaining piglets were euthanized.", [["piglets", "ORGANISM", 53, 60], ["piglets", "SPECIES", 53, 60]]], ["Expressions of mRNA for TLRs, NF-\u03baBInoculation of Piglets With Porcine Epidemic Diarrhea Virus Strain JS-Aand FcRn on piglet intestinal mucosa in each group were detected by RT-qPCR at 4 and 21 dpi.Real-Time Polymerase Chain ReactionViral RNA of PEDV in piglet feces or intestinal mucosa was detected as previously described (Subramaniam et al., 2018) .Real-Time Polymerase Chain ReactionThe specific porcine primers are referenced in previous publications in Table 3 (Guo et al., 2016a; Temeeyasen et al., 2018) were synthesized by the GenScript Company (Nanjing, China).", [["piglet intestinal mucosa", "ANATOMY", 118, 142], ["piglet feces", "ANATOMY", 254, 266], ["intestinal mucosa", "ANATOMY", 270, 287], ["Diarrhea", "DISEASE", 80, 88], ["TLRs", "GENE_OR_GENE_PRODUCT", 24, 28], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 30, 34], ["Porcine Epidemic Diarrhea Virus", "ORGANISM", 63, 94], ["JS-Aand FcRn", "GENE_OR_GENE_PRODUCT", 102, 114], ["piglet intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 118, 142], ["PEDV", "GENE_OR_GENE_PRODUCT", 246, 250], ["piglet", "ORGANISM", 254, 260], ["feces", "ORGANISM_SUBSTANCE", 261, 266], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 270, 287], ["porcine", "ORGANISM", 401, 408], ["mRNA", "RNA", 15, 19], ["TLRs", "PROTEIN", 24, 28], ["NF-\u03ba", "PROTEIN", 30, 34], ["Real-Time Polymerase Chain ReactionViral RNA", "RNA", 198, 242], ["Piglets", "SPECIES", 50, 57], ["Porcine", "SPECIES", 63, 70], ["piglet", "SPECIES", 118, 124], ["piglet", "SPECIES", 254, 260], ["Porcine Epidemic Diarrhea Virus Strain JS-Aand FcRn", "SPECIES", 63, 114], ["PEDV", "SPECIES", 246, 250], ["piglet", "SPECIES", 254, 260], ["Piglets", "TREATMENT", 50, 57], ["Porcine Epidemic Diarrhea Virus Strain JS", "PROBLEM", 63, 104], ["piglet intestinal mucosa", "PROBLEM", 118, 142], ["qPCR", "TEST", 177, 181], ["PEDV", "PROBLEM", 246, 250], ["intestinal mucosa", "PROBLEM", 270, 287], ["The specific porcine primers", "PROBLEM", 388, 416], ["intestinal mucosa", "ANATOMY", 125, 142], ["PEDV", "OBSERVATION", 246, 250], ["intestinal mucosa", "ANATOMY", 270, 287], ["porcine primers", "OBSERVATION", 401, 416]]], ["The N gene amplified from the PEDV JS-A strain was cloned into pMD18-T (Takara, Dalian).", [["PEDV JS-A strain", "ORGANISM", 30, 46], ["Dalian", "CELL", 80, 86], ["N gene", "DNA", 4, 10], ["pMD18", "DNA", 63, 68], ["PEDV JS-A strain", "SPECIES", 30, 46], ["The N gene", "TREATMENT", 0, 10], ["A strain", "PROBLEM", 38, 46]]], ["The known plasmid concentrations were serially diluted 10-fold to generate a standardReal-Time Polymerase Chain Reactioncurve in each plate.", [["plasmid", "ANATOMY", 10, 17], ["The known plasmid concentrations", "TREATMENT", 0, 32], ["plasmid concentrations", "OBSERVATION", 10, 32], ["plate", "ANATOMY_MODIFIER", 134, 139]]], ["The amount of PEDV viral RNA in the test sample was calculated based on the cycle curve threshold (Ct) value of the standard curve.", [["sample", "ANATOMY", 41, 47], ["PEDV", "GENE_OR_GENE_PRODUCT", 14, 18], ["PEDV viral RNA", "RNA", 14, 28], ["PEDV", "SPECIES", 14, 18], ["PEDV viral RNA", "PROBLEM", 14, 28], ["the test sample", "TEST", 32, 47], ["the cycle curve threshold", "TEST", 72, 97], ["Ct) value", "TEST", 99, 108], ["the standard curve", "TEST", 112, 130], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["PEDV", "OBSERVATION", 14, 18], ["viral RNA", "OBSERVATION", 19, 28]]], ["Expression levels of genes were calculated relative to the expression of GAPDH using the delta-delta cycles to threshold (2 \u2212\u0394\u0394Ct ) method.IgG/IgA Enzyme-Linked Immunosorbent Assay and Neutralization AssayThe PEDV-specific IgG/IgA antibodies were measured in serum samples by ELISA as previously described (Subramaniam et al., 2018) .", [["serum samples", "ANATOMY", 259, 272], ["GAPDH", "GENE_OR_GENE_PRODUCT", 73, 78], ["IgG", "GENE_OR_GENE_PRODUCT", 139, 142], ["IgA", "GENE_OR_GENE_PRODUCT", 143, 146], ["PEDV", "SIMPLE_CHEMICAL", 209, 213], ["IgG", "GENE_OR_GENE_PRODUCT", 223, 226], ["IgA", "GENE_OR_GENE_PRODUCT", 227, 230], ["serum samples", "ORGANISM_SUBSTANCE", 259, 272], ["GAPDH", "PROTEIN", 73, 78], ["IgG", "PROTEIN", 139, 142], ["IgA", "PROTEIN", 143, 146], ["PEDV", "PROTEIN", 209, 213], ["IgG", "PROTEIN", 223, 226], ["IgA antibodies", "PROTEIN", 227, 241], ["Expression levels of genes", "PROBLEM", 0, 26], ["the delta-delta cycles", "TREATMENT", 85, 107], ["IgG", "TEST", 139, 142], ["IgA Enzyme", "TEST", 143, 153], ["Immunosorbent Assay", "TEST", 161, 180], ["Neutralization Assay", "TEST", 185, 205], ["The PEDV", "TEST", 205, 213], ["specific IgG/IgA antibodies", "TEST", 214, 241], ["serum samples", "TEST", 259, 272], ["ELISA", "TEST", 276, 281]]], ["Polystyrene 96-well microplates were coated with purified PEDV N diluted in PBS containing Tween-20 (PBST) and incubated overnight at 4\u00b0C, followed by the removal of the coating solution.", [["Polystyrene", "CHEMICAL", 0, 11], ["PEDV N", "CHEMICAL", 58, 64], ["Tween-20", "CHEMICAL", 91, 99], ["Polystyrene", "CHEMICAL", 0, 11], ["Tween-20", "CHEMICAL", 91, 99], ["Polystyrene", "SIMPLE_CHEMICAL", 0, 11], ["PBS", "SIMPLE_CHEMICAL", 76, 79], ["Tween-20", "SIMPLE_CHEMICAL", 91, 99], ["PEDV", "SPECIES", 58, 62], ["Polystyrene", "TREATMENT", 0, 11], ["purified PEDV N", "TREATMENT", 49, 64], ["Tween", "TEST", 91, 96], ["the removal of the coating solution", "TREATMENT", 151, 186]]], ["The plates were blocked with 100 \u03bcL 5% skimmed milk in PBST and incubated at 37\u00b0C for 30 min.", [["milk", "ANATOMY", 47, 51], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["The plates", "TREATMENT", 0, 10], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["After which, 100 \u03bcL of serum samples (diluted 1:200) per well was added and incubated at 37\u00b0C for 1 h, respectively.", [["serum samples", "ANATOMY", 23, 36], ["serum samples", "ORGANISM_SUBSTANCE", 23, 36], ["serum samples", "TEST", 23, 36]]], ["After washing the plates, HRP-conjugated goat anti-swine IgG or goat anti-swine IgA was incubated for 1 h.", [["HRP", "SIMPLE_CHEMICAL", 26, 29], ["goat", "ORGANISM", 41, 45], ["IgG", "GENE_OR_GENE_PRODUCT", 57, 60], ["goat", "ORGANISM", 64, 68], ["IgA", "GENE_OR_GENE_PRODUCT", 80, 83], ["HRP-conjugated goat anti-swine IgG", "PROTEIN", 26, 60], ["goat anti-swine IgA", "PROTEIN", 64, 83], ["goat", "SPECIES", 41, 45], ["goat", "SPECIES", 64, 68], ["goat", "SPECIES", 41, 45], ["goat", "SPECIES", 64, 68], ["the plates", "TEST", 14, 24], ["HRP", "TEST", 26, 29], ["conjugated goat anti-swine IgG", "TREATMENT", 30, 60]]], ["The plates were washed and incubated with TMB solution (Sigma-Aldrich) for 10 min.", [["TMB", "CHEMICAL", 42, 45], ["TMB", "SIMPLE_CHEMICAL", 42, 45], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 56, 69], ["The plates", "TREATMENT", 0, 10], ["TMB solution", "TREATMENT", 42, 54], ["plates", "OBSERVATION_MODIFIER", 4, 10]]], ["The absorbance was measured at 450 nm with a termination solution (2 M H 2 SO 4 ).", [["The absorbance", "TEST", 0, 14], ["a termination solution", "TREATMENT", 43, 65], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["PEDV isolate JS-A was used to determine the presence of neutralization (PEDV nucleocapsid protein) in serum samples as previously described (Oh et al., 2014) .", [["serum samples", "ANATOMY", 102, 115], ["JS-A", "CELL", 13, 17], ["PEDV nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 72, 97], ["serum samples", "ORGANISM_SUBSTANCE", 102, 115], ["PEDV nucleocapsid protein", "PROTEIN", 72, 97], ["PEDV", "SPECIES", 0, 4], ["neutralization (PEDV nucleocapsid protein", "PROBLEM", 56, 97], ["serum samples", "TEST", 102, 115], ["neutralization", "OBSERVATION", 56, 70]]], ["Vero cells were grown to 90% confluence in the 96-well plates.", [["Vero cells", "ANATOMY", 0, 10], ["Vero cells", "CELL", 0, 10], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "PROBLEM", 0, 10], ["confluence", "OBSERVATION_MODIFIER", 29, 39]]], ["Further, 200 TCID 50 of JS-A virus was diluted in DMEM in a 50 \u03bcL volume.", [["JS-A virus", "ORGANISM", 24, 34], ["JS-A virus", "SPECIES", 24, 34], ["A virus", "TREATMENT", 27, 34]]], ["Subsequently, 50 \u03bcL of 2-fold serial dilutions of inactivated serum samples was added to the diluted virus and incubated at 37\u00b0C for 1 h.", [["serum samples", "ANATOMY", 62, 75], ["serum samples", "ORGANISM_SUBSTANCE", 62, 75], ["2-fold serial dilutions", "TREATMENT", 23, 46], ["inactivated serum samples", "TREATMENT", 50, 75], ["the diluted virus", "TREATMENT", 89, 106]]], ["The mixture was inoculated into Vero cells and incubated at 37\u00b0C for 1 h.", [["Vero cells", "ANATOMY", 32, 42], ["Vero cells", "CELL", 32, 42], ["Vero cells", "CELL_LINE", 32, 42], ["Vero cells", "OBSERVATION", 32, 42]]], ["After removing the mixture and washing the plates, the virus in the maintenance medium was incubated in a 37\u00b0C and 5% CO 2 incubator for 2 days.", [["CO", "CHEMICAL", 118, 120], ["the mixture", "TREATMENT", 15, 26], ["washing the plates", "TREATMENT", 31, 49], ["the virus", "TREATMENT", 51, 60], ["5% CO 2 incubator", "TREATMENT", 115, 132], ["virus", "OBSERVATION", 55, 60]]], ["The neutralization titer was calculated as the reciprocal of the highest serum dilution that neutralizes PEDV infection.Statistical AnalysisData were analyzed as mean \u00b1 SEM.", [["serum", "ANATOMY", 73, 78], ["PEDV", "CHEMICAL", 105, 109], ["infection", "DISEASE", 110, 119], ["serum", "ORGANISM_SUBSTANCE", 73, 78], ["PEDV", "GENE_OR_GENE_PRODUCT", 105, 109], ["PEDV", "SPECIES", 105, 109], ["The neutralization titer", "TREATMENT", 0, 24], ["the highest serum dilution", "TREATMENT", 61, 87], ["neutralizes PEDV infection", "PROBLEM", 93, 119], ["Statistical AnalysisData", "TEST", 120, 144], ["neutralizes", "OBSERVATION_MODIFIER", 93, 104], ["PEDV", "OBSERVATION_MODIFIER", 105, 109], ["infection", "OBSERVATION", 110, 119]]], ["The significance level for all analyses was set as p < 0.001.Virus Isolation and CharacterizationThe treated samples were inoculated onto Vero cells.", [["samples", "ANATOMY", 109, 116], ["Vero cells", "ANATOMY", 138, 148], ["Vero cells", "CELL", 138, 148], ["Vero cells", "CELL_LINE", 138, 148], ["all analyses", "TEST", 27, 39], ["Virus Isolation", "TREATMENT", 61, 76], ["The treated samples", "TEST", 97, 116], ["Vero cells", "OBSERVATION", 138, 148]]], ["Cytopathic effects, including cell fusion, syncytium, and detachment, were observed at 36 h post-infection (hpi).", [["cell", "ANATOMY", 30, 34], ["syncytium", "ANATOMY", 43, 52], ["infection", "DISEASE", 97, 106], ["cell", "CELL", 30, 34], ["Cytopathic effects", "PROBLEM", 0, 18], ["cell fusion", "TREATMENT", 30, 41], ["syncytium", "PROBLEM", 43, 52], ["detachment", "PROBLEM", 58, 68], ["infection", "PROBLEM", 97, 106], ["cell fusion", "OBSERVATION", 30, 41], ["detachment", "OBSERVATION", 58, 68], ["infection", "OBSERVATION", 97, 106]]], ["No cytopathic effects were observed in the control wells ( Figure 1A) .", [["cytopathic effects", "PROBLEM", 3, 21], ["cytopathic", "OBSERVATION_MODIFIER", 3, 13], ["effects", "OBSERVATION", 14, 21]]], ["To confirm the occurrence of virus multiplication, the infectivity of the JS-A strain (purified by plaque in Vero cells) was assessed by western blot (WB) and IFA using the PEDV N protein polyclonal antibody.", [["plaque", "ANATOMY", 99, 105], ["Vero cells", "ANATOMY", 109, 119], ["JS-A strain", "ORGANISM", 74, 85], ["Vero cells", "CELL", 109, 119], ["Vero cells", "CELL_LINE", 109, 119], ["PEDV N protein polyclonal antibody", "PROTEIN", 173, 207], ["JS-A strain", "SPECIES", 74, 85], ["virus multiplication", "PROBLEM", 29, 49], ["A strain", "PROBLEM", 77, 85], ["plaque in Vero cells", "PROBLEM", 99, 119], ["IFA", "TEST", 159, 162], ["the PEDV N protein polyclonal antibody", "TEST", 169, 207], ["virus", "OBSERVATION", 29, 34], ["JS", "ANATOMY", 74, 76], ["plaque", "OBSERVATION", 99, 105], ["Vero cells", "OBSERVATION", 109, 119], ["polyclonal antibody", "OBSERVATION", 188, 207]]], ["IFA results demonstrated a green signal in infected Vero cells, but not in the mock-infected cells (Figure 1A) .Virus Isolation and CharacterizationWestern blot analysis also detected N protein in PEDV-infected Vero cells (Figure 1B) .", [["Vero cells", "ANATOMY", 52, 62], ["cells", "ANATOMY", 93, 98], ["Vero cells", "ANATOMY", 211, 221], ["Vero cells", "CELL", 52, 62], ["cells", "CELL", 93, 98], ["Vero cells", "CELL", 211, 221], ["Figure 1B", "CELL", 223, 232], ["infected Vero cells", "CELL_LINE", 43, 62], ["mock-infected cells", "CELL_TYPE", 79, 98], ["N protein", "PROTEIN", 184, 193], ["PEDV-infected Vero cells", "CELL_LINE", 197, 221], ["PEDV", "SPECIES", 197, 201], ["IFA", "TEST", 0, 3], ["a green signal in infected Vero cells", "PROBLEM", 25, 62], ["Virus Isolation", "TREATMENT", 112, 127], ["CharacterizationWestern blot analysis", "TEST", 132, 169], ["N protein", "TEST", 184, 193], ["PEDV", "TEST", 197, 201], ["infected Vero cells", "PROBLEM", 202, 221], ["green signal", "OBSERVATION", 27, 39], ["infected", "OBSERVATION_MODIFIER", 43, 51], ["Vero cells", "OBSERVATION", 52, 62], ["infected cells", "OBSERVATION", 84, 98], ["infected", "OBSERVATION_MODIFIER", 202, 210], ["Vero cells", "OBSERVATION", 211, 221]]], ["According to the structural analysis of the infected cells by transmission electron microscopy, PEDV virus particles were round and showed obvious radial protrusion (Figure 1C) , which is typical of coronaviruses.", [["cells", "ANATOMY", 53, 58], ["radial", "ANATOMY", 147, 153], ["cells", "CELL", 53, 58], ["coronaviruses", "ORGANISM", 199, 212], ["infected cells", "CELL_TYPE", 44, 58], ["PEDV virus", "SPECIES", 96, 106], ["the infected cells", "PROBLEM", 40, 58], ["transmission electron microscopy", "TEST", 62, 94], ["PEDV virus particles", "TEST", 96, 116], ["radial protrusion", "PROBLEM", 147, 164], ["coronaviruses", "PROBLEM", 199, 212], ["infected cells", "OBSERVATION", 44, 58], ["obvious", "OBSERVATION_MODIFIER", 139, 146], ["radial", "ANATOMY_MODIFIER", 147, 153], ["protrusion", "OBSERVATION", 154, 164], ["typical of", "UNCERTAINTY", 188, 198], ["coronaviruses", "OBSERVATION", 199, 212]]], ["The plaquepurified virus was titrated to 10 5.625 TCID 50 /mL.Phylogenetic Tree Analysis of JS-A Genomic SequenceThe JS-A genome was sequenced and deposited in GenBank (MH748550).", [["JS-A", "CELL", 117, 121], ["JS-A genome", "DNA", 117, 128], ["plaquepurified virus", "SPECIES", 4, 24], ["The plaquepurified virus", "TREATMENT", 0, 24], ["virus", "OBSERVATION", 19, 24], ["JS", "ANATOMY", 117, 119]]], ["To further understand the evolutionary relationship between JS-A and other PEDV strains, a phylogenetic tree was constructed based on its genome and the S gene sequence (Figure 2) .", [["JS-A", "CELL", 60, 64], ["S gene sequence", "DNA", 153, 168], ["PEDV", "SPECIES", 75, 79], ["other PEDV strains", "PROBLEM", 69, 87]]], ["These two phylogenetic trees all indicated that PEDV was mainly divided into two groups: group I consists mainly of classical strains and vaccine strains, while group II consists mainly of variant strains of China and mutant strains of the United States and South Korea.", [["PEDV", "SPECIES", 48, 52], ["PEDV", "PROBLEM", 48, 52], ["classical strains", "PROBLEM", 116, 133], ["vaccine strains", "PROBLEM", 138, 153]]], ["PEDV JS-A shared homology with the GD-1 strain of 99.9%, belong to non-S INDEL strain.", [["GD-1", "SPECIES", 35, 39], ["the GD", "TEST", 31, 37], ["non-S INDEL strain", "PROBLEM", 67, 85], ["INDEL strain", "OBSERVATION", 73, 85]]], ["Homology with the classic strain CV777, LZC, and SM98 was 96.8, 96.5, and 96.6%, respectively.", [["the classic strain", "TEST", 14, 32], ["LZC", "TEST", 40, 43], ["SM98", "TEST", 49, 53]]], ["The results showed that the S gene had 15 base insertions at 20806-20817 nt and 21,046-21,048 nt, and nine base deletions at 21,114-21,119 nt and 24,225-24,227 nt.", [["S gene", "DNA", 28, 34], ["15 base insertions", "DNA", 39, 57], ["20806-20817 nt", "DNA", 61, 75], ["the S gene", "TEST", 24, 34], ["base insertions", "TEST", 42, 57], ["nt", "TEST", 73, 75], ["nt", "TEST", 94, 96], ["nine base deletions", "TEST", 102, 121], ["nt", "TEST", 139, 141]]], ["It is currently a prevalent species compared to the classical strain CV777.Clinical Observations in Pigs Challenged With JS-ATo explore the pathogenicity of PEDV JS-A in piglets, we observed their clinical symptoms.", [["PEDV JS-A", "CELL", 157, 166], ["piglets", "ORGANISM", 170, 177], ["Pigs", "SPECIES", 100, 104], ["piglets", "SPECIES", 170, 177], ["PEDV", "SPECIES", 157, 161], ["a prevalent species", "PROBLEM", 16, 35], ["their clinical symptoms", "PROBLEM", 191, 214], ["PEDV JS", "OBSERVATION", 157, 164]]], ["All piglets from the control group were in great health throughout the study without observation of clinical symptoms.", [["piglets", "ORGANISM", 4, 11], ["piglets", "SPECIES", 4, 11], ["the study", "TEST", 67, 76], ["clinical symptoms", "PROBLEM", 100, 117], ["piglets", "OBSERVATION", 4, 11]]], ["However, three of six piglets in the challenged group developed diarrhea at 1 dpi, and the additional three piglets developed various degrees of diarrhea, vomiting, lethargy, and anorexia at 2-6 dpi.", [["diarrhea", "DISEASE", 64, 72], ["diarrhea", "DISEASE", 145, 153], ["vomiting", "DISEASE", 155, 163], ["lethargy", "DISEASE", 165, 173], ["anorexia", "DISEASE", 179, 187], ["piglets", "ORGANISM", 22, 29], ["piglets", "ORGANISM", 108, 115], ["piglets", "SPECIES", 22, 29], ["piglets", "SPECIES", 108, 115], ["diarrhea", "PROBLEM", 64, 72], ["diarrhea", "PROBLEM", 145, 153], ["vomiting", "PROBLEM", 155, 163], ["lethargy", "PROBLEM", 165, 173], ["anorexia", "PROBLEM", 179, 187], ["diarrhea", "OBSERVATION", 64, 72], ["various degrees", "OBSERVATION_MODIFIER", 126, 141], ["diarrhea", "OBSERVATION", 145, 153]]], ["Drowsiness, anorexia, and watery diarrhea developed most severely at 3-6 dpi, and piglets gradually recovered thereafter ( Figure 3A) .", [["Drowsiness", "DISEASE", 0, 10], ["anorexia", "DISEASE", 12, 20], ["watery diarrhea", "DISEASE", 26, 41], ["piglets", "ORGANISM", 82, 89], ["piglets", "SPECIES", 82, 89], ["Drowsiness", "PROBLEM", 0, 10], ["anorexia", "PROBLEM", 12, 20], ["watery diarrhea", "PROBLEM", 26, 41], ["anorexia", "OBSERVATION", 12, 20]]], ["No significant temperature change was observed between the two groups ( Figure 3B) .", [["significant temperature change", "PROBLEM", 3, 33], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["temperature", "OBSERVATION_MODIFIER", 15, 26], ["change", "OBSERVATION", 27, 33]]], ["The infected group showed significant weight loss, while the uninfected piglets experienced weight gain ( Figure 3C ).", [["weight loss", "DISEASE", 38, 49], ["weight gain", "DISEASE", 92, 103], ["piglets", "ORGANISM", 72, 79], ["piglets", "SPECIES", 72, 79], ["significant weight loss", "PROBLEM", 26, 49], ["weight gain", "PROBLEM", 92, 103], ["infected", "OBSERVATION", 4, 12], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["weight loss", "OBSERVATION", 38, 49]]], ["Despite watery diarrhea with vomiting, drowsiness, and anorexia, no deaths occurred during the study period.", [["watery diarrhea", "DISEASE", 8, 23], ["vomiting", "DISEASE", 29, 37], ["drowsiness", "DISEASE", 39, 49], ["anorexia", "DISEASE", 55, 63], ["deaths", "DISEASE", 68, 74], ["watery diarrhea", "PROBLEM", 8, 23], ["vomiting", "PROBLEM", 29, 37], ["drowsiness", "PROBLEM", 39, 49], ["anorexia", "PROBLEM", 55, 63], ["deaths", "PROBLEM", 68, 74], ["the study", "TEST", 91, 100], ["watery", "OBSERVATION_MODIFIER", 8, 14], ["diarrhea", "OBSERVATION", 15, 23], ["anorexia", "OBSERVATION", 55, 63]]], ["These results indicate that JS-A is pathogenic to newborn pigs.Fecal Shedding, Virus Distribution, and Neutralizing Antibody Against JS-ATo determine the fecal viral shedding, we attempted to detect viral RNA in rectal swab samples from 1 to 21 dpi by RT-PCR.", [["Fecal", "ANATOMY", 63, 68], ["rectal swab samples", "ANATOMY", 212, 231], ["JS-A", "CHEMICAL", 28, 32], ["JS-A", "GENE_OR_GENE_PRODUCT", 28, 32], ["pigs", "ORGANISM", 58, 62], ["Fecal", "ORGANISM_SUBSTANCE", 63, 68], ["fecal", "ORGANISM_SUBSTANCE", 154, 159], ["rectal swab samples", "ORGANISM_SUBSTANCE", 212, 231], ["viral RNA", "RNA", 199, 208], ["pigs", "SPECIES", 58, 62], ["Fecal Shedding, Virus Distribution", "PROBLEM", 63, 97], ["Neutralizing Antibody", "TEST", 103, 124], ["ATo", "TREATMENT", 136, 139], ["the fecal viral shedding", "PROBLEM", 150, 174], ["viral RNA", "PROBLEM", 199, 208], ["rectal swab samples", "TEST", 212, 231], ["RT", "TEST", 252, 254], ["PCR", "TEST", 255, 258], ["Shedding", "OBSERVATION", 69, 77], ["Virus Distribution", "OBSERVATION", 79, 97], ["fecal", "ANATOMY", 154, 159], ["rectal", "ANATOMY", 212, 218]]], ["Viral RNA was detected in 6/6 rectal swab samples collected from 1 to 14 dpi in the challenged group.", [["rectal swab samples", "ANATOMY", 30, 49], ["Viral", "ORGANISM", 0, 5], ["rectal swab samples", "ORGANISM_SUBSTANCE", 30, 49], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["rectal swab samples", "TEST", 30, 49], ["RNA", "OBSERVATION", 6, 9], ["rectal", "ANATOMY", 30, 36]]], ["PEDV RNA copies reached the peak of 10 4 -10 7 copies/mL in the homogenate rectal swab supernatant at 2-7 dpi, and the PEDV RNA was detected up to 14 dpi ( Figure 4A) .", [["rectal swab supernatant", "ANATOMY", 75, 98], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["rectal swab", "ORGANISM_SUBSTANCE", 75, 86], ["PEDV RNA copies", "RNA", 0, 15], ["PEDV RNA", "RNA", 119, 127], ["PEDV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 119, 123], ["PEDV RNA copies", "TEST", 0, 15], ["the homogenate rectal swab", "TEST", 60, 86], ["the PEDV RNA", "TEST", 115, 127], ["rectal", "ANATOMY", 75, 81]]], ["Notably, PEDV RNA was not detected in piglet samples from negative controls throughout the study.B AFIGURE 2 | Phylogenetic analysis was performed using the nucleotide sequences of the complete genome (A) and S genes (B) of the PEDV strain from the GenBank database.", [["piglet samples", "ANATOMY", 38, 52], ["PEDV", "GENE_OR_GENE_PRODUCT", 9, 13], ["piglet samples", "ORGANISM_SUBSTANCE", 38, 52], ["PEDV RNA", "RNA", 9, 17], ["S genes", "DNA", 209, 216], ["PEDV", "SPECIES", 9, 13], ["piglet", "SPECIES", 38, 44], ["PEDV", "SPECIES", 228, 232], ["PEDV RNA", "PROBLEM", 9, 17], ["piglet samples", "TEST", 38, 52], ["the study", "TEST", 87, 96], ["Phylogenetic analysis", "TEST", 111, 132], ["the nucleotide sequences", "TEST", 153, 177], ["the PEDV strain", "PROBLEM", 224, 239], ["PEDV RNA", "OBSERVATION", 9, 17], ["not detected", "UNCERTAINTY", 22, 34], ["PEDV", "OBSERVATION", 228, 232]]], ["The phylogenetic tree was constructed by the adjacency method in MEGA 7 (http://www.megasoftware.net).", [["phylogenetic tree", "OBSERVATION", 4, 21]]], ["Bootstrap analysis was performed using 1,000 iterations and the bootstrap value was indicated on each branch.", [["Bootstrap analysis", "TEST", 0, 18], ["the bootstrap value", "TEST", 60, 79], ["branch", "ANATOMY_MODIFIER", 102, 108]]], ["Scale bar indicates nucleotide substitution at each site.B ATo determine when PEDV IgG, IgA, and neutralizing antibodies were detected in infected piglets, PEDV IgG, IgA, and neutralizing antibodies were measured in serum samples collected at 7, 14, and 21 dpi.", [["piglets", "ANATOMY", 147, 154], ["serum samples", "ANATOMY", 216, 229], ["nucleotide", "CHEMICAL", 20, 30], ["nucleotide", "CHEMICAL", 20, 30], ["B ATo", "GENE_OR_GENE_PRODUCT", 57, 62], ["PEDV IgG", "GENE_OR_GENE_PRODUCT", 78, 86], ["IgA", "GENE_OR_GENE_PRODUCT", 88, 91], ["piglets", "ORGANISM", 147, 154], ["PEDV", "ORGANISM", 156, 160], ["IgG", "GENE_OR_GENE_PRODUCT", 161, 164], ["IgA", "GENE_OR_GENE_PRODUCT", 166, 169], ["serum samples", "ORGANISM_SUBSTANCE", 216, 229], ["PEDV IgG", "PROTEIN", 78, 86], ["IgA", "PROTEIN", 88, 91], ["neutralizing antibodies", "PROTEIN", 97, 120], ["PEDV IgG", "PROTEIN", 156, 164], ["IgA", "PROTEIN", 166, 169], ["neutralizing antibodies", "PROTEIN", 175, 198], ["piglets", "SPECIES", 147, 154], ["PEDV", "SPECIES", 78, 82], ["piglets", "SPECIES", 147, 154], ["PEDV", "SPECIES", 156, 160], ["nucleotide substitution at each site", "PROBLEM", 20, 56], ["PEDV IgG", "TEST", 78, 86], ["IgA", "TEST", 88, 91], ["neutralizing antibodies", "TEST", 97, 120], ["PEDV IgG", "TEST", 156, 164], ["IgA", "TEST", 166, 169], ["neutralizing antibodies", "TEST", 175, 198], ["serum samples", "TEST", 216, 229], ["nucleotide substitution", "OBSERVATION", 20, 43]]], ["The OD values of serum IgG and IgA in piglets inoculated with PEDV gradually increased at 7, 14, and 21 dpi, and the antibody titer gradually increased and peaked at 21 dpi (Figures 4B,C) .", [["serum", "ANATOMY", 17, 22], ["PEDV", "CHEMICAL", 62, 66], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 23, 26], ["IgA", "GENE_OR_GENE_PRODUCT", 31, 34], ["piglets", "ORGANISM", 38, 45], ["serum IgG", "PROTEIN", 17, 26], ["IgA", "PROTEIN", 31, 34], ["piglets", "SPECIES", 38, 45], ["PEDV", "SPECIES", 62, 66], ["The OD values", "TEST", 0, 13], ["serum IgG", "TEST", 17, 26], ["IgA", "TEST", 31, 34], ["PEDV", "PROBLEM", 62, 66], ["dpi", "TEST", 104, 107], ["the antibody titer", "TEST", 113, 131], ["Figures", "TEST", 174, 181]]], ["Neutralizing antibodies in collected serum samples were detected, and it was found that the antibody titer gradually increased and reached a peak at 21 dpi, as high 1:255 ( Figure 4D ).", [["serum samples", "ANATOMY", 37, 50], ["serum samples", "ORGANISM_SUBSTANCE", 37, 50], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["Neutralizing antibodies", "TEST", 0, 23], ["collected serum samples", "TEST", 27, 50], ["the antibody titer", "TEST", 88, 106]]], ["PEDV IgG, IgA, and neutralizing antibodies were not observed in the serum of control piglets.Gross Pathology and HistopathologyIn order to ascertain changes in piglets infected with JS-A about the overall histology and pathology, three of six piglets in each group were randomly selected for autopsy at 4 dpi.", [["serum", "ANATOMY", 68, 73], ["PEDV IgG", "GENE_OR_GENE_PRODUCT", 0, 8], ["IgA", "GENE_OR_GENE_PRODUCT", 10, 13], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["piglets", "ORGANISM", 85, 92], ["piglets", "ORGANISM", 160, 167], ["piglets", "ORGANISM", 243, 250], ["PEDV IgG", "PROTEIN", 0, 8], ["IgA", "PROTEIN", 10, 13], ["neutralizing antibodies", "PROTEIN", 19, 42], ["piglets", "SPECIES", 85, 92], ["piglets", "SPECIES", 160, 167], ["piglets", "SPECIES", 243, 250], ["PEDV", "SPECIES", 0, 4], ["PEDV IgG", "TEST", 0, 8], ["IgA", "TEST", 10, 13], ["neutralizing antibodies", "TEST", 19, 42], ["Gross Pathology", "TEST", 93, 108], ["Histopathology", "TEST", 113, 127], ["the overall histology", "TEST", 193, 214], ["pathology", "TEST", 219, 228], ["autopsy", "TEST", 292, 299], ["Pathology", "OBSERVATION", 99, 108], ["Histopathology", "OBSERVATION", 113, 127]]], ["The typical gross lesion seen in infected pigs is the accumulation of large amounts of yellow watery contents in the small intestine, resulting in thin and transparent intestinal wall and gas expansion due to atrophy of intestinal villi ( Figure 5A) .", [["gross lesion", "ANATOMY", 12, 24], ["small intestine", "ANATOMY", 117, 132], ["intestinal wall", "ANATOMY", 168, 183], ["intestinal villi", "ANATOMY", 220, 236], ["atrophy", "DISEASE", 209, 216], ["gross lesion", "PATHOLOGICAL_FORMATION", 12, 24], ["pigs", "ORGANISM", 42, 46], ["watery", "ORGANISM_SUBDIVISION", 94, 100], ["small intestine", "ORGAN", 117, 132], ["intestinal wall", "MULTI-TISSUE_STRUCTURE", 168, 183], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 220, 236], ["pigs", "SPECIES", 42, 46], ["pigs", "SPECIES", 42, 46], ["The typical gross lesion", "PROBLEM", 0, 24], ["yellow watery contents in the small intestine", "PROBLEM", 87, 132], ["thin and transparent intestinal wall and gas expansion", "PROBLEM", 147, 201], ["atrophy of intestinal villi", "PROBLEM", 209, 236], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["gross", "OBSERVATION_MODIFIER", 12, 17], ["lesion", "OBSERVATION", 18, 24], ["infected pigs", "OBSERVATION", 33, 46], ["accumulation", "OBSERVATION_MODIFIER", 54, 66], ["large", "OBSERVATION_MODIFIER", 70, 75], ["amounts", "OBSERVATION_MODIFIER", 76, 83], ["yellow", "OBSERVATION_MODIFIER", 87, 93], ["watery contents", "OBSERVATION", 94, 109], ["small intestine", "ANATOMY", 117, 132], ["thin", "OBSERVATION_MODIFIER", 147, 151], ["transparent", "ANATOMY_MODIFIER", 156, 167], ["intestinal", "ANATOMY", 168, 178], ["wall", "ANATOMY_MODIFIER", 179, 183], ["gas expansion", "OBSERVATION", 188, 201], ["atrophy", "OBSERVATION", 209, 216], ["intestinal villi", "ANATOMY", 220, 236]]], ["No other injuries were observed in any organs of the control pigs ( Figure 5B) .", [["organs", "ANATOMY", 39, 45], ["injuries", "DISEASE", 9, 17], ["organs", "ORGAN", 39, 45], ["pigs", "ORGANISM", 61, 65], ["pigs", "SPECIES", 61, 65], ["other injuries", "PROBLEM", 3, 17], ["injuries", "OBSERVATION", 9, 17]]], ["Histopathological examination showed necrosis of small intestinal epithelial cells, atrophy of intestinal villi and vacuolation in infected pigs compared with the control group (Figures 5C,D) , but the intestines of the negative control were normal (Figures 5E,F) .Gross Pathology and HistopathologyConsistent with histopathological findings, PEDV antigen was found in the cytoplasm of infected atrophic intestinal villous epithelial cells (Figures 5G,H) , and no PEDV IHC antigen was found in uninfected piglets (Figures 5I,J) .Porcine Epidemic Diarrhea Virus JS-A Infection Suppresses Neonatal Fc Receptor Expression Through Down-Regulation of Toll-Like Receptors and Downstream Signaling MoleculesAt 3 dpi, PEDV JS-A infection downregulated TLR3, TLR4, TLR7, TLR8, and TLR9 expression, as compared to the control group.", [["intestinal epithelial cells", "ANATOMY", 55, 82], ["intestinal villi", "ANATOMY", 95, 111], ["intestines", "ANATOMY", 202, 212], ["cytoplasm", "ANATOMY", 373, 382], ["intestinal villous epithelial cells", "ANATOMY", 404, 439], ["necrosis", "DISEASE", 37, 45], ["Diarrhea", "DISEASE", 546, 554], ["intestinal epithelial cells", "CELL", 55, 82], ["intestinal villi", "MULTI-TISSUE_STRUCTURE", 95, 111], ["pigs", "ORGANISM", 140, 144], ["intestines", "ORGAN", 202, 212], ["PEDV antigen", "GENE_OR_GENE_PRODUCT", 343, 355], ["cytoplasm", "ORGANISM_SUBSTANCE", 373, 382], ["intestinal villous epithelial cells", "CELL", 404, 439], ["Figures 5G,H", "CELL", 441, 453], ["PEDV IHC antigen", "GENE_OR_GENE_PRODUCT", 464, 480], ["piglets", "ORGANISM", 505, 512], ["Porcine", "ORGANISM", 529, 536], ["Epidemic Diarrhea Virus", "ORGANISM", 537, 560], ["Toll-Like Receptors", "GENE_OR_GENE_PRODUCT", 646, 665], ["Downstream Signaling MoleculesAt 3", "GENE_OR_GENE_PRODUCT", 670, 704], ["PEDV JS-A", "ORGANISM", 710, 719], ["TLR3", "GENE_OR_GENE_PRODUCT", 744, 748], ["TLR4", "GENE_OR_GENE_PRODUCT", 750, 754], ["TLR7", "GENE_OR_GENE_PRODUCT", 756, 760], ["TLR8", "GENE_OR_GENE_PRODUCT", 762, 766], ["TLR9", "GENE_OR_GENE_PRODUCT", 772, 776], ["small intestinal epithelial cells", "CELL_TYPE", 49, 82], ["PEDV antigen", "PROTEIN", 343, 355], ["infected atrophic intestinal villous epithelial cells", "CELL_TYPE", 386, 439], ["PEDV IHC antigen", "PROTEIN", 464, 480], ["Toll-Like Receptors", "PROTEIN", 646, 665], ["TLR3", "PROTEIN", 744, 748], ["TLR4", "PROTEIN", 750, 754], ["TLR8", "PROTEIN", 762, 766], ["TLR9", "PROTEIN", 772, 776], ["pigs", "SPECIES", 140, 144], ["piglets", "SPECIES", 505, 512], ["Porcine", "SPECIES", 529, 536], ["PEDV", "SPECIES", 464, 468], ["Porcine Epidemic Diarrhea Virus JS-A", "SPECIES", 529, 565], ["Histopathological examination", "TEST", 0, 29], ["necrosis", "PROBLEM", 37, 45], ["small intestinal epithelial cells", "PROBLEM", 49, 82], ["atrophy of intestinal villi", "PROBLEM", 84, 111], ["vacuolation in infected pigs", "PROBLEM", 116, 144], ["Gross Pathology", "TEST", 265, 280], ["Histopathology", "TEST", 285, 299], ["histopathological findings", "PROBLEM", 315, 341], ["PEDV antigen", "PROBLEM", 343, 355], ["infected atrophic intestinal villous epithelial cells", "PROBLEM", 386, 439], ["Figures", "TEST", 441, 448], ["PEDV IHC antigen", "PROBLEM", 464, 480], ["Porcine Epidemic Diarrhea Virus JS", "PROBLEM", 529, 563], ["A Infection", "PROBLEM", 564, 575], ["MoleculesAt", "TEST", 691, 702], ["PEDV JS", "TEST", 710, 717], ["A infection downregulated TLR3", "PROBLEM", 718, 748], ["TLR4", "TEST", 750, 754], ["TLR7", "TEST", 756, 760], ["TLR8", "TEST", 762, 766], ["TLR9 expression", "TREATMENT", 772, 787], ["necrosis", "OBSERVATION", 37, 45], ["small", "OBSERVATION_MODIFIER", 49, 54], ["intestinal epithelial cells", "OBSERVATION", 55, 82], ["atrophy", "OBSERVATION", 84, 91], ["intestinal villi", "ANATOMY", 95, 111], ["vacuolation", "OBSERVATION_MODIFIER", 116, 127], ["infected pigs", "OBSERVATION", 131, 144], ["intestines", "ANATOMY", 202, 212], ["negative", "OBSERVATION", 220, 228], ["Pathology", "OBSERVATION", 271, 280], ["Consistent with", "UNCERTAINTY", 299, 314], ["infected", "OBSERVATION_MODIFIER", 386, 394], ["atrophic", "OBSERVATION_MODIFIER", 395, 403], ["intestinal villous", "ANATOMY", 404, 422], ["epithelial cells", "OBSERVATION", 423, 439], ["no", "UNCERTAINTY", 461, 463], ["Virus JS", "OBSERVATION", 555, 563], ["Infection", "OBSERVATION", 566, 575], ["infection", "OBSERVATION", 720, 729], ["TLR4", "ANATOMY_MODIFIER", 750, 754], ["TLR7", "ANATOMY", 756, 760], ["TLR8", "ANATOMY", 762, 766], ["TLR9 expression", "OBSERVATION", 772, 787]]], ["Further, the corresponding downstream molecules TRIF, MyD88 (subunits A and B), and TRAF6 were significantly downregulated, eventually leading to down-regulation of the NF-\u03baB pathway (p < 0.05) (Figures 6A,B) .", [["TRIF", "GENE_OR_GENE_PRODUCT", 48, 52], ["MyD88", "GENE_OR_GENE_PRODUCT", 54, 59], ["A", "GENE_OR_GENE_PRODUCT", 70, 71], ["B", "GENE_OR_GENE_PRODUCT", 76, 77], ["TRAF6", "GENE_OR_GENE_PRODUCT", 84, 89], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 169, 174], ["downstream molecules", "PROTEIN", 27, 47], ["TRIF", "PROTEIN", 48, 52], ["MyD88", "PROTEIN", 54, 59], ["subunits A", "PROTEIN", 61, 71], ["B", "PROTEIN", 76, 77], ["TRAF6", "PROTEIN", 84, 89], ["NF-\u03baB", "PROTEIN", 169, 174], ["the corresponding downstream molecules TRIF", "TREATMENT", 9, 52], ["MyD88 (subunits A and B)", "TREATMENT", 54, 78], ["TRAF6", "TREATMENT", 84, 89], ["the NF", "TEST", 165, 171]]], ["However, at 21 dpi, TLR4, TLR7, and corresponding downstream MyD88 (subunits A and B) were up-regulated, further up-regulating NF-\u03baB.", [["TLR4", "GENE_OR_GENE_PRODUCT", 20, 24], ["TLR7", "GENE_OR_GENE_PRODUCT", 26, 30], ["MyD88", "GENE_OR_GENE_PRODUCT", 61, 66], ["A", "GENE_OR_GENE_PRODUCT", 77, 78], ["B", "GENE_OR_GENE_PRODUCT", 83, 84], ["NF-\u03ba", "GENE_OR_GENE_PRODUCT", 127, 131], ["TLR4", "PROTEIN", 20, 24], ["TLR7", "PROTEIN", 26, 30], ["MyD88", "PROTEIN", 61, 66], ["subunits A and B", "PROTEIN", 68, 84], ["NF-\u03baB.", "PROTEIN", 127, 133], ["TLR4", "TEST", 20, 24], ["TLR7", "TEST", 26, 30]]], ["We found that FcRn expression was down-regulated at 4 dpi, yet up-regulated at 21 dpi, and the regulation of FcRn was closely related to regulation of NF-\u03baB (Figures 6C,D) .DISCUSSIONDespite the use of commercially inactivated vaccines, the characteristics of PED infection and its epidemiology are highly significant, with morbidity and mortality rates approaching 100% in piglets (Pan et al., 2012) .", [["PED infection", "DISEASE", 260, 273], ["FcRn", "GENE_OR_GENE_PRODUCT", 14, 18], ["FcRn", "GENE_OR_GENE_PRODUCT", 109, 113], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 151, 156], ["D", "GENE_OR_GENE_PRODUCT", 169, 170], ["piglets", "ORGANISM", 374, 381], ["FcRn", "PROTEIN", 14, 18], ["FcRn", "PROTEIN", 109, 113], ["NF-\u03baB", "PROTEIN", 151, 156], ["piglets", "SPECIES", 374, 381], ["FcRn expression", "PROBLEM", 14, 29], ["commercially inactivated vaccines", "TREATMENT", 202, 235], ["PED infection", "PROBLEM", 260, 273], ["morbidity", "PROBLEM", 324, 333], ["mortality rates", "TEST", 338, 353], ["infection", "OBSERVATION", 264, 273]]], ["In 2013, a sudden PED outbreak occurred in the United States and spread quickly throughout the country, as well as Canada and Mexico, resulting in high mortality of newborn piglets and serious financial problems (Mole, 2013; Stevenson et al., 2013; Vlasova et al., 2014) .", [["piglets", "ORGANISM", 173, 180], ["piglets", "SPECIES", 173, 180], ["a sudden PED outbreak", "PROBLEM", 9, 30]]], ["In this study, the isolated JS-A strain was more similar to the PEDV GD-1 strain, which was distant from classical strains such as CV777, LZC, and SM98, suggesting that PEDV is continuously evolving, with variation in the epidemiological process.", [["PEDV", "CHEMICAL", 169, 173], ["JS-A", "CELL", 28, 32], ["PEDV GD-1 strain", "ORGANISM", 64, 80], ["SM98", "GENE_OR_GENE_PRODUCT", 147, 151], ["PEDV", "GENE_OR_GENE_PRODUCT", 169, 173], ["JS-A strain", "SPECIES", 28, 39], ["PEDV GD-1", "SPECIES", 64, 73], ["PEDV", "SPECIES", 169, 173], ["this study", "TEST", 3, 13], ["the isolated JS-A strain", "PROBLEM", 15, 39], ["the PEDV GD-1 strain", "PROBLEM", 60, 80], ["classical strains", "PROBLEM", 105, 122], ["LZC", "TEST", 138, 141], ["PEDV", "PROBLEM", 169, 173], ["PEDV", "OBSERVATION", 64, 68], ["PEDV", "OBSERVATION", 169, 173]]], ["Therefore, vaccines made from classical strains cannot provide effective protection, which is consistent with current findings.", [["vaccines", "TREATMENT", 11, 19], ["classical strains", "PROBLEM", 30, 47], ["consistent with", "UNCERTAINTY", 94, 109]]], ["The PEDV S gene evolutionary tree and homology were further analyzed.", [["PEDV", "SPECIES", 4, 8], ["The PEDV", "PROBLEM", 0, 8], ["PEDV", "OBSERVATION", 4, 8], ["tree", "OBSERVATION_MODIFIER", 29, 33]]], ["The phylogenetic tree was divided into two evolutionary branches, namely G1 and G2 groups.", [["phylogenetic tree", "OBSERVATION", 4, 21], ["evolutionary", "OBSERVATION_MODIFIER", 43, 55], ["branches", "OBSERVATION_MODIFIER", 56, 64]]], ["The G1 group contained classic strains such as CV777, DR13, and SM98.", [["strains", "ANATOMY", 31, 38], ["classic strains", "PROBLEM", 23, 38], ["classic strains", "OBSERVATION", 23, 38]]], ["The G2 group has been the most prevalent strain since 2010.", [["most prevalent", "OBSERVATION_MODIFIER", 26, 40]]], ["JS-A, which has been separated this time, also belongs to G2a.", [["JS-A", "CHEMICAL", 0, 4], ["JS-A", "GENE_OR_GENE_PRODUCT", 0, 4], ["G2a", "GENE_OR_GENE_PRODUCT", 58, 61], ["G2a", "DNA", 58, 61]]], ["This shows that JS-A is indeed the dominant strain in current pig farms.", [["JS-A", "CHEMICAL", 16, 20], ["JS-A", "GENE_OR_GENE_PRODUCT", 16, 20], ["pig", "ORGANISM", 62, 65], ["pig", "SPECIES", 62, 65], ["pig", "SPECIES", 62, 65], ["dominant", "OBSERVATION_MODIFIER", 35, 43], ["strain", "OBSERVATION_MODIFIER", 44, 50], ["pig farms", "OBSERVATION", 62, 71]]], ["Induced stronger primary and anamnestic immune responses.", [["stronger", "OBSERVATION_MODIFIER", 8, 16], ["primary", "OBSERVATION_MODIFIER", 17, 24]]], ["The JS-A strain belongs to the non-S-INDEL, which is highly pathogenic.DISCUSSIONTo study the pathogenicity of PEDV JS-A, 5-day-old piglets were inoculated orally.", [["JS-A strain", "ORGANISM", 4, 15], ["INDEL", "GENE_OR_GENE_PRODUCT", 37, 42], ["PEDV JS-A", "CANCER", 111, 120], ["piglets", "ORGANISM", 132, 139], ["non-S-INDEL", "PROTEIN", 31, 42], ["piglets", "SPECIES", 132, 139], ["PEDV", "SPECIES", 111, 115], ["The JS", "TEST", 0, 6], ["JS", "ANATOMY", 4, 6], ["highly", "OBSERVATION_MODIFIER", 53, 59], ["pathogenic", "OBSERVATION", 60, 70], ["PEDV JS", "OBSERVATION", 111, 118]]], ["As expected, vomiting and severe diarrhea were observed in piglets from 1 to 6 dpi, indicating that JS-A was pathogenic to newborn piglets.", [["vomiting", "DISEASE", 13, 21], ["diarrhea", "DISEASE", 33, 41], ["JS-A", "CHEMICAL", 100, 104], ["piglets", "ORGANISM", 59, 66], ["JS-A", "GENE_OR_GENE_PRODUCT", 100, 104], ["piglets", "ORGANISM", 131, 138], ["piglets", "SPECIES", 59, 66], ["piglets", "SPECIES", 131, 138], ["vomiting", "PROBLEM", 13, 21], ["severe diarrhea", "PROBLEM", 26, 41], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["diarrhea", "OBSERVATION", 33, 41]]], ["Fecal swabs were collected from piglets infected with PEDV, and viral fecal shedding was detected by real-time PCR.", [["Fecal swabs", "ANATOMY", 0, 11], ["fecal", "ANATOMY", 70, 75], ["Fecal swabs", "ORGANISM_SUBSTANCE", 0, 11], ["piglets", "ORGANISM", 32, 39], ["fecal", "ORGANISM_SUBSTANCE", 70, 75], ["piglets", "SPECIES", 32, 39], ["PEDV", "SPECIES", 54, 58], ["Fecal swabs", "TEST", 0, 11], ["PEDV", "PROBLEM", 54, 58], ["viral fecal shedding", "PROBLEM", 64, 84]]], ["PEDV RNA was detected from 1 to 14 dpi, suggesting that PEDV infection via fecal-oral contamination may be the main transmission route of piglet diarrhea in pig farms.", [["oral", "ANATOMY", 81, 85], ["piglet", "ANATOMY", 138, 144], ["PEDV", "CHEMICAL", 56, 60], ["infection", "DISEASE", 61, 70], ["fecal-oral contamination", "DISEASE", 75, 99], ["piglet diarrhea", "DISEASE", 138, 153], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 56, 60], ["oral", "ORGANISM_SUBDIVISION", 81, 85], ["piglet", "ORGANISM", 138, 144], ["pig", "ORGANISM", 157, 160], ["PEDV RNA", "RNA", 0, 8], ["pig", "SPECIES", 157, 160], ["PEDV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 56, 60], ["piglet", "SPECIES", 138, 144], ["pig", "SPECIES", 157, 160], ["PEDV RNA", "PROBLEM", 0, 8], ["PEDV infection", "PROBLEM", 56, 70], ["fecal-oral contamination", "PROBLEM", 75, 99], ["piglet diarrhea", "PROBLEM", 138, 153], ["PEDV", "OBSERVATION_MODIFIER", 56, 60], ["infection", "OBSERVATION", 61, 70], ["fecal", "ANATOMY", 75, 80]]], ["Previously, it has been reported that coronavirus HKU15 may be transmitted via the respiratory route, in addition to fecal-oral transmission (Woo et al., 2017; Li et al., 2018) .", [["respiratory", "ANATOMY", 83, 94], ["oral", "ANATOMY", 123, 127], ["HKU15", "CHEMICAL", 50, 55], ["fecal-oral transmission", "DISEASE", 117, 140], ["coronavirus", "ORGANISM", 38, 49], ["HKU15", "GENE_OR_GENE_PRODUCT", 50, 55], ["oral", "ORGANISM_SUBDIVISION", 123, 127], ["coronavirus", "SPECIES", 38, 49], ["fecal", "ANATOMY", 117, 122]]], ["Notably, we only observed microlesions in the jejunum and ileum of piglets infected with JS-A, but PEDV infection did not cause death of newborn piglets, despite drowsiness, anorexia, and watery diarrhea in these animals.", [["jejunum", "ANATOMY", 46, 53], ["ileum", "ANATOMY", 58, 63], ["JS-A", "CHEMICAL", 89, 93], ["PEDV", "CHEMICAL", 99, 103], ["infection", "DISEASE", 104, 113], ["death", "DISEASE", 128, 133], ["anorexia", "DISEASE", 174, 182], ["watery diarrhea", "DISEASE", 188, 203], ["jejunum", "MULTI-TISSUE_STRUCTURE", 46, 53], ["ileum", "ORGAN", 58, 63], ["piglets", "ORGANISM", 67, 74], ["PEDV", "ORGANISM", 99, 103], ["piglets", "ORGANISM", 145, 152], ["piglets", "SPECIES", 67, 74], ["piglets", "SPECIES", 145, 152], ["JS-A", "SPECIES", 89, 93], ["PEDV", "SPECIES", 99, 103], ["microlesions in the jejunum", "PROBLEM", 26, 53], ["PEDV infection", "PROBLEM", 99, 113], ["death of newborn piglets", "PROBLEM", 128, 152], ["drowsiness", "PROBLEM", 162, 172], ["anorexia", "PROBLEM", 174, 182], ["watery diarrhea in these animals", "PROBLEM", 188, 220], ["microlesions", "OBSERVATION", 26, 38], ["jejunum", "ANATOMY", 46, 53], ["ileum", "ANATOMY", 58, 63], ["piglets", "OBSERVATION_MODIFIER", 67, 74], ["infected", "OBSERVATION", 75, 83], ["infection", "OBSERVATION", 104, 113], ["watery", "OBSERVATION_MODIFIER", 188, 194], ["diarrhea", "OBSERVATION", 195, 203]]], ["These results suggest that PEDV JS-A has a milder toxicity and may be a weak strain.", [["PEDV", "CHEMICAL", 27, 31], ["JS-A", "CHEMICAL", 32, 36], ["toxicity", "DISEASE", 50, 58], ["PEDV JS-A", "ORGANISM", 27, 36], ["PEDV JS", "PROBLEM", 27, 34], ["a milder toxicity", "PROBLEM", 41, 58], ["a weak strain", "PROBLEM", 70, 83], ["PEDV JS", "OBSERVATION", 27, 34], ["weak strain", "OBSERVATION", 72, 83]]], ["At the same time, there were slight differences in body weight and no significant differences in body temperature during infection.", [["body", "ANATOMY", 51, 55], ["body", "ANATOMY", 97, 101], ["infection", "DISEASE", 121, 130], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["body", "ORGANISM_SUBDIVISION", 97, 101], ["slight differences in body weight", "PROBLEM", 29, 62], ["significant differences in body temperature during infection", "PROBLEM", 70, 130], ["slight", "OBSERVATION_MODIFIER", 29, 35], ["differences", "OBSERVATION_MODIFIER", 36, 47], ["no", "UNCERTAINTY", 67, 69], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["differences", "OBSERVATION_MODIFIER", 82, 93], ["infection", "OBSERVATION", 121, 130]]], ["We also tested the serum-specific IgG, IgA, and neutralizing antibody levels in piglets at 7, 14, and 21 dpi and found that the antibody levels of IgG and IgA gradually increased with time.", [["serum", "ANATOMY", 19, 24], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgA", "GENE_OR_GENE_PRODUCT", 39, 42], ["piglets", "ORGANISM", 80, 87], ["IgG", "GENE_OR_GENE_PRODUCT", 147, 150], ["IgA", "GENE_OR_GENE_PRODUCT", 155, 158], ["IgG", "PROTEIN", 34, 37], ["IgA", "PROTEIN", 39, 42], ["IgG", "PROTEIN", 147, 150], ["IgA", "PROTEIN", 155, 158], ["piglets", "SPECIES", 80, 87], ["the serum", "TEST", 15, 24], ["specific IgG", "TEST", 25, 37], ["IgA", "TEST", 39, 42], ["neutralizing antibody levels", "TEST", 48, 76], ["the antibody levels", "TEST", 124, 143], ["IgG", "TEST", 147, 150], ["IgA", "TEST", 155, 158]]], ["Further, the serum IgA level was higher than that of IgG.", [["serum", "ANATOMY", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["IgA", "GENE_OR_GENE_PRODUCT", 19, 22], ["IgG", "GENE_OR_GENE_PRODUCT", 53, 56], ["IgA", "PROTEIN", 19, 22], ["IgG", "PROTEIN", 53, 56], ["the serum IgA level", "TEST", 9, 28], ["IgG", "TEST", 53, 56]]], ["PEDV-challenged protection during the first infection was positively correlated with IgA and IgG antibodies in intestinal-associated lymphoid tissues and blood (de Arriba et al., 2002) , indicating that VN antibody can be detected in piglets inoculated with PEDV JS-A, and the titer of VN antibody gradually increases and remains high at the end of the experiment (Chen et al., 2016) .", [["intestinal", "ANATOMY", 111, 121], ["lymphoid tissues", "ANATOMY", 133, 149], ["blood", "ANATOMY", 154, 159], ["PEDV", "CHEMICAL", 0, 4], ["infection", "DISEASE", 44, 53], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["IgA", "GENE_OR_GENE_PRODUCT", 85, 88], ["IgG antibodies", "GENE_OR_GENE_PRODUCT", 93, 107], ["intestinal", "TISSUE", 111, 121], ["lymphoid tissues", "TISSUE", 133, 149], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["VN antibody", "GENE_OR_GENE_PRODUCT", 203, 214], ["piglets", "ORGANISM", 234, 241], ["PEDV JS-A", "ORGANISM", 258, 267], ["VN antibody", "GENE_OR_GENE_PRODUCT", 286, 297], ["IgA", "PROTEIN", 85, 88], ["IgG antibodies", "PROTEIN", 93, 107], ["VN antibody", "PROTEIN", 203, 214], ["VN antibody", "PROTEIN", 286, 297], ["piglets", "SPECIES", 234, 241], ["PEDV", "SPECIES", 0, 4], ["PEDV", "SPECIES", 258, 262], ["PEDV", "PROBLEM", 0, 4], ["challenged protection", "TREATMENT", 5, 26], ["the first infection", "PROBLEM", 34, 53], ["IgA", "TEST", 85, 88], ["IgG antibodies", "TEST", 93, 107], ["VN antibody", "TEST", 203, 214], ["PEDV JS", "TEST", 258, 265], ["the titer of VN antibody", "TEST", 273, 297], ["intestinal", "ANATOMY", 111, 121], ["lymphoid tissues", "OBSERVATION", 133, 149], ["high", "OBSERVATION_MODIFIER", 330, 334]]], ["In our study, PEDV VN antibody was detected as early as 7 dpi in piglets infected with PEDV.", [["PEDV", "CHEMICAL", 87, 91], ["PEDV VN antibody", "GENE_OR_GENE_PRODUCT", 14, 30], ["piglets", "ORGANISM", 65, 72], ["PEDV VN antibody", "PROTEIN", 14, 30], ["piglets", "SPECIES", 65, 72], ["PEDV", "SPECIES", 14, 18], ["piglets", "SPECIES", 65, 72], ["PEDV", "SPECIES", 87, 91], ["our study", "TEST", 3, 12], ["PEDV VN antibody", "TEST", 14, 30], ["PEDV", "PROBLEM", 87, 91]]], ["The antibody titer of VN increased and remained high up to 21 dpi, at which point all pigs in the challenged group recovered completely.DISCUSSIONIn vitro studies have proven to be highly dependent on strains, and cell types cannot be used to assess innate immune responses against low virulence strains (Kint et al., 2015) .", [["cell", "ANATOMY", 214, 218], ["VN", "GENE_OR_GENE_PRODUCT", 22, 24], ["pigs", "ORGANISM", 86, 90], ["cell", "CELL", 214, 218], ["VN", "PROTEIN", 22, 24], ["The antibody titer", "TEST", 0, 18], ["VN", "TEST", 22, 24], ["vitro studies", "TEST", 149, 162], ["strains", "PROBLEM", 201, 208], ["low virulence strains", "PROBLEM", 282, 303], ["increased", "OBSERVATION_MODIFIER", 25, 34], ["high", "OBSERVATION_MODIFIER", 48, 52]]], ["PEDV has been reported to induce innate immune responses in vivo.", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "SIMPLE_CHEMICAL", 0, 4], ["PEDV", "PROTEIN", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4]]], ["However, few studies have been reported.", [["few studies", "TEST", 9, 20]]], ["Therefore, in this study, in vivo models were used to further observe the natural TLRs and signaling pathway homeostasis regulated by the gut microbiota.", [["gut microbiota", "ANATOMY", 138, 152], ["TLRs", "GENE_OR_GENE_PRODUCT", 82, 86], ["gut microbiota", "MULTI-TISSUE_STRUCTURE", 138, 152], ["TLRs", "PROTEIN", 82, 86], ["this study", "TEST", 14, 24]]], ["Natural immunity is the first line of host defense against a variety of pathogenic infections .", [["infections", "DISEASE", 83, 93], ["pathogenic infections", "PROBLEM", 72, 93], ["variety", "OBSERVATION_MODIFIER", 61, 68], ["pathogenic", "OBSERVATION_MODIFIER", 72, 82], ["infections", "OBSERVATION", 83, 93]]], ["Furthermore, in vitro PEDV N and E protein mediated NF-\u03baB activation and had effects on cell growth and ER stress, upregulating IL-8 expression (Xu et al., 2013; Cao et al., 2015b) .", [["cell", "ANATOMY", 88, 92], ["PEDV N", "GENE_OR_GENE_PRODUCT", 22, 28], ["E protein", "GENE_OR_GENE_PRODUCT", 33, 42], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 52, 57], ["cell", "CELL", 88, 92], ["ER", "GENE_OR_GENE_PRODUCT", 104, 106], ["IL-8", "GENE_OR_GENE_PRODUCT", 128, 132], ["PEDV N", "PROTEIN", 22, 28], ["NF-\u03baB", "PROTEIN", 52, 57], ["ER", "PROTEIN", 104, 106], ["IL-8", "PROTEIN", 128, 132], ["cell growth", "PROBLEM", 88, 99], ["ER stress", "TEST", 104, 113], ["upregulating IL", "TREATMENT", 115, 130]]], ["However, PEDV non-S-INDEL N and nsp1 protein inhibited NF-\u03baB activation (Ding et al., 2014; Zhang et al., 2017) .", [["PEDV non-S-INDEL N", "GENE_OR_GENE_PRODUCT", 9, 27], ["nsp1", "GENE_OR_GENE_PRODUCT", 32, 36], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 55, 60], ["PEDV non-S-INDEL N", "PROTEIN", 9, 27], ["nsp1 protein", "PROTEIN", 32, 44], ["NF-\u03baB", "PROTEIN", 55, 60], ["PEDV", "SPECIES", 9, 13], ["PEDV", "TEST", 9, 13], ["nsp1 protein", "TEST", 32, 44]]], ["MyD88 is an essential component of the innate immune response to SARS-CoV infection in mice in vivo (Totura et al., 2015) .", [["SARS-CoV infection", "DISEASE", 65, 83], ["MyD88", "GENE_OR_GENE_PRODUCT", 0, 5], ["SARS-CoV", "ORGANISM", 65, 73], ["mice", "ORGANISM", 87, 91], ["MyD88", "PROTEIN", 0, 5], ["mice", "SPECIES", 87, 91], ["SARS-CoV", "SPECIES", 65, 73], ["mice", "SPECIES", 87, 91], ["SARS", "PROBLEM", 65, 69], ["CoV infection", "PROBLEM", 70, 83], ["essential component", "OBSERVATION_MODIFIER", 12, 31], ["infection", "OBSERVATION", 74, 83]]], ["The pathogenesis of PEDV is strain specific.", [["PEDV", "CHEMICAL", 20, 24], ["PEDV", "GENE_OR_GENE_PRODUCT", 20, 24], ["PEDV", "SPECIES", 20, 24], ["PEDV", "PROBLEM", 20, 24], ["PEDV", "OBSERVATION", 20, 24], ["strain", "OBSERVATION_MODIFIER", 28, 34], ["specific", "OBSERVATION_MODIFIER", 35, 43]]], ["The lack of TRAF6 leads to enhanced viral replication and a significant reduction in the production of type I IFN after infection with RNA virus.", [["infection", "DISEASE", 120, 129], ["TRAF6", "GENE_OR_GENE_PRODUCT", 12, 17], ["type I IFN", "GENE_OR_GENE_PRODUCT", 103, 113], ["TRAF6", "PROTEIN", 12, 17], ["type I IFN", "PROTEIN", 103, 113], ["enhanced viral replication", "TREATMENT", 27, 53], ["a significant reduction", "PROBLEM", 58, 81], ["type I IFN", "PROBLEM", 103, 113], ["infection", "PROBLEM", 120, 129], ["RNA virus", "PROBLEM", 135, 144], ["viral replication", "OBSERVATION", 36, 53], ["significant", "OBSERVATION_MODIFIER", 60, 71], ["reduction", "OBSERVATION_MODIFIER", 72, 81]]], ["In vivo, PEDV non-S-INDEL down-regulates the NF-\u03baB signaling pathway through negative regulation of TLR4, TLR7, TLR8, and TLR9, resulting in the final attenuation of MyD88, TRIF, and TRAF6 gene expression (Temeeyasen et al., 2018) .DISCUSSIONThe IgA plays a major role in the mucosal anti-PEDV infection immunity.", [["mucosal", "ANATOMY", 276, 283], ["infection", "DISEASE", 294, 303], ["INDEL", "GENE_OR_GENE_PRODUCT", 20, 25], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 45, 50], ["TLR4", "GENE_OR_GENE_PRODUCT", 100, 104], ["TLR7", "GENE_OR_GENE_PRODUCT", 106, 110], ["TLR8", "GENE_OR_GENE_PRODUCT", 112, 116], ["TLR9", "GENE_OR_GENE_PRODUCT", 122, 126], ["MyD88", "GENE_OR_GENE_PRODUCT", 166, 171], ["TRIF", "GENE_OR_GENE_PRODUCT", 173, 177], ["TRAF6", "GENE_OR_GENE_PRODUCT", 183, 188], ["IgA", "GENE_OR_GENE_PRODUCT", 246, 249], ["mucosal", "ORGANISM_SUBDIVISION", 276, 283], ["NF-\u03baB", "PROTEIN", 45, 50], ["TLR4", "PROTEIN", 100, 104], ["TLR7", "PROTEIN", 106, 110], ["TLR8", "PROTEIN", 112, 116], ["TLR9", "PROTEIN", 122, 126], ["MyD88", "PROTEIN", 166, 171], ["TRIF", "PROTEIN", 173, 177], ["TRAF6", "PROTEIN", 183, 188], ["IgA", "PROTEIN", 246, 249], ["PEDV", "SPECIES", 9, 13], ["anti-PEDV", "SPECIES", 284, 293], ["PEDV", "TEST", 9, 13], ["the NF", "TEST", 41, 47], ["TLR4", "TEST", 100, 104], ["TLR7", "TEST", 106, 110], ["TLR8", "TEST", 112, 116], ["TLR9", "TEST", 122, 126], ["TRIF", "TREATMENT", 173, 177], ["the mucosal anti-PEDV infection immunity", "TREATMENT", 272, 312], ["TLR4", "ANATOMY", 100, 104], ["mucosal", "ANATOMY", 276, 283]]], ["However, recent studies have found that IgG also plays an important role against pathogen infection in mucosal sites, while the neonatal Fc receptor (FcRn) is the only IgG transport receptor (Tsuruta et al., 2012) .", [["mucosal sites", "ANATOMY", 103, 116], ["infection", "DISEASE", 90, 99], ["IgG", "GENE_OR_GENE_PRODUCT", 40, 43], ["mucosal sites", "MULTI-TISSUE_STRUCTURE", 103, 116], ["Fc receptor", "GENE_OR_GENE_PRODUCT", 137, 148], ["FcRn", "GENE_OR_GENE_PRODUCT", 150, 154], ["IgG transport receptor", "GENE_OR_GENE_PRODUCT", 168, 190], ["IgG", "PROTEIN", 40, 43], ["neonatal Fc receptor", "PROTEIN", 128, 148], ["FcRn", "PROTEIN", 150, 154], ["IgG transport receptor", "PROTEIN", 168, 190], ["recent studies", "TEST", 9, 23], ["IgG", "PROBLEM", 40, 43], ["pathogen infection in mucosal sites", "PROBLEM", 81, 116], ["infection", "OBSERVATION", 90, 99], ["mucosal sites", "ANATOMY", 103, 116]]], ["Down-regulation of FcRn and pIgR has been shown in the tracheal mucosa of SHIV/ SIV-infected rhesus macaques (Wang and Yang, 2016; Li et al., 2017) .", [["tracheal mucosa", "ANATOMY", 55, 70], ["FcRn", "GENE_OR_GENE_PRODUCT", 19, 23], ["pIgR", "GENE_OR_GENE_PRODUCT", 28, 32], ["tracheal mucosa", "MULTI-TISSUE_STRUCTURE", 55, 70], ["SHIV", "ORGANISM", 74, 78], ["SIV", "ORGANISM", 80, 83], ["rhesus", "ORGANISM", 93, 99], ["macaques", "ORGANISM", 100, 108], ["FcRn", "PROTEIN", 19, 23], ["pIgR", "PROTEIN", 28, 32], ["rhesus macaques", "SPECIES", 93, 108], ["SHIV/ SIV-infected rhesus macaques", "SPECIES", 74, 108], ["tracheal mucosa", "ANATOMY", 55, 70], ["SHIV", "OBSERVATION", 74, 78], ["SIV", "ANATOMY", 80, 83], ["infected", "OBSERVATION_MODIFIER", 84, 92], ["rhesus macaques", "OBSERVATION", 93, 108]]], ["Further, transmissible gastroenteritis virus infection up-regulates FcRn through TLR3 and RIG-I in porcine intestinal epithelial cells (unpublished results).", [["intestinal epithelial cells", "ANATOMY", 107, 134], ["gastroenteritis", "DISEASE", 23, 38], ["infection", "DISEASE", 45, 54], ["transmissible gastroenteritis virus", "ORGANISM", 9, 44], ["FcRn", "GENE_OR_GENE_PRODUCT", 68, 72], ["TLR3", "GENE_OR_GENE_PRODUCT", 81, 85], ["RIG-I", "GENE_OR_GENE_PRODUCT", 90, 95], ["porcine", "ORGANISM", 99, 106], ["intestinal epithelial cells", "CELL", 107, 134], ["FcRn", "PROTEIN", 68, 72], ["TLR3", "PROTEIN", 81, 85], ["RIG-I", "PROTEIN", 90, 95], ["porcine intestinal epithelial cells", "CELL_TYPE", 99, 134], ["transmissible gastroenteritis virus", "SPECIES", 9, 44], ["transmissible gastroenteritis virus infection", "PROBLEM", 9, 54], ["transmissible", "OBSERVATION_MODIFIER", 9, 22], ["gastroenteritis", "OBSERVATION", 23, 38], ["porcine", "ANATOMY_MODIFIER", 99, 106], ["intestinal", "ANATOMY", 107, 117], ["epithelial cells", "OBSERVATION", 118, 134]]], ["PEDV JS-A can down-regulate NF-\u03baB signaling pathway by inhibiting mRNA expression of TLR3, TLR4, TLR7, TLR8, and TLR9 at 4 dpi, resulting in the final attenuation of FcRn gene expression.", [["PEDV", "CHEMICAL", 0, 4], ["JS-A", "CHEMICAL", 5, 9], ["JS-A", "GENE_OR_GENE_PRODUCT", 5, 9], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 28, 33], ["TLR3", "GENE_OR_GENE_PRODUCT", 85, 89], ["TLR4", "GENE_OR_GENE_PRODUCT", 91, 95], ["TLR7", "GENE_OR_GENE_PRODUCT", 97, 101], ["TLR8", "GENE_OR_GENE_PRODUCT", 103, 107], ["TLR9", "GENE_OR_GENE_PRODUCT", 113, 117], ["FcRn", "GENE_OR_GENE_PRODUCT", 166, 170], ["NF-\u03baB", "PROTEIN", 28, 33], ["TLR3", "PROTEIN", 85, 89], ["TLR4", "PROTEIN", 91, 95], ["TLR7", "PROTEIN", 97, 101], ["TLR8", "PROTEIN", 103, 107], ["TLR9", "PROTEIN", 113, 117], ["FcRn gene", "DNA", 166, 175], ["PEDV", "SPECIES", 0, 4], ["TLR3", "TEST", 85, 89], ["TLR4", "TEST", 91, 95], ["TLR7", "TEST", 97, 101], ["TLR8", "TEST", 103, 107], ["TLR9", "TREATMENT", 113, 117], ["TLR3", "ANATOMY", 85, 89]]], ["In contrast, FcRn expression was up-regulated through TLR3, TLR4, TLR8 at 21 dpi.DISCUSSIONIn conclusion, we successfully isolated the PEDV JS-A strain, and phylogenetic analysis indicated that the major parent of JS-A strain was identified as strain FL2013 or GD-1.", [["FcRn", "GENE_OR_GENE_PRODUCT", 13, 17], ["TLR3", "GENE_OR_GENE_PRODUCT", 54, 58], ["TLR4", "GENE_OR_GENE_PRODUCT", 60, 64], ["TLR8", "GENE_OR_GENE_PRODUCT", 66, 70], ["PEDV JS-A", "CELL", 135, 144], ["JS-A strain", "ORGANISM", 214, 225], ["GD-1", "CELL", 261, 265], ["FcRn", "PROTEIN", 13, 17], ["TLR3", "PROTEIN", 54, 58], ["TLR4", "PROTEIN", 60, 64], ["TLR8", "PROTEIN", 66, 70], ["PEDV JS-A", "SPECIES", 135, 144], ["JS-A strain", "SPECIES", 214, 225], ["GD-1", "SPECIES", 261, 265], ["TLR8", "TREATMENT", 66, 70], ["the PEDV JS", "TEST", 131, 142], ["A strain", "PROBLEM", 143, 151], ["phylogenetic analysis", "TEST", 157, 178], ["A strain", "PROBLEM", 217, 225]]], ["The study results showed that JS-A was a variant PEDV strain with weak pathology to piglets, compared to other emerging strains.", [["JS-A", "CHEMICAL", 30, 34], ["JS-A", "SIMPLE_CHEMICAL", 30, 34], ["PEDV", "GENE_OR_GENE_PRODUCT", 49, 53], ["piglets", "ORGANISM", 84, 91], ["piglets", "SPECIES", 84, 91], ["The study", "TEST", 0, 9], ["a variant PEDV strain", "PROBLEM", 39, 60], ["weak pathology to piglets", "PROBLEM", 66, 91]]], ["High levels of serum IgG, IgA, and VN antibodies were also detected in the sera of infected piglets at 21 dpi.", [["serum", "ANATOMY", 15, 20], ["sera", "ANATOMY", 75, 79], ["serum", "ORGANISM_SUBSTANCE", 15, 20], ["IgG", "GENE_OR_GENE_PRODUCT", 21, 24], ["IgA", "GENE_OR_GENE_PRODUCT", 26, 29], ["VN antibodies", "GENE_OR_GENE_PRODUCT", 35, 48], ["sera", "ORGANISM_SUBSTANCE", 75, 79], ["piglets", "ORGANISM", 92, 99], ["serum IgG", "PROTEIN", 15, 24], ["IgA", "PROTEIN", 26, 29], ["VN antibodies", "PROTEIN", 35, 48], ["piglets", "SPECIES", 92, 99], ["serum IgG", "TEST", 15, 24], ["IgA", "TEST", 26, 29], ["VN antibodies", "TEST", 35, 48]]], ["In addition, inoculation of piglets with JS-A suppressed FcRn expression via TLR, RIG-I, and NF-\u03baB mRNA expressions at 4 dpi, yet induced FcRn expression at 21 dpi in infected intestinal mucosa.", [["intestinal mucosa", "ANATOMY", 176, 193], ["JS-A", "CHEMICAL", 41, 45], ["piglets", "ORGANISM", 28, 35], ["JS-A", "SIMPLE_CHEMICAL", 41, 45], ["FcRn", "GENE_OR_GENE_PRODUCT", 57, 61], ["TLR", "GENE_OR_GENE_PRODUCT", 77, 80], ["RIG-I", "GENE_OR_GENE_PRODUCT", 82, 87], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 93, 98], ["FcRn", "GENE_OR_GENE_PRODUCT", 138, 142], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 176, 193], ["FcRn", "PROTEIN", 57, 61], ["FcRn", "PROTEIN", 138, 142], ["piglets", "SPECIES", 28, 35], ["NF", "TEST", 93, 95], ["infected", "OBSERVATION", 167, 175], ["intestinal mucosa", "ANATOMY", 176, 193]]], ["The down-regulated expression of FcRn resulted in its incapacity to transport antibodies, providing another insight into the immune escape strategy of PEDV.DATA AVAILABILITY STATEMENTThe datasets generated for this study can be found in the PEDV JS-A (GenBank: MH748550.1).ETHICS STATEMENTThe animal study was reviewed and approved by the Scientific Ethic Committee of Huazhong Agricultural University; Huazhong Agricultural University.", [["FcRn", "GENE_OR_GENE_PRODUCT", 33, 37], ["PEDV", "SIMPLE_CHEMICAL", 151, 155], ["FcRn", "PROTEIN", 33, 37], ["antibodies", "PROTEIN", 78, 88], ["PEDV", "SPECIES", 151, 155], ["its incapacity", "PROBLEM", 50, 64], ["transport antibodies", "TREATMENT", 68, 88], ["PEDV", "PROBLEM", 151, 155], ["this study", "TEST", 210, 220], ["The animal study", "TEST", 289, 305]]], ["Written informed consent was obtained from the owners for the participation of their animals in this study.AUTHOR CONTRIBUTIONSSQ and ZL wrote the paper and conceived and initiated the study.", [["this study", "TEST", 96, 106], ["the study", "TEST", 181, 190]]], ["SQ, WZ, and XJ extracted the data set.", [["WZ", "TREATMENT", 4, 6]]], ["SQ, WZ, XJ, ZS, YZ, and YX performed the analysis.", [["the analysis", "TEST", 37, 49]]]], "f4b3e7dfb974d7908a0577e86accc54ce915d17e": [["IntroductionSecondary trauma (ST) refers to the impact of indirect exposure to traumatic experiences; effects which can be 'disruptive and painful' and can 'persist for months or years' (McCann and Pearlman 1990) .", [["trauma", "DISEASE", 22, 28], ["trauma", "PROBLEM", 22, 28], ["traumatic experiences", "PROBLEM", 79, 100], ["traumatic", "OBSERVATION", 79, 88]]], ["The effects, as described by McCann, in relation to working directly with clients, are considered to be a usual response which results from witnessing a distressing traumatic event or from knowledge about such an event, particularly if the person is connected with the victim-survivor (Figley 1998) .", [["person", "SPECIES", 240, 246], ["a distressing traumatic event", "PROBLEM", 151, 180]]], ["ST is one of a number of terms used somewhat interchangeably (including vicarious trauma, burnout, compassion fatigue) to convey ideas about the transference, or rippling-out effects, of trauma from the original incident and the original victim-survivor.", [["trauma", "DISEASE", 82, 88], ["burnout", "DISEASE", 90, 97], ["fatigue", "DISEASE", 110, 117], ["trauma", "DISEASE", 187, 193], ["vicarious trauma", "PROBLEM", 72, 88], ["burnout", "PROBLEM", 90, 97], ["compassion fatigue", "PROBLEM", 99, 117], ["trauma", "PROBLEM", 187, 193]]], ["Burnout is more usually related to the demands of work (including caregiving and studying) and its contextual components, such as long hours, insufficient support or control, and heavy workload, than the specific nature of work involved, and thus may be different, if overlapping, with the topic we are looking at (Freudenberger 1974) .", [["Burnout", "DISEASE", 0, 7], ["Burnout", "PROBLEM", 0, 7], ["insufficient support", "TREATMENT", 142, 162]]], ["Brown (2017) refers to the Maslach Burnout Inventory (2015) , which differentiates burnout from other forms of exhaustion or depression, due to its inclusion of an element of compassion fatigue.", [["burnout", "DISEASE", 83, 90], ["depression", "DISEASE", 125, 135], ["fatigue", "DISEASE", 186, 193], ["exhaustion", "PROBLEM", 111, 121], ["depression", "PROBLEM", 125, 135], ["compassion fatigue", "PROBLEM", 175, 193]]], ["Because this previous research has often focused on front line workers rather than researchers and we know collectively very little about the impacts of studying trauma on this group, we use the term ST within this paper as a more descriptive term which doesn't imply an outcome or particular impacts, yet can include a similar range of impacts found in the phenomena of burnout or compassion fatigue.", [["trauma", "DISEASE", 162, 168], ["burnout", "DISEASE", 371, 378], ["fatigue", "DISEASE", 393, 400], ["trauma", "PROBLEM", 162, 168], ["compassion fatigue", "PROBLEM", 382, 400]]], ["The term secondary trauma is not ideal but it is important to recognise where this paper sits in relation to the wider literature on the impacts of working with trauma as the focus of ones work.", [["trauma", "DISEASE", 19, 25], ["trauma", "DISEASE", 161, 167], ["The term secondary trauma", "PROBLEM", 0, 25], ["trauma", "PROBLEM", 161, 167], ["secondary trauma", "OBSERVATION", 9, 25]]], ["We also use the term 'emotional safety' to recognise ways in which the potential for ST can be acknowledged.IntroductionThe American Counselling Association describes ST as the 'emotional residue of exposure', explaining that it results from people witnessing trauma (by direct exposure or by hearing narratives about it), and thus becoming 'witnesses to the pain, fear, and terror that trauma survivors have endured' (American Counselling Association 2010).", [["trauma", "DISEASE", 260, 266], ["pain", "DISEASE", 359, 363], ["trauma", "DISEASE", 387, 393], ["people", "ORGANISM", 242, 248], ["people", "SPECIES", 242, 248], ["the term 'emotional safety'", "TREATMENT", 12, 39], ["trauma", "PROBLEM", 260, 266], ["the pain", "PROBLEM", 355, 363]]], ["The idea that front-line emergency responders, and people working therapeutically with those who have experienced trauma, might experience vicarious impacts is not new (Maslach 2015) .", [["trauma", "DISEASE", 114, 120], ["people", "ORGANISM", 51, 57], ["people", "SPECIES", 51, 57], ["trauma", "PROBLEM", 114, 120], ["vicarious impacts", "PROBLEM", 139, 156], ["not", "UNCERTAINTY", 160, 163], ["new", "OBSERVATION_MODIFIER", 164, 167]]], ["Professionals considered to be at potential risk of traumatisation have historically included: rescue workers, police officers, military personnel, emergency healthcare staff, and counsellors/ therapists (Brown (2017) ; McCann and Pearlman 1990; Ursano et al. 1999) .", [["traumatisation", "DISEASE", 52, 66]]], ["Increasingly, it has become recognised that there are many more groups of people who might experience ST, particularly those in a range of 'helping professions', who may assist trauma survivors, including: humanitarian workers, social workers, suicide helpline workers, a wide range of healthcare professionals, justice system professionals, journalists, and faith leaders (Rafferty 2004; Figley 1998; Day et al. 2006; Pryce et al. 2007; Shah et al. 2007; Sansbury et al. 2015) .IntroductionSo, where do researchers fit in this picture?", [["trauma", "DISEASE", 177, 183], ["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80]]], ["We intuitively understand that front-line professionals exposed to the traumatic and sometimes horrific experiences of others might be affected, but the shift towards acknowledging the impacts on researchers working with information about traumatic events or with traumatised individuals has been slower (Dickson-Swift et al. 2008 .", [["traumatic", "DISEASE", 71, 80], ["the traumatic", "PROBLEM", 67, 80], ["traumatic events", "PROBLEM", 239, 255], ["traumatised individuals", "PROBLEM", 264, 287]]], ["Or because it is not considered or acknowledged?", [["not considered", "UNCERTAINTY", 17, 31]]], ["Or is it because, as considered below, this type of impact can be cumulative?IntroductionIn the past, we might have considered researchers outside of the 'at-risk' groups for ST for a number of reasons: they rarely see the traumatic events that people experience, they rarely interact with people who have experienced trauma for more than a handful of occasions, and they do not have an explicit helping role in the situation.", [["trauma", "DISEASE", 318, 324], ["people", "ORGANISM", 245, 251], ["people", "ORGANISM", 290, 296], ["people", "SPECIES", 245, 251], ["people", "SPECIES", 290, 296], ["trauma", "PROBLEM", 318, 324]]], ["In reality, research is rarely an entirely neutral process, and researchers are often neither impassive nor unaffected by the research they conduct (Hallowell et al. 2005) .", [["neutral", "OBSERVATION_MODIFIER", 43, 50], ["process", "OBSERVATION", 51, 58]]], ["This is particularly true for research using qualitative methods, where people may narrate their experiences in depth, though we would argue that it can also be the case for studies using a quantitative paradigm.IntroductionThe topic of the research is, perhaps, most crucial in terms of risk of ST.", [["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78]]], ["This paper focuses on the field of Gender Based Violence (GBV).", [["Violence", "DISEASE", 48, 56]]], ["The World Health Organisation (WHO) identifies the most common risk for fieldworkers in this area as the 'emotional toll of listening to women's 1 repeated stories of despair, physical pain and degradation' (Ellsberg and Heise 2005) , with interviewers describing the imprint that bearing witness to violent narratives had had on them:IntroductionWhen I heard stories about women [sic] being beaten and tied up, I would leave there feeling desperate\u2026 I would be a wreck, and my supervisor would tell me \"get a hold of yourself, you cry for every little thing.\"", [["pain", "DISEASE", 185, 189], ["women", "ORGANISM", 137, 142], ["women", "ORGANISM", 374, 379], ["women", "SPECIES", 137, 142], ["women", "SPECIES", 374, 379], ["despair", "PROBLEM", 167, 174], ["physical pain", "PROBLEM", 176, 189]]], ["I couldn't stand it\u2026 I would try, but sometimes it was impossible, and I would burst into tears during the next interview\u2026 (Ellsberg and Heise 2005: 42) .IntroductionThe practical guide produced by the WHO for researchers of GBV clearly describes the ethical responsibilities within research; not only to keep all parties physically safe, and to minimise participant distress, but also to consider the impact that this work has on researchers' wellbeing (Ellsberg and Heise 2005) .", [["participant distress", "PROBLEM", 355, 375]]], ["Of course, these are not unique considerations for those researching GBV, researchers working with trauma in other fields may encounter similar.", [["trauma", "DISEASE", 99, 105], ["trauma", "PROBLEM", 99, 105]]], ["In fact, a brief scoping of the literature indicates that secondary distress has been raised as an issue in recent years by researchers working in a number of fields, including suicide (McKenzie et al. 2016) , cancer (Benoot and Bilsen 2016; ) , and bereavement (Butler et al. 2017) , in addition to those working on topics relating to violence and abuse (Nikischer 2019) .", [["cancer", "ANATOMY", 210, 216], ["secondary distress", "DISEASE", 58, 76], ["cancer", "DISEASE", 210, 216], ["violence and abuse", "DISEASE", 336, 354], ["cancer", "CANCER", 210, 216], ["secondary distress", "PROBLEM", 58, 76], ["cancer", "PROBLEM", 210, 216], ["secondary", "OBSERVATION_MODIFIER", 58, 67], ["distress", "OBSERVATION", 68, 76], ["cancer", "OBSERVATION", 210, 216]]], ["These topics have risk of serious harm or death in common and, as a recent revision of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) also indicates, extend the populations seen as potentially vulnerable to developing ST to include anyone with indirect exposure to aversive details of events where a person has been 'exposed to: death, threatened death, actual or threatened serious injury, or actual or threatened sexual violence' (APA 2013).", [["death", "DISEASE", 42, 47], ["death", "DISEASE", 348, 353], ["death", "DISEASE", 366, 371], ["sexual violence", "DISEASE", 434, 449], ["person", "SPECIES", 319, 325], ["death", "PROBLEM", 42, 47], ["a recent revision", "TREATMENT", 66, 83], ["Mental Disorders", "PROBLEM", 128, 144], ["death", "PROBLEM", 348, 353], ["threatened death", "PROBLEM", 355, 371], ["threatened serious injury", "PROBLEM", 383, 408], ["serious", "OBSERVATION_MODIFIER", 26, 33]]], ["Some may consider this definition too broad, as it includes the potential for anyone to be defined as vulnerable and therefore any researcher engaging with humans to be traumatised as a result.", [["humans", "ORGANISM", 156, 162], ["humans", "SPECIES", 156, 162], ["humans", "SPECIES", 156, 162]]], ["However, we would argue that there are sensitive areas of research where this risk of negative impacts on researchers is judged to be high, where additional support measures ought to be considered.", [["additional support measures", "TREATMENT", 146, 173]]], ["These additional measures might include Ethics Committees reviewing the emotional safety of research in protocols (as suggested by McKenzie et al. 2016) or clinical supervision as we suggest in this article.IntroductionFor GBV researchers, there may be potential compounding factors relating either to exposure to traumatic information, or to the people who have experienced the trauma.", [["trauma", "DISEASE", 379, 385], ["people", "ORGANISM", 347, 353], ["people", "SPECIES", 347, 353], ["GBV researchers", "TEST", 223, 238], ["the trauma", "PROBLEM", 375, 385], ["trauma", "OBSERVATION", 379, 385]]], ["The first is that the trauma has resulted from the actions of another person, most often someone close to the victim-survivor.", [["trauma", "DISEASE", 22, 28], ["person", "SPECIES", 70, 76], ["the trauma", "PROBLEM", 18, 28]]], ["This person has intentionally chosen to inflict pain, harm, violence, and/or abuse, and Herman describes how this brings those studying in this field face-to-face with 'the capacity for evil in human nature' (Herman 2015) .", [["pain", "DISEASE", 48, 52], ["violence", "DISEASE", 60, 68], ["human", "ORGANISM", 194, 199], ["person", "SPECIES", 5, 11], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["pain", "PROBLEM", 48, 52]]], ["The second dynamic is that because stigma, embarrassment, shame and guilt often exist around the experiences of abuse, participants may not have communicated their experiences previously.", [["participants", "SPECIES", 119, 131], ["stigma", "PROBLEM", 35, 41]]], ["Klein (2012) describes the possibility of participants making their first-ever disclosure of sexual violence in response to questioning by an interviewer.", [["sexual violence", "DISEASE", 93, 108], ["participants", "SPECIES", 42, 54]]], ["Consequently, when given an opportunity to speak in a safe environment, with someone independent of their situation who is empathetic, people may share material which is raw and unprocessed, finding a release of expression, and pour out detailed descriptions of events and incidents, also allowing themselves to feel, at depth, their emotions (Ellsberg and Heise 2005) .", [["people", "ORGANISM", 135, 141], ["people", "SPECIES", 135, 141]]], ["This is often experienced as an empowering, cathartic and purging encounter for participants, (Smith 2000; Moch and Cameron 2000; Hutchinson et al. 1994 ) but can leave a researcher reeling from the deluge, and feeling besieged and unsteadied (Klein 2012) .", [["participants", "SPECIES", 80, 92]]], ["A third factor which might amplify experiences of ST is personal experience.", [["A third factor", "PROBLEM", 0, 14]]], ["It is not uncommon for people who have experienced GBV in their own life to gravitate towards an active role in this topic of research, including undertaking related research.", [["people", "ORGANISM", 23, 29], ["people", "SPECIES", 23, 29], ["not uncommon", "UNCERTAINTY", 6, 18], ["active", "OBSERVATION", 97, 103]]], ["This 'insider view' is incredibly valuable and may, through enhanced empathy with participants, lead to more in-depth and nuanced research findings.", [["participants", "SPECIES", 82, 94]]], ["However, for researcher protection and self-care, the possibility that exposure to other people's experiences may trigger memories relating to personal trauma, or may increase cumulative effects of exposure, needs to be considered (Ellsberg and Heise 2002) .IntroductionIn addition to the topic area, the types of research conducted and the models used may unintentionally amplify secondary distress for researchers.", [["trauma", "DISEASE", 152, 158], ["people", "ORGANISM", 89, 95], ["people", "SPECIES", 89, 95], ["researcher protection", "TREATMENT", 13, 34], ["self-care", "TREATMENT", 39, 48], ["personal trauma", "PROBLEM", 143, 158], ["secondary distress", "PROBLEM", 381, 399]]], ["Qualitative methods are frequently used, which not only bring researchers face-to-face with people who have experienced trauma, but also require researchers to remain immersed in the data over lengthy periods, through the iterative processes of data collection, transcription, coding, analysis and paper writing.", [["trauma", "DISEASE", 120, 126], ["people", "ORGANISM", 92, 98], ["people", "SPECIES", 92, 98], ["Qualitative methods", "TREATMENT", 0, 19], ["trauma", "PROBLEM", 120, 126]]], ["In addition, research in this field tends to attempt to conduct with people rather than on people, and to incorporate feminist ideals around reducing power imbalances between researcher and participant (Legard et al. 2012 ).", [["people", "ORGANISM", 69, 75], ["people", "ORGANISM", 91, 97], ["people", "SPECIES", 69, 75], ["people", "SPECIES", 91, 97]]], ["However, attempting to conduct research in this way requires researchers to be fully present and fully congruent, with a shared sense of humanity with participants, honouring emotional connectedness with people (Williamson et al, 2019a) .", [["people", "ORGANISM", 204, 210], ["participants", "SPECIES", 151, 163], ["people", "SPECIES", 204, 210]]], ["When done successfully, this certainly enhances the research, but it can also increase the risk of ST due to, what Figley describes as, the 'cost of caring' for others in emotional pain (Figley 1982) .IntroductionThe aim of this paper is to explore reflexively the impact of research on the lives of GBV researchers, and the ways in which they guard against ST.", [["emotional pain", "DISEASE", 171, 185], ["emotional pain", "PROBLEM", 171, 185]]], ["We draw on the experiences of a team of researchers who recently completed a large study looking at GBV, although we believe that this paper can contribute to wider discussions about the wellbeing of researchers working in a range of subjects.MethodologyThis paper is based on the experiences of a research team working on a large-scale project exploring GBV.", [["GBV", "CANCER", 355, 358], ["a large study", "TEST", 75, 88], ["a large-scale project", "TREATMENT", 323, 344]]], ["The wider project involved literature reviews, analysing police and women's support services' data, and conducting and analysing interviews with 251 victims/survivors of GBV.", [["GBV", "DISEASE", 170, 173], ["women", "ORGANISM", 68, 73], ["GBV", "CANCER", 170, 173], ["women", "SPECIES", 68, 73], ["GBV", "PROBLEM", 170, 173]]], ["The interviewing team consisted of ten researchers, nine women and one male.", [["women", "ORGANISM", 57, 62], ["women", "SPECIES", 57, 62]]], ["Relevant to some of the themes that emerged, three of the ten researchers were based off-site, two working from home, and the third at another institution.MethodologyFurther information about the project, including processes of recruitment, sampling, and data collection can be found elsewhere (Williamson et al. 2019b ).", [["sampling", "TEST", 241, 249], ["data collection", "TEST", 255, 270], ["recruitment", "OBSERVATION", 228, 239]]], ["This paper, however, is concerned with reflecting on the ways in which the team addressed emotional safety and wellbeing within the project, and the mechanisms which were put in place to support researchers and to recognise and address problems should they arise.MethodologyEthical approval for the project itself was obtained from the University of Bristol, Faculty of Social Science and Law Research Ethics Committee.", [["MethodologyEthical approval", "TREATMENT", 263, 290]]], ["A further amendment to the ethics document was requested following the data collection, to ensure that this specific paper could be written without causing distress to the researchers in the team.", [["the data collection", "TEST", 67, 86], ["distress", "PROBLEM", 156, 164]]], ["Consent was discussed with researchers at this point in terms of how the information they shared would be used in the paper and that they would have the right to see how extracts from them had been included.", [["extracts", "ANATOMY", 170, 178], ["extracts", "ORGANISM_SUBSTANCE", 170, 178]]], ["Five researchers made contact with the co-lead and discussed, either in person or via email, the issues they wished to raise about the impact of the project.MethodologyAs the team was small and known to one another, no identifications are offered linked to the extracts used in the findings below.", [["extracts", "ANATOMY", 261, 269], ["extracts", "ORGANISM_SUBSTANCE", 261, 269], ["person", "SPECIES", 72, 78], ["small", "OBSERVATION_MODIFIER", 184, 189]]], ["Contributions from all researchers who responded are included in this paper.MethodologyIn terms of analysis, written comments and the text of oral conversations were thematically coded and included within the analysis by the lead researcher.", [["oral", "ANATOMY", 142, 146], ["oral", "ORGANISM_SUBDIVISION", 142, 146]]], ["All extracts and the themes were shared with the relevant individual researchers who all agreed with the analysis of the data they had provided.", [["extracts", "ANATOMY", 4, 12], ["extracts", "ORGANISM_SUBSTANCE", 4, 12]]], ["If researchers do not want to discuss the impact of this type of work with their managers, or if we assume that problems don't exist (as is currently the case), then opportunities to provide support are reduced.MethodologyFinally, in terms of method, we recognise and share principles with the autoethnographic approach used by Nikischer (2019) when reflecting on similar issues.", [["the autoethnographic approach", "TREATMENT", 290, 319]]], ["It has however been analysed and presented by a third party in order to bring together different perspectives to add depth and breadth to the perspectives being offered as well as offering a level of anonymity for those wishing to contribute.Supporting Emotional Safety and Well-BeingBefore conducting any of the qualitative and quantitative research, we put in place a standard researcher safety protocol, submitted to the Research Ethics Committee, which specifically mentioned emotional safety.Supporting Emotional Safety and Well-BeingThis protocol 2 recognises that emotional wellbeing is important, and additionally flags this as something which the research team is concerned about.", [["This protocol", "TREATMENT", 539, 552]]], ["The protocol could be construed as directive, as it requires researchers to be aware of the potential emotional impact of the research process and act on it.", [["The protocol", "TREATMENT", 0, 12]]], ["Any key points and actions which emerged from these discussions were noted.Supporting Emotional Safety and Well-BeingWe also note that transcribers too can be impacted by listening too this kind of interview (Gregory et al. 1997 ) and the lead researcher in this phase made regular contact with the transcriber to check-in with them and offer support if it were needed.Supporting Emotional Safety and Well-BeingIn practice, team members had a variety of ways of dealing with the emotional impacts of the fieldwork (both interviews and analysis of police data), with some favouring 1:1 and others favouring discussion in team meetings.Supporting Emotional Safety and Well-BeingHaving this protocol in place was definitely appreciated and made me feel that even though I am , the team did care about my emotional well-being-I wasn't always proactive at calling in every time I had completed an interviewmostly because after an intensive interview I generally took time to myself to calm down, to reflect etc plus taking the time to complete the participant overview spreadsheet immediately after an interview provided some down time so you didn't leave your desk still thinking about that person and their story.", [["person", "SPECIES", 1187, 1193], ["this protocol", "TREATMENT", 683, 696]]], ["Just as the potential emotional risk to participants is unknown in terms of impact, we did not know what the impact on researchers might be.", [["participants", "SPECIES", 40, 52]]], ["This can be done immediately after the visit, by telephone or in person.", [["person", "SPECIES", 65, 71]]], ["2) In regular team meetings, the team will discuss any emotional aspects of the work and address any particular issues which have arisen.", [["any particular issues", "PROBLEM", 97, 118]]], ["Workbased counselling services are available by contacting .\" however, the term secondary trauma is not ideal but it is important to recognise where this paper sits in relation to the wider literature on the impacts of working with trauma as the focus of ones work.Triggers to ST or Negative ImpactsTeam members recalled a number of instances where the research had a profound impact, leading to their own disclosure of abuse and/or frustration and anger at the lack of solutions/ resolution available for participants:Triggers to ST or Negative ImpactsFor me, within this research, it was a participant talking about the verdict of the inquest into the Hillsborough Disaster 3 that had the most impact.", [["trauma", "DISEASE", 90, 96], ["trauma", "DISEASE", 232, 238], ["participants", "SPECIES", 506, 518], ["trauma", "PROBLEM", 90, 96], ["trauma", "PROBLEM", 232, 238], ["frustration", "PROBLEM", 433, 444]]], ["It had nothing directly to do with her multiple experiences of rape, but this participants' hope, following that verdict that justice might be possible, and my overwhelming fear about what would happen if that didn't happen for her.", [["participants", "SPECIES", 78, 90]]], ["The possibility of justice was something that stayed with me long after the interview and it led me to decide to report to the police my own historic case of child sexual abuse.", [["sexual abuse", "DISEASE", 164, 176], ["possibility of", "UNCERTAINTY", 4, 18], ["justice", "OBSERVATION", 19, 26]]], ["The first was a woman who had suffered domestic abuse, but had not wanted to deny her young daughter contact with her fathershe agreed to joint custody despite what she had gone through thinking it was the best interests of her child-however she has seen changes in her daughter and was totally regretting allowing the daughter to live with her father as she suspected that he was being emotionally abusive to her now tooshe was in tears during the interview because she felt so helpless to protect her child and I felt her pain, it was very emotional and I felt very angry, frustrated and helpless afterwards.", [["domestic abuse", "DISEASE", 39, 53], ["pain", "DISEASE", 524, 528], ["woman", "ORGANISM", 16, 21], ["woman", "SPECIES", 16, 21], ["her pain", "PROBLEM", 520, 528], ["very angry", "PROBLEM", 563, 573], ["joint", "ANATOMY", 138, 143]]], ["The second was a woman who had suffered prolonged sexual abuse by partner and familyshe didn't feel able to do an interview in the end but because she had my [work] mobile phone number (which I used to text her) she texted me a couple of times (at 10pm and 6am) saying how she couldn't sleep and how awful she felt.", [["prolonged sexual abuse", "DISEASE", 40, 62], ["woman", "ORGANISM", 17, 22], ["woman", "SPECIES", 17, 22]]], ["Not a good position to be in really but to be expected as we were including talking to people who had not necessarily talked through their issues with specialists/professionals first.Triggers to ST or Negative ImpactsIn cases like these, even though the involvement with the participant is not extensive, it can leave the researcher with that feeling of 'unfinished business' or feelings of on-going concern and worry for the fate of the person (Burr 1995) .", [["people", "ORGANISM", 87, 93], ["people", "SPECIES", 87, 93], ["participant", "SPECIES", 275, 286], ["person", "SPECIES", 438, 444]]], ["It also raises feelings of having an ethical responsibility as a researcher of vulnerable people (Stalker 1998 ).Triggers to ST or Negative ImpactsAll of the interviews were difficult because you feel empathy, anger, a sense of injustice and helplessness when someone is describing something so terrible happening to them.", [["helplessness", "DISEASE", 242, 254], ["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["On top of this, having worked on the issue of sexual exploitation for several years, one particular trigger for me was when participants described this form of abuse.", [["participants", "SPECIES", 124, 136]]], ["Specifically, a couple of women who had experienced brutal (physical and psychological) domestic violence described how their partners also advertised them online and forced them to have sex with other menone of the women was heavily pregnant during some of this.", [["physical and psychological) domestic violence", "DISEASE", 60, 105], ["women", "ORGANISM", 26, 31], ["women", "ORGANISM", 216, 221], ["women", "SPECIES", 26, 31], ["women", "SPECIES", 216, 221]]], ["This was extremely upsetting because, in addition to these women already experiencing sexual violence from their abusive partners, they were also being raped by several other perpetrators; it also makes you angry that these men would come and pay for sexual access to women who were clearly being pimped by someone, were obviously vulnerable and were not consenting.Triggers to ST or Negative ImpactsThese testimonies from the team highlight a number of factors.", [["sexual violence", "DISEASE", 86, 101], ["women", "ORGANISM", 59, 64], ["men", "ORGANISM", 224, 227], ["women", "ORGANISM", 268, 273], ["women", "SPECIES", 59, 64], ["men", "SPECIES", 224, 227], ["women", "SPECIES", 268, 273]]], ["4 This unique role as a researcher can be difficult when it results in researchers feeling unable to intervene or make things better.Triggers to ST or Negative ImpactsIt became apparent that triggers could be linked not only to actual interviews, but also to secondary data collection; in this case, detailed police files about rape and domestic violence which were reviewed as part of the study.", [["domestic violence", "DISEASE", 337, 354], ["the study", "TEST", 386, 395]]], ["The trauma here was described as being caused, in part, by not having a link to the person under discussion in the reviewed documents, and also as a result of very factual and detailed ways in which the information about horrific events was conveyed:Triggers to ST or Negative ImpactsReading through police case files could be just as depressing and upsetting in some of the worst cases and especially the cases involving child victims of rape and family abuse.", [["trauma", "DISEASE", 4, 10], ["family abuse", "DISEASE", 448, 460], ["person", "SPECIES", 84, 90], ["trauma", "OBSERVATION", 4, 10]]], ["There was also a time when I was collecting data on a DV case and there was a warning attached to the victim's file which said so I had read all about her history of domestic violence, family abuse, drug and alcohol abuse and then found out that she had actually been found dead 2 weeks after the latest incident and her partner had [previously] been arrested on suspicion of her murder but no further action had been taken (when you could see the pattern of abuse she had suffered and was obviously extremely vulnerable) -that made me gasp out loud in the open plan (and quiet) office I was in (embarrassing) and made me incredibly sad.", [["domestic violence", "DISEASE", 166, 183], ["family abuse", "DISEASE", 185, 197], ["drug and alcohol abuse", "DISEASE", 199, 221], ["alcohol", "CHEMICAL", 208, 215]]], ["I cried on my drive home that day.Triggers to ST or Negative ImpactsClearly, examining this type of data for analysis is 'part of the job' of a researcher, and this will be examined shortly, but in the course of conducting this type of work, even if desk based, there will be times when researchers may need additional support to process the emotions they experience from dealing with such information and in order to prevent burnout, as described in the background section.", [["burnout", "DISEASE", 426, 433], ["analysis", "TEST", 109, 117], ["additional support", "TREATMENT", 308, 326], ["burnout", "PROBLEM", 426, 433]]], ["These types of emotional impacts are commonly discussed in counselling literatures (Sanderson 2013) and also on the margins of discussions around reflexive qualitative methodological approaches (Etherington 2009 ).Triggers to ST or Negative ImpactsIncluding trauma experienced when looking through case notes may appear questionable to some readers.", [["trauma", "DISEASE", 258, 264], ["trauma", "PROBLEM", 258, 264]]], ["There is an inherent contradiction in the statement made above that researchers can be impacted negatively when they are close to the 'research subject', and also impacted when not close, as in the case of case file analysis.", [["case file analysis", "TEST", 206, 224], ["inherent", "OBSERVATION_MODIFIER", 12, 20], ["contradiction", "OBSERVATION", 21, 34]]], ["Referring to the impact on researchers reviewing case files of sexual violence, research in the 1980s and 1990s also found that researchers using unobtrusive methods experience similar physical and emotional impacts to those who use in-depth interviews (Milling-Kinard 1996 , in Liamputtong 2007 .Triggers to ST or Negative ImpactsThere were occasional notes of optimism too, where team members described feeling hopeful following exposure to data that indicated professionals' efforts on behalf of victim-survivors:Triggers to ST or Negative ImpactsOn a more positive note about working with the police files it did also give me a bit of hope about police practice in this area -after reading the comments and efforts employed by individual officers and getting the impression of how far some officers go to investigate the incidents/allegations and how overall victims were being believed and there was inter-agency working and frustration on the part of the police regarding cases not proceeding to prosecution for whatever reason\u2026 Whilst not explicitly mentioned by the team for this study, we also recognise that reading difficult material within the wider literature can have emotional impact for some people.", [["sexual violence", "DISEASE", 63, 78], ["people", "ORGANISM", 1208, 1214], ["people", "SPECIES", 1208, 1214], ["this study", "TEST", 1083, 1093], ["reading difficult material", "PROBLEM", 1118, 1144]]], ["This means it is important not to assume that desk-based work will be automatically less emotionally traumatic.", [["traumatic", "DISEASE", 101, 110], ["automatically less emotionally traumatic", "PROBLEM", 70, 110]]], ["For some people, that greater knowledge and experience adds to a \"crystalline memory\" where a trigger, whether a research-related interview, or something in the wider context of the person's life, such as a book or a film, can pull out those memories and traumas, and actually compound the impact of a trigger point.The Cumulative ImpactYou think it would get easier over the years, but it doesn't.", [["traumas", "DISEASE", 255, 262], ["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15], ["person", "SPECIES", 182, 188], ["a film", "TEST", 215, 221], ["traumas", "PROBLEM", 255, 262]]], ["The fact that we keep having to have these conversations is in itself depressing on top of the nature of the issues we are dealing with.The Cumulative ImpactThis illustrates how, no matter how long we may have been in the field, sometimes as researchers we still underestimate our own emotional well-being in undertaking research with vulnerable people (Liamputtong 2007:87) .The Cumulative ImpactThe longer-term impact of dealing with these narratives, without clinical supervision as a matter of course, is that some people reach a point where they can no longer immerse themselves in this type of information, choosing to move away from the work, or remaining, but making a choice to work on the issue of GBV within a broader political context.", [["people", "ORGANISM", 346, 352], ["people", "ORGANISM", 519, 525], ["GBV", "CANCER", 708, 711], ["people", "SPECIES", 346, 352], ["people", "SPECIES", 519, 525]]], ["We might perhaps suppose that front line work is even more impactive than research, in terms of ST, however, as this team member described, it has the advantage of feeling more 'effective':The Cumulative ImpactFor me it's the other way aroundworking within the broader political context \u2026 and then becoming immersed in the actual narratives and experiences made me feel like nothing much has changed in terms of the extent that abuse still exists on a massive scale and is allowed to continuedespite decision makers becoming more aware through improved knowledge/research over the last 20 years this doesn't always translate to the victim/survivor.", [["a massive scale", "TREATMENT", 450, 465]]], ["I know cultural change takes time and most of the time it feels like we are facing an uphill battle in tackling violence against women and girls but for me this project has made me feel like I might be more effective or immediate in helping v/ s if I was working more closely/practically.Competing DemandsWith any research there are time and resource pressures which managers need to take on board.", [["violence", "DISEASE", 112, 120], ["women", "ORGANISM", 129, 134], ["women", "SPECIES", 129, 134], ["girls", "SPECIES", 139, 144], ["resource pressures", "TREATMENT", 342, 360]]], ["For example, if there are time pressures to complete a certain number of interviews within a certain amount of time, and the researcher requires additional time to process the emotional impacts of the research, these two factors can come into conflict.", [["time pressures", "TEST", 26, 40]]], ["This potential conflict between selfcare and getting the research done is important to address.", [["conflict", "OBSERVATION", 15, 23]]], ["Within the current project, there were very clear targets and timeframes.", [["very", "OBSERVATION_MODIFIER", 39, 43], ["clear", "OBSERVATION", 44, 49]]], ["By raising the issue of emotional impacts at the outset, we were able to address the potential conflicts directly, and discuss possibilities for the boundaries of support.", [["the boundaries of support", "TREATMENT", 145, 170]]], ["Getting the balance right is not always straight forward.", [["right", "ANATOMY_MODIFIER", 20, 25]]], ["For us, having a supportive team made a big difference.", [["a big difference", "PROBLEM", 38, 54]]], ["Where required, we could shift the types of interviews people were conducting.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["In those circumstances, individuals would feel a greater sense of pressure to get on with the job, irrespective of how they were feeling.Competing DemandsUltimately, there may be occasions when the experience of conducting this type of research leads to a realisation that this might not be the right job for an individual.", [["individuals", "ORGANISM", 24, 35], ["right", "ANATOMY_MODIFIER", 295, 300]]], ["If someone is not able to attain relatively healthy coping mechanisms, then continuing in this field of work is likely to be traumatic for them, their managers, and their colleagues, in the long-term.", [["traumatic", "DISEASE", 125, 134], ["traumatic", "PROBLEM", 125, 134]]], ["It is one of the reasons why independent clinical supervision may be more appropriate in this type of research which is discussed in the conclusion in terms of policy implications.General Coping StrategiesThe issue of coping strategies has been raised in previous sections.", [["sections", "ANATOMY", 264, 272], ["coping strategies", "TREATMENT", 218, 235]]], ["There is a wider recognition (Holahan and Moos 1987) that some of these are healthy coping strategies and others, particularly if not in moderation, are less healthy strategies.", [["wider", "OBSERVATION_MODIFIER", 11, 16]]], ["We make no judgment on this, but recognise that they are approaches people might use in the short-term, long-term, or both, in order to manage the impacts they experienced.", [["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74]]], ["Some researchers have also talked about avoiding certain topics on TV, radio and in books and magazines (Brown 2017; McKenzie et al. 2016) .General Coping StrategiesComfort Eating and drinking alcohol:General Coping StrategiesDefinitely mindfulness, meditation, and running (not at the same time!).", [["alcohol", "CHEMICAL", 193, 200], ["alcohol", "CHEMICAL", 193, 200], ["meditation", "TREATMENT", 250, 260]]], ["Also wine, chocolate and binge TV watching.", [["chocolate", "ORGANISM_SUBDIVISION", 11, 20]]], ["It is a way, unhealthy admittedly, of switching off and shutting down some of the emotions that come with carrying other people's, and my own, trauma.Distractions:Members of the team also talked about forms of distraction, such as reading trashy (simple, shallow) magazines, watching television and reading fiction, or of sharing the burden by talking to friends or colleagues.Distractions:I particularly like murder mysteries which might seem odd.", [["trauma", "DISEASE", 143, 149], ["people", "ORGANISM", 121, 127], ["people", "SPECIES", 121, 127], ["trauma", "PROBLEM", 143, 149], ["distraction", "PROBLEM", 210, 221]]], ["'I spoke today to yet another woman who has been raped multiple times in her life'.", [["woman", "ORGANISM", 30, 35], ["woman", "SPECIES", 30, 35]]], ["We could vent our frustration, anger and other emotions at yet another instance of someone (mainly women) experiencing violence and abuse.", [["violence and abuse", "DISEASE", 119, 137], ["women", "ORGANISM", 99, 104], ["women", "SPECIES", 99, 104]]], ["I found almost no difference in terms of talking over the phone or in person [with colleagues]-both were helpful.Exercise:Some described the benefits of exercise, particularly if it was outdoors.Exercise:Taking a walk/getting fresh air.", [["person", "SPECIES", 70, 76]]], ["I would find myself getting very caught up in some interviews and in somewhat of a depressed/anxious daze afterwards.", [["depressed", "DISEASE", 83, 92], ["a depressed/anxious daze", "PROBLEM", 81, 105]]], ["The fresh air, change of scenery and quiet of the park I would walk in always helped.Exercise:Counselling/Therapy: Others mentioned the need for therapeutic counselling, acknowledging that it might be helpful, but that it is rarely available for researchers:Exercise:Counsellors get clinical supervision to help them deal with the emotions they engage with within the therapeutic relationship.", [["therapeutic counselling", "TREATMENT", 145, 168], ["fresh air", "OBSERVATION", 4, 13]]], ["This means recognising that there are limits to the amount of emotional impacts people can absorb, and that having the space to stop and reflect is crucial.", [["people", "ORGANISM", 80, 86], ["people", "SPECIES", 80, 86]]], ["This can only happen, however, if researchers feel able and safe within the team, or with their line manager, or have other avenues to raise concerns when they arise.Standing Still:The examples above illustrate how this team used a wide range of strategies with varying degrees of success.", [["a wide range of strategies", "TREATMENT", 230, 256]]], ["This is something with Liamputtong (2007) raises in relation to providing access to a professional confidante and formal supervision, which includes both academic and therapeutic supervision.RewardsThis paper has so far looked at the emotional impacts of conducting research in the field of GBV, and the potential emotional safety issues which arise.", [["GBV", "DISEASE", 291, 294], ["GBV", "CANCER", 291, 294], ["therapeutic supervision", "TREATMENT", 167, 190]]], ["There are also (Edwards 1993; Abrahams 2017 ) rewards which come from sharing someone's story and 'actively listening'.RewardsThe broader rewards for researchers in this project were about the potential of the research to bring about change:RewardsAs well as the negative impacts of the interviews I mentioned above, those same interviews gave me a real sense that this research could make a difference to real people and real lives.", [["people", "ORGANISM", 411, 417], ["people", "SPECIES", 411, 417]]], ["That was a privilege to be a part of, and although difficult, made coming into work worthwhile.RewardsAnd this was apparent on a person-to-person level too, where victim-survivors expressed the 'usefulness' to them personally of being involved in the research and having had the opportunity to share their experiences Having participants thank me for listening, and thank our team for doing this research, was always massively rewarding.", [["person", "SPECIES", 129, 135], ["person", "SPECIES", 139, 145], ["participants", "SPECIES", 325, 337]]], ["Even if I felt helpless regarding their experience of violence/abuse, I felt somewhat better if they expressed that the interview/research was useful.RewardsAn additional reward was remarked upon where the research and the experiences of individual participants, created an opportunity for the researcher to perceive their own life in a different, perhaps more favourable light:RewardsIt was difficult to do the interviews (and I have a lot of experience doing similar interviews) but it was also very rewarding.", [["violence/abuse", "DISEASE", 54, 68], ["participants", "SPECIES", 249, 261]]], ["And I guess it taught me something about myself, about the things that matter to me and how lucky I am compared to some of the women I spoke to, but how much we share as well.RewardsFinally, of the 251 victims/survivors who we interviewed within the main project, over 30% had, subsequent to the abuse they had experienced, become involved in politics or organisations as a way to respond to the abuse they had experienced and in their search for justice (Williamson et al. 2019a) .", [["women", "ORGANISM", 127, 132], ["women", "SPECIES", 127, 132]]], ["As with some of the participants who went on to work in this field and were seeking justice for others where they had not got justice for themselves, we too may be engaged in that process of seeking justice not only for others, but for ourselves.", [["participants", "SPECIES", 20, 32]]], ["In this regard we need to recognise that, where this is the case, it brings both resilience and risks to the researcher with experiential knowledge of GBV.ConclusionUltimately, many of us continue to carry out research in this field knowing that the work may have a negative impact.", [["GBV", "CANCER", 151, 154], ["GBV", "PROBLEM", 151, 154]]], ["As such, we negotiate a balance between rewards and potentially traumatic impacts.", [["traumatic impacts", "PROBLEM", 64, 81], ["traumatic", "OBSERVATION", 64, 73]]], ["This doesn't however address the issue of what additional support might be appropriate for researchers working on trauma related topics.ConclusionThe project on which this paper is based succeeded, in terms of meeting the original target of interviews, and giving victim/survivors a voice, because it was conducted by a team of experienced individuals who had a range of options made available to them to help address the impacts of working in this area.", [["trauma", "DISEASE", 114, 120], ["trauma", "PROBLEM", 114, 120]]], ["This was identified as more difficult for those staff working remotely, as they have been located outside the main site.", [["main", "OBSERVATION_MODIFIER", 110, 114]]], ["This mainly affected the ability to have informal check-ins with others in the team, although they did still feel supported by the fact that support was there if needed.", [["informal check", "TEST", 41, 55]]], ["There were no differences in the coping strategies used by those working off the main site.", [["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25]]], ["Many work in isolation, outside of a team context, and unless they are provided with 'clinical' or in-depth supervision, which is very rare, are at risk of experiencing some level of trauma themselves when listening too, and engaging with, data of this nature (Nikischer 2019) .", [["trauma", "DISEASE", 183, 189]]], ["As such, a proactive clinical supervision arrangement may provide better safeguards than a reactive approach to addressing the needs of researchers in distressing sensitive subjects.", [["a proactive clinical supervision arrangement", "TREATMENT", 9, 53], ["a reactive approach", "TREATMENT", 89, 108]]], ["This might take the form of a pre-fieldwork session to identify potential triggers and coping strategies and bi-monthly checkins so that arising issues can be identified and discussed.", [["a pre-fieldwork session", "TREATMENT", 28, 51], ["coping strategies", "TREATMENT", 87, 104]]], ["This conclusion echoes those of Dickson-Swift et al. (2008 ) who recommended that: \"professional supervision, policy development, and minimum training standards for researchers are provided\" (Dickson-Swift et al. 2009 ).ConclusionUndermining the suggestion here about clinical supervision is the issue of cost and funding.", [["cost and funding", "TREATMENT", 305, 321]]], ["However, we would question whether funders and employers are doing enough to support researchers in dealing with the emotional impacts of their work and thus avoid the burnout which can result.", [["burnout", "DISEASE", 168, 175]]], ["Losing experienced and highly trained staff is not an insignificant cost to these institutions.ConclusionFor many of the researchers in this project, the greatest emotional impacts were linked to frustrations related to feeling that socially nothing has changed, sometimes described as hopelessness.", [["hopelessness", "DISEASE", 286, 298]]], ["Conversely, the rewards related to making a difference by hearing people's stories and giving them a voice.", [["people", "ORGANISM", 66, 72], ["people", "SPECIES", 66, 72]]], ["With this in mind, the importance of public engagement and impact of research cannot be underestimated.", [["public engagement", "TREATMENT", 37, 54]]], ["Whilst research generally has moved in recent years to recognise the importance of 'impact', this is something which has been central to the GBV field from its outset (Lilley (Walker) and Hester 2012).ConclusionTo conclude, researching GBV is hard, but the negative emotional impacts or ST which researchers may experience can, for many people, be managed through support and understanding.", [["people", "ORGANISM", 337, 343], ["people", "SPECIES", 337, 343]]], ["For some researchers however, the impact of researching GBV and abuse will be damaging.", [["GBV", "CHEMICAL", 56, 59]]], ["From a policy context we would like to see funders and institutions recognise the potential benefits of clinical supervision being available for researchers working with sensitive issues, whether interviews or data derived from such populations/participants.", [["participants", "SPECIES", 245, 257], ["clinical supervision", "TREATMENT", 104, 124]]], ["We hope to continue such policy discussions with the aim of ensuring that the impacts of research are better recognised, acknowledged, and that different options and safeguards are considered to support researchers working in all areas of research dealing with trauma and/or abuse.Compliance with Ethical StandardsDeclaration of Interest Statement I confirm that none of the authors have any conflicts of interest relating to the research on which this paper is based.Compliance with Ethical StandardsOpen Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.", [["trauma", "DISEASE", 261, 267], ["trauma", "PROBLEM", 261, 267], ["Ethical Standards", "TREATMENT", 297, 314], ["Ethical Standards", "TREATMENT", 484, 501], ["Open Access", "TREATMENT", 501, 512]]], ["The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material.", [["The images", "TEST", 0, 10]]]]}